Book Impurities
Book Impurities
Book Impurities
reference substances
and impurities
2011/2012
For further information, or if you require substances or materials
not currently listed please contact one of our local sales offces.
Brazil
Tel: +55 12 3302 5880
Email: bz@lgcstandards.com
Bulgaria
Tel: +359 (0)2 971 4955
Email: bg@lgcstandards.com
Countries served:
Bulgaria, Macedonia (FYRM)
China
Tel: +86 10 85324820
Email: infochina@lgcstandards.com
Countries served:
China, Hongkong, Macau, Taiwan
Czech Republic
Tel: +420 543 529 205
Email: cz@lgcstandards.com
Countries served:
Czech Republic, Slovakia
Finland
Tel: +358 (0)2 233 9355
Email: fi@lgcstandards.com
France
Tel: +33 (0)3 88 04 82 82
Email: fr@lgcstandards.com
Countries served:
Algeria, Belgium, France, Ivory Coast,
Jordan, Lebanon, Libya, Madagascar,
Morocco, Senegal, Syria, Tanzania,
Tunesia
Germany
Tel: +49 (0)281 9887 0
Email: de@lgcstandards.com
Countries served:
Austria, Cyprus, Germany, Greece, Israel,
Japan, Korea, Singapore, Switzerland,
Thailand, Vietnam
Hungary
Tel: +36 (06) 26 314 891
Email: hu@lgcstandards.com
Countries served:
Croatia, Hungary, Slovenia
India
Tel: +91 (0)80 6701 2000
Email: in@lgcpromochem.com
Countries served:
Bangladesh, India, Nepal, Pakistan
Ireland
Tel: +44 (0)7879 556983
Email: ire@lgcstandards.com
Italy
Tel: +39 02 2412 6830
Email: it@lgcstandards.com
Netherlands
Tel: +31 (0)643 775 422
Email: nl@lgcstandards.com
Poland
Tel: +48 (0)22 751 31 40
Email: pl@lgcstandards.com
Countries served:
Armenia, Azerbaijan, Belarus, Georgia,
Kazakhstan, Kyrgizstan, Lithuania, Poland,
Slovakia, Tajikistan, Turkmenistan, Ukraine,
Uzbekistan
Romania
Tel: +40 364 116890
Email: ro@lgcstandards.com
Countries served:
Moldova, Romania, Serbia
Russia
Tel: +7 (812)935 1180
Email: ru@lgcstandards.com
Spain
Tel: +34 (0)93 308 4181
Email: es@lgcstandards.com
Countries served:
Andorra, Latin America, Portugal, Spain
Sweden
Tel: +46 (0)33 20 90 60
Email: se@lgcstandards.com
Countries served:
Denmark, Estonia, Iceland, Latvia,
Norway, Sweden
Turkey
Tel: +90 216 360 0870
Email: tur@lgcstandards.com
Middle East
Tel: +971 555 570 664
Email: uae@lgcstandards.com
Countries served:
Egypt, Sudan, UAE, Yemen
United Kingdom
Tel: +44 (0)20 8943 8480
Email: uksales@lgcstandards.com
Countries served:
Australia, Brunei, Channel Islands, Ireland,
Kenya, Kuwait, Malta, New Zealand,
Philippines, Saudi Arabia, South Africa,
United Kingdom
USA + Canada
Tel: +44 (0)20 8943 8480
Email: lgcusa@lgcstandards.com
www.lgcstandards.com
International locations LGCS.indd 1 23/08/2011 16:30:15
Introduction
Global quality management solutions
for the laboratory
www.lgcstandards.com
Brazil Bulgaria China Czech Republic Finland France Germany Hungary reland ndia taly Netherlands
Poland Romania Russia Spain Sweden Turkey UAE United Kingdom USA
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,
recording or any retrieval system, without the written permission of the copyright holder. LGC Limited, 2011. All rights reserved. 2788/CB/0211
LGC Standards provides products and services to improve
measurement and quality control within your laboratory:
Reference materials for a wide range of sectors including
food, environmental, pharmaceutical, clinical and industrial
Biological standards and reagents
Production of pharmaceutical impurities
High purity solvents
Profciency testing schemes
Analytical quality training courses.
Why choose LGC Standards?
Widest range of reference materials from a single source
giving laboratories access to over 100,000 products, from over 90 suppliers worldwide
Access to 30 prociency testing schemes
offering rapid turnaround of results and expert advice
Expert technical support
on product usage and selecting the appropriate material for your needs
Network of internationaI ofces
offering customer service in your local language and time zone
Access to knowledge
on import requirements, licensing, shipping regulations and
controlled substances management.
o l G
r o f
y t i l a u q l a b o
a r o b a l e h t
m e g a n a m y
y r o t a
o i t u l o s t n e m
s n o
LGC Standards provides products and services to improve
measurement and quality control within your laboratory:
Reference materials for a wide range of sectors including
food, environmental, pharmaceutical, clinical and industrial
Biolog
Production of pharmaceutic
High purity solvents
LGC Standards provides products and services to improve
measurement and quality control within your laboratory:
Reference materials for a wide range of sectors including
food, environmental, pharmaceutical, clinical and industrial
gents ical standards and rea Biolog
al impurities Production of pharmaceutic
High purity solvents
LGC Standards provides products and services to improve
measurement and quality control within your laboratory:
Reference materials for a wide range of sectors including
food, environmental, pharmaceutical, clinical and industrial
gents
al impurities
LGC Standards provides products and services to improve
measurement and quality control within your laboratory:
Profciency testing schemes
Analytical qua
Why choose LGC Standards?
idest range of W
giving laboratories access to over 100,000 products, from over 90 suppliers worldwide
Acce
Profciency testing schemes
urses. lity training co Analytical qua
Why choose LGC Standards?
idest range of reference materials fr
giving laboratories access to over 100,000 products, from over 90 suppliers worldwide
ss to 30 prociency testing schemes Acce
urses.
Why choose LGC Standards?
om a single source reference materials fr
giving laboratories access to over 100,000 products, from over 90 suppliers worldwide
ss to 30 prociency testing schemes
om a single source
giving laboratories access to over 100,000 products, from over 90 suppliers worldwide
fering rapid turnaround of results and expert advice of offering rapid turnaround of results and expert advice
Expert technical sup
on product usage and selecting the appropriate material for your needs
Network of internationaI ofces
fering customer service in your local language and time zone of offering customer service in your local language and time zone
Acce
on import requirements, licensing, shipping regulations and
ss to 30 prociency testing schemes
fering rapid turnaround of results and expert advice
port Expert technical sup
on product usage and selecting the appropriate material for your needs
Network of internationaI ofces
fering customer service in your local language and time zone
e ss to knowledg Acce
on import requirements, licensing, shipping regulations and
ss to 30 prociency testing schemes
fering rapid turnaround of results and expert advice
port
on product usage and selecting the appropriate material for your needs
Network of internationaI ofces
fering customer service in your local language and time zone
on import requirements, licensing, shipping regulations and
on product usage and selecting the appropriate material for your needs
on import requirements, licensing, shipping regulations and
controlled substances management.
on import requirements, licensing, shipping regulations and
controlled substances management.
on import requirements, licensing, shipping regulations and
controlled substances management.
Brazil Bulgaria China Czech Republic
www
Brazil Bulgaria China Czech Republic Finland France G
Poland Romania Russia Spain Sweden
.lgcstandards.com www
Finland France Germany Hungary reland ndia taly Netherlands
urkey UAE United Kingdom USA T Poland Romania Russia Spain Sweden
.lgcstandards.com
ermany Hungary reland ndia taly Netherlands
urkey UAE United Kingdom USA
ermany Hungary reland ndia taly Netherlands
New dividers.qxp:Layout 1 21/3/11 14:18 Page 3
Content
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 1
Content
Introduction
Introduction 2
Pharmaceutical impurities 5
Background 7
List of products 9
European Pharmacopoeia 221
ATCC microbiological products 280
Certified liquids for viscosity measurements 282
International commission on pharmaceutical enzymes 283
European Pharmacopoeia reagents 284
WHO International Standards for Antibiotics 289
British Pharmacopoeia 291
ATCC microbiological products 307
Pharmacope Franaise 309
Pharmacopoeia Helvetica 311
International Pharmacopeia 312
United States Pharmacopeia and National Formulary 317
ATCC microbiological products 387
Secondary standards 389
Institute of Dyes and Organic products 395
Refractive index CRMs 398
Publications and subscriptions 399
High purity solvents and acids 403
Introduction
2 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Introduction
About LGC Standards
LGC Standards has successfully established a global reputation for the production of impurities and working
standards, and as a single source for the supply of pharmacopeia reference materials. Our menu of custom
services, including custom synthesis of impurities and metabolites, characterisation, certification, packaging
and distribution, adds value to the scientific support we provide to our pharmaceutical customers.
Our relationships with the worlds leading pharmacopoeias and their range of Chemical Reference
Substances (CRS) and Reference Standards (RS), combined with in-house production of certified reference
materials and pharmaceutical impurities, enable us to meet our customers specific needs. LGC Standards
is also the exclusive European distributor for ATCC cultures and bio products.
LGC Standards extensive network of sales offices and distribution centres mean we offer the widest range
of reference materials from one single source for rapid delivery. Our staff can provide scientific and technical
guidance, including shipping and customs advice, in the local language.
Our range of products also includes reference materials for clinical and forensic applications,
phytochemicals, environmental analysis, physical properties determination, and food and beverage analysis.
For more information about our range of services, or to receive any of our catalogues, please refer to our
website www.lgcstandards.com or contact your local office.
About LGC
LGC Standards is part of LGC. LGC, whose Science and Technology Division acts as the designated UK
National Measurement Institute (NMI) for Chemical and Biochemical measurement, has a long history in the
development and validation of analytical methods and the production of reference materials.
Many of the analytical methods, which cover the food, environment, industrial, clinical and pharmaceutical
sectors, are accredited to ISO/IEC 17025 (Requirements for the competency of testing and calibration
laboratories). Full details of the accreditation schedule can be found on the UKAS website www.ukas.com).
LGCs Research and Technology Division is accredited to ISO Guide 34 (General Requirements for the
competence of reference materials producers) for the production of reference materials. The measurement
capabilities used to produce certified reference materials in its capacity as the UK NMI are verified through
participation on key comparison studies organised by the Consultative Committee for the Amount of
Substance (CCQM) of the International Weights and Measures Organisation (BIPM). The certificates are
recognised by other National Measurement Institutes, under the Mutual Recognition Arrangement.
In its role as the NMI, LGC serves on the International Organisation for Standardisation (ISO) Committee for
Reference Materials (REMCO), which aims to carry out and encourage a broad international effort for the
harmonization, production and application of certified reference materials (CRMs).
About the catalogue
The 2011/2012 edition of the LGC Standards catalogue Pharmaceutical reference substances and
impurities, replaces the Pharmaceutical reference substances and impurities 2010/2011 edition and the
newsletter updates.
The information provided in this catalogue as regards compendial articles is based on the official
pharmacopoeial lists and is correct at the time of print. Original descriptions and spellings used by the
producers are retained. In some cases additional information has been included to make the lists more
convenient to use.
The catalogue will be updated with three to four newsletters; these will be downloadable under
www.lgcstandards.com. You can also contact your local LGC Standards office and ask to be provided with
the newsletters once they are published.
Pharmaceutical reference substances
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 3
Pharmaceutical reference substances
Certification
The products described in this catalogue include pharmacopeial reference substances for use in
pharmaceutical analysis. Pharmacopeial CRSs and RSs should be distinguished from certified reference
materials (CRMs), which are produced in conformity with the ISO guides 30 to 35, and supplied with a
detailed certification document.
Pharmacopeial reference substances are produced for a specific purpose, and the manufacturers follow
rigorous protocols to ensure the reference substance is fit for the intended purpose. The certification
processes follow the basic requirements of the relevant ISO REMCO guides, but are modified by the
pharmacopoeias to reflect the particular demands of the associated pharmaceutical monograph.
Details are given in the introduction to each section listing the various CRS collections in this catalogue.
Shelf Life, storage and expiry dates
Pharmacopeial CRSs and RSs should be purchased when required and not stored for a prolonged period.
Pack sizes are designed to allow a limited number of replicate analyses, as required by Good Analytical
Practice, but the opened pack should not be kept for future use. Please check all individual storage
temperature requirements and note that the substances should be kept away from humidity and light (unless
otherwise stated).
Specific lot numbers or letters are allocated to all pharmacopeial reference substances, but no expiry dates
are set. New lots are normally prepared well in advance of the expected "sell-out" of the current lot.
When a substance is withdrawn from sale because the lot has depleted a final expiry date is given, by which
any material from the outgoing lot held by users must be used. This means that for a period of time both lots
are official. Lot information is provided by USP and EP in their literature and is available from LGC
Standards.
If a material is withdrawn by the producer, then all stocks held by the users are no longer valid and have to
be destroyed. Should this occur, LGC Standards will inform all customers who have purchased the
withdrawn substance. Please note that such a situation is outside LGC Standards control and products are
not refundable.
Impurity standards
Impurities in a pharmaceutical substance can change the effects and side effects of a drug significantly.
Therefore, it is important to have an accurate detection of these substances. The pharmaceutical
monographs regulate the legal definition, the analysis and the limits of impurities of a given substance. An
official range of impurity standards is available from the main pharmacopoeias where a CRS or RS is
required in the monograph.
Over 2700 other impurity standards are listed in the pharmaceutical impurities section of this catalogue.
These materials are produced by LGC, whose Science and Technology Division acts as the designated UK
National Measurement Institute for Chemical and Biochemical Measurements. They are produced at our
facility in Luckenwalde near Berlin, Germany and are supplied with a certificate of analysis. Our impurity
reference standards are intended for the identification and control of impurities in drug substances and drug
preparations, as well as for method development and validation.
Controlled substances
A number of the pharmaceutical substances, such as narcotics and tranquillisers, described in this catalogue
are Controlled Substances in their country of origin and are marked Controlled Substance against the
product description.
The purchase, possession and use of Controlled Substances are subject to national and international
regulations designed to limit their abuse. It is the responsibility of the customer to obtain any authorisation
necessary to both purchase and possess Controlled Substances, complying with the laws of the importing
country, before ordering.
Customers wishing to obtain Controlled Substances must contact their LGC Standards sales office before
ordering, and clarify with the sales specialists the relevant national requirements, the associated charges and
consequential delivery times. All orders for Controlled Substances must be provided in writing and signed by
an authorised person. The orders must be accompanied with the original import permit and/or possession
permit.
Pharmaceutical reference substances
4 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Use, safety and handling
Please read any documents supplied with the product before opening or using it. Particular attention must be
paid to instructions referring to pre-mixing, addition of diluent to lyophilised materials and to the minimum
size of sample to be used.
The latter point is particularly important as it has normally been set by the producer after considering fully the
homogeneity testing data obtained as a part of the certification exercise. The use of smaller than
recommended samples is one of the most common sources of error.
Some pharmaceutical substances are toxic and require special handling. Virtually all pharmaceutical
reference substances have a pharmacological and/or biological activity. We therefore recommend that all the
products described in this catalogue should be handled as if they were bio-active, toxic or infective, and that
opened packs should only be handled by trained laboratory personnel. We also strongly recommend to read
the information provided by material safety data sheets coming with our impurity reference standards and the
reference standards from major pharmacopoeias.
All pharmaceutical reference substances and standards are for laboratory anal ytical use onl y and not
for use in humans.
General ordering information
Prices and delivery procedures are described in the price list that accompanies this catalogue, or are
available from your local LGC Standards office. For products requiring special delivery procedures (cooled
shipping, special licensing, Controlled Substances) additional charges may be applied.
Please note that once delivered to the customer, reference substances are not returnable.
Customers requiring assistance with the purchase, use or application of a particular reference substance
should contact LGC Standards where technical staff are available to advise on the use and suitability of the
products.
Pharmaceutical
impurities
Ne w di vi de r s . qxp: La yout 1 21/ 3/ 11 14: 19 Pa ge 11
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 7
Pharmaceutical impurities
Background
The pharmacopeial monographs regulate the legal definition but also the analysis and the limits of impurities
in a given substance. Impurities in a pharmaceutical substance can change the effects and side effects of a
drug significantly. It is therefore important to have an accurate detection of impurities.
The increasing importance of impurity reference materials is also becoming apparent in the registration of
drugs, where an exact identification and quantification of susceptible impurities is required for an assured
documentation.
A wide range of known impurities is listed in individual pharmacopeial monographs. However, by far not all of
these standards are available from the pharmcopoeias. The impurity standards listed below from LGC are
filling this gap to a large extent.
Guidelines and limits for impurities have been laid out in compendial monographs, in specifications from the
manufacturer internally or in the International Conference on Harmonisation (ICH) Guidelines which have
been agreed by Europe, Japan and the United States. The ICH conducted three guidelines on impurity
issues:
ICH Q3A (R1): Impurities in New Drug Substances
ICH Q3B (R2): Impurities in New Drug Products
ICH Q3C (R5): Impurity Guidelines for Residual Solvents.
The full wording of the ICH guidelines is available at the official website of the ICH: www.ich.org.
The ICH guidelines on impurities were originally developed for new, original drug substances and products.
However, it is now commonly agreed in the three ICH regions by FDA, EMA and Japanese regulation
documents that these guidelines need to be applied to generic compounds as well, in addition to the
pharmacopoeial monographs.
If you want to hear more about the background on impurity testing, please contact your local LGC Standards
office and refer to our recently launched campaign Our 7 truths of impurities and their reference
standards for further valuable information on the subject.
About LGC
The pharmaceutical impurities listed in this section are produced by LGC, whose Research & Technology
Division acts as the designated UK National Measurement Institute for Chemical and Biochemical
Measurements.
LGC is an independent, science-based service company providing chemical, biochemical and DNA based
analytical and diagnostic services, and reference standards. As Europe's largest, independent analytical
laboratory, LGC's services include analytical testing, research, consultancy, validation, training and
knowledge transfer.
LGC Standards, a division of LGC, provides the most comprehensive source of certified reference materials
and standards, pharmaceutical reference substances and impurities, biomaterials, cell lines and high purity
solvents to the scientific community worldwide.
LGC Standards has successfully established a global reputation for the production of impurities and working
standards, and as a single source for the supply of pharmacopeia reference materials. Our menu of custom
services, including custom synthesis of impurities and metabolites, characterisation, certification, packaging
and distribution, adds value to the scientific support we provide to our pharmaceutical customers.
For more information about these services, please contact your local LGC Standards office.
Pharmaceutical impurities
8 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Certification
Each product is accompanied by a detailed certificate of analysis, which gives information on the identity and
purity, together with the various analytical methods and their conditions. A sample of such a certificate is
printed on the following pages.
In the past, we received some inquiries from a few customers wondering why there is no declaration on the
certificates of analysis (CofA) for LGC products stating that the substances are fulfilling the specifications for
reagents, as described for example in chapter 4 of the European Pharmacopeia.
The LGC impurity standards are thoroughly tested chemical reference substances and are used for reliable
identification and quantification of impurities in pharmaceutical ingredients and products. They are also
valuable tools for spiking experiments during validation studies of specificity and accuracy of analytical
methods.
The abbreviations EP, Pharmeuropa, BP and USP in the article description are indicating that the particular
substance is mentioned as an impurity in that particular compendial publication. They do not indicate that
certain specification of reagents or drug substances mentioned in the publications are fulfilled. The standards
where they are actually listed as reagents or drug substances may fulfill this specification, but this is not
the intention and is not certified on the CofA.
The production of our 2700+ LGC impurities reference standards follows the principles of ISO Guide 34
"General requirements for the competence of reference materials producers". This applies to new products
and new batches of already existing products. In combination with ISO 17025, the ISO Guide 34 principles
provide the best approach to the production of reference materials.
Narcotics and drug precursors
Some of the substances described in this section are subject to narcotics respective drug precursors
legislation. These are marked as [Controlled Substance] or [Drug Precursors], respectively. Please
contact your local LGC Standards office for information on the legal requirements in order to purchase these
products.
Delivery time
The majority of products mentioned in this section are available from stock; others may have a delivery time
of approximately four weeks. For substances marked with "on request", longer delivery times may apply. For
custom synthesis, the time is estimated from previous experience. Customers will be notified if unforeseen
complications arise during the synthesis. In the unlikely event that a synthesis does not reach the expected
result, LGC Standards reserves the right to cancel the order.
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 9
Code Product Price Unit
4-Aminobenzoic Acid
MM 0094.00 Imp. B (EP): Benzocaine
H
2
N
O
O
(A) 500 mg
MM 0093.17 Imp. C (EP) as Hydrochloride: Aniline Hydrochloride
H
2
N
x HCl
(B) 100 mg
Acebutolol Hydrochloride
MM 0435.00 Acebutolol Hydrochloride
O
O
OH
H
N
N
H
O
x HCl
(A) 500 mg
MM 0435.01 Imp. A (EP): N-[3-Acetyl-4-[(2RS)-oxiran-
2-ylmethoxy]phenyl]butanamide
O
O
O
N
H
O
(A) 50 mg
MM 0435.02 Imp. B (EP) as Hydrochloride:N-[3-Acetyl-4-[(2RS)-
2-hydroxy-3-[(1-methylethyl)amino]-
propoxy]phenyl]acetamide Hydrochloride
(Diacetolol Hydrochloride)
O
O
OH
H
N
N
H
O x HCl
(A) 100 mg
MM 0435.03 Imp. C (EP): N-(3-Acetyl-4-hydroxyphenyl)butanamide
O
OH
N
H
O
(A) 100 mg
MM 0435.04 Imp. D (EP) as Hydrochloride: 1-[5-Amino-2-
[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]-
propoxy]phenyl]ethanone Dihydrochloride
O
O
OH
H
N
H
2
N
x 2 HCl
(A) 50 mg
MM 0435.05 Imp. E (EP) as Hydrochloride: N-[4-[(2RS)-2-
Hydroxy-3-[(1-methylethyl)amino]propoxy]-
phenyl]butanamide Hydrochloride
O
OH
H
N
N
H
O x HCl
(A) 50 mg
MM 0435.06 Imp. F (EP): N-[3-Acetyl-4-[(2RS)-
2,3-dihydroxypropoxy]phenyl]butanamide
O
O
OH
OH
N
H
O
(A) 50 mg
MM 0435.07 Imp. G (EP): N,N'-[[(1-Methylethyl)imino]-
bis[(2-hydroxypropane-1,3-diyl)oxy(3-acetyl-
1,4-phenylene)]]dibutanamide (Acebutolol
Biamine)
O
O
OH
N
HN
O
OH
O
O
NH
O
(A) 50 mg
MM 0435.08 Imp. H (EP): N,N'-[(2-Hydroxypropane-
1,3-diyl)bis[oxy(3-acetyl-1,4-phenylene)]]di-
butanamide
O
O
OH
O
HN
O
O
NH
O
(A) 50 mg
MM 0435.09 Imp. I (EP): N-[3-Acetyl-4-[(2RS)-3-(ethylamino)-
2-hydroxypropoxy]phenyl]butanamide
O
O
OH
H
N
N
H
O
(A) 50 mg
MM 0435.10 Imp. J (EP) as Hydrochloride: N-[3-Acetyl-4-
[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]-
propoxy]phenyl]propanamide Hydrochloride
O
O
H
N
N
H
O
OH
x HCl
(A) 50 mg
MM 0435.11 Imp. K (EP) as Hydrochloride: N-[3-Butanoyl-
4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]-
propoxy]phenyl]butanamide Hydrochloride
O
O
OH
H
N
N
H
O
x HCl
(A) 50 mg
Pharmaceutical impurities
10 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Aceclofenac
MM 0181.00 Aceclofenac
NH
Cl Cl
O
O
OH
O
(A) 250 mg
MM 0006.20 Imp. A (EP): [2-[(2,6-Dichlorophenyl)amino]phenyl]acetic Acid
(Diclofenac)
NH
Cl Cl
OH
O
(A) 100 mg
MM 0006.10 Imp. B (EP): Methyl [2-[(2,6-Dichlorophenyl)amino]phenyl]acetate
(Methyl Ester of Diclofenac)
NH
Cl Cl
O
O
(A) 100 mg
MM 0006.11 Imp. C (EP): Ethyl 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate
(Ethyl Ester of Diclofenac)
NH
Cl Cl
O
O
(A) 100 mg
MM 0181.01 Imp. D (EP): Methyl [[[2-[(2,6-Dichloro-
phenyl)amino]phenyl]acetyl]oxy]acetate (Methyl Ester of
Aceclofenac) NH
Cl Cl
O
O
O
O
(A) 100 mg
MM 0181.02 Imp. E (EP): Ethyl [[[2-[(2,6-Dichlorophenyl)amino]-
phenyl]acetyl]oxy]acetate (Ethyl Ester of Aceclofenac)
NH
Cl Cl
O
O
O
O
(A) 100 mg
MM 0181.03 Imp. F (EP): ): Benzyl[[[2-[(2,6-Dichlorophenyl)amino]-
phenyl]acetyl]oxy]acetate (Benzyl Ester of Aceclofenac)
NH
Cl Cl
O
O
O
O
(A) 100 mg
MM 0181.04 Imp. G (EP): [[[[[2-[(2,6-Dichlorophenyl)amino]phenyl]-
acetyl]oxy]acetyl]oxy]acetic Acid (Acetic Aceclofenac)
NH
Cl Cl
O
O
O
O
OH
O
(A) 100 mg
MM 0181.05 Imp. H (EP): [[[[[[[2-[(2,6-Dichlorophenyl)-
amino]phenyl]acetyl]oxy]acetyl]oxy]acetyl]-
oxy]acetic Acid (Diacetic Aceclofenac)
NH
Cl Cl
O
O
O
O
O
O
OH
O
(A) 50 mg
MM 0006.01 Imp. I (EP):1-(2,6-Dichlorophenyl)-1,3-dihydro-2H-indol-2-one
Cl Cl
N
O
(A) 100 mg
MM 0181.06 Isopropyl [2-[(2,6-Dichlorophenyl)amino]phenyl]acetate
(Isopropyl Ester of Diclofenac)
NH
Cl Cl
O
O
(A) 100 mg
Acesulfame Potassium
New MM 1093.01 Imp. A (EP): 3-Oxobutanamide (Acetylacetamide)
NH
2
O
O
(A) 100 mg
Acetazolamide
MM 0648.00 Acetazolamide
N N
S S
NH
2
H
N
O
O O
(A) 500 mg
New MM 0648.04 Imp. A (EP): N-(5-Chloro-1,3,4-thiadiazol-2-yl)acetamide
N N
S
Cl
H
N
O
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 11
Code Product Price Unit
New MM 0648.01 Imp. B (EP): N-(1,3,4-Thiadiazol-2-yl)acetamide
N N
S
H
N
O
(A) 50 mg
Acetylcysteine
MM 0024.00 N-Acetyl-L-cysteine
HS OH
O
HN
O
(A) 500 mg
MM 0024.03 Imp. A (EP): L-Cystine
S OH
O
NH2
S HO
O
NH2
(B) 100 mg
MM 0024.02 Imp. B (EP): L-Cysteine
HS OH
O
NH2
(B) 100 mg
MM 0024.04 Imp. C (EP): N,N-Diacetyl-L-cystine
S OH
O
HN
S HO
O
NH
O
O
(A) 100 mg
MM 0024.01 Imp. D (EP): N,S-Diacetyl-L-cysteine
S OH
O
HN
O
O
(A) 100 mg
MM 0024.05 Sodium 2-Methyl-4,5-dihydro-1,3-thiazol-4-carboxylate
N
S
ONa
O
(A) 100 mg
MM 0024.06 N-Propionyl-L-cysteine
HS OH
O
HN
O
(A) 100 mg
Acetylsalicylic Acid
MM 0133.00 Acetylsalicylic Acid
O
HO O
O
(A) 500 mg
MM 0045.01 Imp. A (EP): 4-Hydroxybenzoic Acid
HO
OH
O
(B) 100 mg
MM 0045.02 Imp. B (EP): 4-Hydroxybenzene-1,3-dicarboxylic Acid
(4-Hydroxyisophthalic Acid)
HO
OH
O
OH
O
(A) 100 mg
MM 0045.00 Imp. C (EP): Salicylic Acid
OH
O
OH
(A) 500 mg
MM 0133.01 Imp. D (EP): 2-[[2-(Acetyloxy)benzoyl]oxy]benzoic Acid
(Acetylsalicylsalicylic Acid)
O
O
OH
O
O
O
(A) 100 mg
MM 0133.03 Imp. E (EP):2-[(2-Hydroxybenzoyl)oxy]benzoic Acid
(Salicylsalicylic Acid)
O
O
OH
O
OH
(A) 100 mg
MM 0133.02 Imp. F (EP): 2-(Acetyloxy)benzoic Anhydride
(Acetylsalicylic Anhydride)
O
O
O
O O O
O
(A) 100 mg
Pharmaceutical impurities
12 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0133.04 2-(2,4-Dihydroxybenzoyl)benzoic Acid
OH
O
O
OH
OH
(A) 100 mg
New MM 0133.08 4-Acetoxyisophthalic Acid
O
OH
O
HO
O
O
(A) 50 mg
New MM 0133.09 Acetylsalicylsalicylsalicylic Acid
O
O
O
O
O
O
OH
O
(A) 50 mg
N-Acetyltryptophan
MM 1267.01 Imp. A (EP): Tryptophan
H
N
O
OH
NH
2
(A) 100 mg
MM 0172.03 Imp. D (EP): (S)-2-Amino-3-(5-hydroxy-
1H-indol-3-yl)propanoic Acid (5-Hydroxy-
tryptophan)
H
N
O
OH
NH
2
HO
(A) 100 mg
Aciclovir
MM 0061.00 Aciclovir
N
HN
N
N
O
H2N
O
OH
(A) 500 mg
MM 0061.01 Imp. A (EP): 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-
9-yl)methoxy]ethyl Acetate
N
HN
N
N
O
H
2
N
O
O
O
(A) 100 mg
MM 0061.02 Imp. B (EP): 2-Amino-1,7-dihydro-6H-purin-6-one (Guanine)
N
HN
H
N
N
O
H
2
N
(B) 100 mg
MM 0061.04 2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-
9-yl)methoxy]ethyl Benzoate
N
HN
N
N
O
H
2
N
O
O
O
(A) 100 mg
MM 0061.06 Imp. F (EP): N-[9-[(2-Hydroxyethoxy)methyl]-6-oxo-
6,9-dihydro-1H-purin-2-yl]acetamide
N
HN
N
N
O
N
H
O
OH
O
(A) 100 mg
MM 0061.07 Imp. G (EP): 2-[[(2-(Acetylamino)-6-oxo-1,6-dihydro-9H-purin-
9-yl]methoxy]ethyl Acetate
N
HN
N
N
O
N
H O
O
O
O
(A) 100 mg
MM 0061.08 2-[[2-(Acetylamino)-6-oxo-1,6-dihydro-9H-purin-
9-yl]methoxy]ethyl Benzoate
N
HN
N
N
O
N
H
O
O
O
O
(A) 100 mg
MM 0061.10 2,6-Dichloropurine
N
N
N
N
H
Cl
Cl
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 13
Code Product Price Unit
Adalapene
New MM 0681.03 Imp. A (EP): 2,2'-Binaphthalene-6,6'-dicarboxylic Acid
HO
O
O
OH
(A) 50 mg
New MM 0681.01 Imp. C (EP): 1-(2-Methoxyphenyl)tricyclo-
[3.3.1.1
3,7
]decane
O
(A) 50 mg
Adenosine
MM 0784.00 Adenosine
N
N
N
N
NH
2
O
HO
OH OH
(A) 500 mg
New MM 0784.01 Imp. A (EP) as Sulphate: 7H-Purin-6-amine
Sulphate (Adenine Sulphate)
N
H
N
N
N
NH
2
2
x H
2
SO
4
(A) 100 mg
New MM 0784.02 Imp. F (EP): 1--D-Ribofuranosylpyrimidine-
2,4(1H,3H)-dione (Uridine)
N
O
HO
OHOH
HN
O
O
(A) 100 mg
New MM 0784.03 Imp. G (EP): 9--D-Ribofuranosyl-1,9-dihydro-
6H-purin-6-one (Inosine)
N
N
HN
N
O
O
HO
OHOH
(A) 100 mg
New MM 0784.04 Imp. H (EP): 2-Amino-9--D-ribofuranosyl-
1,9-dihydro-6H-purin-6-one (Guanosine)
N
N
HN
N
O
O
HO
OHOH
H
2
N
(A) 100 mg
Adiphenine Hydrochloride
MM 1172.00 Adiphenine Hydrochloride
O
O
N
x HCl
(A) 250 mg
Adrenaline Tartrate
MM 0614.00 Adrenaline Tartrate
OH
HO
OH
H
N
HO
OH
OH
OH
O
O
x
(A) 500 mg
MM 0614.02 L-Adrenaline
OH
HO
OH
H
N
(A) 500 mg
MM 0614.13 Imp. C (EP) as Hydrochloride: 1-(3,4-Di-
hydroxyphenyl)-2-(methylamino)ethanone
Hydrochloride (Adrenalone Hydrochloride)
HO
O
H
N HO
x HCl
(A) 100 mg
MM 0614.01 (1R)-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanesulphonic Acid
(Adrenaline -Sulphonate)
OH
HO
H
N
SO
3
H
(A) 100 mg
Pharmaceutical impurities
14 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Alanine
MM 0566.00 Alanine
OH
O
NH2
(A) 500 mg
Albendazole
MM 0382.00 Albendazole
N
H
N
S
NH
O
O
(A) 500 mg
MM 0382.01 Imp. A (EP): 5-(Propylsulphanyl)-1H-benzimidazol-2-amine
N
H
N
S
NH
2
(A) 100 mg
MM 0382.02 Imp. B (EP): Methyl [5-Propylsulphinyl)-1H-benzimidazol-
2-yl]carbamate
N
H
N
S
NH
O
O
O
(A) 100 mg
MM 0382.03 Imp. C (EP): Methyl [5-Propylsulphonyl)-1H-benzimidazol-
2-yl]carbamate
N
H
N
S
NH
O
O
O O
(A) 100 mg
MM 0382.04 Imp. D (EP): 5-(Propylsulphonyl)-1H-benzimidazol-2-amine
N
H
N
S
NH
2
O O
(A) 100 mg
MM 2500.00 Imp. E (EP): Methyl (1H-Benzimidazol-2-yl)carbamate
(Carbendazim)
N
H
N
NH
O
O
(A) 100 mg
Alfuzosin Hydrochloride
MM 0085.04 Imp. B (EP): 2-Chloro-6,7-dimethoxyquinazolin-4-amine
N
N O
O
NH
2
Cl
(A) 100 mg
New MM 1004.04 Imp. D (EP) as Dihydrochloride:
N-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-
N-methylpropane-1,3-diamine Dihydrochloride
N
N O
O
NH
2
N NH
2
x 2 HCl
(A) 50 mg
Allobarbital
MM 0899.00 Allobarbital [Controlled Substance]
NH
H
N O O
O
(A) 100 mg
Allopurinol
MM 0034.00 Allopurinol
NH
N
N
H
N
O
(A) 500 mg
MM 0034.01 Imp. A (EP) as Hemisulphate: 5-Amino-1H-pyrazole-
4-carboxamide Hemisulphate
NH
2
NH
2
N
H
N
O
x
1
/
2
H
2
SO
4
(A) 100 mg
MM 0034.05 Imp. D (EP): Ethyl 5-Amino1H-pyrazole-4-carboxylate
O
NH2
N
H
N
O
(A) 100 mg
MM 0034.06 Imp. E (EP): Ethyl 5-(Formylamino)-1H-pyrazole-4-carboxylate
O
N
H
N
H
N
O
O
(A) 100 mg
MM 0034.07 Oxypurinol
N
H
NH
N
N
H
O
O
(A) 100 mg
Alprazolam
MM 0028.03 Imp. E (EP): (2-Amino-5-chlorophenyl)phenylmethanone
O
Cl
NH
2
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 15
Code Product Price Unit
Alverine Citrate
MM 0454.00 Alverine Citrate
N
OH
O
OH
O
OH
O
OH
x
(A) 250 mg
MM 0454.02 Imp. A (EP): 1-Chloro-3-phenyl-propane
Cl
(A) 100 mg
MM 0454.03 Imp. B (EP): 3-Phenylpropan-1-ol
OH
(A) 100 mg
MM 0454.04 Imp. C (EP) as Hydrochloride: N-Ethyl-
3-phenylpropan-1-amine Hydrochloride
NH
x HCl
(A) 100 mg
MM 0454.05 Imp. D (EP) as Hydrochloride: N-(3-
Cyclohexylpropyl)-N-ethyl-3-phenyl-
propan-1-amine Hydrochloride
N
x HCl
(A) 100 mg
MM 0454.06 Imp. E (EP) as Hydrochloride: 3-Phenyl-
N,N-bis(3-phenylpropyl)propan-1-amine
Hydrochloride
N
x HCl
(A) 100 mg
Amantadine Hydrochloride
MM 0564.00 Amantadine Hydrochloride
NH
2
x HCl
(A) 500 mg
Ambroxol Hydrochloride
MM 0005.00 Ambroxol Hydrochloride
x HCl
Br
NH
2
Br
N
H
OH
(A) 500 mg
MM 0005.01 Imp. A (EP): (2-Amino-3,5-dibromophenyl)methanol
Br
NH
2
Br
OH
(A) 100 mg
MM 0005.04 Imp. B (EP) as Hydrochloride: trans-4-(6,8-Dibromo-
1,4-dihydroquinazolin-3(2H)-yl)cyclohexanol Hydrochloride
x HCl
Br
N
H
Br
N
OH
(A) 100 mg
MM 0005.03 Imp. C (EP): trans-4-[[(E)-2-Amino-
3,5-dibromobenzyliden]amino]cyclohexanol
Br
NH2
Br
N
OH
(A) 100 mg
MM 0005.05 Imp. D (EP) as Hydrochloride: cis-4-[(2-Amino-
3,5-dibromobenzyl)amino]cyclohexanol Hydrochloride
x HCl
Br
NH
2
Br
N
H
OH
(A) 100 mg
MM 0005.02 Imp. E (EP): 2-Amino-3,5-dibromobenzaldehyde
Br
NH
2
Br
O
(A) 100 mg
MM 0005.06 trans-4-Aminocyclohexanol Hydrochloride
x HCl
H2N
OH
(A) 100 mg
MM 0005.07 cis-4-Aminocyclohexanol Hydrochloride
x HCl
H2N
OH
(A) 100 mg
Amiloride Hydrochloride
MM 0560.00 Amiloride Hydrochloride Dihydrate
N
N Cl
NH2 H2N
N
H
O
NH
2
NH
x HCl
x 2 H
2
O
(A) 500 mg
Aminocaproic Acid
MM 0896.00 Aminocaproic Acid
H
2
N
OH
O
(A) 500 mg
Pharmaceutical impurities
16 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Amiodarone Hydrochloride
MM 0697.00 Amiodarone Hydrochloride
O
O
I
I
O
N
x HCl
(A) 250 mg
MM 0697.11 Imp. A (EP) as Oxalate:
(2-Butylbenzofuran-3-yl)-
[4-[2-(diethylamino)ethoxy]-
phenyl]methanone Oxalate
O
O
O
N
HO O
O HO
x
(A) 100 mg
MM 0697.03 Imp. B (EP) as Hydrochloride:
(2-Butylbenzofuran-
3-yl)[4-[2-(ethylamino)ethoxy]-3,5-
diiodophenyl]methanone Hydrochloride
(Desethylamiodarone Hydrochloride)
O
O
I
I
O
H
N
x HCl
(D) 100 mg
MM 0697.04 Imp. C (EP) as Hydrochloride:
(2-Butylbenzofuran-
3-yl)[4-[2-(diethylamino)ethoxy]-
3-iodophenyl]methanone Hydrochloride
O
O
I
O
N
x HCl
(A) 100 mg
MM 0697.05
Imp. D (EP): (2-Butylbenzofuran-3-yl)(4-hydroxy-
3,5-diiodophenyl)methanone
O
O
I
I
OH
(A) 100 mg
MM 0697.06
Imp. E (EP): (2-Butylbenzofuran-
3-yl)(4-hydroxyphenyl)methanone
O
O
OH
(A) 100 mg
MM 0697.07
Imp. F (EP): (2-Butylbenzofuran-3-yl)(4-hydroxy-
3-iodophenyl)methanone
O
O
I
OH
(A) 100 mg
MM 0697.09 Imp. H (EP) as Hydrochloride: 2-Chloro-N,N-diethylethanamine
Hydrochloride (2-Chlorotriethylamine Hydrochloride;
(2-Chloroethyl)diethylamine Hydrochloride)
Cl
N
x HCl
(C) 100 mg
MM 0697.10 Amiodarone N-Oxide Hydrochloride
O
O
I
I
O
N
x HCl O
(A) 100 mg
Amisulpride
MM 0051.01 Imp. A (EP): [(2RS)-1-Ethylpyrrolidin-2-yl]methanamine H
2
N
N
(A) 100 mg
New MM 0793.03 Imp. C (EP): 4-Amino-N-[[(2RS)-1-ethyl-pyrrolidin-
2-yl]methyl]-5-iodo-2-methoxy-benzamide
I
H
2
N O
N
H
O
N
(A) 50 mg
New MM 0793.04 Imp. D (EP): 4-Amino-N-[[(2RS)-1-ethyl-pyrrolidin-2-yl]methyl]-
2-methoxy-5-(methylsulphonyl)benzamide
S
O O
H
2
N O
N
H
O
N
(A) 50 mg
New MM 0793.05 Imp. E (EP): 4-Amino-5-(ethylsulphonyl)-
2-methoxybenzoic Acid
S
O O
H
2
N O
OH
O
(A) 100 mg
Amitraz
MM 1018.01 Imp. A (BP): 2,4-Dimethylaniline
(2,4-Xylidine)
NH
2
(A) 100 mg
MM 1018.02 Imp. B (BP): Form-2',4'-xylidide
H
N O (A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 17
Code Product Price Unit
Amitriptyline Hydrochloride
MM 0062.00 Amitriptyline Hydrochloride
N
x HCl
(A) 500 mg
MM 0062.01 Imp. A (EP): 10,11-Dihydro-5H-dibenzo-
[a,d][7]annulen-5-one (Dibenzosuberone) O
(B) 100 mg
MM 0062.02 Imp. B (EP) as Hydrochloride: 3-(5H-Dibenzo[a,d][7]annulen-
5-ylidene)-N,N-dimethylpropan-1-amine Hydrochloride
(Cyclobenzaprine Hydrochloride)
N
x HCl
(A) 100 mg
MM 0079.00 Imp. C (EP) as Hydrochloride: 3-(10,11-Dihydro-5H-
dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine
Hydrochloride (Nortriptyline Hydrochloride)
N
H
x HCl
(A) 500 mg
MM 0062.03 Imp. D (EP): 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-
dibenzo[a,d][7]annulen-5-ol
OH
N
(A) 100 mg
MM 0062.05 Imp. F (EP): (5EZ,10RS)-5-[3-(Dimethyl-amino)propylidene]-
10,11-dihydro-5H-dibenzo[a,d][7]annulen-10-ol
HO
N
(A) 100 mg
MM 0062.14 Imp. G (EP): 10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ol
(Dibenzosuberol) OH
(A) 100 mg
MM 0062.12 Amitriptyline N-Oxide Hydrochloride
N
x HCl
O
(B) 10 mg
MM 0062.13 10,11-Dihydro-5H-dibenzo[a,d]cycloheptene (Dibenzosuberane) (A) 100 mg
Amlodipine Besilate
MM 0383.00 Amlodipine Besilate
H
N
O
O
O
O
O
NH
2
Cl
S O
O
OH
x
(D) 100 mg
MM 0383.06 Amlodipine
H
N
O
O
O
O
O
NH2
Cl
(A) 100 mg
MM 0383.01 Imp. A (EP): 3-Ethyl-5-Methyl (4RS)-4-(2-Chlorophenyl)-
2-[[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]methyl]-
6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
O
O
O
Cl
N
O
O
(D) 100 mg
Pharmaceutical impurities
18 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0383.02 Imp. B (EP): 3-Ethyl 5-Methyl (4RS)-
4-(2-Chlorophenyl)-6-methyl-
2-[[2-[[2-(methylcarbamoyl)benzoyl]amino]-
ethoxy]methyl]-1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
O
O
O
H
N
Cl
O
N
H
O
(D) 100 mg
MM 0383.03 Ethyl Methyl (4RS)-2,6-Bis[(2-aminoethoxy)methyl]-
4-(2-chlorophenyl)-1,4-dihydropyridine-
3,5-dicarboxylate Dihydrochloride
H
N
O
O
O
O
O
NH
2
Cl
O
H
2
N
x 2 HCl
(D) 100 mg
MM 0383.04 Imp. D (EP): 3-Ethyl-5-Methyl 2-[(2-Aminoethoxy)methyl]-
4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate
N
O
O
O
O
O
NH2
Cl
(D) 100 mg
MM 0383.10 Imp. E (EP): Diethyl (4RS)-2-[(2-Amino-
ethoxy)methyl]-4-(2-chlorophenyl)-6-
methyl-1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
O
O
O
NH
2
Cl
on request
New MM 0383.09 Imp. F (EP): Dimethyl (4RS)-2-[(2-Amino-
ethoxy)methyl]-4-(2-chlorophenyl)-6-
methyl-1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
O
O
O
NH
2
Cl
(D) 100 mg
MM 0383.07 Imp. G (EP): Dimethyl 4-(2-Chlorophenyl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
O
O
Cl
(A) 100 mg
MM 0383.11 Imp. H (EP): 2-[[2-[[(4RS)-4-(2-Chlorophenyl)-
3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-
methyl-1,4-dihydropyridin-2-yl]methoxy]ethyl]-
carbamoyl]benzoic Acid
H
N
O
O
O
O
O
H
N
Cl
O
OH O
(D) 100 mg
MM 0383.05 Benzenesulfonic Acid
S O
O
OH
(B) 100 mg
Amlodipine Maleate
MM 0631.00 Amlodipine Maleate
H
N
O
O
O
O
O
NH
2
Cl
O
OH
O
OH
x
(D) 100 mg
Amlodipine Mesilate
MM 0592.00 Amlodipine Mesilate
H
N
O
O
O
O
O
NH
2
Cl
S
HO
x
O O
(D) 100 mg
Amodiaquine Dihydrochloride Dihydrate
MM 0617.00 Amodiaquine Dihydrochloride Dihydrate
N Cl
HN
OH
N x 2 HCl
x 2 H
2
O
(A) 500 mg
MM 0617.01 4-Acetamido-2-diethylaminomethylphenol
OH
N
O
H
N
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 19
Code Product Price Unit
MM 0617.02 7-Chloro-4-(4-hydroxyphenylamino)quinoline
N Cl
HN
OH
(A) 100 mg
MM0617.03 4,7-Dichloroquinoline
N Cl
Cl
(C) 100 mg
MM 0617.04 Monodesethylamodiaquine Dihydrochloride
N Cl
HN
OH
HN
x 2 HCl
(A) 100 mg
Amoxicillin Trihydrate
MM 0232.00 Amoxicillin Trihydrate
N
S
OH
O
H
O
H
N
HO
NH
2
O
x 3 H
2
O
(A) 500 mg
MM 0026.04 Imp. A (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid
(6-Aminopenicillanic Acid)
N
S
OH
O
H
O
H
2
N
(B) 100 mg
New MM 0232.02 Imp. B (EP): (2S,5R,6R)-6-[[(2S)-2-Amino-2-
(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-
2-carboxylic Acid (L-Amoxicillin)
N
S
OH
O
H
O
H
N
HO
NH
2
O
(D) 100 mg
MM 0232.03 Imp. C (EP): (4S)-2-[5-(4-Hydroxyphenyl)-
3,6-dioxopiperazin-2-yl]-5,5-dimethyl-thiazolidine-
4-carboxylic Acid (Amoxicillin Diketopiperazines) H
N
S
HN
OH
O
N
H
HO
O
O
(A) 100 mg
MM 0232.04 Imp. D (EP) as Sodium Salt:(4S)-2-[[[(2R)-2-Amino-
2-(4-hydroxyphenyl)acetyl]amino]carboxymethyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid Sodium Salt
(Penicilloic Acids of Amoxicillin Sodium Salt)
H
N
HO
NH
2
O
S
HN
ONa
O
O HO
(A) 100 mg
MM 0232.05 Imp. E (EP): (2RS,4S)-2-[[[(2R)-2-Amino-
2-(4-hydroxyphenyl)acetyl]amino]methyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid
(Penilloic Acids of Amoxicillin)
H
N
HO
NH
2
O
S
HN
O
OH (A) 50 mg
MM 0232.06 Imp. F (EP): 3-(4-Hydroxyphenyl)pyrazin-2-ol
N
N
HO
HO
(A) 100 mg
MM 0232.08 Imp. H (EP): (2R)-2-[(2,2-Dimethylpropanoyl)amino]-2-
(4-hydroxyphenyl)acetic Acid
HO
NH
O
O
OH
(A) 100 mg
MM 0232.09 Imp. I (EP): (2R)-2-Amino-2-(4-hydroxyphenyl)acetic Acid
HO
NH
2
OH
O
(B) 100 mg
MM 0232.12 (2R)-2-Amino-2-(4-hydroxyphenyl)acetamide
HO
NH2
NH2
O
(A) 100 mg
Ampicillin Sodium
MM 0253.00 Ampicillin Sodium
N
S
ONa
O
H
O
H
N
NH
2
O
(A) 500 mg
Pharmaceutical impurities
20 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0253.15 Ampicillin Trihydrate
N
S
O
OH
H
O
H
N
NH
2
O
x 3 H
2
O
(A) 500 mg
MM 0026.04 Imp. A (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid (6-Aminopenicillanic
Acid)
N
S
OH
O
H
O
H
2
N
(B) 100 mg
MM 0253.02 Imp. B (EP): (2S,5R,6R)-6-[[(2S)-2-Amino-
2-phenylacetyl]amino]-3,3-
dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic
Acid
(L-Ampicillin)
N
S
O
OH
H
O
H
N
NH
2
O
(A) 100 mg
MM 0253.03 Imp. C (EP): (4S)-2-(3,6-Dioxo-5-phenylpiperazin-2-yl)-
5,5-dimethylthiazolidine-4-carboxylic Acid (Diketopiperazines of
Ampicillin) H
N
S
HN
O
OH
N
H
O
O
(A) 100 mg
MM 0253.04 Imp. D (EP) as Sodium Salt: (4S)-2-[[[(2R)-2-Amino-
2-phenylacetyl]amino]carboxymethyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid Sodium Salt
(Penicilloic Acids of Ampicillin Sodium Salt)
H
N
NH
2
O
S
HN
ONa
O
O HO
(A) 100 mg
MM 0253.06 Imp. F (EP): (2RS,4S)-2-[[[(2R)-2-Amino-
2-phenylacetyl]amino]methyl]-5,5-dimethyl-thiazolidine-
4-carboxylic Acid (Penilloic Acids of Ampicillin) H
N
NH
2
O
S
HN
O
OH (A) 100 mg
MM 0253.08 Imp. H (EP): 3-Phenylpyrazin-2-ol
N
N HO
(A) 100 mg
MM 0253.11 Imp. K (EP): (2R)-2-[(2,2-Dimethylpropanoyl)amino]-2-phenylacetic
Acid
O
OH
NH
O
(A) 100 mg
MM 0253.12 Imp. L (EP): (2R)-2-Amino-2-phenylacetic Acid
(D-Phenylglycine)
O
OH
NH
2
(B) 100 mg
MM 0253.16 Ampicillin, anhydrous
N
S
O
OH
H
O
H
N
NH
2
O
(A) 500 mg
Androstanolone
MM 0565.00 Androstanolone
O
OH
(A) 250 mg
Anise Oil
MM 0164.01 trans-Anethole
O
(C) 100 mg
MM 0164.02 Estragole
O
(C) 100 mg
MM 0164.03 Anisaldehyde
O
O (C) 100 mg
MM 0164.05 Linalol
HO
(C) 100 mg
MM 0164.06 cis-Anethole
O
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 21
Code Product Price Unit
Antazoline Hydrochloride
MM 0171.00 Antazoline Hydrochloride
N
N
H
N
x HCl
(A) 500 mg
MM 0171.01 Imp. A (EP) as Dihydrochloride: N-(2-Aminoethyl)-
2-(benzylphenylamino)acetamide Dihydrochloride
N
N
H
O
NH
2
x 2 HCl
(A) 100 mg
MM 0171.04 Imp. B (Pharmeuropa) as Hydrochloride: 2-(Chloro-
methyl)-4,5-dihydro-1H-imidazole Hydrochloride
Cl
N
H
N
x HCl
(A) 100 mg
MM 0171.03 N-Benzylaniline NH (B) 100 mg
Antazoline Phosphate
MM 0561.00 Antazoline Phosphate
N
N
H
N
x H
3
PO
4
(A) 500 mg
Apomorphine Hydrochloride
MM 0562.00 Apomorphine Hydrochloride Hemihydrate
N
OH
HO
H
x HCl
x H2O
(A) 250 mg
MM 0037.00 Imp. B (EP) as Hydrochloride Trihydrate: Morphine
Hydrochloride Trihydrate
[Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
Aprindine Hydrochloride
MM 0467.00 Aprindine Hydrochloride
N
N
HCl
on request
Arginine
MM 0568.00 Arginine
OH
O
H
N H
2
N
NH
NH2
(A) 500 mg
Arginine Hydrochloride
MM 0569.00 Arginine Hydrochloride
OH
O
H
N H
2
N
NH
NH2
x HCl
(A) 500 mg
Articaine Hydrochloride
MM 0369.00 Articaine Hydrochloride
H
N
N
H S
O
O
O
x HCl
(A) 100 mg
MM 0369.01 Imp. A (EP) as Hydrochloride: Methyl
3-[[2-(Propylamino)acetyl]amino]-4-methylthiophene-
2-carboxylate Hydrochloride
(Acetamidoarticaine Hydrochloride)
x HCl
H
N
N
H
S
O
O
O
(A) 100 mg
MM 0369.02 Imp. B (EP) as Hydrochloride: 4-Methyl-3-[[(2RS)-
2-(propylamino)propanoyl]amino]thiophene-2-carboxylic
Acid Hydrochloride (Articaine Acid Hydrochloride)
x HCl
H
N
N
H
S
O
HO
O
(A) 50 mg
MM 0369.03 Imp. C (EP) as Hydrochloride: 1-Methylethyl 4-Methyl-
3-[[(2RS)-2-(propylamino)propanoyl]amino]thiophene-
2-carboxylate Hydrochloride (Articaine Isopropyl Ester
Hydrochloride)
x HCl
H
N
N
H
S
O
O
O
(A) 100 mg
MM 0369.04 Imp. D (EP) as Hydrochloride: Methyl 3-[[(2RS)-
2-(Ethylamino)propanoyl]amino]-4-methylthiophene-
2-carboxylate Hydrochloride (Ethylarticaine Hydrochloride)
x HCl
H
N
N
H
S
O
O
O
(B) 10 mg
Pharmaceutical impurities
22 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0369.05 Imp. E (EP) as Hydrochloride: Methyl 4-Methyl-3-[[(2RS)-
2-[(1-methylethyl)amino]propanoyl]amino]thiophene-
2-carboxylate Hydrochloride (Isopropylarticaine
Hydrochloride)
x HCl
H
N
N
H
S
O
O
O
(A) 100 mg
MM 0369.06 Imp. F (EP) as Hydrochloride: 4-Methyl-N-propyl-
3-[[(2RS)-2-(propylamino)propanoyl]amino]thiophene-
2-carboxamide Hydrochloride (Articaine Acid
Propionamide Hydrochloride)
x HCl
H
N
N
H
S
O
H
N
O
(A) 50 mg
MM 0369.07 Imp. G (EP) as Hydrochloride: Methyl 3-[[(2RS)-
2-(Butylamino)propanoyl]amino]-4-methylthiophene-
2-carboxylate Hydrochloride (Butylarticaine Hydrochloride)
x HCl
H
N
N
H
S
O
O
O
(A) 100 mg
MM 0369.08 Imp. H (EP) as Hydrochloride: Methyl 3-[[(2RS)-
2-(Dipropylamino)propanoyl]amino]-4-methylthiophene-
2-carboxylate Hydrochloride (Dipropylarticaine
Hydrochloride)
x HCl
H
N
N
S
O
O
O
(A) 100 mg
MM 0369.09 Imp. I (EP): Methyl 3-Amino-4-methylthiophene-2-carboxylate
(3-Aminoarticaine)
S
NH
2
O
O
(C) 100 mg
MM 0369.10 Imp. J (EP): Methyl 3-[[(2RS)-2-Bromopropanoyl]amino]-
4-methylthiophene-2-carboxylate (Bromo Compound)
H
N
Br
S
O
O
O
(B) 10 mg
Ascorbic Acid
MM 0166.00 L-Ascorbic Acid
O
HO
OH
OH HO
O
(A) 500 mg
Asparagine Monohydrate
MM 0765.01 Phenylacetylasparagine
O
H
2
N
OH
O
HN
O (C) 50 mg
Aspartame
MM 0314.00 Aspartame H
N
O
O
O
NH
2
HO
O
(A) 500 mg
MM 0314.01 Imp. A (EP): 2-(5-Benzyl-3,6-dioxopiperazin-2-yl)acetic Acid
(Diketopiperazine)
NH
O
HN
HO
O
O
(A) 100 mg
MM 0314.02 Imp. B (EP): L-Aspartyl-L-phenylalanine H
N
OH
O
O
NH
2
HO
O
(A) 100 mg
MM 0314.03 Imp. C (EP): Phenylalanine
H
2
N
OH
O
(B) 100 mg
Aspartic Acid
MM 0567.00 Aspartic Acid
OH
O
HO
NH2 O
(A) 500 mg
New MM 0460.10 Imp. B (Pharmeuropa): (E)-Butenedioic Acid
(Fumaric Acid) OH
O
HO
O
(B) 100 mg
New MM 0566.00 Imp. D (Pharmeuropa): (S)-2-Aminopropanoic
Acid (Alanine)
OH
O
NH
2
(A) 500 mg
New MM 0169.00 Imp. F (Pharmeuropa): (2S)-2,5-Diamino-5-
oxopentanoic Acid (L-Glutamine)
OH
O
NH
2
H
2
N
O
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 23
Code Product Price Unit
Astemizole
MM 0184.00 Astemizole
N
N
HN
N
O
F
(A) 250 mg
MM 0184.13 Desmethyl Astemizole Hydrochloride
N
N
HN
N
OH
F
x HCl
(B) 10 mg
Atenolol
MM 0013.00 Atenolol
H2N
O
O
OH
H
N
(A) 500 mg
MM 0013.03 Imp. A (EP): 2-(4-Hydroxyphenyl)acetamide
H2N
O
OH
(B) 100 mg
MM 0013.05 Imp. B (EP): 2-[4-[(2RS)-
2,3-Dihydroxypropoxy)phenyl]acetamide
H2N
O
O
OH
OH
(A) 100 mg
MM 0013.01 2-[4-[[(2RS)-Oxiran-2-yl]methoxy]phenyl]acetamide
H2N
O
O
O
(A) 100 mg
MM 0013.06 Imp. D (EP): 2-[4-[(2RS)-3-Chloro-
2-hydroxypropoxy]phenyl]acetamide
H2N
O
O
OH
Cl
(A) 50 mg
MM 0013.07 Imp. E (EP): 2,2'-[(2-Hydroxypropane-1,3-
diyl)bis(oxy-4,1-phenylene)]diacetamide
H2N
O
O
NH2
O
O
OH
(A) 50 mg
MM 0013.02
Imp. F (EP): 2,2'-[[(1-Methylethyl)-
imino]bis[(2-hydroxypropane-3,1-
diyl)oxy-4,1-phenylene]]diacetamide
H2N
O
O
OH
N
NH2
O
O
OH (A) 50 mg
MM 0013.04 Imp. G (EP): 2-[4-[(2RS)-2-Hydroxy-
3-[(1-methylethyl)amino]propoxy]phenyl]acetic Acid
HO
O
O
OH
H
N
(A) 50 mg
MM 0013.08 Imp. H (EP): 2-[4-[(2RS)-2-Hydroxy-
3-[(1-methylethyl)amino]propoxy]phenyl]acetonitrile
O
OH
H
N
N
(A) 100 mg
New MM 0013.17 Imp. I (EP): 2-[4-[(2RS)-3-(Ethylamino)-2-
hydroxypropoxy]phenyl]acetamide
H
2
N
O
O
OH
H
N
(A) 50 mg
MM 0013.13 4-Hydroxyphenylacetic Acid
HO
O
OH
(B) 100 mg
Atorvastatin Calcium
MM 0400.00 Atorvastatin Calcium
N
F
N
H
O
O
O OH
OH
-
2
Ca
2+
(D) 100 mg
MM 0400.12 Imp. G (EP) as Calcium Salt: (3R,5R)-7-[2-(4-
Fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-
(phenylcarbamoyl)-1H-pyrrol-1-yl]-5-hydroxy-
3-methoxyheptanoic Acid Calcium Salt
(3-O-Methylatorvastatin Calcium Salt)
N
F
N
H
O
O
O OH
O
-
2
Ca
2+
(D) 100 mg
Pharmaceutical impurities
24 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0400.16 Imp. G (EP) as Lithium Salt: (3R,5R)-7-[2-(4-
Fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-
(phenylcarbamoyl)-1H-pyrrol-1-yl]-5-hydroxy-
3-methoxyheptanoic Acid Lithium Salt
(3-O-Methylatorvastatin Lithium Salt)
N
F
N
H
O
O
OLi OH
O
(D) 100 mg
MM 0400.01 Imp. H (EP): (4R,6R)-6-[2-[2-(4-Fluorophenyl)-
5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-
1H-pyrrol-1-yl]ethyl]-4-hydroxytetrahydro-2H-
pyran-2-one (Atorvastatin Lactone)
N
F
N
H
O O
OH
O
(D) 100 mg
MM 0400.04 1,1-Dimethylethyl (4R-cis)-
6-[2-[2-(4-Fluorophenyl)-5-(1-methylethyl)-
3-phenyl-4-[(phenylamino)carbonyl]-1-H-pyrrol-
1-yl]ethyl]-2,2-dimethyl-1,3-dioxane-4-acetate
N N
H
O O O O
F
O
(A) 100 mg
MM 0400.05 1,1-Dimethylethyl (4R-cis)-6-Aminoethyl-2,2-dimethyl-
1,3-dioxane-4-acetate
O
O
O O
H
2
N
(A) 100 mg
MM 0400.13 1-[2-[(2S)-3,6-Dihydro-6-oxo-2H-pyran-2-yl]-ethyl]-
5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-
pyrrole-3-carboxamide (Atorvastatin eliminated Lactone)
N
F
N
H
O O
O
(A) 100 mg
Atracurium Besilate
MM 0858.13 Imp. J (EP): Methyl Benzenesulphonate
S
O
O O
(A) 100 mg
Atropine
MM 0289.18 Atropine
O
O
N
OH
H
H
H
and enantiomer
(A) 250 mg
MM 0289.00 Atropine Sulphate
O
O
N
OH
H
2
and enantiomer
x H
2
SO
4
x H
2
O
H
H
(A) 500 mg
MM 0289.01 Imp. A (EP) as Hydrochloride: (1R,3r,5S)-8-Methyl-
8-azabicyclo[3.2.1]oct-3-yl 2-Phenylpropenoate
Hydrochloride
(Apoatropine Hydrochloride)
O
O
N
H
x HCl
H
H
(D) 100 mg
MM 0601.03 Imp. C (EP): (2RS)-3-Hydroxy-2-phenylpropanoic Acid (Tropic Acid)
OH
OH
O (A) 100 mg
MM 0546.00 Imp. F (EP) as Hydrobromide Trihydrate: Hyoscine
Hydrobromide Trihydrate
O
N
OH
H
H
H
O
H
H
x HBr
x 3 H
2
O
O
(A) 500 mg
MM 0289.03 Atropic Acid
OH
O (A) 100 mg
Avobenzone
MM 0902.00 Avobenzone
O O
O
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 25
Code Product Price Unit
Azelaic Acid
MM 0687.00 Azelaic Acid
HO OH
O O
(A) 500 mg
Azelastine Hydrochloride
MM 0362.00 Azelastine Hydrochloride
N
N
O
N
Cl
x HCl
(A) 100 mg
MM 0362.04 Imp. A (EP): Benzoyldiazane (Benzohydrazide)
NH
O
NH
2
(C) 100 mg
New MM 0362.07 Imp. B (EP) as Dihydrochloride: 1-Benzoyl-
2-[(4RS)-1-methylhexahydro-1H-azepin-4-yl]
diazane Dihydrochloride
H
N
O
x 2 HCl
N
H
N
(A) 100 mg
MM 0362.05 Imp. C (EP): 2-[(4-Chlorophenyl)acetyl]benzoic Acid
OH
O
O
Cl
(A) 100 mg
MM 0362.01 Imp. D (EP): 4-(4-Chlorobenzyl)phthalazin-1(2H)-one
N
NH
O
Cl
(A) 100 mg
MM 0362.06 Imp. E (EP) Z-Isomer: (Z)-3-(4-Chlorobenzylidene)-
isobenzofuran-1(3H)-one
O
O
Cl
(A) 100 mg
MM 0362.03 1-Methylazepan-4-one Hydrochloride
O
N x HCl
(A) 100 mg
Azithromycin
New MM 1075.00 Azithromycin
O
HO
OH
O
HO
O
O
O
OH
N
O
N
O
OH
(A) 100 mg
MM 1075.01 Imp. A (EP): 6-Demethylazithromycin
(Azaerythromycin A)
O
HO
OH
O
HO
O
O
O
O H
O
O
N
OH
H
N
(D) 100 mg
Baclofen
MM 1235.03 Imp. B (EP): (3RS)-5-Amino-3-(4-chlorophenyl)-
5-oxopentanoic Acid
Cl
OH
O
O
H
2
N
(A) 100 mg
MM 1235.01 3-(4-Chlorophenyl)glutaric Acid
Cl
OH
O
O
HO
(A) 100 mg
Pharmaceutical impurities
26 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Bambuterol Hydrochloride
MM 0773.04 Imp. D (EP): 5-[(1RS)-1-Hydroxyethyl]-1,3-phenylene
Bis(dimethylcarbamate)
O N
O
O
OH
O
N
(A) 100 mg
MM 0773.05 Imp. E (EP): 5-Acetyl-1,3-phenylene Bis-(dimethylcarbamate)
O N
O
O
O
O
N
(A) 100 mg
Basic Butylated Methacrylate Copolymer
MM 0753.01 Imp. A (EP): Butyl Methacrylate
O
O
(A) 100 mg
MM 0753.02 Imp. B (EP): Methyl Methacrylate
O
O
(A) 100 mg
MM 0753.03 Imp. C (EP): 2-(Dimethylamino)ethyl Methacrylate
O
O
N
(A) 100 mg
Beclometasone Dipropionate
MM 0199.00 Beclometasone Dipropionate
O
HO
O
O
O
Cl
O
O
(A) 250 mg
MM 0199.02 Imp. A (EP): 9-Chloro-11,17-dihydroxy-16-
methyl-3,20-dioxopregna-1,4-dien-21-yl
Propanoate (Beclometasone 21-Propionate)
O
HO
Cl
OH
O
O
O
(A) 100 mg
MM 0199.06 Imp. B (EP): 21-(Acetyloxy)-9-chloro-11-
hydroxy-16-methyl-3,20-dioxopregna-1,4-
dien-17-yl Propanoate (Beclometasone 21-
Acetate 17-Propionate)
O
HO
Cl
O
O
O
O
O
(A) 100 mg
MM 0199.05 Imp. C (EP): 9-Chloro-11-hydroxy-16-methyl-
3,20-dioxo-17-(propanoyloxy)-pregna-1,4-dien-
21-yl Butanoate (Beclometasone 21-Butyrate
17-Propionate)
O
HO
Cl
O
O
O
O
O
(A) 100 mg
MM 0199.01 Imp. H (EP): 9-Chloro-11,21-dihydroxy-16-
methyl-3,20-dioxopregna-1,4-dien-17-yl
Propanoate (Beclometasone 17-Propionate)
O
HO
Cl
O
O
OH
O
(A) 100 mg
MM 0199.03
9-Chloro-11,17,21-trihydroxy-16-methylpregna-
1,4-diene-3,20-dione (Beclometasone)
O
HO
Cl
OH
O
OH
(A) 100 mg
Benazepril Hydrochloride
New MM 1229.00 Benazepril Hydrochloride
N
O
OH
O
H
N
O O
x HCl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 27
Code Product Price Unit
Bendroflumethiazide
MM 0674.01 Imp. A (EP): 4-Amino-6-(trifluoromethyl)benzene-1,3-disulphonamide
S S
NH
2
H
2
N
O
F
F
F
O
O
NH
2
O
(A) 100 mg
Benfluorex Hydrochloride
New MM 0278.01 Imp. C (EP): Benzoic Acid
HO
O
(B) 100 mg
Benperidol
MM 0113.00 Benperidol
F
O
N
NH
N
O
(A) 100 mg
MM 0113.03
Imp. A (EP): 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
HN
NH
N
O
(A) 100 mg
MM 0113.07 4-Chloro-4'-fluorobutyrophenone
F
O
Cl
(B) 100 mg
Benzalkonium Chloride
MM 0224.00 Benzalkonium Chloride
N
Cl
n
(A) 500 mg
MM 0795.00 Imp. A (EP): Benzyl Alcohol
OH
(A) 500 mg
MM 0224.01 Benzyldimethyldodecylammonium Chloride
N
Cl
5
(A) 500 mg
MM 0224.02 Benzyldimethyltetradecylammonium Chloride
N
Cl
6
(A) 500 mg
MM 0224.03 Benzyldimethylhexadecylammonium Chloride
N
Cl
7
(A) 500 mg
Benzbromarone
MM 0456.00 Benzbromarone
O
O
Br
OH
Br
(A) 500 mg
Benzocaine
MM 0094.00 Benzocaine
H
2
N
O
O
(A) 500 mg
MM 0094.01 Benzocaine Acetylsalicylamide
N
H
O
O
O
O
O
(C) 50 mg
MM 0094.02 N-Acetylbenzocaine
N
H
O
O
O
(A) 100 mg
MM 0094.03 4-Aminobenzoic Acid
H
2
N
OH
O
(B) 100 mg
MM 0094.04 Ethyl 4-Nitrobenzoate
O
2
N
O
O
(B) 100 mg
Pharmaceutical impurities
28 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Benzydamine Hydrochloride
MM 0142.00 Benzydamine Hydrochloride
N
N
O N
x HCl
(A) 500 mg
MM 0142.04 Imp. C (BP): 1-Benzyl-1H-indazol-3-ol
N
N
OH
(A) 100 mg
MM 0142.08 Benzydamine N-Oxide Hydrochloride
N
N
O N
x HCl
O
(A) 100 mg
MM 0290.02 1-Chloropropyl(dimethyl)amine Hydrochloride (N,N-Dimethyl-
3-chloropropylamine Hydrochloride)
Cl N
x HCl
(B) 100 mg
Benzyl Alcohol
MM 0795.00 Benzyl Alcohol
OH
(A) 500 mg
MM 0795.02 Imp. B (EP): Cyclohexylmethanol OH (A) 100 mg
Benzyl Benzoate
MM 0570.00 Benzyl Benzoate
O
O
(A) 500 mg
Benzyl Nicotinate
MM 0104.00 Benzyl Nicotinate
N O
O
(A) 500 mg
MM 0553.00 Nicotinic Acid
N OH
O
(A) 500 mg
Benzylpenicillin Benzathine
MM 0513.00 Benzylpenicillin Benzathine
N
S
H
O
O
OH
H
N
N
H
2
x
H
N
O
(A) 500 mg
MM 0513.02 Imp. A (EP): Monobenzylethylendiamine HN
NH2
(C) 100 mg
MM 0160.03 Imp. B (EP): Phenylacetic Acid [Drug Precursor]
OH
O
(B) 100 mg
MM 0160.07 Imp. D (EP): (3S,7R,7aR)-5-Benzyl-2,2-dimethyl-2,3,7,7a-
tetrahydroimidazo[5,1-b]-thiazole-3,7-dicarboxylic Acid (Penillic Acid
of Benzylpenicillin)
N
S
O
OH
N
O
HO
H
(A) 100 mg
MM 0160.01 Imp. E (EP): (4S)-2-[Carboxy[(phenylacetyl)amino]methyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid (Penicilloic Acids of
Benzylpenicillin)
HN
S
O
OH
H
N
O
O OH
(A) 100 mg
MM 0160.05 Imp. F (EP): (2RS,4S)-2-[[(Phenylacetyl)amino]methyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid (Penilloic Acids of
Benzylpenicillin)
HN
S
O
OH
H
N
O
(A) 100 mg
MM 0513.01 N,N-Dibenzylethylenediamine Diacetate
HO
O
x
2
H
N
N
H
(C) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 29
Code Product Price Unit
Benzylpenicillin Potassium
MM 0160.00 Benzylpenicillin Potassium
N
S
H
O
N
H
O
O
OK
(A) 250 mg
MM 0026.04 Imp. A (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid (6-Aminopenicillanic
Acid)
N
S
H
O
H2N
O
OH
(B) 100 mg
MM 0160.03 Imp. B (EP): Phenylacetic Acid [Drug Precursor] O
OH
(B) 100 mg
MM 0160.07 Imp. D (EP): (3S,7R,7aR)-5-Benzyl-2,2-dimethyl-2,3,7,7a-
tetrahydroimidazo[5,1-b]-thiazole-3,7-dicarboxylic Acid
(Penillic Acid of Benzylpenicillin)
N
S
O
OH
N
O
HO
H
(A) 100 mg
MM 0160.01 Imp. E (EP): (4S)-2-[Carboxy[(phenylacetyl)amino]methyl]-
5,5-dimethyl-thiazolidine-4-carboxylic Acid (Penicilloic Acids of
Benzylpenicillin)
HN
S
O
OH
H
N
O
O OH
(A) 100 mg
MM 0160.05 Imp. F (EP): (2RS,4S)-2-[[(Phenylacetyl)amino]methyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid (Penilloic Acids of
Benzylpenicillin)
HN
S
O
OH
H
N
O
(A) 100 mg
Benzylpenicillin Procaine
MM 0094.03 Imp. A (EP): 4-Aminobenzoic Acid
OH
H
2
N
O
(B) 100 mg
MM 0160.01 Imp. B (EP): (4S)-2-[Carboxy[(phenyl-acetyl)amino]methyl]-
5,5-dimethyl-thiazolidine-4-carboxylic Acid
(Penicilloic Acids of Benzylpenicillin)
HN
S
O
OH
H
N
O
O OH
(A) 100 mg
MM 0160.05 Imp. C (EP): (2RS,4S)-2-[[(Phenylacetyl)-amino]methyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid
(Penilloic Acids of Benzylpenicillin)
HN
S
O
OH
H
N
O
(A) 100 mg
MM 0160.07 Imp. D (EP): (3S,7R,7aR)-5-Benzyl-2,2-dimethyl-2,3,7,7a-
tetrahydroimidazo[5,1-b]thiazole-3,7-dicarboxylic Acid
(Penillic Acid of Benzylpenicillin)
N
S
O
OH
N
O
HO
H
(A) 100 mg
MM 0160.03 Imp. E (EP): Phenylacetic Acid [Drug Precursor]
OH
O
(B) 100 mg
Betahistine Dihydrochloride
MM 0587.00 Betahistine Dihydrochloride
N
H
N
x 2 HCl
(A) 500 mg
MM 0587.01 Imp. A (EP): 2-Ethenylpyridine (2-Vinylpyridine)
N
(C) 100 mg
MM 0587.02 Imp. B (EP): 2-(Pyridin-2-yl)ethanol (2-(2-Hydroxyethyl)pyridine)
N OH
(B) 100 mg
MM 0587.03 Imp. C (EP) as Trihydrochloride: N-Methyl-2-(pyridin-
2-yl)-N-[2-(pyridin-2-yl)ethyl]ethanamine Trihydrochloride
N N N
x 3 HCl
(A) 100 mg
MM 0587.04 Imp. C (EP) as Trimesilate: N-Methyl-2-(pyridin-2-yl)-
N-[2-(pyridin-2-yl)ethyl]ethanamine Trimesilate
N N N
x 3 S
OH
O O
(A) 100 mg
Betaine Hydrochloride
MM 0611.00 Betaine Hydrochloride
N
OH
O
Cl
(A) 500 mg
Pharmaceutical impurities
30 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Betamethasone
MM 0200.00 Betamethasone
O
HO
F
OH
O
OH
(A) 250 mg
MM 0213.00 Imp. A (EP): Dexamethasone
O
HO
F
OH
O
OH
(A) 250 mg
MM 0200.01 Imp. B (EP): 21-Chloro-9-fluoro-11,17-dihydroxy-16-
methylpregna-1,4-diene-3,20-dione (Clobetasol)
O
HO
F
OH
O
Cl
(A) 100 mg
Betamethasone Acetate
MM 0201.00 Betamethasone Acetate
O
O
OH HO
F
O
O
(A) 250 mg
MM 0200.00 Imp. A (EP): Betamethasone
O
O
OH HO
F
OH
(A) 250 mg
MM 0445.00 Imp. B (EP): Dexamethasone Acetate
O
O
OH HO
F
O
O
(A) 250 mg
MM 0201.03 Imp. C (EP): Betamethasone 11,21-Diacetate
O
O
F
OH
O
O
O
O (A) 100 mg
Betamethasone Dipropionate
MM 0200.00 Imp. A (Pharmeuropa): 9-Fluoro-11,17,21-
trihydroxy-16-methylpregna-1,4-diene-3,20-
dione (Betamethasone)
O
HO
F
OH
O
OH
(A) 250 mg
MM 0202.00 Betamethasone Dipropionate
O
O
O HO
F
O
O
O
(A) 250 mg
MM 0202.04 Imp. C (Pharmeuropa): 9-Fluoro-11,17-dihydroxy-
16-methyl-3,20-dioxopregna-1,4-dien-21-yl Propanoate
(Betamethasone 21-Propionate)
O
HO
F
OH
O
O
O
(A) 100 mg
MM 0199.00 Imp. E (Pharmeuropa): 9-Chloro-11-hydroxy-
16-methyl-3,20-dioxopregna-1,4-diene-17,21-
diyl Dipropanoate (Beclometasone Dipropionate)
O
HO
Cl
O
O
O
O
O
(A) 250 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 31
Code Product Price Unit
Betamethasone Sodium Phosphate
MM 0303.00 Betamethasone Sodium Phosphate
O
O
OH HO
F
O P
O
ONa
ONa
on request
Betamethasone 17-Valerate
MM 0203.00 Betamethasone 17-Valerate
O
O
O HO
F
OH
O
(A) 250 mg
MM 0200.00 Imp. A (EP): Betamethasone
O
HO
F
OH
O
OH
(A) 250 mg
Betaxolol Hydrochloride
MM 0436.01 Imp. A (EP) as Hydrochloride: (2RS)-
1-(4-Ethylphenoxy)-3-[(1-methylethyl)amino]-propan-
2-ol Hydrochloride
O
OH
H
N
x HCl
(A) 50 mg
MM 0027.10
Imp. B (EP): (2RS)-1-[4-(2-Hydroxyethyl)phenoxy]-
3-[(1-methylethyl)amino]propan-2-ol
HO
O
OH
H
N
(A) 100 mg
MM 0436.03 Imp. C (EP): 2-[[4-[2-(Cyclopropylmethoxy)-
ethyl]phenoxy]methyl]oxirane
O
O
O
(A) 50 mg
MM 0436.04 Imp. D (EP): 4-[2-(Cyclopropylmethoxy)ethyl]phenol
O
OH
(A) 50 mg
MM 0436.05 Imp. E (EP) as Hydrochloride: (2RS)-
1-[4-(2-Butoxyethyl)phenoxy]-
3-[(1-methylethyl)amino]propan-2-ol Hydrochloride
O
O
OH
H
N
x HCl
(A) 50 mg
New MM 0436.06 1-[4-(2-Cyclobutoxyethyl)phenoxy]-
3-(isopropylamino)propan-2-ol Hydrochloride
O
O
OH
H
N
x HCl
(D) 50 mg
Bezafibrate
MM 0063.00 Bezafibrate
Cl
N
H
O
O
OH
O
(A) 500 mg
MM 0063.01 Imp. A (EP): 4-Chloro-N-[2-(4-hydroxyphenyl)ethyl]benzamide
(4-Chlorobenzoyltyramine)
Cl
N
H
O
OH
(A) 100 mg
MM 0063.03 Imp. B (EP): 4-Chlorobenzoic Acid
Cl
O
OH
(B) 100 mg
MM 0063.04 Imp. C (EP): Methyl-
2-[4-[2-[(4-Chlorobenzoyl)amino]ethyl]phenoxy]-
2-methylpropanoate
Cl
N
H
O
O
O
O
(A) 100 mg
MM 0063.02 Imp. D (EP): Ethyl 2-[4-[2-[(4-Chlorobenzoyl)amino]-
ethyl]phenoxy]-2-methylpropanoate
Cl
N
H
O
O
O
O
(A) 100 mg
MM 0063.05 Imp. E (EP): Butyl 2-[4-[2-[(4-Chlorobenzoyl)amino]-
ethyl]phenoxy]-2-methylpropanoate
Cl
N
H
O
O
O
O
(A) 100 mg
Pharmaceutical impurities
32 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0063.06 Tyramine
H2N
OH
(B) 100 mg
MM 0063.07 N,O-Bis-(4-chlorobenzoyl)tyramine
N
H
O
O
O
Cl
Cl
(A) 100 mg
Bicalutamide
MM 0894.00 Bicalutamide
F
S
O O
N
H
O
OH
N
F
F F
(A) 100 mg
MM 0894.01 N-[4-Cyano-3-(trifluoromethyl)phenyl]-
3-[(4-fluorophenyl)sulfinyl]-2-hydroxy-
2-methylpropanamide
F
S
H
N
O
HO
N
F
F F
O
(A) 50 mg
Bifonazole
MM 0318.00 Bifonazole
N
N
(A) 500 mg
MM 0318.01 Imp. A (EP): (RS)-(Biphenyl-4-yl)phenylmethanol
OH
(A) 100 mg
MM 0015.02 Imp. C (EP): 1H-Imidazole (Imidazole)
N
H
N
(B) 100 mg
MM 0318.03 Imp. D (EP) as Chloride: 1,3-Bis[(biphenyl-4-yl)-
phenylmethyl]-1H-imidazolium Chloride
N
+
N
Cl
-
(D) 100 mg
Bisacodyl
MM 0031.00 Bisacodyl
N
O
O
O
O
(A) 500 mg
MM 0031.01
Imp. A (EP): 4,4'-(Pyridin-2-ylmethylene)diphenol
N
HO OH
(A) 100 mg
MM 0031.04
Imp. B (EP): 2-[(RS)-(4-Hydroxyphenyl)(pyridin-2-yl)methyl]phenol
N
OH OH
(A) 50 mg
MM 0031.02 Imp. C (EP): 4-[(RS)-(4-Hydroxyphenyl)(pyridin-
2-yl)methyl]phenyl Acetate
N
HO O
O
(A) 100 mg
MM 0031.03 Imp. E (EP): 2-[(RS)-[4-(Acetyloxy)phenyl](pyridin-
2-yl)methyl]phenyl Acetate
N
O
O
O
O
(A) 50 mg
MM 0054.01 4-[(RS)-(4-Hydroxyphenyl)(pyridin-2-yl)-methyl]phenyl
Sodium Sulphate
(4-[(Pyridin-2-yl)(4-hydroxyphenyl)methyl]phenyl
Sodium Sulphate)
N
HO O
S
ONa
O O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 33
Code Product Price Unit
MM 0054.02 2-[(RS)-(Pyridin-2-yl)[4-(sulphonatooxy)-
phenyl]methyl]phenyl Disodium Sulphate
(2,4'-[(Pyridin-2-yl)methylene]bisphenyl Bis(Sodium
Sulphate))
N
O
O
S
S
NaO
ONa
O O
O O
(D) 50 mg
Bisoprolol Fumarate
MM 0460.00 Bisoprolol
O
OH
H
N
O
O
(A) 100 mg
MM 0460.08 Bisoprolol Fumarate
O
OH
H
N
O
O
OH
HO
O
O
2
x
(A) 100 mg
MM 0460.01 Imp. A (EP): (RS)-1-(4-Hydroxymethyl-
phenoxy)-3-isopropylaminopropan-2-ol
O
OH
H
N
OH
(A) 100 mg
MM 0460.07 Imp. B (EP): (RS)-1-Isopropylamino-3-[4-(2-
propoxyethoxymethyl)phenoxy]propan-2-ol
O
OH
H
N
O
O
(A) 100 mg
MM 0460.15 Imp. C (EP): (RS)-1-[4-[4-(2-Hydroxy-
3-isopropylaminopropoxy)benzyl]-
phenoxy]-3-isopropylaminopropan-2-ol
O
OH
H
N O
H
N
OH
(A) 100 mg
MM 0460.21 Imp. G (EP): (2RS)-1-[4-[[(2-Isopropoxy-
ethoxy)methoxy]methyl]phenoxy]-3-iso-
propylaminopropan-2-ol
O
OH
H
N
O O
O
(D) 100 mg
MM 0460.24 Imp. J (Pharmeuropa): (2RS)-3-[4-((2-Isopropoxy-
ethoxy)methyl)phenoxy]-1,2-propanediol
O
OH
OH
O
O
(A) 100 mg
MM 0460.18 Imp. K (EP): 2-Isopropoxyethyl 4-[[(2RS)-
2-Hydroxy-3-(isopropylamino)propyl]oxy]-
benzoate (Bisoprolol Ester)
O
OH
H
N
O
O
O
(A) 100 mg
MM 0027.24
Imp. L (EP) as Hydrochloride: 4-[[(2RS)-2-Hydroxy-
3-(isopropylamino)propyl]oxy]benzaldehyde
Hydrochloride
(4-[(2RS)-2-Hydroxy-3-[(1-methylethyl)amino]propoxy]-
benzaldehyde Hydrochloride)
O
OH
H
N
O
x HCl
(A) 100 mg
MM 0460.02 Imp. M (Pharmeuropa): 4-[(2-Isopropoxyethoxy)methyl]phenol
OH
O
O
(A) 100 mg
MM 0460.25 Imp. N (EP): [(2RS)-1-[4-[(2-Ethoxyethoxy)-
methyl]phenoxy]-3-isopropylaminopropan-2-ol
O
OH
H
N
O
O
(A) 100 mg
MM 0460.05 Imp. Q (EP): (2RS)-1-(Isopropylamino)-3-[4-(2-
methoxyethoxy)methyl]phenoxypropan-2-ol
O
OH
H
N
O
O
(A) 100 mg
MM 0460.28 Imp. R (EP): (2RS)-1-(Isopropylamino)-3-(4-
methylphenoxy)propan-2-ol
O
OH
H
N
(A) 50 mg
MM 0460.14 Imp. S (EP): 4-Hydroxybenzaldehyde
OH
O
(C) 100 mg
MM 0460.17 Imp. T (EP): 4-[(3-Isopropyl-2-oxo-1,3-oxazolidin-5-
yl)methoxy]benzaldehyde (Bisoprolol Oxazolidinone-
benzaldehyde)
O
N
O
O
O
(A) 50 mg
Pharmaceutical impurities
34 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0460.16 Imp. U (EP): 5-[[4-(Hydroxymethyl)phenoxy]-
methyl]-3-isopropyl-1,3-oxazolidin-2-one
(Bisoprolol Oxazolidinonebenzylalcohol)
O
N
O
O
HO
(A) 50 mg
MM 0460.27 (2RS)-4-[2-Hydroxy-3-(isopropylamino)propoxy]-
benzoic Acid Hydrochloride
O
OH
H
N
O
HO
x HCl
(A) 50 mg
MM 0460.03 2-[4-(2-Isopropoxyethoxymethyl)phenoxymethyl]oxirane
O
O
O
O
(A) 100 mg
MM 0460.06 4-Hydroxybenzyl Alcohol
OH
HO
(B) 100 mg
MM 0460.10 Fumaric Acid
OH
HO
O
O
(B) 100 mg
New MM 0460.23 (2RS)-1-[4-((2-Hydroxyethoxy)methyl)phenoxy]-
3-(isopropylamino)-2-propanol
O
OH
H
N
O
HO
(A) 50 mg
Boldenone
MM 0864.00 Boldenone
O
OH
(A) 100 mg
Brimonidine Tartrate
New MM 1324.00 Brimonidine Tartrate
N
H
Br
N
H
N
N
N
HO
OH
OH
OH
O
O
x
(A) 100 mg
Bromazepam
MM 0064.00 Bromazepam [Controlled Substance]
N
H
N
N
O
Br
(A) 100 mg
MM 0064.01 Imp. A (EP): (2-Amino-5-bromophenyl)(pyridin-2-yl)methanone
Br
NH2
O
N
(A) 100 mg
MM 0064.02 Imp. B (EP): N-[4-Bromo-2-(pyridin-2-
ylcarbonyl)phenyl]-2-chloroacetamide
Br
NH
O
N
O
Cl
(A) 50 mg
MM 0064.09 Imp. C (EP): 7-Bromo-5-(6-methylpyridin-2-yl)-1,3-dihydro-2H-
1,4-benzodiazepin-2-one
N
H
N
N
O
Br
(A) 50 mg
MM 0064.04 Imp. D (EP): 3-Amino-6-bromo-4-(pyridin-
2-yl)quinolin-2(1H)-one
Br
H
N
N
NH
2
O
(A) 50 mg
MM 0064.07 Imp. E (EP): 2-Bromo-N-[4-bromo-2-(pyridin-
2-ylcarbonyl)phenyl]acetamide
Br
NH
O
N
O
Br
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 35
Code Product Price Unit
Bromhexine Hydrochloride
MM 0065.00 Bromhexine Hydrochloride
Br
Br
NH
2
N
x HCl
(A) 500 mg
MM 0005.01 Imp. A (EP): (2-Amino-3,5-dibromophenyl)methanol
Br
NH
2
Br
OH
(A) 100 mg
MM 0005.02 Imp. B (EP): 2-Amino-3,5-dibromobenzaldehyde
Br
NH2
Br
O
(A) 100 mg
MM 0065.02 Imp. C (EP): N-(2-Aminobenzyl)-N-methylcyclohexanamine
NH
2
N
(A) 100 mg
MM 0065.03 Imp. D (EP) as Dihydrochloride: N-(2-Amino-5-bromobenzyl)-N-
methylcyclohexanamine Dihydrochloride
NH2
N
Br
x 2 HCl
(A) 100 mg
MM 0065.01 N-(2-Nitrobenzyl)-N-cyclohexyl-N-methylamine
NO
2
N
(A) 100 mg
MM 0065.05 6,8-Dibromo-3-cyclohexyl-3,4-dihydro-2(1H)-quinazolinone
Br
Br
HN N
O
(A) 100 mg
MM 0065.09 Bromhexine N-Oxide
Br
Br
NH
2
N
O
(A) 100 mg
Bromisoval
MM 1128.01 Ethyl 2-Bromoisovalerate
Br
O
O
(A) 100 mg
Brompheniramine Maleate
MM 0060.00 Brompheniramine Maleate O
OH
O
OH
x
N
Br
N
(A) 500 mg
MM 0090.00 Imp. A (EP) as Maleate: Chlorphenamine Maleate O
OH
O
OH
x
N
Cl
N
(A) 500 mg
MM 1114.00 Imp. B (EP) as Maleate: Dexchlorpheniramine Maleate O
OH
O
OH
x
N
Cl
N
(A) 100 mg
MM 0059.01 Imp. C (EP): (3RS)-N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)-
propan-1-amine (Pheniramine)
N
N
(A) 100 mg
MM 0059.00 Imp. C (EP) as Maleate: (3RS)-N,N-Dimethyl-
3-phenyl-3-(pyridin-2-yl)propan-1-amine Maleate
(Pheniramine Maleate)
O
OH
O
OH
x
N
N
(A) 100 mg
Pharmaceutical impurities
36 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0060.12 Brompheniramine N-Oxide
N
Br
N
O
on request
MM 0060.16 Desmethylbrompheniramine Maleate O
OH
O
OH
x
N
Br
N
H
(A) 100 mg
Buclizine Hydrochloride
MM 0380.04 Imp. A (BP): 1,4-Bis(4-chlorobenzhydryl)piperazine
(1,4-Bis[(4-chlorophenyl)phenylmethyl]piperazine)
N
N
Cl
Cl
(A) 100 mg
MM 0380.09 4-Chlorobenzhydrol
OH
Cl
(B) 100 mg
MM 0380.10 4-Chlorobenzophenone
O
Cl
(B) 100 mg
MM 0380.01 1-(4-Chlorobenzhydryl)piperazine((RS)-
1-[(4-Chlorophenyl)phenylmethyl]piperazine)
NH
N
Cl
(A) 100 mg
Budesonide
MM 0204.01 Imp. A (EP): 11,16,17,21-Tetrahydroxy-
pregna-1,4-diene-3,20-dione (16-Hydroxy-
prednisolone)
O
HO
OH
O
OH
OH
(A) 100 mg
New MM 0204.02 Imp. B (EP): 16,17-[(1RS)-Ethylidenebis(oxy)]-
11,21-dihydroxypregna-1,4-diene-3,20-dione
O
HO
O
O
OH
O
(A) 50 mg
Bufexamac
MM 0179.00 Bufexamac
O
H
N
OH
O
(A) 500 mg
MM 0179.01 Imp. A (EP): 2-(4-Butoxyphenyl)acetic Acid
O
OH
O
(A) 100 mg
MM 0179.02 Imp. B (EP): Methyl 2-(4-Butoxyphenyl)acetate
O
O
O
(A) 100 mg
MM 0179.03 Imp. C (EP): Butyl 2-(4-Butoxyphenyl)acetate
O
O
O
(A) 100 mg
MM 0179.04 Imp. D (EP): 2-(4-Butoxyphenyl)acetamide
O
NH2
O
(A) 100 mg
MM 0179.05 4'-Butoxyacetophenone
O
O
(A) 100 mg
MM 0179.06 Ethyl 2-(4-Butoxyphenyl)acetate
O
O
O
on request
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 37
Code Product Price Unit
Buflomedil Hydrochloride
MM 0066.00 Buflomedil Hydrochloride
N
O O
O O
x HCl
(A) 500 mg
MM 0066.01 Imp. A (EP) as Hydrochloride: 4-(Pyrrolidin-1-yl)-1-
(2-hydroxy-4,6-dimethoxyphenyl)butan-1-one Hydrochloride
(o-Desmethyl-Buflomedil Hydrochloride)
N
O OH
O O
x HCl
(A) 100 mg
MM 0066.02 Imp. B (EP) as Hydrochloride: 4-(Pyrrolidin-1-yl)-
1-(4-hydroxy-2,6-dimethoxyphenyl)butan-1-one Hydrochloride
(p-Desmethyl-Buflomedil Hydrochloride)
N
O O
O HO
x HCl
(A) 100 mg
MM 0066.03 4-(1-Pyrrolidino)butyronitrile
N
N
(C) 100 mg
MM 0066.05 1,3,5-Trimethoxybenzene O
O O
(C) 100 mg
Bunolol Hydrochloride
MM 0642.00 Bunolol Hydrochloride
O
OH
H
N
x HCl
O
(A) 100 mg
Buphenine Hydrochloride
MM 0710.00 Buphenine Hydrochloride
HO
OH
HN
x HCl
(A) 500 mg
Bupivacaine Hydrochloride
MM 0613.00 Bupivacaine Hydrochloride Monohydrate
H
N
O
N
x HCl
x H
2
O
(A) 500 mg
MM 0368.03 Imp. A (EP): N-(2,6-Dimethylphenyl)pyridine-
2-carboxamide
H
N
O
N
(A) 100 mg
MM 0613.05 Imp. E (EP) as Hydrochloride: 6-(Butylamino)-N-
(2,6-dimethylphenyl)hexanamide Hydrochloride
H
N
O
N
H
x HCl
(A) 50 mg
MM 0102.02 Imp. F (EP): 2,6-Dimethylaniline
NH
2
(B) 100 mg
MM 0613.07 Bupivacaine N-Oxide
H
N
O
N
O
(A) 100 mg
Bupropion Hydrochloride
MM 0745.00 Bupropion Hydrochloride
Cl
O
H
N
x HCl
(A) 100 mg
MM 0745.02 2-(tert-Butylamino)-4'-chloropropiophenone Hydrochloride
O
H
N
x HCl
Cl
(A) 100 mg
MM 0745.03 2-(tert-Butylamino)-3'-bromopropiophenone Hydrochloride
O
H
N
x HCl
Br
on request
MM 0745.05 2-(tert-Butylamino)propiophenone Hydrochloride
O
H
N
x HCl
(A) 100 mg
MM 0745.07 1-(3-Chlorophenyl)-1-hydroxy-2-propanone
Cl
OH
O
(D) 100 mg
MM 0745.08 3-Chloropropiophenone
Cl
O
(B) 100 mg
Pharmaceutical impurities
38 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Buspirone Hydrochloride
MM 0464.00 Buspirone Hydrochloride N
N N
N
N
O
O
x HCl
(A) 500 mg
MM 0464.02 Imp. A (EP) as Dihydrochloride: 2-(Piperazin-
1-yl)pyrimidine Dihydrochloride
HN
N
N
N
x 2 HCl
(A) 100 mg
New MM 0464.04 Imp. C (EP): 2,2'-[Butane-
1,4-diylbis(piperazine-
1,4-diyl)]dipyrimidine
N
N
N
N
N
N
N
N
(A) 50 mg
New MM 0464.12 Imp. G (EP): 2,2'-(Piperazine-1,4-diyl)dipyrimidine
N
N N
N
N
N
(A) 50 mg
New MM 0464.14 Imp. I (EP): 8-[4-[4-(5-Chloropyrimidin-2-
yl)-piperazin-1-yl]butyl]-8-azaspiro
[4.5]decane-7,9-dione
N
O
O
N
N
N
N
Cl
(A) 50 mg
MM 0464.08 Imp. K (EP): 8-Azaspiro[4,5]-decane-7,9-dione
NH
O
O
(B) 100 mg
New MM 0464.09 Imp. L (EP): 8-(4-Chlorobutyl)-8-azaspiro[4.5]-decane-7,9-dione
N
O
O
Cl
(A) 50 mg
New MM 0464.16 Imp. M (EP): 8-(4-Bromobutyl)-8-azaspiro[4.5]-
decane-7,9-dione
N
O
O
Br
(A) 50 mg
Butalbital
MM 0899.00 5,5-Diallybarbituric acid (Allobarbital)
[Controlled Substance]
NH
H
N O O
O
(A) 100 mg
Butenafine Hydrochloride
MM 1041.00 Butenafine Hydrochloride
N
x HCl
on request
Butetamate Citrate
MM 0606.00 Butetamate Citrate
O
O
N
x
OH
O
OH
O
OH
O
OH
(A) 500 mg
Butyl Parahydroxybenzoate
MM 0496.00 Butyl Parahydroxybenzoate
HO
O
O
(A) 500 mg
MM 0045.01 Imp. A (EP): 4-Hydroxybenzoic Acid
HO
OH
O
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 39
Code Product Price Unit
MM 0431.00 Imp. B (EP): Methyl 4-Hydroxybenzoate (Methyl
Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0498.00 Imp. C (EP): Ethyl 4-Hydroxybenzoate (Ethyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0432.00 Imp. D (EP): Propyl 4-Hydroxybenzoate (Propyl
Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0496.05 Imp. E (EP): 2-Methylpropyl 4-Hydroxy-
benzoate (Isobutyl Parahydroxybenzoate)
HO
O
O
(A) 100 mg
Butylhydroxytoluene
MM 0679.00 Butylhydroxytoluene
OH
(A) 500 mg
Caffeine
MM 0494.00 Caffeine
N
N
N
N
O
O
(A) 500 mg
MM 0176.00 Imp. A (EP): Theophylline
N
N
N
H
N
O
O
(A) 500 mg
MM 0176.02 Imp. B (EP): N-(6-Amino-1,3-dimethyl-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-5-yl)formamide
N
N O
O
NH
2
H
N O
(A) 100 mg
MM 0494.03 Imp. C (EP): 1,3,9-Trimethyl-3,9-dihydro-
1H-purine-2,6-dione (Isocaffeine)
N
N
N
N
O
O
(A) 50 mg
MM 0577.00 Imp. D (EP): Theobromine
HN
N
N
N
O
O
(A) 500 mg
MM 0494.06 Imp. E (EP) as Nitrate: N,1-Dimethyl-4-
(methylamino)-1H-imidazole-5-carbox-
amide Nitrate (Caffeidine Nitrate)
N
H
HN
N
N
O
x HNO
3
(A) 100 mg
MM 0494.04 Imp. F (EP): 1,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione
(Paraxanthine; 1,7-Dimethylxanthine)
N
N
N
H
N
O
O
(D) 50 mg
Candesartan Cilexetil
New MM 0776.00 Candesartan Cilexetil
NH
N N
N
N
N
O
O
O
O
O
O
(A) 100 mg
New MM 0776.01 Imp. A (EP): Ethyl 2-Ethoxy-1-[[2'-(1H-
tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-
benzimidazole-7-carboxylate NH
N N
N
N
N
O
O
O
(A) 100 mg
Pharmaceutical impurities
40 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
New MM 0776.09 Imp. G (EP): 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)-
biphenyl-4-yl]methyl]-1H-benzimidazole-7-
carboxylic Acid (Candesartan) NH
N N
N
N
N
O
O
OH
(A) 100 mg
New MM 0776.07 Imp. H (EP): (1RS)-1-[[(Cyclohexyloxy)carbonyl]-
oxy]ethyl 2-Ethoxy-1-[[2'-[1-(triphenylmethyl)-1H-
tetrazol-5-yl]biphenyl-4-yl]methyl]-1H-benz-
imidazole-7-carboxylate (N-Tritylcandesartan
Cilexetil)
N
N N
N
N
N
O
O
O
O
O
O
(A) 100 mg
New MM 0776.08 Trityl Candesartan
N
N N
N
N
N
O
O
OH
(A) 100 mg
Capecitabine
New MM 0992.00 Capecitabine
O
N
N
O
HN O
F
O
OH OH
on request
New MM 0992.02 2,3-O-Carbonyl-5-deoxy-5-fluoro-
N4-(pentyloxycarbonyl)cytidine
O
N
N
O
HN O
F
O
O O
O
(A) 100 mg
Captopril
MM 0067.00 Captopril
N HS
O
O OH
(A) 500 mg
MM 0067.01 Imp. A (EP): 1,1'-[Disulfanediylbis-
[(2S)-2-methyl-1-oxopropane-3,1-diyl]-
bis[(2S)-pyrrolidine-2-carboxylic] Acid
(Captopril Disulfide)
N S
O
O OH
N S
O
O HO
(A) 100 mg
MM 0067.02 Imp. C (EP): (2RS)-2-Methyl-3-sulfanylpropanoic Acid
OH HS
O
(A) 100 mg
MM 0067.06 Imp. D (EP): (2RS)-3-Bromo-2-methylpropanoic Acid
O
OH Br
(A) 100 mg
MM 0067.08 Imp. E (EP): (2S)-1-[2-Methylpropanoyl]pyrrolidine-2-carboxylic Acid
N
O
O OH
(A) 100 mg
MM 0067.05 Imp. J (EP) as Hydrate: (2S)-1-[(2S)-3-(Acetylsulfanyl)-2-
methylpropanoyl]-pyrrolidine-2-carboxylic Acid Hydrate
(Acetylcaptopril Hydrate)
N S
O
O OH
O
x H
2
O
(A) 100 mg
MM 0067.04 Imp. K (Pharmeuropa): (2S)-3-(Acetylthio)-2-methylpropanoic Acid
OH S
O O
(C) 100 mg
MM 0067.15 Imp. N (EP): 3,3'-Disulfanediylbis[(2S)-2-
methylpropanoic] Acid OH S
O
S HO
O
(A) 50 mg
MM 0067.03 Captopril Ethyl Ester
N HS
O
O O
on request
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 41
Code Product Price Unit
Carbamazepine
MM 0076.00 Carbamazepine
O
NH
2
N
(A) 250 mg
MM 0076.04 Imp. A (EP): 10,11-Dihydro-5H-dibenzo[b,f]-azepine-5-carboxamide
(10,11-Dihydrocarbamazepine)
O
NH
2
N
(A) 100 mg
MM 0076.09 Imp. B (EP): 9-Methylacridine
N
(A) 100 mg
MM 0076.12 Imp. C (EP): (5H-Dibenzo[b,f]azepin-5-yl-carbonyl)urea
(N-Carbamoylcarbamazepine)
O
N
H
N NH
2
O
(A) 100 mg
MM 0076.08 Imp. D (EP): 5H-Dibenzo[b,f]azepine (Iminostilbene)
NH
(B) 100 mg
MM 0076.06 Imp. E (EP): 10,11-Dihydro-5H-dibenzo[b,f]-azepine (Iminodibenzyl)
NH
(B) 100 mg
MM 0076.01 Carbamazepine 10,11-Epoxide
O
NH
2
N
O
(A) 100 mg
MM 0076.05 Imp. G (EP): 10-Bromo-5H-dibenzo[b,f]azepine-
5-carboxamide (10-Bromocarbamazepine)
O
NH
2
N
Br
(A) 100 mg
MM 0076.10 10-Hydroxy-10,11-dihydrocarbamazepine
O
NH
2
N
HO
(A) 100 mg
MM 0076.17 Oxcarbazepine
O
NH
2
N
O
(A) 100 mg
Carbasalate Calcium
MM 0133.02 Imp. A (EP): 2-(Acetyloxy)benzoic Anhydride
(Acetylsalicylic Anhydride)
O
O O O
O
O
O
(A) 100 mg
MM 0133.01 Imp. B (EP): 2-[[2-(Acetyloxy)benzoyl]oxy]benzoic Acid
(Acetylsalicylsalicylic Acid)
O
OH
O
O
O
O
(A) 100 mg
MM 0045.00 Imp. C (EP): Salicylic Acid
OH
O
OH
(A) 500 mg
Pharmaceutical impurities
42 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0133.03 Imp. D (EP): 2-[(2-Hydroxybenzoyl)oxy]benzoic Acid (Salicylsalicylic
Acid)
O
OH
O
O
OH
(A) 100 mg
Carbendazim
MM 2500.00 Carbendazim
N
H
N
NH
O
O
(A) 100 mg
MM 2500.01 2,3-Diaminophenazine
N
N NH2
NH2
(A) 100 mg
MM 2500.02 2-Amino-3-hydroxyphenazine
N
N NH2
OH
(A) 100 mg
Carbenicillin Sodium
MM 0805.00 Carbenicillin Sodium
N
S
H
O
N
H
O
O
ONa
ONa O
(A) 250 mg
Carbocisteine
MM 0236.00 Carbocisteine
S OH
NH2
O
HO
O
(A) 500 mg
MM 0236.01 (S)-Carboxymethyl-L-cysteine
(R/S)-Sulphoxide
S OH
NH2
O
HO
O O
(A) 100 mg
MM 0236.02 Lactam of (S)-Carboxymethyl-L-cysteine
OH
O
NH
S
O
(A) 100 mg
MM 0236.03 L-Cysteinesulfinic Acid
S OH
NH2
O
HO
O
(C) 100 mg
Carisoprodol
MM 0782.03 Imp. C (EP): 2-Methyl-2-propylpropane-1,3-diol HO OH (A) 100 mg
Carvedilol
MM 0291.00 Carvedilol
O
O
H
N
OH
O
HN
(A) 100 mg
MM 0291.02 Imp. B (EP): 1,1'-[[2-(2-Methoxyphenoxy)-
ethyl]nitrilo]bis[3-(9H-carbazol-4-yloxy)propan-2-ol]
O
O
N
OH
O
HN
OH
O
NH
(A) 100 mg
MM 0291.03 Imp. C (EP): (2RS)-1-[Benzyl[2-(2-methoxyphenoxy)-
ethyl]amino]-3-(9H-carbazol-4-yloxy)propan-2-ol
O
O
N
OH
O
HN
(A) 100 mg
MM 0291.04 Toluene (C) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 43
Code Product Price Unit
MM 0291.10 4-(2,3-Epoxypropoxy)carbazole
O
HN
O
(A) 100 mg
MM 0291.11 2-(2-Methoxyphenoxy)ethylamine Hydrochloride
O
O
H
2
N
x HCl
(A) 100 mg
Cefaclor
MM 0326.00 Cefaclor Monohydrate
N
S
Cl
O OH
O
H
H
N
O
NH
2
x H
2
O
(A) 100 mg
MM 0253.12 Imp. A (EP): (2R)-2-Amino-2-phenylacetic Acid
(D-Phenylglycine)
O
OH
NH
2
(B) 100 mg
MM 0253.08 Imp. F (EP): 3-Phenylpyrazin-2-ol
N
N OH
(A) 100 mg
Cefadroxil Monohydrate
MM 0232.09
Imp. A (EP): (2R)-2-Amino-2-(4-hydroxyphenyl)acetic Acid
HO
NH
2
OH
O
(B) 100 mg
MM 0811.01 Imp. B (EP): (6R,7R)-7-Amino-3-methyl-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(7-ADCA; 7-Aminodesacetoxycephalosporanic Acid)
N
S
O OH
O
H
2
N
H
(A) 100 mg
Cefalexin Monohydrate
MM 0605.00 Cefalexin Monohydrate
N
H
O
H
N
NH2
O
x H2O
S
O OH
(A) 500 mg
MM 0253.12 Imp. A (EP): (2R)-2-Amino-2-phenylacetic Acid
(D-Phenylglycine)
O
OH
NH
2
(B) 100 mg
MM 0811.01 Imp. B (EP): (6R,7R)-7-Amino-3-methyl-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(7-Aminodesacetoxycephalosporanic Acid; 7-ADCA)
N
S
O OH
O
H
2
N
H
(A) 100 mg
Cefazolin Sodium
MM 0238.00 Cefazolin Sodium
N
S
O ONa
O
S
S
N
N
H
H
N
N
N
N
N
O
(A) 100 mg
MM 0238.05 Imp. E (EP): 5-Methyl-1,3,4-thiadiazol-2-thiol (MMTD)
N
N S
SH
(A) 100 mg
MM 0238.08 Imp. H (EP): (6R,7R)-3-[(Acetyloxy)methyl]-7-amino-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid (7-ACA)
N
S
O OH
O
O
H
H
2
N
O
(A) 100 mg
Cefetamet
MM 0811.01 7-Aminodesacetoxycephalosporanic Aicd
N
S
O OH
O
H
2
N
H
(A) 100 mg
Pharmaceutical impurities
44 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Cefoperazone Sodium
MM 0853.03 Imp. C (EP): 1-Methyl-1H-tetrazole-5-thiol
N N
N N
SH
(A) 100 mg
MM 0238.08 Imp. E (EP): (6R,7R)-3-[(Acetyloxy)methyl]-7-amino-8-oxo-
5-thia-1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic Acid (7-ACA)
N
S
O OH
O
O
H
H
2
N
O
(A) 100 mg
Cefradine
MM 0811.01 Imp. A (EP): (6R,7R)-7-Amino-3-methyl-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
(7-Aminodeacetoxycephalosporanic Acid, 7-ADCA)
N
S
O OH
O
H
H
2
N
(A) 100 mg
Celecoxib
New MM 0344.00 Celecoxib
N
S
NH
2
O O
N
F
F
F
on request
New MM 0344.06 Imp. A (Pharmeuropa): 4-[5-(3-Methylphenyl)-
3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-
sulfonamide
N
S
NH
2
O O
N
F
F
F
(A) 50 mg
MM 0344.02 4-[5-[4-(Hydroxymethyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-
1-yl]-benzenesulfonamide
N
S
NH
2
O O
N
F
F
F
HO
(D) 100 mg
MM 0344.03 4-[1-[4-(Aminosulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-
5-yl]benzoic Acid
N
S
NH
2
O O
N
F
F
F
O
HO (D) 100 mg
Celiprolol Hydrochloride
MM 0128.00 Celiprolol Hydrochloride
O
N
H
O
N
O
OH
H
N
x HCl
(A) 100 mg
MM 0128.01 Imp. A (EP): 1-[5-Amino-2-[(2RS)-
3-[(1,1-dimethylethyl)amino]-
2-hydroxypropoxy]phenyl]ethanone
O
H
2
N
O
OH
H
N
(A) 100 mg
MM 0128.03 Imp. C (EP): 1-[3-Acetyl-4-[(2RS)-
3-[(1,1-dimethylethyl)amino]-
2-hydroxypropoxy]phenyl]-3-(1,1-dimethylethyl)urea
O
N
H
O
N
H
O
OH
H
N
(A) 100 mg
MM 0128.10 Imp. D (EP):3-[3-Acetyl-4-[(RS)-3-(diethylamino)-
2-hydroxypropoxy]phenyl]-1,1-diethylurea
O
N
H
O
N
O
OH
N
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 45
Code Product Price Unit
MM 0128.05 Imp. E (EP): 1,1'-[[(1,1-Dimethylethyl)-
imino]bis[(2-hydroxypropane-1,3-diyl)-
oxy(3-acetyl-
1,4-phenylene)]]bis(3,3-diethylurea)
O
HN
O
OH
N
O N
OH
O
O
NH
N O
(D) 50 mg
MM 0128.07 Imp. F (EP): 3-(3-Acetyl-4-hydroxyphenyl)-1,1-diethylurea
O
N
H
O
N
OH
(A) 100 mg
MM 0128.06 Imp. G (EP): 3-[3-Acetyl-4-[[(RS)-oxiranyl]methoxy]phenyl]-
1,1-diethylurea
O
N
H
O
N
O
O
(A) 100 mg
MM 0128.04 Imp. H (EP): 3-[3-Acetyl-4-[(2RS)-3-bromo-
2-hydroxypropoxy]phenyl]-1,1-diethylurea (Bromhydrin
Compound)
O
N
H
O
N
O
OH
Br
(A) 100 mg
MM 0128.11 3-Acetyl-4-hydroxyaniline Hydrochloride
O
H
2
N
OH
x HCl
(A) 100 mg
MM 0128.58 5-Acetamido-2-hydroxyacetophenone
O
N
H
O
OH
(A) 100 mg
Cethexonium Bromide
MM 0501.01 rac-trans-2-Dimethylaminocyclohexanol Hydrochloride
OH
N
x HCl
and enantiomer
(A) 100 mg
Cetirizine Dihydrochloride
MM 0380.00 Cetirizine Dihydrochloride
N
N
O Cl
x 2 HCl
OH
O
(A) 100 mg
MM 0380.01 Imp. A (EP): (RS)-1-[(4-Chlorophenyl)phenylmethyl]piperazine
N
NH
Cl
(A) 100 mg
MM 0380.02 Imp. B (EP) as Dihydrochloride: (RS)-
2-[4-[(4-Chlorophenyl)phenylmethyl]-
piperazin-1-yl]acetic Acid Dihydrochloride
N
N
OH
O
Cl
x 2 HCl
(A) 100 mg
MM 0380.03 Imp. C (EP) as Dihydrochloride: (RS)-2-[2-[4-[(2-Chloro-
phenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid
Dihydrochloride
N
N
O
OH
O
Cl
x 2 HCl
(A) 100 mg
MM 0380.04 Imp. D (EP): 1,4-Bis[(4-chlorophenyl)-
phenylmethyl]piperazine
N
N
Cl
Cl
(A) 100 mg
MM 0380.05 Imp. E (EP) as Dihydrochloride: (RS)-
2-[2-[2-[4-[(4-Chlorophenyl)phenyl-
methyl]piperazin-1-yl]ethoxy]ethoxy]-
acetic Acid Dihydrochloride
(Ethoxycetirizine Dihydrochloride)
N
N
O Cl
O
OH
O
x 2 HCl
(D) 100 mg
Pharmaceutical impurities
46 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0380.06 Imp. F (EP) as Dihydrochloride:
[2-[4-[Diphenylmethyl]piperazin-1-yl]ethoxy]acetic Acid
Dihydrochloride
N
N
O
OH
O
x 2 HCl
(A) 100 mg
MM 0380.11 Imp. G (EP) as Dihydrochloride: 2-[4-[(RS)-
(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethanol
Dihydrochloride
N
N
OH Cl
x 2 HCl
(A) 100 mg
MM 0380.08 Isopropyl Ester of Cetirizine
N
N
O Cl
O
O
(A) 100 mg
MM 0380.09 4-Chlorobenzhydrol
OH
Cl
(B) 100 mg
MM 0380.10 4-Chlorobenzophenone
O
Cl
(B) 100 mg
MM 0380.13 Cetirizine N-Oxide
N
N
O
OH
O
Cl
O
(A) 100 mg
MM 0380.15 Ethyl Ester of Cetirizine Dihydrochloride
N
N
O Cl
O
O
x 2 HCl
(A) 100 mg
New MM 0380.16 Methyl Ester of Cetirizine Dihydrochloride
N
N
O
O
O
Cl
x 2 HCl
(A) 100 mg
New MM 0380.17 3-Chlorocetirizine Dihydrochloride ((RS)-
2-[2-[4-[(3-Chlorophenyl)phenylmethyl]piperazin-
1-yl]ethoxy]acetic Acid Dihydrochloride) N
N
O
OH
O
x 2 HCl
Cl
(A) 100 mg
Chlorambucil
MM 0821.00 Chlorambucil
OH
O
N
Cl
Cl
(A) 500 mg
Chloramphenicol
MM 0516.00 Chloramphenicol
NO
2
N
H
OH
O
Cl
Cl OH
(A) 500 mg
MM 0516.01 (D)-(-)-threo-2-Amino-1-(4-nitrophenyl)-1,3-propanediol
NO
2
H
2
N
OH
OH
(A) 100 mg
Chlordiazepoxide Hydrochloride
MM 0028.02 Imp. A (EP): 7-Chloro-5-phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one 4-Oxide
(Demoxepam) N
H
N
O
O
Cl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 47
Code Product Price Unit
MM 0028.04 Imp. B (EP): 6-Chloro-2-(chloromethyl)-4-phenylquinazoline
3-Oxide
Cl
N
N
O
Cl
(A) 100 mg
MM 0028.03 Imp. C (EP): (2-Amino-5-chlorophenyl)phenyl-methanone
(Aminochlorobenzophenone)
Cl
NH
2
O
(B) 100 mg
Chlorhexidine Diacetate
MM 0162.00 Chlorhexidine Diacetate
H
N
H
N
H
N
N
H
N
H
Cl
NH NH
NH
N
H
NH
Cl
O
OH
x 2
(A) 500 mg
MM 0162.05 4-Chloroaniline
NH
2
Cl
(B) 100 mg
MM 0162.07 (4-Chlorophenyl)urea
H
N NH
2
Cl
O
(A) 100 mg
MM 0162.08 (4-Chlorophenyl)guanidine Hydrochloride
H
N NH
2
Cl
NH
x HCl
(C) 50 mg
Chlorhexidine Dihydrochloride
MM 0946.00 Chlorhexidine Dihydrochloride
Cl
H
N
H
N
NH
H
N
NH
N
H
N
H
NH
N
H
NH
Cl
x 2 HCl
(A) 500 mg
Chlormezanone
MM 0017.00 Chlormezanone
N
S
O
O O
Cl
(A) 250 mg
MM 0017.02 2-(4-Chlorophenyl)-3-methylperhydro-1,3-thiazin-4-one
N
S
O
Cl
on request
MM 0017.03 4-Chlorobenzaldehyde
H
Cl
O
(B) 100 mg
Chlorobutanol Hemihydrate
MM 0535.00 Chlorobutanol Hemihydrate
Cl
Cl
Cl
OH
x H
2
O
(A) 500 mg
Chlorocresol
MM 0459.00 Chlorocresol
OH
Cl
(A) 500 mg
Chlorphenamine Maleate
MM 0090.00 Chlorphenamine Maleate
N
N
O
OH
O
OH
x
Cl
(A) 500 mg
MM 0090.03 Imp. A (EP) as Dihydrochloride: 2-(4-Chlorophenyl)-
4-(dimethylamino)-2-[2-(dimethylamino)ethyl]butanenitrile
Dihydrochloride
N N
N
Cl
x 2 HCl
(D) 100 mg
Pharmaceutical impurities
48 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0090.04 Imp. B (EP): N-(Pyridin-2-yl)pyridin-2-amine
(2,2'-Dipyridylamine)
H
N N
N
(A) 100 mg
MM 0090.13 Imp. C (EP) as Maleate: (3RS)-3-(4-Chloro-phenyl)-N-
methyl-3-(pyridin-2-yl)propan-1-amine Maleate
NH
N
O
OH
O
OH
x
Cl
(A) 100 mg
MM 0090.05 Imp. D (EP) as Maleate: (2RS)-2-(4-Chloro-phenyl)-4-
(dimethylamino)-2-(pyridin-2-yl)butanenitrile Maleate
N
N
N
Cl
O
OH
O
OH
x
(D) 100 mg
MM 0090.11 Chlorphenamine N-Oxide Dihydrochloride
N
N
Cl
O
x 2 HCl
(A) 100 mg
Chlorphenoxamine Hydrochloride
New MM 1291.00 Chlorphenoxamine Hydrochloride
O
N
Cl
x HCl
(A) 100 mg
Chlorpromazine Hydrochloride
MM 0420.00 Chlorpromazine Hydrochloride
N
S
Cl
N
x HCl
(A) 500 mg
MM 0420.01 Imp. A (EP): 3-(2-Chloro-10H-phenothiazin-
10-yl)-N,N-dimethylpropan-1-amine S-Oxide
(Chlorpromazine Sulfoxide)
N
S
Cl
N
O
(A) 100 mg
MM 0420.06 Imp. B (EP) as Dihydrochloride: N-[3-(2-Chloro-
10H-phenothiazin-10-yl)propyl]-N,N',N'-trimethyl-
propane-1,3-diamine Dihydrochloride
N
S
Cl
N N
x 2 HCl
(A) 100 mg
MM 0290.00 Imp. C (EP) as Hydrochloride: 3-(10H-Phenothiazin-
10-yl)-N,N-dimethylpropan-1-amine Hydrochloride
(Promazine Hydrochloride)
N
S
N
x HCl
(A) 500 mg
MM 0420.07 Imp. D (EP) as Hydrochloride: 3-(2-Chloro-10H-phenothiazin-
10-yl)-N-methylpropan-1-amine Hydrochloride
(Desmethylchlorpromazine Hydrochloride)
N
S
Cl
NH
x HCl
(A) 100 mg
MM 0420.04 Imp. E (EP): 2-Chloro-10H-phenothiazine
NH
S
Cl
(A) 100 mg
MM 0420.02 Chlorpromazine Sulphoxide N-Oxide Maleate
N
S
Cl
N
O
O
O
OH
O
OH
x
(B) 10 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 49
Code Product Price Unit
Chlorprothixene Hydrochloride
New MM 1321.01 Imp. A (EP): (RS)-2-Chloro-9-[3-(dimethylamino)-
propyl]-9H-thioxanthen-9-ol
S
Cl
N
OH
(A) 100 mg
New MM 1321.07 Imp. B (EP) as Hydrochloride: N,N-Dimethyl-3-
(9H-thioxanthen-9-ylidene)propan-1-amine Hydrochloride
S
N
x HCl
(A) 50 mg
New MM 1321.05 Imp. E (EP): 2-Chloro-9H-thioxanthen-9-one
S
Cl
O
(A) 100 mg
Chlorquinaldol
MM 0390.00 Chlorquinaldol
OH
Cl
Cl
N
(A) 500 mg
Chlortalidone
MM 0297.00 Chlortalidone
HN
HO
O
Cl
S
H
2
N
O O
(A) 250 mg
Chlortetracycline Hydrochloride
MM 0607.00 Chlortetracycline Hydrochloride
OH O OH O
NH2
O
OH
OH
N
H H x HCl
Cl
OH
(A) 500 mg
MM 0636.00 Imp. B (EP) as Hydrochloride: Demeclocycline
Hydrochloride
OH O OH O
NH2
O
OH
OH
N
H H x HCl
Cl OH
(A) 250 mg
MM 0452.00 Tetracycline Hydrochloride
OH O OH O
NH
2
O
OH
OH
N
H H x HCl
HO
(A) 500 mg
Cholecalciferol
MM 0249.02 Imp. B (EP): Cholesta-5,7-dien-3-ol
(7,8-Didehydrocholesterol; Provitamin D3)
HO
(A) 100 mg
Ciclopirox Olamine
MM 0418.00 Ciclopirox Olamine
N O
OH
H
2
N
OH
x
(A) 250 mg
MM 0418.03 Imp. C (EP): 6-Cyclohexyl-4-methylpyridin-2(1H)-one
H
N O
(A) 50 mg
Cimetidine Hydrochloride
MM 0020.00 Cimetidine
N
N
H
N
H
S
N
HN
N
(A) 500 mg
Pharmaceutical impurities
50 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0020.08 Imp. A (EP): 3-Cyano-2-methyl-1-[2-
[[(5-methyl-1H-imidazol-4-yl)methyl]-
sulphanyl]ethyl]isothiourea
N
S N
H
S
N
HN
N
(A) 100 mg
MM 0020.12 Imp. B (EP): 3-Cyano-2-methyl-1-[2-[[(5-methyl-1H-imidazol-
4-yl)methyl]sulphanyl]ethyl]isourea
N
O N
H
S
N
HN
N
(A) 100 mg
MM 0020.03 Imp. C (EP) as Dihydrochloride:
1-[(Methylamino)[[2-[[(5-methyl-1H-imidazol-4-yl)-
methyl]sulphanyl]ethyl]amino]methylene]urea
Dihydrochloride
(Cimetidine Amide Dihydrochloride)
x 2 HCl
N
N
H
N
H
S
N
HN
NH
2
O
(A) 100 mg
MM 0020.06 Imp. D (EP) as Dihydrochloride:1-Methyl-
3-[2-[[(5-methyl-1H-imidazol-
4-yl)methyl]sulphanyl]ethyl]guanidine Dihydrochloride
x 2 HCl
NH
N
H
N
H
S
N
HN
(A) 100 mg
MM 0020.04 Imp. E (EP): 2-Cyano-1-methyl-3-[2-[[(5-methyl-1H-imidazol-
4-yl)methyl]sulphinyl]ethyl]guanidine (Cimetidine Sulphoxide)
N
N
H
N
H
S
N
HN
N
O
(A) 100 mg
MM 0020.15 Imp. G (EP): 2-Cyano-1,3-dimethylguanidine
N
H
N
H
N
N
(A) 100 mg
MM 0020.07 Imp. H (EP): 1,1'-(Disulphanediyldiethylene)bis
(2-cyano-3-methylguanidine)
N
H
N
H
N
S
S
N
N
H
N
H
N
N
(A) 100 mg
MM 0020.50
Imp. J (EP) as Dihydrobromide: 2-[[(5-Methyl-1H-imidazol-
4-yl)methyl]sulphanyl]ethanamine Dihydrobromide
x 2 HBr
NH
2
S
N
HN
(A) 100 mg
MM 0020.10 1,1-Dimethyl-3-cyanoguanidine
N
H
N
NH
N
(A) 100 mg
MM 0056.01 Cyanoguanidine
H2N
H
N
NH
N
(B) 100 mg
Cinchocaine Hydrochloride
MM 0604.00 Cinchocaine Hydrochloride
x HCl
N
N
H
O
N O
(A) 500 mg
MM 0604.02 Imp. B (EP): 2-Hydroxyquinoline-4-carboxylic Acid
N
OH
O
HO
(A) 100 mg
MM 0604.05 Cinchocaine N-Oxide
N
N
H
O
N O
O
(A) 100 mg
Cinnarizine
MM 1038.01 Imp. A (EP): 1-(Diphenylmethyl)piperazine
N
NH (A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 51
Code Product Price Unit
MM 1038.03 Imp. B (EP): (Z)-1-(Diphenylmethyl)-4-(3-phenylprop-
2-enyl)piperazine
N
N
(A) 100 mg
MM 1038.04 Imp. C (EP): (4-(Diphenylmethyl)-1,1-bis[(E)-
3-phenylprop-2-enyl]piperazinium Chloride
N
N
+
Cl
-
(A) 100 mg
MM 1038.06 Imp. E (EP): 1,4-Bis(diphenylmethyl)piperazine
N
N
(A) 100 mg
Ciprofloxacin Hydrochloride
MM 0018.06 Ciprofloxacin Hydrochloride Monohydrate
N N
O
OH
O
HN
F
x HCl
x H
2
O
(A) 500 mg
MM 0018.01 Imp. A (EP): 7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-
1,4-dihydroquinoline-3-carboxylic Acid (Fluoroquinolonic Acid) N Cl
O
OH
O
F
(A) 100 mg
MM 0018.05 Imp. B (EP): 1-Cyclopropyl-4-oxo-7-(piperazin-1-yl)-
1,4-dihydroquinoline-3-carboxylic Acid (Desfluoro Compound) N N
O
OH
O
HN
(A) 100 mg
MM 0018.04 Imp. C (EP): 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylic Acid (Ethylenediamine
Compound)
N
H
N
O
OH
O
F
H2N
(D) 50 mg
MM 0018.02
Imp. D (EP): 7-Chloro-1-cyclopropyl-4-oxo-6-(piperazin-1-yl)-
1,4-dihydroquinoline-3-carboxylic Acid
N Cl
O
OH
O
N
HN
(D) 50 mg
MM 0018.03 Imp. E (EP): 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)-quinolin-4(1H)-
one (Decarboxylated Compound) N N
O
HN
F
(A) 100 mg
MM 0018.10 6-(2-Aminoethylamino)-7-chloro-1-cyclopropyl-4-oxo-
1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
N Cl
O
OH
O
N
H
H
2
N
x HCl
(D) 100 mg
Citalopram Hydrobromide
MM 0242.00 Citalopram Hydrobromide
O
N
F
N
x HBr
(A) 250 mg
MM 0242.14 Imp. A (EP): (1RS)-1-[3-(Dimethylamino)-
propyl]-1-(4-fluorophenyl)-1,3-dihydro-
isobenzofuran-5-carboxamide (Citalopram-
Amide)
O
N
F
H
2
N
O
(A) 100 mg
Pharmaceutical impurities
52 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0242.17 Imp. C (EP): (3RS)-6-Cyano-3-[3-(dimethyl-
amino)propyl]-3-(4-fluorophenyl)isobenzofuran-1(3H)-one
O
N
F
N
O
(A) 100 mg
MM 0242.09 Imp. D (EP) as Hydrochloride: (1RS)-1-(4-Fluorophenyl)-
1-[3-(methylamino)propyl]-1,3-dihydroisobenzofuran-
5-carbonitrile Hydrochloride
(Desmethylcitalopram Hydrochloride)
O
N
H
F
x HCl
N
(A) 100 mg
MM 0242.12 Imp. E (EP) as Oxalate: 3-[(1RS)-5-Chloro-
1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-
N,N-dimethylpropan-1-amine Oxalate
O
N
F
Cl
HO O
O HO
x
(A) 50 mg
New MM 0242.13 Imp. F (EP) as Hydrogen Oxalate: 3-[(1R)-5-Bromo-
1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-
N,N-dimethylpropan-1-amine Hydrogen Oxalate
O
N
F
Br
HO O
O HO
x
(A) 100 mg
Citric Acid Anhydrous
MM 0988.00 Citric Acid Anhydrous
O
HO OH
O
HO
O
OH
(A) 250 mg
Citric Acid Monohydrate
MM 0575.00 Citric Acid Monohydrate
x H
2
O
O
HO OH
O
HO
O
OH
(A) 500 mg
Clarithromycin
MM 0057.00 Clarithromycin
O
O
O
O
O
OH
OH
O O
N
HO
O
O
OH
on request
MM 0057.05 Imp. E (EP): 6,11-Di-O-methylerythromycin A
O
O
O
OH
O
O
O
O
O
O H
O
O
N
OH
(D) 100 mg
Clindamycin Hydrochloride
New MM 0259.00 Clindamycin Hydrochloride
O
OH
HO
H
N
OH
S
Cl
O
N
x HCl
(A) 100 mg
Clioquinol
MM 0312.00 Clioquinol
N
Cl
OH
I
(A) 500 mg
MM 0312.01 Imp. A (EP): 5-Chloroquinolin-8-ol
N
Cl
OH
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 53
Code Product Price Unit
MM 0312.02 Imp. B (EP): 5,7-Dichloroquinolin-8-ol
N
Cl
OH
Cl
(B) 100 mg
MM 0312.03 Imp. C (EP): 5,7-Diiodoquinolin-8-ol
N
I
OH
I
(B) 100 mg
Clobenzorex Hydrochloride
MM 0649.00 Clobenzorex Hydrochloride
H
N
Cl
x HCl
(A) 500 mg
Clobetasol Propionate
MM 0769.00 Clobetasol Propionate
HO
F
O
O
O
Cl
O
(A) 100 mg
MM 0200.01 Imp. G (EP): 21-Chloro-9-fluoro-11,17-dihydroxy-16-
methylpregna-1,4-diene-3,20-dione (Clobetasol)
HO
F
OH
O
Cl
O
(A) 100 mg
MM 0202.04
Imp. K (EP):9-Fluoro-11,17-dihydroxy-
16-methyl-3,20-dioxopregna-1,4-dien-
21-yl Propanoate (Betamethasone 21-
Propionate)
HO
F
OH
O
O
O
O
(A) 100 mg
Clobutinol Hydrochloride
MM 0038.00 Clobutinol Hydrochloride
N
Cl
OH
x HCl
on request
MM 0038.01 1-Dimethylamino-2-methylbutan-3-one
N
O
(A) 100 mg
Clomifene Citrate
MM 0650.00 Clomifene Citrate
Cl
O
N
OH
O
OH
O
OH
O
OH
x
and Z-Isomer
(A) 250 mg
MM 0650.01 Clomifene N-Oxide Hydrochloride
Cl
O
N
and Z-Isomer
O
x HCl
(A) 100 mg
MM 0650.03 Desethylclomifene Hydrochloride
Cl
O
N
H
and Z-Isomer
x HCl
(A) 100 mg
Clomipramine Hydrochloride
MM 0545.00 Clomipramine Hydrochloride
N
x HCl
N
Cl
(A) 500 mg
Pharmaceutical impurities
54 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0545.01
Imp. A (EP) as Dihydrochloride: N-[3-(3-
Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-
5-yl)propyl]-N,N',N'-trimethylpropane-1,3-
diamine Dihydrochloride
N
x 2 HCl
N
Cl
N
on request
MM 0077.00 Imp. B (EP) as Hydrochloride: Imipramine Hydrochloride
N
x HCl
N
(A) 500 mg
MM 0545.03 Imp. C (EP) as Hydrochloride: 3-(3-Chloro-5H-
dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
Hydrochloride
N
x HCl
N
Cl
(C) 10 mg
MM 0545.04
Imp. D (EP) as Hydrochloride: 3-(3,7-Dichloro-
10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-
dimethylpropan-1-amine Hydrochloride
N
x HCl
N
Cl
Cl
on request
MM 0076.06 Imp. E (EP): 10,11-Dihydro-5H-dibenzo[b,f]-azepine (Iminodibenzyl)
NH
(B) 100 mg
MM 0545.06 Imp. F (EP): 3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
NH
Cl
(A) 100 mg
MM 0545.07 Imp. G (EP): 3-Chloro-5-(prop-2-enyl)-10,11-dihydro-5H-
dibenzo[b,f]azepine
N
Cl
(C) 50 mg
MM 0545.08 Desmethylclomipramine Hydrochloride
N
H
x HCl
N
Cl
(A) 100 mg
MM 0545.09 Clomipramine N-Oxide
N N
Cl
O
on request
MM 0545.13 3-Chloro-10-[3(dimethylamino)propyl]-9-acridanone
N N
O
Cl
(A) 100 mg
Clonazepam
New MM 0945.01 Imp. A (EP): (2-Amino-5-nitrophenyl)(2-
chlorophenyl)methanone
O
2
N
O
Cl
NH
2
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 55
Code Product Price Unit
New MM 0945.02 Imp. B (EP): 3-Amino-4-(2-chlorophenyl)-6-nitroquinolin-2(1H)-one
H
N O
NH
2
O
2
N
Cl
(A) 50 mg
New MM 0945.04 Methylclonazepam
O
2
N N
N
O
Cl
(A) 50 mg
New MM 0945.05 2-Bromo-2'-(2-chlorobenzoyl)-4'-nitroacetanilide
O
2
N
O
Cl
NH
O
Br
(A) 50 mg
Clonidine Hydrochloride
MM 0983.00 Clonidine Hydrochloride
N
Cl
Cl
N
H
HN
x HCl
(A) 100 mg
MM 0983.04 Imp. A (EP): 1-Acetylimidazolidin-2-one
O N
HN
O
(A) 100 mg
New MM 0983.03 Imp. B (EP): 1-Acetyl-2-[(2,6-dichloro-
phenyl)amino]-4,5-dihydro-1H-imidazole
N
H
Cl
Cl
N
N
O
(A) 50 mg
MM 0006.21 Imp. C (EP): 2,6-Dichloroaniline
NH
2
Cl
Cl
(B) 100 mg
MM 0983.02 1-(2,6-Dichlorophenyl)thiourea
Cl
Cl
N
H
NH
2
S
(A) 100 mg
Clopidogrel Hydrogen Sulphate
MM 0455.10 Clopidogrel Hydrogen Sulphate
Cl
N
O
O
S
x H
2
SO
4
(A) 100 mg
MM 0455.13 Imp. B (EP) as Racemate Hydrogen Sulfate:
Methyl (2RS)-(2-Chlorophenyl)[4,7-dihydro-
thieno[2,3-c]pyridin-6(5H)-yl]acetate Hydrogen
Sulfate
Cl
N
O
O
S
x H
2
SO
4
(A) 100 mg
MM 0455.12 Imp. C (EP) as Hydrogen Sulfate: Methyl
(2R)-(2-Chlorophenyl)[6,7-dihydrothieno[3,2-c]-
pyridin-5(4H)-yl]acetate Hydrogen Sulfate
((R)-Clopidogrel Hydrogen Sulfate)
Cl
N
O
O
S
x H
2
SO
4
(A) 100 mg
MM 0455.09 Clopidogrel Alcohol
Cl
N
OH
S
(D) 100 mg
Clotrimazole
MM 0015.00 Clotrimazole
N
N
Cl
(A) 500 mg
MM 0015.01 Imp. A (EP): (2-Chlorophenyl)diphenylmethanol
OH Cl
(A) 100 mg
Pharmaceutical impurities
56 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0015.10 Imp. B (EP): 1-[(4-Chlorophenyl)diphenylmethyl]-1H-imidazole
N
N
Cl
(A) 100 mg
MM 0015.03 Imp. C (EP): 1-Chloro-2-(chlorodiphenylmethyl)benzene
Cl Cl
(A) 100 mg
MM 0015.02 Imp. D (EP): Imidazole
N
H
N
(B) 100 mg
MM 0015.06 Imp. E (EP): (2-Chlorophenyl)phenylmethanone
(2-Chlorobenzophenone)
Cl O
(A) 100 mg
MM 0015.11 Imp. F (EP): 1-(Triphenylmethyl)-1H-imidazole
(Deschloroclotrimazole)
N
N
(A) 100 mg
MM 0015.04 (2-Chlorophenyl)diphenylmethane
Cl
(A) 100 mg
MM 0015.05 (2-Chlorophenyl)diphenylmethyl Ethyl Ether
O Cl
(A) 100 mg
MM 0015.07 (2-Chlorophenyl)phenyldichloromethane
Cl
Cl Cl
(A) 100 mg
MM 0015.08 (2-Chlorophenyl)trichlormethane
Cl
Cl Cl
Cl
(A) 100 mg
MM 0015.09 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole
N
N Cl
(C) 50 mg
Cloxacillin Sodium
MM 0682.00 Cloxacillin Sodium Monohydrate
N
O
S
O
ONa
H
x H
2
O H
N
O
N
O
Cl
(A) 500 mg
MM 0026.04 Imp. C (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]heptane-2-carboxylic Acid (6-Aminopenicillanic
Acid)
N
O
S
O
OH
H
H
2
N
(B) 100 mg
MM 0682.04 Imp. D (EP): 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic Acid
N
O
Cl
OH
O
(A) 100 mg
Cloxiquine
MM 0391.00 Cloxiquine
OH
Cl
N
(A) 500 mg
Clozapine
MM 0480.00 Clozapine
N
N
N
HN
Cl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 57
Code Product Price Unit
MM 0480.01 Imp. A (EP): 8-Chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
11-one
O
H
N
HN
Cl
(A) 100 mg
MM 0480.03 Imp. C (EP): 8-Chloro-11-(piperazin-1-yl)-5H-
dibenzo[b,e][1,4]diazepine
N
NH
N
HN
Cl
(A) 100 mg
Codeine
MM 0442.00 Codeine Phosphate Hemihydrate
[Controlled Substance]
O OH O
N
x H
2
O
x H
3
PO
4
(A) 100 mg
MM 0004.00 Codeine Monohydrate [Controlled Substance]
O OH O
N
x H2O
(A) 100 mg
MM 0004.03 Imp. A (EP): 7,8-Didehydro-4,5-epoxy-3,6-dimethoxy-
17-methylmorphinan (O-Methylcodeine)
[Controlled Substance]
O O O
N
(A) 100 mg
MM 0037.00 Imp. B (EP) as Hydrochloride Trihydrate: Morphine
Hydrochloride Trihydrate [Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
MM 0280.00 Imp. B (EP) as Hemisulphate Pentahemihydrate:
Morphine Hemisulphate Pentahemihydrate
[Controlled Substance]
O
OH HO
N
x H
2
SO
4
x 5 H
2
O
2
(A) 250 mg
MM 0037.02 Imp. C (EP): 7,7',8,8'-Tetradehydro-4,5:4',5'-diepoxy-
3,3'-dimethoxy-17,17'-dimethyl-2,2'-bimorphinanyl-6,6'-
diol (Codeine Dimer; Dimethyl Pseudomorphine)
O OH O
N
O HO O
N
(A) 100 mg
MM 0004.01 Codeine N-Oxide [Controlled Substance]
O OH O
N
O
(A) 250 mg
MM 0004.02 Codeinone
O O O
N
(A) 100 mg
MM 0004.04 Codeimethine
O OH O
N
(C) 50 mg
MM 0004.05 Norcodeine [Controlled Substance]
O OH O
HN
(A) 100 mg
MM 0004.06 Acetylcodeine [Controlled Substance]
O O O
N
O
(A) 100 mg
MM 0004.08 Isocodeine [Controlled Substance]
O OH O
N
(A) 100 mg
Pharmaceutical impurities
58 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0037.01 Pseudomorphine
O OH HO
N
O HO OH
N
(A) 100 mg
Colchicine
MM 1083.00 Colchicine
O
O
O
O
O
NH
O
(A) 100 mg
MM 1083.04 Imp. D (EP): N-[(7S,12aRa)-3-(-D-Glucopyranosyl-
oxy)-1,2,10-trimethoxy-9-oxo-5,6,7,9-tetrahydro-
benzo[a]heptalen-7-yl]acetamide (Colchicoside)
O
O
NH
O
O
O
O
HO
HO
OH
OH
O
(A) 100 mg
Cortisone
MM 0214.00 Cortisone
O
O
OH
O
OH
(A) 500 mg
Cortisone Acetate
MM 0186.00 Cortisone Acetate
O
O
OH
O
O
O
(A) 500 mg
MM 0187.00 Imp. A (EP): Hydrocortisone Acetate
O
HO
OH
O
O
O
(A) 500 mg
Cyclizine Hydrochloride
New MM 1265.01 Imp. A (EP): 1-Methylpiperazine
HN
N (A) 100 mg
MM 0490.02 Imp. B (EP): Diphenylmethanol (Benzhydrol)
OH
(B) 100 mg
Cyclobenzaprine Hydrochloride
MM 0062.02 Cyclobenzaprine Hydrochloride
N
x HCl
(A) 100 mg
Cyclopentolate Hydrochloride
MM 0580.00 Cyclopentolate Hydrochloride O
O
N
x HCl
HO
(A) 500 mg
MM 0580.01 Imp. A (EP): (2RS)-(1-Hydroxycyclopentyl)(phenyl)acetic Acid O
OH
HO
(A) 100 mg
MM 0160.03 Imp. B (EP): Phenylacetic Acid [Drug Precursor] O
OH
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 59
Code Product Price Unit
MM 0580.03 Imp. C (EP) as Hydrochloride: 2-(Dimethylamino)ethyl
Phenylacetate Hydrochloride
O
O
N
x HCl
(A) 100 mg
Cynarine
MM 0048.01 3,4-Dihydroxycinnamic Acid (Caffeic Acid)
OH
O
HO
HO
(B) 100 mg
Cyproheptadine Hydrochloride
MM 0609.00 Cyproheptadine Hydrochloride Sesquihydrate
N
x HCl x 1
1
/2 H2O
(A) 500 mg
New MM 0609.01 Imp. A (EP): 5H-Dibenzo[a,d][7]annulene
(Dibenzocycloheptene)
(A) 50 mg
MM 0062.01 Imp. B (EP): 10,11-Dihydro-5H-dibenzo[a,d][7]-
annulen-5-one (Dibenzosuberone) O
(B) 100 mg
New MM 0609.07 Imp. C (EP) as Hydrochloride: 5-(1-Methyl-
piperidin-4-yl)-5H-dibenzo[a,d][7]annulen-5-
ol Hydrochloride
OH
N
x HCl
(A) 50 mg
MM 0609.02 5H-Dibenzo[a,d]cyclohepten-5-one (Dibenzosuberenone)
O
(C) 100 mg
MM 0609.04 Demethylcyproheptadine Hydrochloride
NH
x HCl
(A) 100 mg
MM 0609.05 Cyproheptadine -N-Oxide
N
O
(A) 100 mg
MM 0609.06 Cyproheptadine -N-Oxide
N
O
(A) 100 mg
Cyproterone Acetate
MM 0215.00 Cyproterone Acetate
O
O
O
Cl
O
(A) 250 mg
Dacarbazine
New MM 1289.00 Dacarbazine
O
NH
2
N
HN
N
N
N
(A) 50 mg
New MM 1289.02 Imp. B (EP): 5-Amino-1H-imidazole-4-carboxamide
O
NH
2
N
HN
H
2
N
(A) 100 mg
MM 0056.06 Imp. D (EP) as Hydrochloride: N-Methylmethanamine
Hydrochloride
H
N x HCl (C) 100 mg
Pharmaceutical impurities
60 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
DDT
MM 2513.01 2,2-Bis(4-chlorophenyl)-1-chloroethane
Cl
Cl
Cl
(A) 100 mg
MM 2513.02 1-Chloro-3-[1-(4-chlorophenyl)ethyl]benzene
Cl
Cl
(A) 100 mg
MM 2513.05 1,1-Bis(4-chlorophenyl)ethane
Cl Cl
(A) 100 mg
Dembrexine Hydrochloride Monohydrate
New MM 1200.03 Imp. C (EP): 3,5-Dibromo-2-hydroxybenzaldehyde
Br Br
OH
O
(A) 100 mg
MM 1200.04 Imp. D (EP): 2-Hydroxybenzaldehyde
(Salicylaldehyde) OH
O
(A) 100 mg
New MM 1200.05 Imp. E (EP): 2,4,6-Tribromophenol
Br Br
OH
Br
(A) 100 mg
Demeclocycline Hydrochloride
MM 0636.00 Demeclocycline Hydrochloride
OH O OH O
NH2
O
OH
OH
N
H H x HCl
Cl OH
(A) 250 mg
Desipramine Hydrochloride
MM 0589.00 Desipramine Hydrochloride
N
H
x HCl
N
(A) 250 mg
MM 0077.00 Imipramine Hydrochloride
N
x HCl
N
(A) 500 mg
MM 0076.06 Iminodibenzyl
NH
(B) 100 mg
Dexamethasone
MM 0213.00 Dexamethasone
O
HO
F
OH
O
OH
(A) 250 mg
MM 0200.00 Imp. B (EP): Betamethasone
O
HO
F
OH
O
OH
(A) 250 mg
MM 0213.01 Imp. C (EP): 9--Fluoro-11,17,21-
trihydroxy-16-methylpregn-4-ene-3,20-dione
O
HO
F
OH
O
OH
(D) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 61
Code Product Price Unit
MM 0445.00 Imp. G (EP): Dexamethasone Acetate
O
HO
F
OH
O
O
O
(A) 250 mg
Dexamethasone Acetate
MM 0445.00 Dexamethasone Acetate
O
HO
F
OH
O
O
O
(A) 250 mg
MM 0213.00 Imp. A (EP): 9-Fluoro-11,17,21-trihydroxy-
16-methylpregna-1,4-diene-3,20-dione
(Dexamethasone)
O
HO
F
OH
O
OH
(A) 250 mg
MM 0201.00 Imp. D (EP): 9-Fluoro-11,17-dihydroxy-16-
methyl-3,20-dioxopregna-1,4-dien-21-yl Acetate
(Betamethasone Acetate)
O
HO
F
OH
O
O
O
(A) 250 mg
Dexamethasone Sodium Phosphate
MM 0210.00 Dexamethasone Sodium Phosphate
O
HO
F
OH
O
O
P
ONa
O
ONa
(A) 250 mg
MM 0213.00 Imp. A (EP): Dexamethasone
O
HO
F
OH
O
OH
(A) 250 mg
MM 0303.00 Imp. B (EP): Betamethasone Sodium Phosphate
O
HO
F
OH
O
O
P
ONa
O
ONa
on request
Dexchlorpheniramine Maleate
MM 1114.00 Dexchlorpheniramine Maleate
N
N
Cl
OH
O
O
OH
x
(A) 100 mg
MM 0059.00 Imp. A (EP) as Maleate: (3RS)-N,N-Dimethyl-3-
phenyl-3-(pyridin-2-yl)propan-1-amine Maleate
(Pheniramine Maleate)
N
N
OH
O
O
OH
x
(A) 100 mg
Dextromethorphan Hydrobromide
MM 0033.00 Dextromethorphan Hydrobromide Monohydrate
O
N
x HBr
x H2O
(A) 500 mg
MM 0033.10 Imp. A (EP) as Hydrochloride: ent-3-Methoxymorphinan
Hydrochloride
O
HN
x HCl
(A) 100 mg
Pharmaceutical impurities
62 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0033.09 Imp. B (EP) as (L)-Tartrate: ent-17-Methylmorphinan-
3-ol (L)-Tartrate
HO
N
HO
OH
OH
OH
O
O
x
(A) 100 mg
MM 0033.02 Imp. C (EP): ent-3-Methoxy-17-methylmorphinan-10-one
O
N O
(D) 100 mg
MM 0033.11 Dextromethorphan N-Oxide Hydrochloride
O
N
x HCl
O
(A) 100 mg
Dextropropoxyphene Hydrochloride
MM 0098.01 Dextropropoxyphene Hydrochloride
[Controlled Substance]
O
O
N
x HCl
(A) 50 mg
MM 0098.00 Dextropropoxyphene [Controlled Substance]
O
O
N (A) 50 mg
MM 0098.06 Imp. A (EP): (2S,3R)-4-(Dimethylamino)-1,2-diphenyl-3-methylbutan-
2-ol
OH
N (A) 100 mg
MM 0098.07 Imp. B (EP) as Hydrochloride: (1S,2R)-1-Benzyl-
3-(dimethylamino)-2-methyl-1-phenylpropyl
Acetate Hydrochloride
(Acetoxyphene Hydrochloride)
O
O
N
x HCl
(A) 100 mg
MM 0098.08 Imp. C: (EP) as Hydrochloride: (1S,2R)-1-Benzyl-
3-(dimethylamino)-2-methyl-1-phenyl-propyl
Butanoate Hydrochloride
(Butyroxyphene Hydrochloride)
O
O
N
x HCl
(A) 50 mg
MM 0291.04 Toluene (C) 100 mg
New MM 0098.11 Imp. F (EP) as Hydrochloride: (2RS)-3-(Dimethyl-
amino)-2-methyl-1-phenylpropan-1-one Hydro-
chloride
x HCl
O
N
(A) 50 mg
Diazepam
MM 0023.00 Diazepam [Controlled Substance]
N
N
O
Cl
(A) 100 mg
MM 0023.02 Imp. A (EP): 7-Chloro-5-phenyl-1,3-dihydro-2H-
1,4-benzodiazepin-2-one (Nordazepam)
[Controlled Substance]
N
H
N
O
Cl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 63
Code Product Price Unit
MM 0023.04 Imp. B (EP): 2-Chloro-N-(4-chloro-2-benzoylphenyl)-N-
methylacetamide
Cl
N
O
O
Cl
(A) 100 mg
MM 0023.03 Imp. C (EP): 3-Amino-6-chloro-1-methyl-4-phenylquinolin-2(1H)-
one
Cl
N
NH
2
O
(A) 100 mg
MM 0023.01 Imp. D (EP): [5-Chloro-2-(methylamino)phenyl]phenylmethanone
(5-Chloro-2-(methylamino)benzophenone)
Cl
NH
O
(B) 100 mg
MM 0023.05 2'-Benzoyl-2,4'-dichloroacetanilide
Cl
NH
O
O
Cl
(A) 100 mg
Dibutyl Sebacate
MM 0925.00 Dibutyl Sebacate
O O
O O
(A) 500 mg
Dichlorobenzyl Alcohol
MM 0739.01 Bis-(2,4-dichlorobenzyl)Ether
Cl Cl
O
Cl Cl
(A) 100 mg
Diclofenac Sodium
MM 0006.00 Diclofenac Sodium
NH
O ONa
Cl Cl
(A) 500 mg
MM 0006.01 Imp. A (EP): 1-(2,6-Dichlorophenyl)-1,3-dihydro-2H-indol-2-one
Cl Cl
N
O
(A) 100 mg
MM 0006.03 Imp. B (EP): 2-[(2,6-Dichlorophenyl)amino]benzaldehyde
NH
Cl Cl
O (A) 100 mg
MM 0006.04 Imp. C (EP): [2-[(2,6-Dichlorophenyl)amino]phenyl]methanol
NH
Cl Cl
OH (A) 100 mg
MM 0006.09 Imp. D (EP): 2-[2-[(2-Bromo-6-chlorophenyl)amino]phenyl]acetic Acid
NH
Cl Br
OH
O
(D) 100 mg
MM 0006.05 Imp. D (EP) as Sodium Salt: Sodium 2-[2-[(2-Bromo-
6-chlorophenyl)amino]phenyl]acetate
NH
Cl Br
ONa
O
(D) 100 mg
MM 0006.02 Imp. E (EP): 1,3-Dihydro-2H-indol-2-one
N
H
O
(B) 100 mg
Pharmaceutical impurities
64 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0006.06 1-(2-Bromo-6-chlorophenyl)indolin-2-one
Cl Br
N
O
(C) 10 mg
MM 0006.10 Methyl 2-[2-[(2,6-Dichlorophenyl)amino]phenyl]acetate
(Methyl Ester of Diclofenac)
NH
Cl Cl
O
O
(A) 100 mg
MM 0006.11 Ethyl [2-[(2,6-Dichlorophenyl)amino]phenyl]acetate
(Ethyl Ester of Diclofenac)
NH
Cl Cl
O
O
(A) 100 mg
MM 0181.06 Isopropyl 2-[2-[(2,6-Dichlorophenyl)amino]phenyl]acetate
(Isopropyl Ester of Diclofenac)
NH
Cl Cl
O
O
(A) 100 mg
MM 0006.12 2-(2,6-Dichlorophenylamino)benzoic Acid
NH
Cl Cl
OH
O
(A) 100 mg
MM 0006.15 2,6-Dichlorodiphenylamine
NH
Cl Cl
(A) 100 mg
MM 0006.16 2-Bromo-6-chlorodiphenylamine
NH
Cl Br
(A) 100 mg
MM 0006.17 1-(2,6-Dichlorophenyl)indolin-2,3-dione
Cl Cl
N
O
O
(A) 100 mg
MM 0006.18 Diclofenac Potassium
NH
Cl Cl
OK
O
(A) 100 mg
MM 0006.19 2-Chloro-N-(2,6-dichlorophenyl)-N-phenylacetamide
N
Cl Cl
O
Cl
(A) 100 mg
MM 0006.20 2-[2-[(2,6-Dichlorophenyl)amino]phenyl]acetic Acid (Diclofenac)
NH
Cl Cl
OH
O
(A) 100 mg
MM 0006.21 2,6-Dichloroaniline
NH2
Cl Cl
(B) 100 mg
MM 0006.22 2-Bromo-6-chloroaniline
NH2
Cl Br
on request
MM 0006.27 N-Acetyl-N-phenyl-2,6-dichloroaniline
N
Cl Cl
O (A) 100 mg
MM 0006.28 Diethyl Phthalate
O
O
O
O
(C) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 65
Code Product Price Unit
Dicloxacillin Sodium
MM 0229.00 Dicloxacillin Sodium Monohydrate
N
S
H
O
O
ONa
x H
2
O H
N
O
N
O
Cl
Cl
on request
MM 0026.04 Imp. C (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid
(6-Aminopenicillanic Acid)
N
S
H
O
H2N
O
OH
(B) 100 mg
Diflucortolone Valerate
MM 0600.00 Diflucortolone Valerate
O
F
F
HO
O
O
O
(A) 100 mg
Digitoxin
MM 0336.01 Digitoxigenin
HO
OH
O
O
(A) 50 mg
Digoxin
MM 0212.00 Digoxin
O
OH
O
O
H
O
OH
O
O
O
O
OH
HO
OH
OH
(A) 250 mg
Dihydrocodeine Hydrogen Tartrate
New MM 0004.00 Imp. A (EP) as Monohydrate: Codeine
Monohydrate [Controlled Substance]
O OH O
N
x H
2
O
(A) 100 mg
New MM 0442.00 Imp. A (EP) as Phosphate Hemihydrate:
Codeine Phosphate Hemihydrate
[Controlled Substance]
O OH O
N
x H
3
PO
4
x 1/2 H
2
O
(A) 100 mg
New MM 0280.00 Imp. B (EP) as Hemisulphate Pentahemihydrate:
Morphine Hemisulphate Pentahemihydrate
[Controlled Substance]
O OH HO
N
2
x H
2
SO
4
x 5 H
2
O
(A) 250 mg
New MM 0037.00 Imp. B (EP) as Hydrochloride Trihydrate:
Morphine Hydrochloride Trihydrate
[Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
Pharmaceutical impurities
66 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Diltiazem Hydrochloride
MM 0068.00 Diltiazem Hydrochloride
N
S
O
O
N
O
O
x HCl
(A) 500 mg
MM 0068.02 Imp. B (EP): (2S,3S)-2-(4-Methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-
1,5-benzothiazepin-3-yl Acetate
N
H
S
O
O
O
O
(A) 100 mg
MM 0068.03 Imp. D (EP) as Hydrochloride: (2S,3S)-2-(4-Methoxyphenyl)-
5-[2-(methylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-
1,5-benzothiazepin-3-yl Acetate Hydrochloride
(N-Desmethyldiltiazem Hydrochloride)
N
S
O
O
HN
O
O
x HCl
(A) 100 mg
MM 0068.04 Imp. E (EP):(2S,3S)-3-Hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-
1,5-benzothiazepin-4(5H)-one
N
H
S
OH
O
O
(A) 100 mg
MM 0068.05 Imp. F (EP):(2S,3S)-5-[2-(Dimethylamino)ethyl]-3-hydroxy-
2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one
N
S
OH
N
O
O
(A) 100 mg
MM 0068.07 Diltiazem Sulphoxide
N
S
O
O
N
O
O
O
(A) 100 mg
MM 0068.08 Diltiazem Maleate
N
S
O
O
N
O
O
O
OH
O
OH
x
(A) 100 mg
Dimenhydrinate
MM 0599.00 Dimenhydrinate
O
N N
N
N
H
N
Cl
O
O
x
(A) 500 mg
MM 0176.00 Imp. A (EP): Theophylline
N
N
N
H
N
O
O
(A) 500 mg
MM 0599.04 8-[(2-(Diphenylmethoxy)ethyl)(methyl)-
amino]-1,3-dimethyl-3,7-dihydro-1H-
purine-2,6-dione
N
N
O
O
N
H
N
N
O
(A) 100 mg
MM 0494.00 Imp. C (EP): Caffeine
N
N
N
N
O
O
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 67
Code Product Price Unit
New MM 0599.08 Imp. E (EP): 8-Chloro-1,3,7-trimethyl-3,7-
dihydro-1H-purine-2,6-dione
(8-Chlorocaffeine)
N
N
N
N
O
O
Cl
(A) 50 mg
MM 0490.03 Imp. F (EP) as Hydrochloride:
2-(Diphenylmethoxy)-N-methylethanamine
Hydrochloride (Diphenhydramine Imp. A
Hydrochloride; Nordiphenhydramine Hydrochloride)
O
H
N
x HCl
(A) 100 mg
MM 0490.04 Imp. G (EP) as Hydrochloride:
N,N-Dimethyl-2-[(4-methylphenyl)-
(phenyl)methoxy]ethanamine Hydrochloride
(4-Methyldiphenhydramine Hydrochloride)
O
N
x HCl
(A) 100 mg
MM 0640.00 Imp. H (EP) as Hydrochloride: 2-[(RS)-(4-
Bromophenyl)(phenyl)methoxy]-N,N-dimethyl-
ethanamine Hydrochloride (4-Bromodiphen-
hydramine Hydrochloride; Bromazine Hydro-
chloride)
O
N
x HCl
Br
(A) 100 mg
MM 0490.02 Imp. I (EP): Diphenylmethanol
(Benzhydrol)
OH
(B) 100 mg
MM 0630.01 Imp. J (EP): Diphenylmethanone
(Benzophenone)
O
(B) 100 mg
New MM 0599.14 Imp. K (EP): [Oxybis(methanetriyl)]tetrabenzene
(Bis(diphenylmethyl) Ether)
O
(A) 50 mg
MM 0490.00 Diphenhydramine Hydrochloride
O
N
x HCl
(A) 500 mg
MM 0155.02 8-Chlorotheophylline
N
N
N
H
N
Cl
O
O
(B) 100 mg
MM 0599.03 8-[N-(2-Diphenylmethoxyethyl)-N,N-
dimethylaminium]-1,3-dimethylxanthine
inner salt
N
N
O
O
N
N
-
N
+
O
(A) 100 mg
Dimetindene Maleate
MM 0595.01 Imp. A (EP): 2-Ethylpyridine
N
(B) 100 mg
New MM 0595.02 Imp. B (EP) as Hydrochloride: 2-(1H-Inden-
2-yl)-N,N-dimethylethanamine Hydrochloride
N
x HCl
(A) 50 mg
New MM 0595.10 Imp. E (EP) as Hydrochloride: (2RS)-2-[2-(Dimethyl-
amino)ethyl]indan-1-one Hydrochloride
N
O
x HCl
(A) 50 mg
New MM 0595.06 Imp. F (EP) as Hydrochloride: 2-(3-Butyl-1H-
inden-2-yl)-N,N-dimethylethanamine Hydro-
chloride
N
x HCl
(A) 50 mg
Pharmaceutical impurities
68 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
New MM 0595.07 Imp. G (EP) as Hydrochloride: N,N-Dimethyl-
2-(3-phenyl-1H-inden-2-yl)ethanamine Hydro-
chloride
N
x HCl
(A) 50 mg
Diphemanil Metilsulfate
MM 1163.00 Diphemanil Metilsulfate
N
+
O
S
O
O O
x
-
(D) 100 mg
Diphenhydramine Hydrochloride
MM 0490.00 Diphenhydramine Hydrochloride
O
N
x HCl
(A) 500 mg
MM 0490.03 Imp. A (EP) as Hydrochloride: 2-(Diphenylmethoxy)-N-
methylethanamine Hydrochloride
(Nordiphenhydramine Hydrochloride)
O
H
N
x HCl
(A) 100 mg
MM 0490.04 Imp. B (EP) as Hydrochloride: 2-[(RS)-
(4-Methylphenyl)phenylmethoxy]-N,N-
dimethylethanamine Hydrochloride
(4-Methyldiphenhydramine Hydrochloride)
O
N
x HCl
(A) 100 mg
MM 0640.00 Imp. C (EP) as Hydrochloride: 2-[(RS)-
(4-Bromophenyl)phenylmethoxy]-N,N-
dimethylethanamine Hydrochloride
(Bromazine Hydrochloride)
O
N
x HCl
Br
(A) 100 mg
MM 0490.02 Imp. D (EP): Diphenylmethanol (Benzhydrol)
OH
(B) 100 mg
MM 0630.01 Imp. E (EP): Diphenylmethanone (Benzophenone)
O
(B) 100 mg
MM 0490.01 Diphenhydramine N-Oxide
O
N
O
(A) 100 mg
Diphenylpyraline Hydrochloride
MM 0557.00 Diphenylpyraline Hydrochloride
O
N
x HCl
(A) 500 mg
MM 0155.01 Diphenylpyraline
O
N
(A) 100 mg
MM 0490.02 Diphenylmethanol (Benzhydrol)
OH
(B) 100 mg
MM 0630.01 Diphenylmethanone (Benzophenone)
O
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 69
Code Product Price Unit
MM 0557.04 Diphenylpyraline N-Oxide
O
N
O
(A) 100 mg
MM 0468.04
N-Desmethyldiphenylpyraline Hydrochloride
(4-(Diphenylmethoxy)piperidine Hydrochloride)
O
NH
x HCl
(A) 100 mg
Dipipanone Hydrochloride
MM 0760.01 1,1-Diphenylbut-1-ene (A) 100 mg
MM 0760.02 1-(1-Methyl-3,3-diphenylpropyl)piperidine Hydrochloride
N
x HCl
(A) 100 mg
Dipotassium Clorazepate
MM 0028.03 Imp. A (EP): (2-Amino-5-chlorophenyl)phenylmethanone
(Aminochlorobenzophenone)
Cl
NH
2
O
(B) 100 mg
MM 0023.02 Imp. B (EP): 7-Chloro-5-phenyl-1,3-dihydro-2H-
1,4-benzodiazepin-2-one (Nordazepam)
[Controlled Substance] N
H
N
O
Cl
(A) 100 mg
Diprafenon Hydrochloride
MM 0428.01 2'-Hydroxy-3-phenylpropiophenone
O
OH
(A) 100 mg
Diprophylline
MM 0176.01 Imp. A (EP): N-Methyl-5-(methylamino)-1H-
imidazole-4-carboxamide (Theophyllidine) N
H
HN
N
H
N
O
(A) 100 mg
MM 0176.00 Imp. B (EP): 1,3-Dimethyl-3,7-dihydro-1H-
purine-2,6-dione (Theophylline) N
N
N
H
N
O
O
(A) 500 mg
MM 0603.00 Imp. C (EP): 7-(2-Hydroxyethyl)-1,3-dimethyl-
3,7-dihydro-1H-purine-2,6-dione (Etofylline) N
N
N
N
O
O
OH
(A) 500 mg
Dipyridamole
MM 0462.03 Imp. C (EP): 2,2'-[[6-Chloro-4,8-di(piperidin-1-
yl)pyrimido[5,4-d]pyrimidin-2-yl]nitrilo]diethanol
N
N
N
N
N
Cl
N
N
OH
OH
(A) 100 mg
Pharmaceutical impurities
70 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Disopyramide
MM 0108.00 Disopyramide
O
NH
2
N
N
(A) 500 mg
Dithranol
MM 0137.00 Dithranol
OH O OH
(A) 500 mg
MM 0137.04 Imp. A (EP): Anthracen-9(10H)-one (Anthrone)
O
(A) 100 mg
MM 0137.01 Imp. B (EP): 1,8-Dihydroxyanthracene-9,10-dione (Danthron)
OH O OH
O
(A) 100 mg
MM 0137.02 Imp. C (EP): 4,4',5,5'-Tetrahydroxy-9,9'-bianthracenyl-10,10'(9H,9'H)-
dione (Dithranol Dimer)
OH O OH
OH O OH
(A) 100 mg
Dobutamine Hydrochloride
MM 0384.00
Imp. A (EP) as Hydrochloride: Dopamine Hydrochloride HO
HO
NH
2
x HCl
(A) 500 mg
MM 0675.02 Imp. B (EP): 4-(4-Hydroxyphenyl)butan-2-one
O
OH
(C) 100 mg
Dodecylguanidinium Acetate
MM 0451.03 Dodecylnitrile
N
(B) 100 mg
MM 0451.05 Dimethyldodecylamine
N
(B) 100 mg
Domperidone
MM 0107.00 Domperidone
N
NH N
N HN
O
O
Cl
(D) 100 mg
MM 0107.06 Imp. A (EP): 5-Chloro-1-(piperidin-4-yl)-
1,3-dihydro-2H-benzimidazol-2-one
HN
NH N
O
Cl
(A) 100 mg
MM 0107.05 Imp. B (EP): 4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-
1-formylpiperidine
N
NH N
O
Cl
O (A) 100 mg
MM 0107.03 Imp. F (EP): 1,3-Bis[3-[4-(5-chloro-2-oxo-
2,3-dihydro-1H-benzimidazol-1-yl)piperidin-
1-yl]propyl]-1,3-dihydro-2H-benzimidazol-
2-one
N
NH N
N N
O
O
Cl
N
HN N
O
Cl
(A) 50 mg
MM 0107.07 1,3-Dihydro-2H-benzimidazol-2-one
H
N
N
H
O
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 71
Code Product Price Unit
Donepezil Hydrochloride
MM 0677.00 Donepezil Hydrochloride
O
O
O
N
x HCl
(D) 100 mg
MM 0677.01 Donepezil
O
O
O
N
(D) 100 mg
New MM 0677.16 1-Benzyl-4-[(5,6-dimethoxy-1H-inden-
2-yl)methyl]piperidine
O
O
N
(A) 50 mg
Dopamine Hydrochloride
MM 0384.00 Dopamine Hydrochloride
HO
HO
NH
2
x HCl
(A) 500 mg
MM 0384.02 Imp. A (EP) as Hydrochloride: 5-(2-Aminoethyl)-
2-methoxyphenol Hydrochloride
(4-O-Methyldopamine Hydrochloride)
HO
O
NH
2
x HCl
(A) 100 mg
MM 0384.04 Imp. C (EP): 2-(3,4-Dimethoxyphenyl)ethanamine
O
O
NH
2
(A) 100 mg
MM 0384.01 (R,S)--Methyldopamine Hydrobromide
HO
HO
NH
2
x HBr
(A) 100 mg
Dorzolamide Hydrochloride
New MM 0403.00 Dorzolamide Hydrochloride
S
S
HN
S
H
2
N
O
O
O O
x HCl
(A) 50 mg
Dosulepin Hydrochloride
MM 0510.00 Dosulepin Hydrochloride
x HCl
N
S
(A) 100 mg
MM 0510.02 Imp. B (EP): Dibenzo[b,e]thiepin-11(6H)-one
O
S
(A) 100 mg
MM 0510.08 Nordosulepin Hydrochloride
x HCl
N
H
S
(A) 50 mg
Doxazosin Mesilate
MM 0386.00 Doxazosin Mesilate
N
N O
O
NH
2
N
N
O
O
O
S
OH
O O
x
(A) 100 mg
MM 0386.08 Doxazosin
N
N O
O
NH
2
N
N
O
O
O
(A) 100 mg
Pharmaceutical impurities
72 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0386.04 Imp. A (EP): (2RS)-2,3-Dihydro-1,4-benzodioxine-2-carboxylic Acid
O
O HO
O
(A) 100 mg
MM 0386.05 Imp. B (EP) as Hydrochloride: 1-[(2RS)-2,3-Dihydro-
1,4-benzodioxin-2-ylcarbonyl]piperazine Hydrochloride
O
O N
O
HN
x HCl
(A) 100 mg
MM 0386.06 Imp. C (EP): 1,4-Bis(2,3-dihydro-1,4-benzodioxin-
2-ylcarbonyl)piperazine
O
O N
O
N
O
O
O
(A) 100 mg
MM 0085.07 Imp. D (EP): 6,7-Dimethoxyquinazoline-2,4(1H,3H)-dione
NH
H
N O
O
O
O
(C) 100 mg
MM 0085.06 Imp. E (EP): 2,4-Dichloro-6,7-dimethoxyquinazoline
N
N O
O
Cl
Cl
(A) 100 mg
MM 0386.01 Imp. F (EP): 2-Chloro-6,7-dimethoxyquinazolin-4-amine
N
N
O
O
Cl
NH2
(A) 100 mg
MM 0386.12 Imp. F (EP) as Mesilate: 2-Chloro-6,7-dimethoxy-
quinazolin-4-amine Mesilate N
N O
O
NH
2
Cl
S
OH
O O
x
(A) 100 mg
MM 0085.01 Imp. G (EP): 6,7-Dimethoxy-2-(piperazin-1-yl)quinazolin-
4-amine
N
N O
O
N
NH
2
NH (A) 100 mg
MM 0085.03 Imp. H (EP): 2,2'-(Piperazine-
1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine)
N
N O
O
N
NH
2
N N
N
O
O
NH
2
(D) 100 mg
Doxepin Hydrochloride
MM 0032.00 Doxepin Hydrochloride
O
N
x HCl
(A) 500 mg
New MM 0032.03 Imp. A (EP): Dibenzo[b,e]oxepin-11(6H)-one
(Doxepinone) O
O
(A) 100 mg
New MM 0032.04 Imp. B (EP): (11RS)-11-[3-(Dimethylamino)-
propyl]-6,11-dihydrodibenzo[b,e]oxepin-
11-ol (Doxepinol)
O
OH
N
(A) 50 mg
New MM 0032.08 Imp. C (EP) as E/Z-Mixture: (E,Z)-3-(Dibenzo[b,e]-
oxepin-11(6H)-ylidene)-N-methylpropan-1-amine
((E,Z)-Desmethyldoxepin)
O
NH
(A) 50 mg
Doxylamine Hydrogen Succinate
MM 0101.00 Doxylamine Hydrogen Succinate
N
O
N
OH
O
OH
O
x
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 73
Code Product Price Unit
New MM 0101.02 Imp. B (EP) as Hydrochloride: (1RS)-1-Phenyl-
1-(pyridin-2-yl)ethanol Hydrochloride
N
OH
x HCl
(A) 50 mg
New MM 0101.03 Imp. C (EP) as Hydrogen Fumarate: N,N-
Dimethyl-2-[(RS)-1-phenyl(pyridin-2-yl)-
methoxy]ethanamine Hydrogen Fumarate
N
O
N
OH
O
HO
O
x
(A) 50 mg
MM 0101.04
Imp. D (EP): Phenyl(pyridin-2-yl)methanone
(2-Benzoylpyridine)
N
O
(A) 100 mg
MM 0101.05 Doxylamine N-Oxide Dihydrochloride
N
O
N
O
x 2 HCl
(A) 100 mg
New MM 0101.08 N-Desmethyldoxylamine Hydrogen Succinate
N
O
H
N
x
OH
O
O
OH
(A) 50 mg
Drofenine Hydrochloride
MM 0768.00 Drofenine Hydrochloride
O
O
N
x HCl
(A) 500 mg
MM 0768.01 Drofenine N-Oxide Hydrochloride
O
O
N
x HCl
O
(A) 100 mg
Droperidol
MM 0138.01 Imp. A (EP): 1-(1,2,3,6-Tetrahydropyridin-
4-yl)-1,3-dihydro-2H-benzimidazol-2-one
HN
N
NH
O
(A) 50 mg
MM 0138.04 Imp. D (EP) as Hydrochloride: (1RS)-
1-[4-(4-Fluorophenyl)-4-oxobutyl]-
4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-
1,2,3,6-tetrahydro-
pyridine 1-Oxide Hydrochloride
N
N
O
F
NH
O
O
x HCl
(A) 100 mg
Dropropizine
MM 1017.00 Dropropizine
N
N
OH
OH (A) 500 mg
Duloxetine Hydrochloride
New MM 1122.00 Duloxetine Hydrochloride
x HCl
O N
H
S
on request
New MM 0043.04 Imp. D (Pharmeuropa): Naphthalen-1-ol (1-Naphthol)
OH
(B) 100 mg
Ebastine
MM 0468.00 Ebastine
O
N
O
(A) 100 mg
Pharmaceutical impurities
74 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0490.02 Imp. A (EP): Diphenylmethanol (Benzhydrol)
OH
(B) 100 mg
MM 0468.03 Imp. B (EP): 1-[4-(1,1-Dimethylethyl)phenyl]ethanone
O
(A) 100 mg
MM 0468.04 Imp. C (EP) as Hydrochloride: 4-(Diphenyl-
methoxy)piperidine Hydrochloride
O
NH
x HCl
(A) 100 mg
MM 0468.05 Imp. D (EP): 1-[4-(1,1-Dimethylethyl)phenyl]-
4-(4-hydroxypiperidin-1-yl)butan-1-one
HO
N
O
(A) 100 mg
MM 0468.06 Imp. E (EP) as Hydrogen Fumarate:
1-[4-(1,1-Dimethylpropyl)phenyl]-
4-[4-(diphenylmethoxy)piperidin-
1-yl]butan-1-one Hydrogen Fumarate
O
N
O
O
OH
HO
O
x
(A) 100 mg
Econazole Nitrate
MM 0524.00 Econazole Nitrate
O
Cl
x HNO
3
N
N
Cl
Cl
(A) 500 mg
MM 0281.01 Imp. A (EP): (1RS)-1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanol
HO
N
N
Cl
Cl
(A) 100 mg
MM 0524.02 Imp. B (EP) as Nitrate: (2RS)-2-[(4-Chlorobenzyl)oxy]-
2-(2,4-dichlorophenyl)ethanamine Nitrate
O
Cl
x HNO
3
NH
2
Cl
Cl
(D) 100 mg
MM 0524.03 Imp. C (EP) as Chloride: 1-(4-Chlorobenzyl)-
3-[(2RS)-2-[(4-chlorobenzyl)oxy]-2-(2,4-
dichlorophenyl)ethyl]imidazolium Chloride
O
Cl
N
+
N
Cl
Cl
Cl
Cl
-
(A) 100 mg
Emedastine Difumarate
New MM 1277.02 Imp. B (EP): 2-Chloro-1-(2-ethoxyethyl)-1H-
Benzimidazole
N
N Cl
O
(A) 100 mg
Enalapril Maleate
MM 0010.00 Enalapril Maleate
H
N
O O
N
O
OH
OH
O
O
x
O
OH
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 75
Code Product Price Unit
MM 0010.05 Imp. B (EP): (2S)-2-[[(1S)-1-(Ethoxycarbonyl)-
3-phenylpropyl]amino]propanoic Acid
H
N
O O
OH
O (A) 100 mg
MM 0010.01 Imp. C (EP): (2S)-1-[(2S)-2-[[(1S)-1-Carboxy-
3-phenylpropyl]amino]propanoyl]pyrrolidine-2-
carboxylic Acid (Enalaprilat)
H
N
HO O
N
O
O
OH
(D) 100 mg
MM 0010.06 Imp. D (EP): Ethyl (2S)-2-[(3S,8aS)-3-Methyl-1,4-dioxo-
octahydropyrrolo[1,2-]pyrazin-2-yl]-4-phenylbutanoate
(Enalapril diketopiperazine)
N
O O
O
N
O
H
(A) 100 mg
MM 0015.02 Imp. I (EP): 1H-Imidazole (Imidazole)
N
H
N
(B) 100 mg
MM 0010.15 (2S)-2[[(1S)-1-(Ethoxycarbonyl)-
3-phenylpropyl]amino]propanoic Acid Ethyl Ester
Hydrochloride
H
N
O O
O
O
x HCl
(A) 100 mg
Enilconazole
MM 0281.01 Imp. E (EP): (1RS)-1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanol
N
HO
N
Cl
Cl
(A) 100 mg
Enrofloxacin
MM 0395.00 Enrofloxacin
N N
O
OH
O
N
F
(A) 100 mg
MM 0018.01 Imp. A (EP): 7-Chloro-1-cyclo-
propyl-6-fluoro-4-oxo-1,4-dihydroquinoline-
3-carboxylic Acid
N Cl
O
OH
O
F
(A) 100 mg
MM 0018.06 Imp. B (EP) as Hydrochloride Monohydrate:
Ciprofloxacin Hydrochloride Monohydrate
N N
O
OH
O
HN
F
x HCl
x H
2
O
(A) 500 mg
MM 0395.01 Imp. C (EP) as Hydrochloride:
1-Cyclopropyl-7-(4-ethylpiperazin-1-yl)-4-
oxo-1,4-dihydroquinoline-3-carboxylic Acid
Hydrochloride (Desfluoroenrofloxacin
Hydrochloride)
N N
O
OH
O
N
x HCl
(A) 100 mg
MM 0018.04 Imp. G (EP): 7-[(2-Aminoethyl)amino]-1-cyclopropyl-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
N HN
O
OH
O
H
2
N
F
(D) 50 mg
MM 0395.07 Enrofloxacin N-Oxide Hydrochloride
N N
O
OH
O
N
F
O
x HCl
(A) 100 mg
Entacapone
MM 1221.02 Imp. A (EP): (2Z)-2-Cyano-3-(3,4-dihydroxy-
5-nitrophenyl)-N,N-diethylprop-2-enamide
NO
2
HO
HO
N
N O
(A) 50 mg
Pharmaceutical impurities
76 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
New MM 1221.04 Imp. B (EP): Ethyl (2E)-2-Cyano-3-(3,4-
dihydroxy-5-nitrophenyl)prop-2-enoate
O
2
N
HO
OH
N
O
O
(A) 50 mg
MM 1221.01 Imp. C (EP): 3,4-Dihydroxy-5-nitrobenzaldehyde
O
2
N
HO
OH
O
(A) 100 mg
New MM 1221.05 Imp. D (EP): (2E)-2-Cyano-3-(3-ethoxy-4-
hydroxy-5-nitrophenyl)-N,N-diethylprop-2-
enamide
O
2
N
HO
O
N
N
O
(A) 50 mg
New MM 1221.06 Imp. E (EP): 3,5-Dinitrobenzene-1,2-diol
O
2
N
HO
OH
NO
2
(A) 50 mg
New MM 1221.07 Imp. F (EP): (2E)-2-Cyano-3-(3,4-dihydroxy-
5-nitrophenyl)prop-2-enoic Acid
O
2
N
HO
OH
N
O
OH
(A) 50 mg
New MM 1221.03 Imp. H (EP): (2E)-3-(3,4-Dihydroxy-5-nitro-
phenyl)-2-(piperidin-1-ylcarbonyl)prop-2-
ennitrile
O
2
N
HO
OH
N
N
O
(A) 50 mg
MM 1221.09 Imp. I (EP): Propyl (2E)-2-Cyano-3-(3,4-
dihydroxy-5-nitrophenyl)prop-2-enoate
O
2
N
HO
OH
N
O
O
(A) 50 mg
Ephedrine Hydrochloride
MM 0652.00 Ephedrine Hydrochloride [Drug Precursor] H
N
OH
x HCl
(A) 500 mg
MM 2115.00
Imp. B (EP) as Hydrochloride: Pseudoephedrine
Hydrochloride [Drug Precursor]
H
N
OH
x HCl
(A) 500 mg
New MM 0652.03 (1S,2R)-(+)-Ephedrine Hydrochloride [Drug Precursor]
H
N
OH
x HCl
(A) 100 mg
Ephedrine Sulphate
MM 1147.00 Ephedrine Sulphate [Drug Precursor]
H
N
OH
2
x H
2
SO
4
(A) 250 mg
Erdosteine
MM 0544.00 Erdosteine
N
H
S
OH
O O
S
O
(A) 100 mg
MM 0544.01 2-Chloro-N-(2-oxotetrahydrothiophen-3-yl)acetamide
N
H
Cl
O
S
O
(A) 100 mg
Erythromycin
MM 0132.13 Imp. B (EP): N-Demethylerythromycin A
O
O
HO
OH
O
HO
O
O
O
O H
O
O
NH
OH
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 77
Code Product Price Unit
MM 0132.10 Imp. E (EP): Erythromycin A Enol Ether
O
O
HO
OH
O
O
O
O
O H
O
O
N
OH
(A) 50 mg
Esomeprazole Magnesium Trihydrate
MM 0095.03 Imp. A (EP): 5-Methoxy-1H-benzimidazole-2-thiol
SH
NH
N
O
(A) 100 mg
MM 0095.04 Imp. B (EP): 2-[(RS)-[(3,5-Dimethylpyridin-
2-yl)methyl]sulphinyl]-5-methoxy-1H-benzimidazole
N
S
O
NH
N
O
(A) 100 mg
MM 0095.06 Imp. C (EP): 5-Methoxy-2-[[(4-methoxy-
3,5-dimethylpyridin-2-yl)methyl]-
sulphanyl]-1H-benzimidazole (Ufiprazole)
N
O
S
NH
N
O
(A) 100 mg
MM 0095.05 Imp. D (EP): 5-Methoxy-2-[[(4-methoxy-
3,5-dimethylpyridin-2-yl)methyl]sulphonyl]-1H-
benzimidazole (Omeprazole Sulphone)
N
O
S
NH
N
O
O O
(A) 100 mg
MM 0095.07 Imp. E (EP): 4-Methoxy-2-[[(RS)-(5-methoxy-1H-
benzimidazol-2-yl)sulphinyl]methyl]-3,5-dimethylpyridine
1-Oxide (Omeprazole N-Oxide)
N
O
S
O
NH
N
O
O
(A) 100 mg
Estradiol Benzoate
MM 0301.00 Estradiol Benzoate
OH
O
O
(A) 500 mg
MM 0300.00 Imp. A (EP) as Hemihydrate: Estradiol Hemihydrate
OH
HO
x
1
/
2
H
2
O
(A) 500 mg
MM 0301.02 Imp. C (EP): Estra-1,3,5(10)-triene-3,17-diyl
Dibenzoate (Estradiol 3,17-Dibenzoate)
O
O
O
O
(A) 100 mg
MM 0301.07 Imp. D (EP): 3-Hydroxyestra-1,3,5(10)-trien-17-
yl Benzoate (Estradiol 17-Benzoate) O
HO
O
(A) 100 mg
MM 0301.03 Imp. E (EP): 17-Hydroxyestra-1,3,5(10)-trien-3-yl Benzoate
(17-epi-Estradiol Benzoate)
OH
O
O
(C) 10 mg
MM 0301.08 Imp. G (EP): 17-Oxoestra-1,3,5(10)-trien-3-yl Benzoate
(Estrone Benzoate)
O
O
O
(A) 100 mg
MM 0278.01 Benzoic Acid
OH
O
(B) 100 mg
Pharmaceutical impurities
78 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Estradiol Enanthate
MM 0473.00 Estradiol Enanthate
O
HO
O
(A) 100 mg
Estradiol Hemihydrate
MM 0300.00 Estradiol Hemihydrate
OH
HO
x
1
/
2
H
2
O
(A) 500 mg
MM 0282.00 Imp. A (EP): 3-Hydroxyestra-1,3,5(10)-trien-17-one (Estrone)
O
HO
(A) 500 mg
MM 0300.01 Imp. B (EP): Estra-1,3,5(10)-triene-3,17-diol (17-Estradiol;
17-epi-Estradiol)
OH
HO
(A) 100 mg
MM 0300.06
Imp. C (EP): 4-Methylestra-1,3,5(10)-triene-3,17-diol
(4-Methylestradiol)
OH
HO
(A) 100 mg
MM 0300.02 Imp. D (EP): Estra-1,3,5(10),9(11)-tetraene-3,17-diol
(9,11-Didehydroestradiol)
OH
HO
(D) 100 mg
MM 0300.03 6-Hydroxyestradiol
OH
HO
OH
(D) 50 mg
MM 0300.08 6-Ketoestradiol
OH
HO
O
(A) 100 mg
Estradiol Valerate
MM 0209.00 Estradiol Valerate
O
HO
O
(A) 500 mg
MM 0300.00 Imp. A (EP) as Hemihydrate: Estradiol Hemihydrate
OH
HO
x
1
/
2
H
2
O
(A) 500 mg
MM 0209.06 Imp. B (EP): 17-Hydroxyestra-1,3,5(10)-trien-3-yl
Pentanoate (Estradiol 3-Valerate)
OH
O
O
(A) 100 mg
MM 0209.01 Imp. C (EP): 3-Hydroxyestra-1,3,5(10),9(11)-tetraen-17-yl
Pentanoate (9,11-Didehydroestradiol Valerate)
O
HO
O
(D) 100 mg
MM 0209.07 Imp. D (EP): 3-Hydroxy-4-methylestra-1,3,5(10)-trien-
17-yl Pentanoate (4-Methylestradiol Valerate) O
HO
O
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 79
Code Product Price Unit
MM 0209.02 Imp. E (EP): Estra-1,3,5(10)-trien-3,17-diyl
Dipentanoate (Estradiol 3,17-Divalerate)
O
O
O
O
(A) 100 mg
MM 0209.04 Imp. F (EP): 3-Hydroxyestra-1,3,5(10)-trien-17-yl Butanoate
(Estradiol Butyrate)
O
HO
O
(A) 100 mg
MM 0209.03 17-epi-Estradiol Valerate (17-Estradiol Valerate)
O
HO
O
(D) 100 mg
Estramustine Sodium Phosphate
MM 0100.01 Estramustine
OH
O N
O
Cl
Cl
(D) 100 mg
MM 0100.02 17-17'-
Bis3-{bis(2-chloro-
ethyl)carbamoyl-
oxy}estra-1,3,5(10)-
trienyl
Pyrophosphate
Disodium Salt
O
O N
O
Cl
Cl
P
O
P
O
NaO O O ONa
O N
O
Cl
Cl
(D) 50 mg
Estriol
MM 0130.00 Estriol
OH
HO
OH
(A) 100 mg
MM 0130.06 Imp. A (EP): Estra-1,3,5(10),9(11)-tetraene-3,16,17-triol
(9,11-Didehydroestriol)
OH
HO
OH
(D) 100 mg
MM 0282.00 Imp. B (EP): 3-Hydroxyestra-1,3,5(10)-trien-17-one (Estrone)
O
HO
(A) 500 mg
MM 0130.01 Imp. C (EP): 3-Methoxyestra-1,3,5(10)-triene-16,17-diol
(Estriol 3-Methyl Ether)
OH
O
OH
(D) 100 mg
MM 0300.00 Imp. D (EP) as Hemihydrate: Estradiol
Hemihydrate
OH
HO
x
1
/
2
H
2
O
(A) 500 mg
MM 0130.05 Imp. E (EP): Estra-1,3,5(10)-triene-3,16,17-triol
(17-epi-Estriol)
OH
HO
OH
(D) 100 mg
MM 0130.04 Imp. F (EP): Estra-1,3,5(10)-triene-3,16,17-triol
(16-epi-Estriol)
OH
HO
OH
(D) 100 mg
MM 0130.03 Imp. G (EP): Estra-1,3,5(10)-triene-3,16,17-triol
(16,17-epi-Estriol)
OH
HO
OH
(D) 100 mg
MM 0130.22 Imp. I (EP): 3-Hydroxy-17-oxa-D-homoestra-1,3,5(10)-trien-17a-
one
HO
O
O
on request
Pharmaceutical impurities
80 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0130.02 6-Hydroxyestriol
OH
HO
OH
OH
(D) 100 mg
MM 0130.14 Estriol 16,17-Diacetate
O
HO
O
O
O
(D) 100 mg
MM 0130.15 Estriol Triacetate
O
O
O
O
O O
(D) 100 mg
MM 0130.16 Estriol 3-Benzyl Ether
OH
O
OH
(D) 100 mg
MM 0130.17 16-Oxoestradiol
OH
HO
O
(D) 100 mg
MM 0130.18 6-Oxoestriol
OH
HO
OH
O
(D) 100 mg
Estrogens conjugated
New MM 0282.00 Imp. I (EP): 3-Hydroxyestra-1,3,5(10)-trien-
17-one (Estrone)
O
HO
(A) 500 mg
Estrone
MM 0282.00 Estrone
O
HO
(A) 500 mg
MM 0282.01 Estrone 3-Methyl Ether
O
O
(A) 100 mg
Ethacridine Lactate Monohydrate
MM 0798.00 Ethacridine Lactate Monohydrate
N H
2
N
NH
2
O
OH
O
OH
x x H
2
O
(A) 250 mg
Ethinylestradiol
MM 0123.00 Ethinylestradiol
OH
HO
(A) 500 mg
MM 0123.02 Imp. B (EP): 19-Nor-17-pregna-1,3,5(10),9(11)-tetraen-
20-yne-3,17-diol (9,11-Didehydroethinylestradiol)
OH
HO
(D) 50 mg
MM 0282.00 Imp. C (EP): 3-Hydroxyestra-1,3,5(10)-trien-17-one (Estrone)
O
HO
(A) 500 mg
MM 0300.00 Imp. D (EP) as Hemihydrate:
Estradiol Hemihydrate
OH
HO
x
1
/
2
H
2
O
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 81
Code Product Price Unit
MM 0123.07 Imp. E (EP): 19-Nor-17-pregna-
1,3,5(10)-trien-20-yne-3,6,17-triol
(6-Hydroxyethinylestradiol)
OH
HO
OH
(D) 100 mg
MM 0123.06 Imp. F (EP): 19-Nor-17-pregna-
1,3,5(10)-trien-20-yne-3,6,17-triol
(6-Hydroxyethinylestradiol)
OH
HO
OH
(D) 25 mg
MM 0123.05 Imp. G (EP): 3,17-Dihydroxy-19-
nor-17-pregna-1,3,5(10)-trien-20-yn-6-one
(6-Oxoethinylestradiol, 6-Ketoethinylestradiol)
OH
HO
O
(D) 100 mg
MM 0123.08
Imp. I (EP): 19-Nor-17-pregna-
1,3,5(10),6-tetraen-20-yne-3,17-diol
(6,7-Didehydroethinylestradiol)
HO
OH
(D) 50 mg
MM 0300.01 Imp. L (EP): Estra-1,3,5(10)-triene-
3,17-diol (17-Estradiol; 17-epi-Estradiol)
OH
HO
(A) 100 mg
Ethionamide
MM 0845.00 Ethionamide
N
NH
2
S
(A) 250 mg
MM 0845.01 Ethionamide Sulphoxide
N
NH
2
S
O
(D) 100 mg
Ethosuximide
MM 0750.00 Ethosuximide
H
N
O O
(A) 500 mg
Ethyl Parahydroxybenzoate
MM 0498.00 Ethyl Parahydroxybenzoate
HO
O
O
(A) 500 mg
MM 0498.05 Sodium Ethyl Parahydroxybenzoate
NaO
O
O
(A) 500 mg
MM 0045.01 Imp. A (EP): 4-Hydroxybenzoic Acid
HO
OH
O
(B) 100 mg
MM 0431.00 Imp. B (EP): Methyl 4-Hydroxybenzoate (Methyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0432.00 Imp. C (EP): Propyl 4-Hydroxybenzoate
(Propyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0496.00 Imp. D (EP): Butyl 4-Hydroxybenzoate
(Butyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
Ethylmorphine Hydrochloride
MM 0037.00 Imp. B (EP) as Hydrochloride Trihydrate:
Morphine Hydrochloride Trihydrate
[Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
Pharmaceutical impurities
82 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0280.00 Imp. B (EP) as Hemisulphate Pentahemihydrate: Morphine
Hemisulphate Pentahemihydrate [Controlled Substance]
O OH HO
N
2
x H
2
SO
4
x 5 H
2
O
(A) 250 mg
MM 0004.00 Imp. C (EP) as Monohydrate: Codeine Monohydrate
[Controlled Substance]
O OH O
N
x H
2
O
(A) 100 mg
MM 0442.00 Imp. C (EP) as Phosphate Hemihydrate: Codeine
Phosphate Hemihydrate [Controlled Substance]
O OH O
N
x H
3
PO
4
x 1/2 H
2
O
(A) 100 mg
Etilefrine Hydrochloride
MM 0035.00 Etilefrine Hydrochloride
HO
OH
H
N
x HCl
(A) 500 mg
MM 0081.00 Imp. B (EP) as Hydrochloride: (1RS)-
1-(3-Hydroxyphenyl)-2-(methylamino)ethanol
Hydrochloride (Phenylephrine Hydrochloride)
HO
OH
H
N
x HCl
(A) 500 mg
MM 0973.00 Imp. C (EP) as Hydrochloride: (1RS)-2-Amino-
1-(3-hydroxyphenyl)ethanol Hydrochloride
(Norfenefrine Hydrochloride)
HO
OH
NH
2
x HCl
(A) 500 mg
New MM 0035.08 Imp. D (EP) as Hydrochloride: 2-(Benzylethyl-amino)-
1-(3-hydroxyphenyl)ethanone Hydrochloride
(Benzyletilefrone Hydrochloride)
HO
O
N
x HCl
(A) 100 mg
MM 0035.05 Imp. E (EP): 1-(3-Hydroxyphenyl)ethanone (3-Hydroxyacetophenone)
HO
O
(C) 100 mg
MM 0035.06 Imp. F (EP): N-Benzylethanamine (Benzylethylamine)
HN
(C) 100 mg
MM 0035.50 3-Benzoyloxyacetophenone
O
O
O
(A) 100 mg
MM 0035.51
3-Benzoyloxy--bromoacetophenone
O
O
O
Br
on request
Etodolac
MM 0911.00 Etodolac
O
H
N
O
OH
(A) 250 mg
MM 0911.01 Imp. A (EP): 2-[(1RS)-1-Ethyl-1,3,4,9-tetrahydro-
pyrano[3,4-b]indol-1-yl]acetic Acid (8-Desethyl
Etodolac)
O
H
N
O
OH
(A) 100 mg
MM 0911.02 Imp. B (EP): 2-[(1RS)-1-Ethyl-8-methyl-1,3,4,9-
tetrahydropyrano[3,4-b]indol-1-yl]acetic Acid
(8-Methyl Etodolac)
O
H
N
O
OH
(A) 100 mg
MM 0911.03 Imp. C (EP): 2-[(1RS)-8-Ethyl-1-methyl-1,3,4,9-
tetrahydropyrano[3,4-b]indol-1-yl]acetic Acid
(1-Methyl Etodolac)
O
H
N
O
OH
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 83
Code Product Price Unit
New MM 0911.04 Imp. D (EP): 2-[(1RS)-1-Ethyl-8-(1-methylethyl)-
1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic
Acid (8-Isopropyl Etodolac)
O
H
N
O
OH
(A) 50 mg
MM 0911.06 Imp. F (EP): 2-[(1RS)-8-Ethyl-1-(1-methylethyl)-
1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic
Acid (1-Isopropyl Etodolac)
O
H
N
O
OH
(A) 100 mg
MM 0911.07 Imp. G (EP): 2-[(1RS)-8-Ethyl-1-propyl-1,3,4,9-
tetrahydropyrano[3,4-b]indol-1-yl]acetic Acid
(1-Propyl Etodolac)
O
H
N
O
OH
(A) 100 mg
MM 0911.08 Imp. H (EP): 2-(7-Ethylindol-3-yl)ethanol
OH
H
N
(A) 100 mg
MM 0911.10 Imp. J (EP): (1RS)-1,8-Diethyl-1-methyl-1,3,4,9-
tetrahydropyrano[3,4-b]indole (Decarboxy
Etodolac
O
H
N
(A) 100 mg
MM 0911.11 Imp. K (EP): Methyl 2-[(1RS)-1,8-Diethyl-1,3,4,9-
tetrahydropyrano[3,4-b]indol-1-yl]acetate
(Etodolac Methyl Ester)
O
H
N
O
O
(A) 100 mg
Etofenamate
MM 0410.00 Imp. A (EP): 2-[[3-(Trifluoromethyl)phenyl]amino]benzoic Acid
(Flufenamic Acid)
O
OH
NH
F
F F
(A) 500 mg
MM 0105.02 Imp. B (EP): Butyl 2-[[3-(Trifluoromethyl)phenyl]amino]benzoate
(Butyl Flufenamate)
O
O
NH
F
F F
(A) 100 mg
MM 0105.03 Imp. C (EP): N-Phenyl-3-(trifluoromethyl)aniline
NH
F
F F
(A) 100 mg
MM 0105.04 Imp. D (EP): 2,2'-Oxybis(ethylene)
Bis[2-[[3-(trifluoromethyl)phenyl]amino]benzoate]
O
O
NH
F
O
O
HN
F
O
F F F F
(A) 100 mg
MM 0105.05 Imp. E (EP): 2-(2-Butoxyethoxy)ethyl 2-[[3-
(Trifluoromethyl)phenyl]amino]benzoate
O
O
NH
F
O
O
F F
(A) 100 mg
MM 0105.06 Imp. F (EP): 2,2'-Oxydiethanol
HO
O
OH
(A) 100 mg
Pharmaceutical impurities
84 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0105.07 Imp. G (EP): 2-Hydroxyethyl
2-[[3-(Trifluoromethyl)phenyl]amino]benzoate
O
O
NH
F
OH
F F
(A) 100 mg
MM 0105.08 Etofenamate Myristate
O
O
NH
F
O
O
O
F F
(A) 100 mg
MM 0105.09 Etofenamate Palmitate
O
O
NH
F
O
O
O
F F
(A) 100 mg
MM 0105.10 Etofenamate Stearate
O
O
NH
F
O
O
O
F F
(A) 100 mg
MM 0105.11 Triethylene Glycol Flufenamate
O
O
NH
F
O
O
OH
F F
(A) 100 mg
Etofylline
MM 0603.00 Etofylline
N
N
N
N
O
O
OH
(A) 500 mg
Etomidate
New MM 1264.00 Etomidate
O
O
N
N
(A) 100 mg
New MM 1264.04 Imp. A (EP) as R-Enantiomer: 1-[(1R)-1-
Phenylethyl]-1H-imidazole-5-carboxylic
Acid (Etomidate Acid)
O
OH
N
N
(A) 50 mg
Famciclovir
New MM 0620.01 9-[4-Acetoxy-3-(acetoxymethyl)butyl]-2-amino-
6-chloropurine N
N
N
N
H
2
N
O
O
O
O
Cl
(A) 100 mg
Famotidine
MM 0029.00 Famotidine
S N
NH
2
N
S
N
H
2
N
NH
2
S
NH
2
O O
(A) 250 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 85
Code Product Price Unit
MM 0029.06 Imp. A (EP) as Hydrochloride: 3-[[[2-
[(Diaminomethylene)amino]thiazol-4-yl]-
methyl]sulphanyl]propanimidamide
Hydrochloride
S NH
2
NH
N
S
N
H
2
N
NH2
x HCl
(A) 100 mg
MM 0029.05 Imp. B (EP) as Dimaleate:
3,5-Bis[2-[[[2-[(diaminomethylene)amino]-
thiazol-4-yl]methyl]sulphanyl]ethyl]-4H-
1,2,4,6-thiatriazine 1,1-Dioxide Dimaleate
S
N
S
N
N
H
N
S
N
O O
S
N
S
N
H
2
N
NH
2
NH
2
H
2
N
OH
OH
O
O
x 2
(D) 50 mg
MM 0029.01 Imp. C (EP) as Hydrochloride:
3-[[[2-[(Diaminomethylene)amino]thiazol-
4-yl]methyl]sulphanyl]-N-sulphamoylpropanamide
Hydrochloride
S N
H
O
N
S
N
H
2
N
NH
2
S
NH
2
O O
x HCl
(A) 100 mg
MM 0029.02 Imp. D (EP): 3-[[[2-[(Diaminomethylene)amino]thiazol-4-
yl]methyl]sulphanyl]propanamide S NH
2
O
N
S
N
H
2
N
NH
2 (A) 100 mg
MM 0029.07 Imp. E (EP): 2,2'-[Disulphanediylbis-
(methylenethiazole-4,2-diyl)]diguanidine
S
N
S
N
H2N
NH
2
S
S
N
N
NH
2
H2N
(A) 100 mg
MM 0029.03 Imp. F (EP): 3-[[[2-[(Diaminomethylene)amino]thiazol-4-
yl]methyl]sulphanyl]propanoic Acid S OH
O
N
S
N
H
2
N
NH
2 (A) 100 mg
MM 0029.09 Imp. G (EP) as Maleate: N-Cyano-
3-[[[2-(diaminomethylene)amino]thiazol-
4-yl]methyl]sulphanyl]propanimidamide Maleate
S N
H
NH
N
S
N
H2N
NH
2 N
OH
OH
O
O
x
(A) 100 mg
MM 0029.10 Imp. I (Pharmeuropa): 3-[[[2-
[(Diaminomethylene)amino]thiazol-4-
yl]methyl]sulfinyl]-N-sulfamoylpropanamide
S N
H
O
N
S
N
H
2
N
NH
2
S
NH
2
O O
O
(D) 50 mg
MM 0029.04 Famotidine Sulphoxide
S N
NH
2
N
S
N
H
2
N
NH
2
S
NH
2
O O
O
(A) 100 mg
MM 0029.51 2-[(Diaminomethylene)amino]-4-(4-cyanobutyl)thiazole
Hydrochloride
N
S
N
H2N
NH2
N
x HCl
on request
Felodipine
MM 0139.00 Felodipine
H
N
O
O
Cl
O
O
Cl
(A) 100 mg
MM 0139.01 Imp. A (EP): Ethyl Methyl 4-(2,3-Dichlorophenyl)-
2,6-dimethylpyridine-3,5-dicarboxylate
N
O
O
Cl
O
O
Cl
(D) 50 mg
MM 0139.02 Imp. B (EP): Dimethyl 4-(2,3-Dichlorophenyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
Cl
O
O
Cl
(A) 100 mg
MM 0139.03 Imp. C (EP): Diethyl 4-(2,3-Dichlorophenyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
Cl
O
O
Cl
(A) 100 mg
Pharmaceutical impurities
86 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Fenbendazole
MM 2500.00 Imp. A (EP): Methyl (1H-Benzimidazol-2-yl)carbamate
(Carbendazim)
N
H
N
NH
O
O
(A) 100 mg
MM 0518.01 Fenbendazole Sulphoxide (Oxfendazole)
S
N
H
N
NH
O
O
O
(A) 100 mg
MM 0518.02 Fenbendazole Sulphone
S
N
H
N
NH
O
O
O O
(A) 100 mg
Fenbufen
MM 0918.00 Fenbufen
O
OH
O
(A) 500 mg
MM 0918.03 Imp. C (EP): Biphenyl (A) 100 mg
MM 0918.05 4-(4-Chlorophenyl)-4-oxobutanoic Acid
(3-(4-Chlorobenzoyl)propionic Acid)
Cl
O
OH
O
(A) 100 mg
Fenfluramine Hydrochloride
MM 0608.00 Fenfluramine Hydrochloride
H
N
x HCl
F
F
F
(A) 500 mg
MM 0608.01 Norfenfluramine Hydrochloride
NH
2
x HCl
F
F
F
(A) 100 mg
MM 0608.02 N-Nitrosofenfluramine
N
F
F
F
N
O
(A) 100 mg
Fenofibrate
MM 0505.00 Fenofibrate
Cl
O
O
O
O
(A) 500 mg
MM 0505.01 Imp. A (EP): (4-Chlorophenyl)(4-hydroxyphenyl)methanone
Cl
O
OH
(C) 100 mg
MM 0505.03 Imp. C (EP): (3RS)-3-[4-(4-Chlorobenzoyl)-
phenoxy]butan-2-one
Cl
O
O
O
(A) 100 mg
MM 0505.04 Imp. D (EP): Methyl 2-[4-(4-Chlorobenzoyl)-
phenoxy]-2-methylpropanoate
Cl
O
O
O
O
(A) 100 mg
MM 0505.05 Imp. E (EP): Ethyl 2-[4-(4-Chlorobenzoyl)-
phenoxy]-2-methylpropanoate
Cl
O
O
O
O
(A) 100 mg
MM 0505.06 Imp. F (EP): (4-Chlorophenyl)[4-(1-methyl-
ethoxy)phenyl]methanone
Cl
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 87
Code Product Price Unit
New MM 0505.07 Imp. G (EP): 1-Methylethyl
2-[[2-[4-(4-Chlorobenzoyl)phenoxy]-2-
methylpropanoyl]oxy]-2-methylpropanoate
Cl
O
O
O
O
O
O
(A) 50 mg
Fenoprofen Calcium
MM 0790.00 Fenoprofen Calcium Dihydrate
Ca
2+
x 2 H
2
O
O O
-
O
2
(A) 500 mg
Fentanyl
MM 0528.00 Fentanyl [Controlled Substance]
N
N
O
(A) 100 mg
MM 0528.09 Imp. A (EP) as Hydrochloride: N-Phenyl-N-
[cis,trans-1-oxido-1-(2-phenylethyl)piperidin-
4-yl]propanamide Hydrochloride (Fentanyl
N-Oxide Hydrochloride)
N
N
O
O
x HCl
(A) 100 mg
MM 0528.08 Imp. B (EP): N-Phenyl-N-(piperidin-4-yl)propanamide NH
N
O (A) 100 mg
MM 0528.03
Imp. C (EP): N-phenyl-N-[1-(2-phenylethyl)-
piperidin-4-yl]acetamide
N
N
O
(A) 100 mg
MM 0528.04 Imp. D (EP): N-phenyl-1-(2-phenylethyl)piperidin-4-amine
N
HN
(A) 100 mg
MM 0093.17 Imp. F (EP) as Hydrochloride: Aniline Hydrochloride
(Phenylamine Hydrochloride)
NH
2
x HCl
(B) 100 mg
MM 0528.07 Imp. G (EP): N-Phenylpropanamide
NH
O
(A) 100 mg
Fexofenadine Hydrochloride
MM 0507.01 Imp. A (EP): 2-[4-[4-[4-(Hydroxydiphenyl-
methyl)piperidin-1-yl]butanoyl]phenyl]-
2-methylpropanoic Acid
(Ketofexofenadine)
O
N
OH
O
OH
(A) 100 mg
MM 0507.03 Imp. C (EP): (1RS)-4-[4-(Hydroxydiphenyl-
methyl)piperidin-1-yl]-1-[4-(1-methylethyl)-
phenyl]butan-1-ol
OH
N
OH
(A) 100 mg
MM 0055.02 Imp. E (EP): Diphenyl(piperidin-4-yl)methanol
NH
OH
(B) 100 mg
Pharmaceutical impurities
88 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Finasteride
MM 0415.00 Finasteride
N
H
O
O H
N
(A) 100 mg
MM 0415.01 Imp. A (EP): N-(1,1-Dimethylethyl)-3-oxo-
4-aza-5-androstane-17-carboxamide
(Dihydrofinasteride)
N
H
O
O H
N
H
(A) 100 mg
MM 0415.02 Imp. B (EP): Methyl 3-Oxo-4-aza-5-androst-
1-ene-17-carboxylate (-1-Aza Ester)
N
H
O
O
O
H
(A) 100 mg
New MM 0415.04 3-Oxo-4-aza-5alpha-androstane-17beta-carboxylic Acid
N
H
O
O
OH
H
(A) 100 mg
Flavoxate Hydrochloride
MM 0156.00 Flavoxate Hydrochloride
O
O O
N
O
x HCl
(A) 100 mg
MM 0156.01 Imp. A (EP): 3-Methyl-4-oxo-2-phenyl-4H-1-
benzopyran-8-carboxylic Acid (3-Methyl-
flavone-8-carboxylic Acid)
O
OH O
O
(A) 100 mg
MM 0156.02
Imp. B (EP): Ethyl 3-Methyl-4-oxo-2-phenyl-
4H-1-benzopyran-8-carboxylate (3-Methyl-
flavone-8-carboxylic Acid Ethyl Ester)
O
O O
O
(A) 100 mg
MM 0156.05 Imp. C (EP): 1-Methylethyl-3-Methyl-4-oxo-
2-phenyl-4H-1-benzopyran-8-carboxylate
(3-Methylflavone-8-carboxylic Acid Isopropyl
Ester)
O
O O
O
(A) 50 mg
Flecainide Acetate
MM 0488.02 Imp. B (EP): (RS)-(Piperidin-2-yl)methanamine H
2
N
HN
(A) 100 mg
MM 0488.04 Imp. D (EP): 2,5-Bis(2,2,2-trifluoroethoxy)benzoic Acid
O
O
OH
O
F
F F
F
F F
(A) 100 mg
Fluanisone
MM 1247.02 1-(2-Methoxyphenyl)piperazine Dihydrochloride
HN
N
O
x 2 HCl
(A) 100 mg
Flubendazole
MM 0463.00 Flubendazole
O
N
H
N
F
NH
O
O
(A) 100 mg
MM 0463.02 Imp. B (EP): (2-Amino-1H-benzimidazol-
5-yl)(4-fluorophenyl)methanone
O
N
H
N
F
NH2
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 89
Code Product Price Unit
MM 0463.03 Imp. C (EP): (4-Fluorophenyl)(2-hydroxy-1H-benzimidazol-
5-yl)methanone
O
N
H
N
F
OH
(C) 50 mg
MM 0463.04 Imp. D (EP): (1H-Benzimidazol-5-yl)(4-fluorophenyl)methanone
O
N
H
N
F
on request
MM 0463.05 Imp. E (EP): Methyl [5-(2-Fluorobenzoyl)-1H-benzimidazol-
2-yl]carbamate
O
N
H
N
NH
O
O
F
(C) 50 mg
MM 0463.06 Imp. F (EP): Methyl [5-(4-Fluorobenzoyl)-1-methyl-1H-
benzimidazol-2-yl]carbamate
O
N
N
F
NH
O
O
(C) 50 mg
MM 0463.07 Imp. G (EP): Methyl [5-[4-(1-Methylethoxy)benzoyl]-1H-
benzimidazol-2-yl]carbamate
O
N
H
N
O
NH
O
O
(D) 100 mg
Flucloxacillin Sodium
MM 0489.00 Flucloxacillin Sodium Hydrate
N
S
H
O
O
ONa
H
N
N
O
F
Cl
O
x H
2
O
(A) 500 mg
MM 0489.01 Imp. A (EP) as Disodium Salt: (4S)-2-[Carboxy[[[3-(2-chloro-
6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl]amino]methyl]-
5,5-dimethylthiazolidine-4-carboxylic Acid Disodium Salt
(Penicilloic Acids of Flucloxacillin Disodium Salt)
HN
S
O
ONa
H
N
N
O
F
Cl
O
O ONa
(A) 100 mg
MM 0489.02 Imp. B (EP): (2RS,4S)-2-[[[[3-(2-Chloro-6-fluorophenyl)-
5-methylisoxazol-4-yl]carbonyl]amino]methyl]-5,5-dimethyl-
thiazolidine-4-carboxylic Acid (Penilloic Acids of Flucloxacillin)
HN
S
O
OH
NH
N
O
F
Cl
O
(A) 50 mg
MM 0026.04 Imp. C (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid (6-Aminopenicillanic
Acid)
N
S
H
O
H
2
N
O
OH
(B) 100 mg
MM 0489.03 Imp. D (EP): 3-(2-Chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic
Acid
OH
N
O
F
Cl
O
(C) 100 mg
Fluconazole
MM 0235.00 Fluconazole
N
N
N
N
N
N
HO
F
F
(A) 100 mg
MM 0235.11 Imp. A (EP): (2RS)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-
3-(4H-1,2,4-triazol-4-yl)propan-2-ol
N
N
N N
N
N
HO
F
F
(A) 100 mg
MM 0235.12 Imp. B (EP): 2-[2-Fluoro-4-(1H-1,2,4-triazol-1-
yl)phenyl]-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
N
N
N
N
N
N
HO
F
N
N N (D) 100 mg
Pharmaceutical impurities
90 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0235.13 Imp. C (EP): 1,1'-(1,3-Phenylene)di-1H-1,2,4-triazole
N
N
N
N
N N (A) 50 mg
MM 0235.14 Imp. D (EP): 2-(4-Fluorophenyl)-1,3-bis(1H-
1,2,4-triazol-1-yl)propan-2-ol
N
N
N
N
N
N
HO
F
(A) 100 mg
MM 0235.02 Imp. F (EP): (2RS)-2-(2,4-Difluorophenyl)-3-(1H-1,2,4-triazol-
1-yl)propane-1,2-diol
OH
N
N
N
HO
F
F
(A) 50 mg
New MM 0235.07 Imp. H (EP): (2RS)-1-Bromo-2-(2,4-difluorophenyl)-
3-(1H-1,2,4-triazol-1-yl)propan-2-ol
Br
N
N
N
HO
F
F
(A) 50 mg
MM 0235.01 2-(2,4-Difluorophenyl)propane-1,2,3-triol
OH
HO
HO
F
F
(A) 100 mg
MM 0235.03 1H-1,2,4-Triazol
H
N
N
N
(B) 100 mg
MM 0235.04 2-Chloro-2',4'-difluoroacetophenone
F
F
O
Cl
(C) 100 mg
MM 0235.06 1-(2,4-Difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanol
F
F
HO
N
N
N
(A) 100 mg
MM 0235.09 4-Amino-1,2,4-triazole
N
N
N
H
2
N
(C) 100 mg
Flucytosine
MM 0593.00 Imp. A (EP): 5-Fluoropyrimidine-2,4(1H,3H)-dione (Fluorouracil)
N
H
O
HN
O
F
(A) 500 mg
Flufenamic Acid
MM 0410.00 Flufenamic Acid
O
OH
NH
F
F F
(A) 500 mg
Flumetasone Pivalate
MM 0427.01 Imp. A (EP): 6,9-Difluoro-11,17,21-trihydroxy-16-
methylpregna-1,4-diene-3,20-dione (Flumetasone)
O
HO
F
F
OH
O
OH
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 91
Code Product Price Unit
Flunarizine Dihydrochloride
MM 0175.00 Flunarizine Dihydrochloride
N
N
F
F
x 2 HCl
(A) 500 mg
MM 0175.04 Imp. A (EP): 1-[Bis(4-fluorophenyl)methyl]piperazine
N
F
F
NH
(A) 100 mg
MM 0175.03 Imp. C (EP) as Dihydrochloride:
1-[(RS)-(2-Fluorophenyl)(4-fluoro-phenyl)methyl]-
4-[(2E)-3-phenylprop-
2-enyl]piperazine Dihydrochloride
N
N
F
F
x 2 HCl
(A) 100 mg
MM 0175.02 Chlorobis-(4-fluorophenyl)methane
Cl
F F
(B) 100 mg
MM 0175.05 1-Bis(4-fluorophenyl)methyl-4-(ethoxycarbonyl)piperazine
N
F F
N
O O
on request
MM 0175.06 Flunarizine N-Oxide Dihydrochloride
N
N
F
F
x 2 HCl
O
(A) 100 mg
Flunitrazepam
MM 0069.00 Flunitrazepam [Controlled Substance]
N
N
O
O2N
F
on request
MM 0069.02 Imp. B (EP): 5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-
1,4-benzodiazepin-2-one (Demethylflunitrazepam)
N
H
N
O
O2N
F
(A) 100 mg
Flunixin Meglumine
MM 0915.00 Flunixin Meglumine
N
OH
O
NH
F
HO
OH
H
N
HO
OH
OH
x
F F
(A) 100 mg
MM 0915.01 Imp. A (EP): 2-Chloropyridine-3-carboxylic Acid
N
OH
O
Cl
(A) 100 mg
MM 0915.03 Imp. C (EP): Ethyl 2-Chloropyridine-3-carboxylate
N
O
O
Cl
(A) 100 mg
Fluorescein Sodium
MM 0294.01 Imp. A (EP): Resorcinol
HO OH
(B) 100 mg
Pharmaceutical impurities
92 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0133.04 Imp. C (EP): 2-(2,4-Dihydroxybenzoyl)benzoic Acid
HO OH
O
OH
O
(A) 100 mg
Fluorouracil
MM 0593.00 Fluorouracil
N
H
O
HN
O
F
(A) 500 mg
MM 0265.03 Imp. A (EP): Pyrimidine-2,4,6-(1H,3H,5H)-
trione (Barbituric Acid)
N
H
O
HN
O
O
(C) 100 mg
MM 0593.01 Imp. B (EP): Dihydropyrimidine-2,4,5(3H)-
trione (Isobarbituric Acid or 5-Hydroxyuracil)
N
H
O
HN
O
O
(A) 100 mg
MM 0593.03 Imp. C (EP): Pyrimidine-2,4(1H,3H)-dione (Uracil)
N
H
O
HN
O
(C) 100 mg
MM 0593.05 Imp. E (EP): 5-Chloropyrimidine-2,4(1H,3H)dione (5-Chlorouracil)
N
H
O
HN
O
Cl
(A) 100 mg
MM 0593.06 Imp. F (EP): 2-Ethoxy-5-fluoropyrimidin-
4(1H)-one (2-Ethoxy-5-fluorouracil)
N
H
O
N
O
F
(A) 100 mg
Fluoxetine Hydrochloride
MM 0256.00 Fluoxetine Hydrochloride
O
H
N
x HCl
F
F F
(A) 50 mg
MM 0256.01 Imp. A (EP): (1RS)-3-(Methylamino)-1-phenylpropan-1-ol
HO
H
N
(A) 100 mg
MM 0256.02 Imp. B (EP) as Hydrochloride: N-Methyl-3-
phenylpropan-1-amine Hydrochloride
(Methyl-3-phenylpropylamine Hydrochloride)
[Controlled Substance]
x HCl
H
N
(A) 100 mg
MM 0256.03 Imp. C (EP) as Hydrochloride:(3RS)-N-Methyl-3-phenyl-
3-[3-(trifluoromethyl]phenoxy]propan-1-amine
Hydrochloride
O
H
N
x HCl
F
F
F
(A) 100 mg
MM 0256.05 4-Hydroxybenzotrifluoride
OH
F
F F
(B) 100 mg
MM 0256.06 4-Chlorobenzotrifluoride
Cl
F
F F
(B) 100 mg
MM 0256.10 3-Dimethylamino-1-phenylpropan-1-ol
OH
N
(A) 100 mg
MM 0256.16 N-Formylfluoxetine
O N
F
O
F F
(A) 100 mg
New MM 256.17 (3RS)-N-Methyl-3-phenyl-3-[2-(trifluoromethyl)-
phenoxy]propan-1-amine Hydrochloride
(2-Trifluoromethylisomer of Fluoxetine Hydro-chloride)
O
H
N
x HCl
F
F
F
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 93
Code Product Price Unit
Fluoxymesterone
MM 0959.00 Fluoxymesterone
HO
OH
F
O
(A) 100 mg
Flupentixol Decanoate
MM 0182.00 Flupentixol Decanoate
S
CF3
N
N
O
O
on request
MM 0182.08 Imp. B (BP): 2-Trifluoromethylthioxanthone
S
CF3
O
(A) 100 mg
MM 0182.05 1-(2-Hydroxyethyl)piperazine
HN
N
OH (B) 100 mg
MM 0182.06 cis/trans-3-[2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene]propene
S
CF
3
on request
MM 0182.07 4-Chloro-3-nitrobenzotrifluoride
CF3 O2N
Cl
(B) 100 mg
MM 0182.09 4-Fluoro-3-nitrobenzotrifluoride
F
CF
3
O
2
N
(B) 100 mg
Flupentixol Dihydrochloride
MM 0182.08 Imp. G (EP): 2-(Trifluoromethyl)-9H-thioxanthen-9-one
(2-Trifluoromethylthioxanthone)
S
CF3
O
(A) 100 mg
MM 0182.05 1-(2-Hydroxyethyl)piperazine
HN
N
OH (B) 100 mg
MM 0182.06 cis/trans-3-[2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene]propene
S
CF
3
on request
MM 0182.07 4-Chloro-3-nitrobenzotrifluoride
CF
3
O
2
N
Cl
(B) 100 mg
New MM 0223.06 Flupentixol Dihydrochloride
N
N
OH
S
F
F F
x 2 HCl
(A) 100 mg
Fluphenazine Dihydrochloride
MM 0114.00 Fluphenazine Dihydrochloride
S
N N
N
OH
F
F F
x 2 HCl
(A) 500 mg
MM 0114.01 Imp. A (EP): 2-[4-[3-[5-Oxo-2-(trifluoromethyl)-
10H-5
4
-phenothiazin-10-yl]propyl]piperazin-1-
yl]ethanol (Fluphenazine S-Oxide)
S
N N
N
OH
F
F F
O
(A) 100 mg
MM 0114.07 Imp. D (EP): 10,10'-[Piperazine-1,4-diylbis(propane-
3,1-diyl)]bis[2-(trifluoromethyl)-10H-phenothiazine]
N
N
N
N
S
S
F
F F
F
F F
(A) 100 mg
Pharmaceutical impurities
94 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM0826.00 Imp. E (EP): 2-[4-[3-[2-Chloro-10H-phenothiazin-
10-yl]propyl]piperazin-1-yl]ethanol (Perphenazine)
S
N N
N
OH
Cl
(A) 100 mg
MM 0114.04 Fluphenazine N,N',S-Trioxide Dihydrochloride
S
N N
N
OH
F
x 2 HCl
O
O
O
F F
on request
Flurazepam Monohydrochloride
MM 0070.01 Imp. A (EP): [5-Chloro-2-[[2-(diethylamino)ethyl]amino]phenyl]-
(2-fluorophenyl)methanone
Cl
H
N
O
F
N
on request
MM 0070.02 Imp. B (EP): 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one
N
H
N
O
Cl
F
(A) 100 mg
MM 0070.03 2-Chloro-10-(2-diethylaminoethyl)-9,10-dihydroacridin-9-one
Cl
N
O
N (A) 100 mg
MM 0070.06 Flurazepam [Controlled Substance]
N
N
O
Cl
F
N
(A) 100 mg
Flurbiprofen
MM 0727.01 Imp. A (EP): (2RS)-2-(Biphenyl-4-yl)propanoic
Acid
OH
O
(A) 50 mg
New MM 0727.03 Imp. C (EP): (2RS)-2-(2-Fluorobiphenyl-4-yl)-
2-hydroxypropanoic Acid
F OH
O
HO
(A) 50 mg
Flutamide
MM 0161.00 Flutamide
NO
2
H
N
O
F
F F
(A) 500 mg
MM 0161.03 Imp. A (EP): 4-Nitro-3-(trifluoromethyl)aniline
NO
2
H
2
N
F
F F
(A) 100 mg
MM 0161.04 Imp. B (EP): N-[4-Nitro-3-(trifluoromethyl)phenyl]acetamide
NO
2
H
N
O
F
F F
(A) 100 mg
MM 0161.05 Imp. C (EP): N-[4-Nitro-3-(trifluoromethyl)phenyl]propanamide
NO
2
H
N
O
F
F F
(A) 100 mg
MM 0161.06 Imp. D (EP): 3-(Trifluoromethyl)aniline
H
2
N
F
F F
(B) 100 mg
MM 0161.07 Imp. E (EP): 2-Methyl-N-[3-(trifluoromethyl)phenyl]propanamide H
N
O
F
F F
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 95
Code Product Price Unit
MM 0161.08 Imp. F (EP): 2-Methyl-N-[2-nitro-
5-(trifluoromethyl)phenyl]propanamide
O
2
N
H
N
O
F
F F
(D) 100 mg
MM 0161.01 2-Hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)-
phenyl]propanamide (2-Hydroxyflutamide)
NO
2
H
N
O
F
F F HO
(A) 100 mg
MM 0161.09 Trifluoromethylbenzene
F
F F
(B) 100 mg
MM 0161.10 3-Nitrobenzotrifluoride
O
2
N
F
F F
(B) 100 mg
MM 0161.12 3-Trifluoromethyl-4-nitrophenol
NO
2
HO
F
F F
(A) 100 mg
Fluticasone Propionate
New MM 1244.10 6,9-Difluoro-11,17-dihydroxy-16-methyl-
3-oxoandrosta-1,4-diene-17-carboxylic Acid
O
HO
F
OH
O
OH
F
(A) 100 mg
Fluvastatin Sodium
MM 0676.00 Fluvastatin Sodium
N
F
OH
OH
O
ONa
(D) 100 mg
Folic Acid
MM 0621.00 Folic Acid
N
H
N
H
O
OH
O
O OH
N
N
N
N
H
O
H
2
N
(A) 500 mg
MM 0621.01 Imp. A (EP): (2S)-2-[(4-Aminobenzoyl)amino]pentanedioic Acid
(N-(4-Aminobenzoyl)-L-glutamic Acid)
H
2
N
N
H
O
OH
O
O OH
(A) 100 mg
MM 0621.02 Imp. B (EP) as Sulphate: 2,5,6-Triaminopyrimidin-4(1H)-one
Sulphate
N
N
H
H
2
N
O
NH
2
NH
2
x H
2
SO
4
(A) 100 mg
MM 0621.04 Imp. D (EP): 4-[[(2-Amino-4-oxo-1,4-dihydropteridin-
6-yl)methyl]amino]benzoic Acid (Pteroic Acid)
N
N
H
H
2
N
O
N
N
N
H
OH
O
(D) 50 mg
MM 0094.03 4-Aminobenzoic Acid
H
2
N
OH
O
(B) 100 mg
MM 0169.00 L-Glutamine
OH
NH
2
O
H
2
N
O
(A) 500 mg
Pharmaceutical impurities
96 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Formoterol Fumarate Dihydrate
MM 0447.00 Formoterol Fumarate Dihydrate
HO
HN
OH
H
N
O
O
O
HO
OH
O
x x 2 H
2
O
and enantiomer
2
(D) 50 mg
Furosemide
MM 0014.00 Furosemide
O OH
S
Cl
H
N
O
H
2
N
O O
(A) 500 mg
MM 0014.02 Imp. A (EP): 2-Chloro-4-[(furan-2-ylmethyl)amino]-
5-sulphamoylbenzoic Acid
O OH
S
Cl
HN
O
H
2
N
O O
(A) 100 mg
MM 0014.03 Imp. B (EP): 2,4-Dichloro-5-sulphamoylbenzoic Acid
O OH
S
Cl
Cl
H
2
N
O O
(B) 100 mg
MM 0014.01 Imp. C (EP): 2-Amino-4-chloro-5-sulphamoylbenzoic Acid
O OH
S
Cl
NH
2
H
2
N
O O
(A) 100 mg
MM 0014.04 Imp. D (EP): 2,4-Bis[(furan-2-ylmethyl)amino]-
5-sulphamoylbenzoic Acid
O OH
S
H
N
O
O
HN
H
2
N
O O
(D) 100 mg
MM 0014.05 Imp. E (EP): 2,4-Dichlorobenzoic Acid
O OH
Cl
Cl
(B) 100 mg
MM 0014.50 Ethyl 2,4-Dichloro-5-sulphamoylbenzoate
O O
S
Cl
Cl
H
2
N
O O
(A) 100 mg
Gabapentin
MM 0684.01 Imp. A (EP): 2-Azaspiro[4.5]decan-3-one
(3,3-Pentamethylene-4-butyrolactam)
HN
O
(A) 100 mg
MM 0684.07 Imp. E (EP): 1-(Carboxymethyl)cyclo-
hexanecarboxylic Acid
HO
O
OH
O
(A) 100 mg
Ganciclovir
New MM 0485.00 Ganciclovir
HN
N
O
H
2
N
N
N
O
HO
OH
(A) 100 mg
MM 0061.02 Imp. F (EP): 2-Amino-1,9-dihydro-6H-purin-6-one (Guanine)
HN
N
O
H
2
N
N
H
N
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 97
Code Product Price Unit
MM 0485.09 Imp. I (EP): 2-[(2-Amino-6-oxo-1,6-dihydro-
9H-purin-9-yl)methoxy]propane-1,3-diyl
Dipropanoate (Ganciclovir Dipropionate)
HN
N
O
H
2
N
N
N
O
O
O
O
O
(A) 100 mg
MM 0485.10 Imp. J (EP): 2-[2-(Propanoylamino)-6-oxo-
1,6-dihydro-9H-purin-9-yl]methoxy]
propane-1,3-diyl dipropanoate
(Ganciclovir Tripropionate)
HN
N
O
N
H
N
N
O
O
O
O
O
O
(A) 100 mg
Gemcitabine Hydrochloride
New MM 1257.00 Gemcitabine Hydrochloride
O
N
N
O
NH
2
OH F
HO
F
x HCl
(A) 100 mg
MM 0749.05 Imp. A (EP): 4-Aminopyrimidin-2(1H)-one
(Cytosine) N
N
H
NH
2
O
(A) 100 mg
Gemfibrozil
MM 0641.00 Gemfibrozil
O OH
O
(A) 250 mg
MM 0641.08 Imp. A (EP): 2,5-Dimethylphenol (p-Xylenol)
OH
(A) 100 mg
MM 0641.07 Imp. E (EP): 5-[2,5-Dimethyl-4-(prop-1-enyl)-
phenoxy]-2,2-dimethylpentanoic Acid
O OH
O
(D) 100 mg
MM 0641.02 Imp. H (EP): 1,3-Bis(2,5-dimethylphenoxy)propane
O O
(A) 100 mg
MM 0641.01 3-(2,5-Dimethylphenoxy)propyl Chloride
(3-(2,5-Xylyloxy)propyl Chloride)
O Cl
(A) 100 mg
MM 0641.03 Gemfibrozil Isobutyl Ester
O O
O
(A) 100 mg
Gestodene
MM 0124.06 Imp. L (EP): 13-Ethyl-17-hydroxy-18,19-
dinor-17-pregna-5,15-dien-20-yn-3-one
(56)-Gestodene)
OH
O
(A) 100 mg
Glibenclamide
MM 0008.00 Glibenclamide
S
N
H
N
H
O
O O
N
H
O
O
Cl
(A) 500 mg
MM 0008.01 Imp. A (EP): 5-Chloro-2-methoxy-N-
(2-(4-sulfamoylphenyl)ethyl)benzamide
S
NH2
O O
N
H
O
O
Cl
(A) 100 mg
MM 0008.02 Imp. B (EP): Methyl [[4-[2-[(5-Chloro-
2-methoxybenzoyl)amino]ethyl]phenyl]-
sulphonyl]carbamate
S
N
H
O
O
O O
N
H
O
O
Cl
(A) 100 mg
Pharmaceutical impurities
98 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
New MM 0942.09 Imp. C (Pharmeuropa):
1-[[4-[2-[(Cyclohexylcarbamoyl)amino]-
ethyl]phenyl]sulfonyl]-3-cyclohexylurea
(N-(Cyclohexylcarbamoyl)-
4-[2-[(cyclohexylcarbamoyl)amino]ethyl]
benzene-Sulphonamide)
N
H
N
H
O
S
N
H
O O
N
H
O (A) 100 mg
New MM 0008.07 Imp. D (Pharmeuropa): 1-[[4-[2-[(5-Chloro-
2-methoxybenzoyl)amino]ethyl]phenyl]-
sulfonyl]-3-butylurea Cl
O
N
H
O
S
N
H
O O
N
H
O
(A) 50 mg
MM 0008.03 5-Chloro-2-methoxybenzoic Acid
OH
O
O
Cl
(B) 100 mg
MM 0008.04 5-Chloro-N-(2-phenylethyl)-2-methoxybenzamide
N
H
O
O
Cl
(A) 100 mg
Gliclazide
MM 0325.00 Gliclazide
N
H
S
O O
N
H
O
N
(A) 500 mg
MM 0325.01 Imp. A (EP): 4-Methylbenzenesulphonamide
NH
2
S
O O
(C) 100 mg
MM 0325.02 Imp. B (EP): 2-Nitroso-octahydrocyclopenta[c]pyrrole
N
N
O
(A) 100 mg
MM 0325.03 Imp. C (EP): Ethyl [(4-Methylphenyl)sulphonyl]-
Carbamate
N
H
S
O
O
O O
(A) 100 mg
MM 0325.06 Imp. F (EP): 1-(Hexahydrocyclopenta[c]pyrrol-
2(1H)-yl)-3-[(2-methylphenyl)sulphonyl]urea
N
H
S
N
H
O
N
O O
(A) 100 mg
MM 0325.09 Methyl N-Methyl-p-tolylsulphoncarbamate
N
S
O
O
O O
(A) 100 mg
Glimepiride
MM 0647.00 Glimepiride
N
O
N
H
O
S
N
H
O O
N
H
O (D) 100 mg
MM 0647.02 Imp. A (EP): 1-[[4-[2-[[(3-Ethyl-4-methyl-2-oxo-
2,3-dihydro-1H-pyrrol-1-yl)carbonyl]-
amino]ethyl]phenyl]sulphonyl]-3-(cis-
4-methylcyclohexyl)urea (cis-Glimepiride)
N
O
N
H
O
S
N
H
N
H
O
O O
(D) 100 mg
MM 0647.01 Imp. B (EP): 3-Ethyl-4-methyl-2-oxo-N-
[2-(4-sulphamoylphenyl)ethyl]-2,3-dihydro-1H-pyrrole-
1-carboxamide (Glimepiride Sulphonamide)
S
NH
2
O O
N
H
N
O
O
(A) 100 mg
MM 0647.03 Imp. C (EP): Methyl [[4-[2-[[(3-Ethyl-4-methyl-2-oxo-
2,3-dihydro-1H-pyrrol-
1-yl)carbonyl]amino]ethyl]phenyl]-
sulphonyl]carbamate (Glimepiride Carbamate)
S
N
H
O O
N
H
N
O
O
O
O
(A) 100 mg
MM 0647.04 Imp. D (EP): 1-[[3-[2-[[(3-Ethyl-4-methyl-2-oxo-
2,3-dihydro-1H-pyrrol-1-yl)carbonyl]amino]ethyl]-
phenyl]sulphonyl]-3-(trans-4-methylcyclohexyl)-
urea
S
N
H
N
H
O
O O
H
N
O
N
O
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 99
Code Product Price Unit
MM 0647.08 cis-4-Methylcyclohexylamine Hydrochloride
H
2
N
x HCl
(A) 100 mg
Glipizide
MM 0942.01 Imp. A (EP): 5-Methyl-N-[2-(4-sulphamoyl-
phenyl)ethyl]pyrazine-2-carboxamide
N
N
N
H
O
S
NH
2
O O
(A) 100 mg
MM 0678.03 Imp. B (EP): Cyclohexanamine
H
2
N
(C) 100 mg
MM 0942.04 Imp. D (EP): 6-Methyl-N-
[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide
N
N
N
H
O
S
NH
2
O O
(A) 100 mg
MM 0942.05 Imp. E (EP): 1-Cyclohexyl-3-[[4-[2-[[(6-methyl-
pyrazin-2-yl)carbonyl]amino]ethyl]phenyl]-
sulphonyl]urea
N
N
N
H
O
S
N
H
O O
N
H
O (A) 100 mg
MM 0942.06 Imp. F (EP): Ethyl [2-(4-Sulphamoylphenyl)-
ethyl]carbamate
O N
H
O
S
NH
2
O O
(A) 100 mg
MM 0942.07 Imp. G (EP): Methyl [[4-[2-[[(5-Methylpyrazin-
2-yl)carbonyl]amino]ethyl]phenyl]-
sulphonyl]carbamate
N
N
N
H
O
S
N
H
O O
O
O
(A) 100 mg
MM 0942.08 Imp. H (EP): 4-[2-[(Cyclohexylcarbamoyl)amino]-
ethyl]benzenesulphonamide
N
H
N
H
O
S
NH
2
O O
(A) 100 mg
MM 0942.09 Imp. I (EP): N-(Cyclohexylcarbamoyl)-
4-[2-[(cyclohexylcarbamoyl)amino]-
ethyl]benzenesulphonamide
N
H
N
H
O
S
N
H
O O
N
H
O (A) 100 mg
Glutamine
MM 0169.00 L-Glutamine
OH
NH
2
O
H
2
N
O
(A) 500 mg
MM 0169.01 N-Phenylacetyl-L-glutamine
(Phenylacetylglutamine)
OH
HN
O
O
H
2
N
O
(A) 100 mg
MM 0169.02 Phenylacetamide
NH2
O
(A) 100 mg
MM 0169.03 D-Glutamine
OH
NH
2
O
H
2
N
O
(A) 100 mg
Glycopyrronium Bromide
MM 0834.00 Glycopyrronium Bromide
O
O
Br
-
OH
N
+
and enantiomer
(A) 100 mg
MM 0834.05 Imp. B (EP): Oxophenylacetic Acid
(Benzoylformic Acid)
O
O
OH
(A) 100 mg
MM 0792.03 Imp. C (EP): (2RS)-2-Hydroxy-2-phenylacetic Acid
(Mandelic Acid)
OH
O
OH
(A) 100 mg
MM 0278.01 Imp. D (EP): Benzoic Acid
O
OH
(B) 100 mg
Pharmaceutical impurities
100 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0834.07 Imp. H (EP): Methyl 2-oxo-2-Phenylacetate
(Methyl Benzoylformate)
O
O
O
(A) 100 mg
MM 0834.01 Imp. J (EP): 2-(RS)-Cyclopentyl-2-hydroxy-
2-phenylacetic Acid
-Cyclopentylmandelic Acid)
OH
O
OH
(A) 100 mg
MM 0834.08 Imp. K (EP): (2RS)-2-Cyclopentyl-2-phenyl-
acetic Acid
OH
O (A) 100 mg
MM 0834.06 Imp. M (EP): Cyclopentylphenylmethanone
O
(A) 100 mg
Granisetron Hydrochloride
MM 0398.00 Granisetron Hydrochloride
N HN
H
H
x HCl
O
N
N
on request
New MM 0398.04 Imp. D (EP): 1-Methyl-1H-indazole-3-carboxylic Acid
OH
O
N
N
(A) 100 mg
New MM 0398.07 Imp. G (EP): 2-Methyl-2H-indazole-3-carboxylic Acid
OH
O
N
N (A) 100 mg
New MM 0398.08 Imp. H (EP): 1H-Indazole-3-carboxylic Acid
OH
O
N
HN
(A) 100 mg
Griseofulvin
MM 0582.00 Griseofulvin
O
O
O
O
Cl
O
O
(A) 500 mg
Guaiacol
MM 0354.04 Guaiacol
OH
O
(A) 500 mg
MM 0814.04 Imp. A (EP): Benzene-1,2-diol (Pyrocatechol)
OH
OH
(C) 100 mg
MM 0045.11 Imp. B (EP): Phenol
OH
(B) 100 mg
MM 0814.06 Imp. C (EP): 1,2-Dimethoxybenzene (Veratrole)
O
O
(C) 100 mg
MM 0814.08 Imp. E (EP): Methyl Benzoate
O
O
(C) 100 mg
MM 1131.00 Imp. G (EP): 4-Methoxyphenol (Mequinol)
OH
O
(A) 500 mg
MM 0007.09 Imp. H (EP): 3-Methoxyphenol
OH
O
(B) 100 mg
Guaifenesin
MM 0354.00 Guaifenesin
O
O
OH
OH
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 101
Code Product Price Unit
MM 0354.04 Imp. A (EP): 2-Methoxyphenol (Guaiacol)
O
OH
(A) 500 mg
MM 0354.01 Imp. B (EP): 2-(2-Methoxyphenoxy)propane-1,3-diol
(B-Isomer)
O
O
OH HO (A) 100 mg
MM 0354.02 Imp. C (EP): 1,1'-Oxybis[3-(2-methoxyphenoxy)
propan-2-ol] (Bisether)
O
O
OH
O
OH
O
O
(A) 100 mg
MM 0354.03 Imp. D (EP): 1,3-Bis(2-methoxyphenoxy)propan-2-ol
O
O
OH
O
O
(A) 100 mg
Guanidine Thiocyanate
New MM 1315.00 Guanidine Thiocyanate
NH
NH
2
H
2
N
HS N
x
(A) 100 mg
Halofantrine Hydrochloride
MM 0433.00 Halofantrine Hydrochloride
x HCl
F
F
F
Cl
Cl
N HO
(A) 100 mg
Haloperidol
MM 1165.00 Haloperidol
F
O
N
OH
Cl
(A) 250 mg
Haloperidol Decanoate
MM 1276.12 Imp. L (EP): 1-(4-Fluorophenyl)ethanone
F
O
(A) 100 mg
Harpagoside
MM 0370.01 Methyl trans-Cinnamate
O
O
(B) 100 mg
Heptaminol Hydrochloride
MM 0653.00 Heptaminol Hydrochloride
NH2
HO
x HCl
on request
Hexetidine
MM 0337.03 Imp. C (EP): 2,6-Bis(2-ethylhexyl)-7a-
methylhexahydro-1H-imidazo[1,5-c]imidazole
(Hexedine)
N
N N
(A) 100 mg
Hexylresorcinol
MM 0111.00 Hexylresorcinol
HO OH
(A) 500 mg
MM 0045.11 Imp. A (EP): Phenol
OH
(B) 100 mg
MM 0294.01 Imp. B (EP): Resorcinol
HO OH
(B) 100 mg
Homatropine Methylbromide
MM 0792.00 Homatropine Methylbromide
O
OH
O
N
+
H
H
H
Br
-
and enantiomer
(A) 250 mg
Pharmaceutical impurities
102 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0792.03 Imp. C (EP): (2RS)-2-Hydroxy-2-phenylacetic Acid
(Mandelic Acid)
OH
OH
O (A) 100 mg
MM 0792.04 Imp. D (EP) as Bromide: (1R,2R,4S,5S,7s)-7-[[(2S)-
3-Hydroxy-2-phenylpropanoyl]oxy]-9,9-dimethyl-3-oxa-
9-azoniatricyclo[3.3.1.0
2,4
]nonane Bromide
(Methylhyoscine Bromide)
O
O
OH
N
+
O
H
H
H
H
H
Br
-
(A) 100 mg
MM 0792.06 Imp. F (EP): Methyl (2RS)-2-Hydroxy-2-phenylacetate (Methyl
Mandelate)
O
OH
O (A) 100 mg
Hydrochlorothiazide
MM 0011.00 Hydrochlorothiazide
N
H
NH
S
O O
S
Cl
H
2
N
O O
(A) 500 mg
MM 0011.03 Imp. A (EP): Chlorothiazide
N
NH
S
O O
S
Cl
H
2
N
O O
(A) 500 mg
MM 0011.01 Imp. B (EP): 4-Amino-6-chlorobenzene-1,3-disulphonamide
(Salamide)
NH2
NH2
S
O O
S
Cl
H2N
O O
(B) 100 mg
Hydrocodone Hydrogen Tartrate 2.5-Hydrate
MM 0037.00 Imp. A (EP) as Hydrochloride Trihydrate: Morphine
Hydrochloride Trihydrate [Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
MM 0280.00 Imp. A (EP) as Hemisulphate Pentahemihydrate: Morphine
Hemisulphate Pentahemihydrate [Controlled Substance]
O OH HO
N
2
x H
2
SO
4
x 5 H
2
O
(A) 250 mg
MM 0004.00 Imp. C (EP) as Monohydrate: Codeine Monohydrate
[Controlled Substance]
O OH O
N
x H
2
O
(A) 100 mg
MM 0442.00 Imp. C (EP) as Phosphate Hemihydrate: Codeine
Phosphate Hemihydrate [Controlled Substance]
O OH O
N
x H
3
PO
4
x 1/2 H
2
O
(A) 100 mg
MM 0672.00 Imp. D (EP) as Hydrochloride: 4,5-Epoxy-14-
hydroxy-3-methoxy-17-methylmorphinan-6-
one Hydrochloride (Oxycodone Hydrochloride)
[Controlled Substance]
O O O
N
HO x HCl
(A) 100 mg
MM 0004.02 Imp. E (EP): 7,8-Didehydro-4,5-epoxy-3-methoxy-
17-methylmorphinan-6-one (Codeinone)
O O O
N (A) 100 mg
MM 0004.03 Imp. F (EP): 7,8-Didehydro-4,5-epoxy-3,6-dimethoxy-
17-methylmorphinan (Methylcodeine; O-Methylcodeine)
[Controlled Substance]
O O O
N (A) 100 mg
MM 0630.01 Imp. H (EP): Diphenylmethanone (Benzophenone)
O
(B) 100 mg
Hydrocortisone
MM 0185.00 Hydrocortisone
O
HO
OH
O
OH
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 103
Code Product Price Unit
MM 0193.00 Imp. A (EP): Prednisolone
O
HO
OH
O
OH
(A) 500 mg
MM 0214.00 Imp. B (EP): 17,21-Dihydroxypregn-4-ene-
3,11,20-trione (Cortisone)
O
O
OH
O
OH
(A) 500 mg
MM 0187.00 Imp. C (EP): Hydrocortisone Acetate
(Hydrocortisone 21-Acetate)
O
HO
OH
O
O
O
(A) 500 mg
MM 0185.06 Imp. D (EP): 6,11,17,21-Tetrahydroxypregn-4-ene-3,20-dione
(6-Hydroxyhydrocortisone)
O
HO
OH
O
OH
OH
(A) 100 mg
MM 0185.07 Imp. E (EP): 11,17,21-Trihydroxypregna-4,6-diene-3,20-dione
(-Hydrocortisone)
O
HO
OH
O
OH
(D) 100 mg
MM 0185.08 Imp. F (EP): 17,21-Dihydroxypregn-4-ene-3,20-dione
(Reichstein's Substance S)
O
OH
O
OH
(A) 100 mg
MM 0185.13 6-Hydroxyhydrocortisone
O
HO
OH
O
OH
OH
(D) 50 mg
Hydrocortisone Acetate
MM 0187.00 Hydrocortisone Acetate
O
HO
OH
O
O
O
(A) 500 mg
MM 0185.00 Imp. A (Pharmeuropa): 11,17,21-Trihydroxy-
pregn-4-ene-3,20-dione (Hydrocortisone)
O
HO
O
OH
OH
(A) 500 mg
MM 0187.06 Hydrocortisone 11,17,21-Triacetate
O
O
O
O
O
O
O
O
(B) 10 mg
MM 0187.09 11,17,21-Trihydroxypregna-4,6-diene-3,20-dione 21-Acetate
O
HO
O
O
OH
O
(D) 100 mg
MM 0194.00 Imp. C (Pharmeuropa): 11,17-Dihydroxy-3,20-
dioxopregna-1,4-dien-21-yl Acetate (Prednisolone Acetate)
O
HO
O
O
O
OH
(A) 500 mg
MM 0186.00 Imp. D (Pharmeuropa): 17-Hydroxy-3,11,20-Trioxopregn-
4-en-21-yl Acetate
(Cortisone Acetate)
O
O
O
O
O
OH
(A) 500 mg
Pharmaceutical impurities
104 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Hydrocortisone 17-Butyrate
MM 0188.00 Hydrocortisone 17-Butyrate
O
HO
O
OH
O
O
(A) 500 mg
MM 0188.01 Hydrocortisone 21-Butyrate
O
HO
O
O
OH
O
(A) 100 mg
Hydrocortisone Hydrogen Succinate
MM 0185.00 Imp. A (EP): Hydrocortisone
O
HO
OH
O
OH
(A) 500 mg
MM 0187.00 Imp. B (EP): Hydrocortisone Acetate
O
HO
OH
O
O
O
(A) 500 mg
Hydromorphone Hydrochloride
MM 0037.00 Imp. C (EP) as Hydrochloride Trihydrate:
Morphine Hydrochloride Trihydrate
[Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
MM 0280.00 Imp. C (EP) as Hemisulphate Pentahemi-
hydrate: Morphine Hemisulphate Pentahemi-
hydrate [Controlled Substance]
O OH HO
N
2
x H
2
SO
4
x 5 H
2
O
(A) 250 mg
Hydroxychloroquine Sulphate
MM 0764.00 Hydroxychloroquine Sulphate
N Cl
HN
N
OH
x H
2
SO
4
(A) 500 mg
MM 0764.02 Desethylhydroxychloroquine Dihydrochloride
N Cl
HN
N
H
OH
x 2 HCl
(D) 100 mg
MM 0764.04 O-Acetylhydroxychloroquine
N Cl
HN
N
O
O
(A) 100 mg
MM 0764.05 Hydroxychloroquine N-Oxide Dihydrochloride
N Cl
HN
N
OH
O
x 2 HCl
(B) 10 mg
Hydroxyethyl Salicylate
MM 0112.00 Hydroxyethyl Salicylate
OH
O
O
OH
(A) 500 mg
MM 0045.00 Imp. A (EP): Salicylic Acid
OH
OH
O
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 105
Code Product Price Unit
Hydroxyzine Hydrochloride
MM 0852.00 Hydroxyzine Hydrochloride
Cl
N
N
O
OH
x 2 HCl
(A) 250 mg
MM 0380.01 Imp. A (EP): (RS)-1-[(4-Chlorophenyl)phenylmethyl]piperazine
Cl
N
NH
(A) 100 mg
MM 0852.02 Imp. B (EP) as Dihydrochloride:
2-[2-[4-(Diphenylmethyl)piperazin-1-yl]ethoxy]-
ethanol Dihydrochloride (Decloxizine
Dihydrochloride)
N
N
O
OH
x 2 HCl
(A) 50 mg
Hymechromone
MM 0294.00 Hymecromone
HO O O
(A) 500 mg
MM 0294.01 Imp. A (EP): 1,3-Dihydroxybenzene (Resorcinol)
HO OH
(B) 100 mg
MM 0294.02 Imp. B (EP): 7-Hydroxy-2-methyl-4H-1-benzopyran-4-one
HO O
O
(A) 100 mg
MM 0294.03 2,4-Dihydroxyacetophenone
HO
O
OH
(B) 100 mg
MM 0294.04 Hymecromone Acetate
O O O
O
(A) 100 mg
MM 0294.50 7-Acetoxy-3-acetyl-2-4H-1-benzopyran-4-one
O O
O O
O
(A) 100 mg
Hyoscine Butylbromide
MM 0683.00 Hyoscine Butylbromide
O
O
OH
N O
H
H
H
Br
+
(A) 500 mg
MM 0546.00 Imp. A (EP) as Hydrobromide Trihydrate: Hyoscine
Hydrobromide Trihydrate
O
N
OH
H
O
H
H
x HBr
x 3 H
2
O
O
H
H
(A) 500 mg
MM 0601.03 Imp. B (EP): (2RS)-3-Hydroxy-2-phenylpropanoic
Acid (DL-Tropic Acid; Tropic Acid)
OH
O
OH
(A) 100 mg
Hyoscine Hydrobromide
MM 0546.00 Hyoscine Hydrobromide Trihydrate
O
N
OH
H
O
H
H
x HBr
x 3 H
2
O
O
H
H
(A) 500 mg
MM 0546.06 Imp. C (EP): (1R,2R,4S,5S,7s)-9-Methyl-3-oxa-
9-azatricyclo[3.3.1.0
2,4
]non-7-yl 2-Phenylprop-
2-enoate (Apohyoscine)
O
N
H
O
H
H
O
H
H
(A) 100 mg
MM 0601.03 Imp. D (EP): (2RS)-3-Hydroxy-2-phenylpropanoic
Acid (DL-Tropic Acid; Tropic Acid)
OH
OH
O (A) 100 mg
Pharmaceutical impurities
106 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0546.07 Hyoscine N-Oxide Hydrobromide
O
N
OH
H
O
H
H
O
H
H
O
x HBr
(A) 100 mg
Hyoscyamine Sulphate
MM 0601.03 Imp. A (EP): (2RS)-3-Hydroxy-2-phenylpropanoic Acid
(DL-Tropic Acid; Tropic Acid)
OH
O
OH
(A) 100 mg
MM 0546.00 Imp. D (EP) as Hydrobromide Trihydrate: Hyoscine
Hydrobromide Trihydrate
O
N
OH
H
O
H
H
x HBr
x 3 H
2
O
O
H
H
(A) 500 mg
MM 0289.01 Imp. G (EP) as Hydrochloride: (1R,3r,5S)-8-Methyl-
8-azabicyclo[3.2.1]oct-3-yl 2-Phenylprop-2-enoate
Hydrochloride (Apoatropine Hydrochloride)
O
O
N
H
x HCl
H
H
(D) 100 mg
Ibandronate Sodium Monohydrate
New MM 1326.00 Ibandronate Sodium Monohydrate
N P
O
P
O
HO
OH
OH
OH
ONa
x H
2
O
(A) 100 mg
Ibuprofen
MM 0002.00 Ibuprofen
OH
O
(A) 500 mg
MM 0002.13 Imp. A (EP): (2RS)-2-[3-(2-Methylpropyl)phenyl]propanoic Acid
OH
O
(A) 100 mg
MM 0002.01 Imp. B (EP):(2RS)-2-(4-Butylphenyl)propanoic Acid
OH
O
(A) 100 mg
MM 0002.10 Imp. C (EP): (2RS)-2-[4-(Methylpropyl)phenyl]propanamide
NH
2
O
(A) 100 mg
MM 0002.11 Imp. D (EP): (2RS)-2-(4-Methylphenyl)propanoic Acid
OH
O
(A) 100 mg
MM 0002.04 Imp. E (EP): 1-[4-(2-Methylpropyl)phenyl]ethanone
O
(A) 100 mg
MM 0002.28 Imp. F (EP): 3-[4-(2-Methylpropyl)phenyl]propanoic Acid
OH
O
(A) 100 mg
MM 0002.38 Imp. G (EP): (1RS,4RS)-7-(2-Methylpropyl)-1-
[4-(2-methylpropyl)phenyl]-1,2,3,4-tetrahydro-
naphthalene-1,4-dicarboxylic Acid
O OH
O
OH
and enantiomer
(D) 50 mg
MM 0002.30 Imp. H (EP):(3RS)-1,3-Bis[4-(2-methylpropyl)phenyl]butan-
1-one
O
(D) 100 mg
MM 0002.31 Imp. I (EP): 1-(2-Methylpropyl)-4-[(3RS)-3-
[4-(2-methylpropyl)phenyl]butyl]benzene
(A) 50 mg
MM 0002.02 Imp. J (EP): (2RS)-2-[4-(2-Methylpropanoyl)phenyl]propanoic Acid
OH
O
O
(A) 100 mg
MM 0002.26 Imp. K (EP): (2RS)-2-(4-Formylphenyl)propanoic Acid
O
OH
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 107
Code Product Price Unit
MM 0002.24 Imp. L (EP): 2-[4-(1-Hydroxy-2-methylpropyl)phenyl]propanoic Acid
(1-Hydroxyibuprofen)
OH
OH
O
(A) 100 mg
MM 0002.34 Imp. M (EP): (2RS)-2-Hydroxy-
2-[4-(2-methylpropyl)phenyl]propanoic Acid
OH
O
OH
(A) 100 mg
MM 0002.35 Imp. N (EP): (2RS)-2-(4-Ethylphenyl)propanoic Acid
OH
O
(A) 100 mg
MM 0002.33 Imp. O (EP): 2-[4-(1-Methylpropyl)phenyl]propanoic Acid
OH
O
(A) 100 mg
MM 0002.19 Imp. P (EP):(2RS)-2-[4-(2-Methylpropyl)phenyl]propan-1-ol
OH
(A) 100 mg
MM 0002.36 Imp. Q (EP): 2-[4-(2-Methylpropyl)phenyl]ethanol
OH
(A) 100 mg
MM 0002.37
Imp. R (EP): 1,1'-(Ethane-1,1-diyl)-4,4'-(2-
methylpropyl)dibenzene
(A) 100 mg
MM 0002.03 4-Isobutylbenzoic Acid
OH
O
(A) 100 mg
MM 0002.07 2-(4-Isobutyrylphenyl)propanamide
NH
2
O
O
(A) 100 mg
MM 0002.08 4-Acetylbenzoic Acid
OH
O
O
(A) 100 mg
MM 0002.09 4-Isobutyrylacetophenone
O
O
(A) 100 mg
MM 0002.14 2-(4-Isobutyrylphenyl)propane
O
(A) 100 mg
MM 0002.15 2-Hydroxypropyl 2-(4-Isobutylphenyl)propanoate
O
O
OH
(A) 100 mg
MM 0002.16 1-Hydroxyprop-2-yl 2-(4-Isobutylphenyl)propanoate
O
O
OH
on request
MM 0002.17 2,3-Dihydroxypropyl 2-(4-Isobutylphenyl)propanoate
O
O
OH
OH
(D) 50 mg
MM 0002.18 1,3-Dihydroxyprop-2-yl 2-(4-Isobutylphenyl)propanonate
O
O
OH
OH
on request
MM 0002.20 2-(4-n-Propylphenyl)propanoic Acid
OH
O
(A) 100 mg
MM 0002.21 2-(4-Isobutylphenyl)propionitrile
N
(A) 100 mg
MM 0002.23 Isopropyl 2-(4-Isobutylphenyl)propanonate
O
O
(A) 100 mg
MM 0002.25 1-Ethyl-4-isobutylbenzene (A) 100 mg
Pharmaceutical impurities
108 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0002.29 (1RS,4SR)-7-(2-Methylpropyl)-1-[4-(2-methyl-
propyl)phenyl]-1,2,3,4-tetrahydronaphthalene-
1,4-dicarboxylic Acid
O OH
O
OH
and enantiomer
(D) 100 mg
MM 0002.32 2-[4-(2-Hydroxy-2-methylpropyl)phenyl]propanoic Acid
(2-Hydroxyibuprofen)
HO
OH
O
(A) 100 mg
MM 0002.45 (2SR)-2-(4-Isobutylphenyl)-N-((SR)-
1-phenylethyl)propanamide
H
N
O
and enantiomer
(A) 100 mg
MM 0002.46 (2SR)-2-(4-Isobutylphenyl)-N-((RS)-
1-phenylethyl)propanamide
H
N
O
and enantiomer
(A) 100 mg
MM 0002.48 4-Isobutylstyrene (B) 10 mg
MM 0002.50 1-(4-Isobutylphenyl)ethanol
OH
(A) 100 mg
MM 0002.51 4-(1-Hydroxy-2-methylpropyl)acetophenone
O
OH
(A) 100 mg
MM 0002.53 Ibuprofen Methyl Ester
O
O
(A) 100 mg
MM 0002.57 1-(4-Isopropylphenyl)ethanone
(4-Isopropylacetophenone)
O
(A) 100 mg
MM 0002.59 2-(4-Isopropylphenyl)acrylic Acid
OH
O
(C) 50 mg
Idoxuridine
MM 0791.00 Idoxuridine
O
HO
N
HN
O
O
I
OH
(A) 500 mg
Imidocarb Dipropionate
MM 0742.00 Imidocarb Dipropionate O
N
H
N
H
N
H
N
H
N
N
x 2
O
OH
(A) 100 mg
Imipramine Hydrochloride
MM 0077.00 Imipramine Hydrochloride
N
x HCl
N
(A) 500 mg
MM 0589.00 Imp. A (EP) as Hydrochloride: 3-(10,11-Dihydro-
5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-
amine Hydrochloride (Desipramine Hydrochloride)
N
H
x HCl
N
(A) 250 mg
MM 0077.05
Imp. B (EP): 3-(5H-Dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-
1-amine (Depramine; 10,11-Dehydroimipramine)
N N
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 109
Code Product Price Unit
MM 0077.08 Imp. C (EP) as Hydrochloride:
10-[3-(Dimethylamino)propyl]acridin-9(10H)-one
Hydrochloride
N N
O
x HCl
(A) 100 mg
MM 0077.03 N-[3-(10,11-Dihydro-5H-dibenzo-[b,f]azepin-5-yl)propyl]-
N,N',N'-trimethylpropane-1,3-diamine Dihydrochloride
N
x 2 HCl
N N
(B) 10 mg
MM 0077.04 10-Hydroxyimipramine BH
3-
Aduct
N N
HO
x BH
3
(A) 100 mg
MM 0076.06 Iminodibenzyl
NH
(B) 100 mg
MM 0077.12 Imipramine N-Oxide
N N
O
(A) 100 mg
Indanazoline Hydrochloride
MM 0588.02 4-Aminoindan Hydrochloride
NH2
x HCl
(A) 100 mg
Indapamide
MM 0477.00 Indapamide
S
H
2
N
O
O
Cl
N
H
O
N
(A) 250 mg
MM 0477.01 Imp. A (EP): (2RS)-2-Methyl-1-nitroso-
2,3-dihydro-1H-indole
ON
N
(A) 100 mg
MM 0477.02 Imp. B (EP): 4-Chloro-N-(2-methyl-1H-
indol-1-yl)-3-sulphamoylbenzamide
S
H2N
O
O
Cl
N
H
O
N
(A) 100 mg
MM 0477.04 4-Chloro-3-sulfamoylbenzoic Acid
S
H
2
N
O
O
Cl
OH
O
(C) 100 mg
MM 0477.05 N-(4-Chloro-3-sulfamoylbenzoyl)-2-methylindoline
S
H
2
N
O
O
Cl
O
N
(D) 100 mg
MM 0477.07 Triethylamine
N
(C) 100 mg
MM 0477.08 2-Methylindoline
HN
(A) 100 mg
MM 0477.09 1-Amino-2-methylindoline Hydrochloride
H
2
N
N
x HCl
(D) 100 mg
Indometacin
MM 0584.00 Indometacin
N
O
O
Cl
OH
O
(A) 500 mg
MM 0063.03 Imp. A (EP): 4-Chlorobenzoic Acid
OH
O
Cl
(B) 100 mg
Pharmaceutical impurities
110 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
New MM 0584.02 3,4-Dichloroindometacin ([1-(3,4-Dichlorobenzoyl)-
5-methoxy-2-methylindol-3-yl]acetic Acid) N
O
O
Cl
OH
O
Cl
(A) 50 mg
Indoramin Hydrochloride
MM 0802.02 Imp. A (BP): 3-(2-Bromoethyl)indole
H
N
Br
(A) 100 mg
Ipecacuanha
MM 0131.02 Emetine Dihydrochloride N
HN
O
O
O
H
O
x 2 HCl
(A) 100 mg
Ipratropium Bromide
New MM 0601.03 Imp. C (EP): (2RS)-3-Hydroxy-2-phenylpropanoic
Acid (dl-Tropic Acid)
OH
O
OH
(A) 100 mg
New MM 0289.03 Imp. D (EP): 2-Phenylpropenoic Acid (Atropic Acid)
OH
O (A) 100 mg
Iprindole Hydrochloride
MM 0478.00 Iprindole Hydrochloride
N
N
x HCl
(A) 100 mg
Irbesartan
MM 0862.01 Imp. A (EP): 1-(Pentanoylamino)-N-[[2'-(1H-
tetrazol-5-yl)biphenyl-4-yl]methyl]cyclo-
pentanecarboxamide
N
H
N
N N
HN
O
NH
O
(A) 50 mg
Isoamyl Benzoate
MM 1086.00 Isoamyl Benzoate
O
O
(A) 500 mg
Isoconazol Nitrate
MM 0541.00 Isoconazole Nitrate
O
x HNO
3
N
N
Cl
Cl
Cl
Cl
(A) 100 mg
MM 0281.01 Imp. A (EP): (1RS)-1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanol
HO
Cl Cl
N
N
(A) 100 mg
MM 0541.02 Imp. B (EP) as Nitrate: (2RS)-2-[(2,6-Dichlorobenzyl)oxy]-
2-(2,4-dichlorophenyl)ethanamine Nitrate
O
x HNO
3
NH
2
Cl
Cl
Cl
Cl
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 111
Code Product Price Unit
MM 0281.00 Imp. C (EP) as Nitrate: 1-[(2RS)-
2-[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl]-
1H-imidazole Nitrate (Miconazole Nitrate)
O
x HNO
3
N
N
Cl
Cl
Cl Cl
(A) 500 mg
Isoflurane
MM 0500.02 Imp. B (EP): 2-(Difluoromethoxy)-1,1,1-trifluoroethane
F O
F
F
F F
(A) 100 mg
MM 0500.03 Imp. C (EP): (2RS)-2-Chloro-2-(chlorodifluoromethoxy)-
1,1,1-trifluoroethane O
Cl
Cl
F F
F
F F
(A) 100 mg
MM 0500.04 Imp. D (EP): 1,1-Dichloro-1-(difluoromethoxy)-2,2,2-trifluoroethane
F O
F
Cl Cl
F
F F
(A) 100 mg
MM 0500.05 Imp. E (EP): 1,1-Dichloro-1-(chlorodifluoromethoxy)-2,2,2-
trifluoroethane O
Cl Cl
Cl
F F
F
F F
(A) 100 mg
MM 0500.06 Imp. F (EP): Acetone
O
(C) 100 mg
Isoproturon
MM 2503.02 3-(2-Isopropylphenyl)-1,1-dimethylurea
H
N N
O
(A) 100 mg
MM 2503.03 3-(3-Isopropylphenyl)-1,1-dimethylurea H
N N
O
(A) 100 mg
Isosorbide Dinitrate
MM 0126.05 Imp. B (EP): Isosorbide 2-Nitrate
O
O
HO
O
H
H
NO
2
(A) 100 mg
MM 0502.00 Imp. C (EP): Isosorbide Mononitrate (Isosorbide 5-Nitrate)
O
O
O
OH
H
H
O
2
N
(A) 500 mg
MM 0126.01 2-Monomethyl Isosorbide
O
O
HO
O
H
H on request
MM 0126.02 Dimethyl Isosorbide
O
O
O
O
H
H (B) 100 mg
MM 0126.03 Isosorbide
O
O
HO
OH
H
H (A) 500 mg
MM 0126.04 Isomannit Dinitrate
O
O
O
O
H
H
NO
2
O
2
N
on request
Isosorbide Mononitrate
MM 0502.00 Isosorbide Mononitrate
O
O
O
OH
H
H
O
2
N
(A) 500 mg
MM 0126.05 Imp. C (EP): Isosorbide 2-Nitrate
O
O
HO
O
H
H
NO
2
(A) 100 mg
Pharmaceutical impurities
112 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0126.03 Isosorbide
O
O
HO
OH
H
H (A) 500 mg
Isoxsuprine Hydrochloride
MM 0576.00 Isoxsuprine Hydrochloride
HO
OH
H
N
O x HCl
and enantiomere
(A) 500 mg
Itraconazole
MM 0258.00 Itraconazole
O
O
O
N
N
N
Cl Cl
N
N
N
N N
O
and enantiomer
(A) 100 mg
MM 0258.02 Imp. A (EP): 4-[4-[4-(4-Methoxyphenyl)piperazin-
1-yl]phenyl]-2-[(1RS)-1-methylpropyl]-2,4-dihydro-
3H-1,2,4-triazol-3-one
O
N
N
N
N N
O
(A) 100 mg
MM 0258.04 Imp. C (EP): 4-[4-[4-[4-[[cis-2-(2,4-Dichlorophenyl)-
2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]-
methoxy]phenyl]piperazin-1-yl]phenyl]-2-propyl-
2,4-dihydro-3H-1,2,4-triazol-3-one
O
O
O
N
N
N
Cl Cl
N
N
N
N N
O
and enantiomer
(A) 100 mg
MM 0258.05 Imp. D (EP): 4-[4-[4-[4-[[cis-2-(2,4-Dichlorophenyl)-
2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]-
methoxy]phenyl]piperazin-1-yl]phenyl]-2-(1-
methylethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
O
O
O
N
N
N
Cl Cl
N
N
N
N N
O
and enantiomer
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 113
Code Product Price Unit
MM 0258.07 Imp. F (EP): 2-Butyl-4-[4-[4-[4-[[cis-2-(2,4-dichloro-
phenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-
4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2,4-
dihydro-3H-1,2,4-triazol-3-one
O
O
O
N
N
N
Cl Cl
N
N
N
N N
O
and enantiomer
(A) 100 mg
MM 0258.10 2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-
3-one
O
N
N
N
NH N
O
(A) 100 mg
MM 0258.11 cis-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-
1,3-dioxolane-4-methanol Mesilate
O
O
O
N
N
N
Cl Cl
and enantiomer
S
O O
(A) 100 mg
Ketamine Hydrochloride
MM 0144.00 Ketamine Hydrochloride
O
Cl
NH
x HCl
(A) 500 mg
MM 0144.01 Imp. A (EP): 1-[(2-Chlorophenyl)-
(methylimino)methyl]cyclopentanol
Cl N
HO
(A) 100 mg
MM 0144.02 Imp. B (EP): (2RS)-2-(2-Chloro-
phenyl)-2-hydroxycyclohexanone
O
Cl OH
(A) 100 mg
Ketoconazole
MM 0145.00 Ketoconazole
O
O
N
N
O
N
N O
and enantiomer
Cl
(A) 500 mg
MM 0145.04 Imp. D (EP): 1-[4-[[(2RS,4SR)-2-(2,4-Dichlorophenyl)-2-(1H-
imidazol-1-ylmethyl)-1,3-dioxolan-
4-yl]methoxy]phenyl]piperazine
O
O
N
N
O
N
HN
and enantiomer
Cl
(A) 100 mg
New MM 0145.05 1-Acetyl-4-(4-hydroxyphenyl)piperazine
N N OH
O
(A) 100 mg
Ketoprofen
MM 0001.00 Ketoprofen
OH
O
O
(A) 500 mg
Pharmaceutical impurities
114 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0001.01 Imp. A (EP):1-(3-Benzoylphenyl)ethanone
(3-Acetylbenzophenone)
O O
(A) 100 mg
MM 0001.03 Imp. B (EP): (3-Benzoylphenyl)acetic Acid
OH
O
O
(A) 100 mg
MM 0001.07 Imp. C (EP):3-[(1RS)-1-Carboxylethyl]benzoic Acid
HO
OH
O
O
(A) 100 mg
MM 0001.12 Imp. D (EP): (2RS)-2-[3-(4-Methylbenzoyl)phenyl]propanoic Acid
OH
O
O
(D) 100 mg
MM 0001.05 Imp. E (EP):(2RS)-2-(3-Benzoylphenyl)propanamide
NH2
O
O
(A) 100 mg
MM 0001.04 Imp. F (EP): (2RS)-2-(3-Benzoylphenyl)propanenitrile
O
N
(A) 100 mg
MM 0001.20 Imp. G (EP): 3-[(1RS)-1-Cyanoethyl]benzoic Acid
HO
O
N
(A) 100 mg
MM 0001.22 Imp. H (EP): 3-(Cyanomethyl)benzoic Acid
HO
O
N
(A) 100 mg
MM 0001.14 Imp. I (EP): (3-Benzoylphenyl)ethanenitrile
O
N
(A) 100 mg
MM 0001.23 Imp. J (EP): (2RS)-2-[3-(2,4-Dimethylbenzoyl)-
phenyl]propanoic Acid
OH
O
O
(D) 50 mg
MM 0001.02 3-Ethylbenzophenone
O
(A) 100 mg
MM 0001.11 3-(1-Hydroxyethyl)benzophenone
O OH
(A) 100 mg
MM 0001.13 3-Methylbenzophenone
O
(B) 100 mg
MM 0001.17 3-(1-Methoxyethyl)benzophenone O O (A) 100 mg
MM 0001.18 2-[3-(-Hydroxybenzyl)phenyl]propanoic Acid
OH
OH
O
(A) 100 mg
MM 0001.19 Ethyl 2-(3-Benzoylphenyl)propionate(Ketoprofen Ethyl Ester)
O
O
O
(A) 100 mg
MM 0001.21 Isopropyl 2-(3-Benzoylphenyl)propionate
O
O
O
(A) 100 mg
MM 0001.50 3-(1-Acetoxyethyl)benzophenone
O
O
O
(A) 100 mg
MM 0001.32 Methyl 2-(3-Benzoylphenyl)propionate (Ketoprofen Methyl
Ester)
O
O
O
(A) 100 mg
MM 0001.33 2-Ethylhexyl 2-(3-Benzoylphenyl)propionate
(Ketoprofen 2-Ethylhexyl Ester)
O
O
O
(A) 100 mg
Ketorolac Trometamol
MM 0851.00 Ketorolac Trometamol
O
N
OH
O
HO
NH
2
OH
OH
x
(A) 250 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 115
Code Product Price Unit
MM 0851.03 Imp. I (EP): Phenyl(2,3-dihydro-1H-pyrrolizin-
5-yl)methanone
O
N
(A) 100 mg
Ketotifen Hydrogen Fumarate
MM 0180.00 Ketotifen Hydrogen Fumarate
OH
HO
O
O
S
O
N
x
(A) 250 mg
MM 0180.04 Ketotifen
S
O
N (A) 100 mg
MM 0180.08 Imp. B (EP): (4RS)-10-Methoxy-4-(1-methyl-
piperidin-4-yl)-4H-benzo[4,5]cyclohepta[1,2-
b]thiophen-4-ol
S
O
N
OH
(A) 100 mg
MM 0180.07 Imp. D (EP): 4-[(aRaS)-1-Methylpiperidin-4-
ylidene]-4,9-dihydro-10H-benzo[4,5]-
cyclohepta[1,2-b]thiophen-10-one N-Oxide
(Ketotifen N-Oxide)
S
O
N
O
(A) 100 mg
MM 0180.11 10-Methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-one
S
O
O
(A) 100 mg
Labetalol Hydrochloride
MM 0438.00 Labetalol Hydrochloride
HO
OH
H
N
O NH
2
x HCl
(A) 500 mg
Lacidipine
MM 0407.00 Lacidipine
H
N
O
O
O
O
O
O
(A) 100 mg
MM 0407.01 Imp. A (BP): Ethyl Methyl (E)-4-{2-[2-(tert-
Butoxycarbonyl)vinyl]phenyl}-1,4-dihydro-2,6-
dimethyl-pyridine-3,5-dicarboxylate
H
N
O
O
O
O
O
O
(A) 100 mg
MM 0407.02
Imp. B (BP): Diethyl (E)-4-{2-[2-(tert-Butoxy-
carbonyl)vinyl]phenyl}-2,6-dimethylpyridine-
3,5-dicarboxylate
N
O
O
O
O
O
O
(A) 100 mg
Pharmaceutical impurities
116 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Lamivudine
New MM 0749.00 Lamivudine
N
N
NH
2
O
O
S
HO
(A) 100 mg
MM 0045.00 Imp. C (EP): Salicylic Acid
OH
O
OH
(A) 500 mg
MM 0749.05 Imp. E (EP): 4-Aminopyrimidin-2(1H)-one(Cytosine)
N
N
H
NH
2
O
(A) 100 mg
MM 0593.03 Imp. F (EP): Pyrimidine-2,4(1H,3H)-dione (Uracil)
HN
N
H
O
O
(C) 100 mg
Lamotrigine
MM 0922.00 Lamotrigine
N
N
N
Cl
Cl
NH
2
NH
2
(A) 100 mg
MM 0922.01 Imp. A (EP): 3-Amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one
N
N
NH
Cl
Cl
NH
2
O
(A) 100 mg
MM 0922.03 Imp. C (EP): (2Z)-[2-(Diaminomethylidene)-
diazanylidene](2,3-dichlorophenyl)acetonitrile
N
N
NH
2
Cl
Cl
NH
2
N
(A) 100 mg
New MM 0922.04 Imp. D (EP): 6-(2,3-Dichlorophenyl)-1,2,4-
triazine-3,5(2H,4H)-dione
N
H
N
NH
Cl
Cl
O
O
(A) 50 mg
MM 0922.05 Imp. E (EP): 2,3-Dichlorobenzoic Acid
O
OH
Cl
Cl
(A) 100 mg
New MM 0922.07 Imp. G (EP): 6-(2,4-Dichlorophenyl)-1,2,4-
triazine-3,5-diamine
N
N
N
NH
2
NH2
Cl
Cl
(A) 50 mg
Lansoprazole
MM 0474.00 Lansoprazole
N
S
O
F
F F
O
NH
N
(A) 100 mg
MM 0474.07 Imp. A (EP): 2-[(RS)-[[3-Methyl-1-oxido-
4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]-
sulphinyl]-1H-benzimidazole
(Lansoprazole N-Oxide)
N
S
O
F
F F
O
NH
N
O
(D) 100 mg
MM 0474.01 Imp. B (EP): 2-[[[3-Methyl-4-(2,2,2-trifluoro-
ethoxy)pyridin-2-yl]methyl]sulphonyl]-1H-
benzimidazole (Lansoprazole Sulphone)
N
S
O
F
F F
NH
N
O O
(A) 100 mg
MM 0474.06 Imp. C (EP): 2-[[[3-Methyl-4-(2,2,2-trifluoro-
ethoxy)pyridin-2-yl]methyl]sulphanyl]-1H-
benzimidazole
N
S
O
F
F F
NH
N
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 117
Code Product Price Unit
MM 0474.03 Imp. D (EP): 1H-Benzimidazol-2-ol
OH
NH
N
(B) 100 mg
MM 0474.05 Imp. E (EP): 1H-Benzimidazole-2-thiol
SH
NH
N
(A) 100 mg
MM 0474.02 Imp. F (EP): 2-[(RS)-[(4-Chloro-3-methylpyridin-
2-yl)methyl]sulphinyl]-1H-benzimidazole
N
S
Cl
O
NH
N
(A) 100 mg
MM 0474.04 4-Ethoxyacetophenone
O
O
(C) 100 mg
MM 0474.08 Lansoprazole Sulphone N-Oxide
N
S
O
F
F F
NH
N
O O
O
(A) 100 mg
MM 0474.09 2-Chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine
Hydrochloride
N
Cl
O
F
F F
x HCl
(A) 100 mg
MM 0474.13 1-Methyl-12-thioxopyrido[1',2':3,4]imidazo[1,2-a]benzimidazol-
2(12H)-one
N
N
N
S
O
(D) 100 mg
Leflunomide
MM 0859.00 Leflunomide
O F
H
N
F F
N
O
(D) 100 mg
MM 0859.01 Imp. A (EP) as Hydrochloride: 4-(Trifluoro-
methyl)aniline Hydrochloride F
H
2
N
F F
x HCl
(A) 100 mg
MM 0859.02 Imp. B (EP): (2Z)-2-Cyano-3-hydroxy-N-[4-
(trifluoromethyl)phenyl]but-2-enamide
(Teriflunomide)
O F
H
N
F F
N
OH
(A) 100 mg
MM 0859.03 Imp. C (EP): 5-Methyl-N-[3-(trifluoromethyl)-
phenyl]isoxazole-4-carboxamide
O
H
N
F
F F
N
O
(A) 100 mg
MM 0859.04 Imp. D (EP): 5-Methylisoxazole-4-carboxylic Acid
O
OH
N
O
(A) 100 mg
MM 0859.05 Imp. E (EP): 3-Methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-
4-carboxamide
O
H
N
N
O
F
F F
(A) 50 mg
MM 0859.06 Imp. F (EP): 5-Methyl-N-[2-(trifluoromethyl)-
phenyl]isoxazole-4-carboxamide
O
H
N
N
O
F
F
F
(A) 100 mg
MM 0859.07 Imp. G (EP): 5-Methyl-N-(4-methylphenyl)-
isoxazole-4-carboxamide
O
H
N
N
O
(A) 100 mg
New MM 0859.08 Imp. H (EP): 2-Cyano-N-[4-(trifluoromethyl)-
phenyl]acetamide
O
H
N
F
F F
N
(A) 50 mg
Levamisole Hydrochloride
New MM 0706.00 Levamisole Hydrochloride
N
S N
x HCl
(A) 100 mg
MM 0706.04 Imp. D (EP): 6-Phenyl-2,3-dihydro-imidazo[2,1-b]thiazole
N
S N
(A) 100 mg
Pharmaceutical impurities
118 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Levocetirizine Dihydrochloride
MM 1035.00 Levocetirizine Dihydrochloride
N
N
O
OH
O
Cl
x 2 HCl
(D) 100 mg
Levodopa
MM 0262.00 Levodopa
OH
O
HO
HO
NH
2
(A) 500 mg
MM 0634.00 Imp. B (EP): (2S)-2-Amino-3-(4-hydroxy-
phenyl)propanoic Acid (Tyrosine) OH
O
HO
NH
2
(A) 100 mg
MM 0262.05 Imp. C (EP): (2RS)-2-Amino-3-(4-hydroxy-
3-methoxyphenyl)propanoic Acid (3-Methoxy-DL-tyrosine; (DL)-
3-O-Methyldopa)
HO
NH
2
O
OH
O
(A) 100 mg
MM 0262.06 4-Hydroxy-3-methoxymandelic Acid
HO
OH
OH
O
O
(A) 100 mg
Levodropropizine
MM 1246.02 Imp. B (EP) as Hydrochloride: 1-Phenyl-
piperazine Hydrochloride
N
NH
x HCl
(A) 100 mg
Levofloxacin
MM 0846.00 Levofloxacin
N
O
N
O
F
N
OH
O
(A) 100 mg
Levomenthol
MM 0388.00 Levomenthol
OH
(A) 500 mg
Levomepromazine Hydrochloride
MM 0266.00 Levomepromazine Hydrochloride
x HCl
N
S
O
N
(A) 500 mg
Levomepromazine Maleate
MM 0019.00 Levomepromazine Maleate O
OH
O
OH
x
N
S
O
N
(A) 100 mg
MM 0019.02 Imp. A (EP): 2-Methoxyphenothiazine
NH
S
O
(A) 100 mg
MM 0019.01 Imp. B (EP): 10-[(2R)-3-(Dimethylamino)-2-
methylpropyl]-2-methoxy-10H-phenothiazine
5-Oxide (Levomepromazine S-Oxide)
N
S
O
N
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 119
Code Product Price Unit
MM 0019.07 N-Demethyllevomepromazine Hydrochloride
x HCl
N
S
O
N
H
(D) 100 mg
MM 0019.09 Levomepromazine Sulphone Hydrochloride
N
S
O
N
O
O
x HCl
(A) 100 mg
Levonorgestrel
MM 0121.00 Levonorgestrel
OH
O
(A) 250 mg
MM 0121.08 Imp. G (Pharmeuropa): 13-Ethyl-617-
dihydroxy-18,19-dinor-17-pregn-4-en-
20-yn-3-one (6-Hydroxylevonorgestrel)
OH
O
OH
(D) 50 mg
MM 0121.01 Imp. H (Pharmeuropa): 13-Ethyl-617-
dihydroxy-18,19-dinor-17-pregn-4-en-
20-yn-3-one (6-Hydroxylevonorgestrel)
OH
O
OH
(D) 100 mg
MM 0121.02 Imp. J (Pharmeuropa): 13-Ethyl-17-hydroxy-
18,19-dinor-17-pregn-4-en-20-yn-3,6-dione
(6-Oxolevonorgestrel, 6-Ketolevonorgestrel)
OH
O
O
(D) 100 mg
MM 0121.12 Imp. L (Pharmeuropa): 13-Ethylgon-4-ene-3,17-
dione (Levodione, 18-Methyl-19-norandrost-4-
ene-3,17-dione)
O
O
(D) 100 mg
MM 0121.11 Imp. M (Pharmeuropa): 13-Ethyl-17-hydroxy-
18,19-dinor-17-pregna-4,6-dien-20-yn-3-one
(6-Levonorgestrel, 6,7-Didehydrolevonorgestrel)
OH
O
(D) 100 mg
Lidocaine Hydrochloride
MM 0102.04 Lidocaine Hydrochloride Monohydrate
O
H
N
N
x HCl
x H
2
O
(A) 500 mg
MM 0102.00 Lidocaine
O
H
N
N
(A) 500 mg
MM 0102.02 Imp. A (EP): 2,6-Dimethylaniline
NH2
(B) 100 mg
MM 0102.01 Imp. B (EP): 2-(Diethylazinoyl)-N-(2,6-
dimethylphenyl)acetamide (Lidocaine N
2-
Oxide)
O
H
N
N
O (A) 100 mg
MM 0102.08 Imp. C (EP): N-(2,6-Dimethylphenyl)acetamide
O
H
N
(A) 100 mg
MM 0102.05
Imp. D (EP) as Hydrochloride: N-(2,6-
Dimethylphenyl)-2-(ethylamino)acetamide
Hydrochloride (Monoethylglycinexylidide
Hydrochloride)
O
H
N
N
H
x HCl
(A) 100 mg
MM 0102.09 Imp. E (EP) as Hydrochloride: 2,2'-
(Azanediyl)bis[N-(2,6-dimethylphenyl)-
acetamide] Hydrochloride
O
H
N
N
H
H
N
O
x HCl
(A) 100 mg
MM 0102.10 Imp. F (EP) as Hydrochloride: 2-(Diethyl-
amino)-N-(2,3-dimethylphenyl)acetamide
Hydrochloride
O
H
N
N x HCl
(A) 100 mg
Pharmaceutical impurities
120 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0102.11 Imp. G (EP) as Hydrochloride: N-(2,6-
Dimethylphenyl)-2-[(1-methylethyl)amino]-
acetamide Hydrochloride
O
H
N
N
H
x HCl
(A) 100 mg
MM 0102.03 Imp. H (EP): 2-Chloro-N-(2,6-dimethylphenyl)acetamide H
N
O
Cl
(B) 100 mg
New MM 0102.12 Imp. I (EP) as Hydrochloride: 2-(Diethylamino)-
N-(2,4-dimethylphenyl)acetamide Hydrochloride
O
H
N
N
x HCl
(A) 100 mg
New MM 0102.13
Imp. J (EP) as Hydrochloride: 2-(Diethylamino)-
N-(2,5-dimethylphenyl)acetamide Hydrochloride
O
H
N
N
x HCl
(A) 50 mg
MM 0102.14 Imp. K (EP) as Hydrochloride: N-(2,6-Dimethyl-
phenyl)-2-(ethylmethylamino)acetamide Hydro-
chloride
O
H
N
N x HCl
(A) 100 mg
Liothyronine Sodium
MM 0626.00 Liothyronine Sodium
O
I
HO I
I
ONa
O
NH
2
(A) 50 mg
MM 0626.01 Liothyronine
O
I
HO I
I
OH
O
NH
2
(A) 100 mg
Lisinopril Dihydrate
MM 0598.00 Lisinopril Dihydrate
H
N
O HO
N
O
O
OH
x 2 H
2
O
H
2
N
(A) 100 mg
MM 0598.01 Imp. A (EP): (2RS)-2-Amino-4-phenylbutanoic Acid
NH
2
O HO
(A) 100 mg
MM 0598.02 Imp. B (EP) as Hydrate: 4-Methylbenzenesulphonic Acid Hydrate
S
OH
O O
x H
2
O
(C) 100 mg
Lomustine
MM 0923.02 Imp. B (EP): 1-(2-Chloroethyl)-3-cyclohexylurea
N
H
N
H
O
Cl
(A) 100 mg
MM 0923.03 Imp. C (EP): 1,3-Dicyclohexylurea
N
H
N
H
O (A) 100 mg
Loperamide Hydrochloride
MM 0025.00 Loperamide Hydrochloride
Cl
x HCl
N
OH
O
N
(A) 500 mg
New MM 0025.14 Imp. A (EP): 4-[4-(4'-Chlorobiphenyl-4-yl)-4-
hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-
diphenylbutanamide
N
OH
O
N
Cl
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 121
Code Product Price Unit
MM 0025.15 Imp. B (EP) as Bromide: 4-(4-Chlorophenyl)-
1,1-bis[4-(dimethylamino)-4-oxo-
3,3-diphenylbutyl]-4-hydroxypiperidinium Bromide
N
+
O
N
O N
OH
Cl
Br
-
(A) 100 mg
MM 0025.04 Imp. C (EP): 4-(4-Chlorophenyl)piperidin-4-ol
Cl
N
H
OH
(B) 100 mg
MM 0025.05 Imp. D (EP): 4-(4-Hydroxy-4-phenylpiperidin-1-yl)-N,N-dimethyl-
2,2-diphenylbutanamide
N
OH
O
N
(A) 100 mg
MM 0025.09 Imp. F (EP): Loperamide Oxide
N
O
N
OH
Cl
O
(A) 100 mg
MM 0025.11 Imp. H (EP): 4-[4-(4-Chlorophenyl)-3,6-
dihydropyridin-1(2H)-yl]-N,N-dimethyl-2,2-
diphenylbutanamide
N
O
N
Cl
(A) 100 mg
MM 0025.07 Ethyl Diphenylacetate
O
O
(A) 100 mg
MM 0025.08 ,-Diphenyl--butyrolactone
O
O
(A) 100 mg
MM 0025.10 Dimethyl-(tetrahydro-3,3-diphenyl-2-furilidine)ammonium Bromide
Br
-
O
N
+
(A) 100 mg
Loratadine
MM 0257.00 Loratadine
N O
O
N
Cl (A) 100 mg
MM 0257.03 Imp. A (EP): Ethyl 4-[(11RS)-8-Chloro-11-
hydroxy-6,11-dihydro-5H-benzo[5,6]cyclo-
hepta[1,2-b]pyridin-11-yl]piperidine-1-
carboxylate
N O
O
N
Cl
OH
(A) 100 mg
Pharmaceutical impurities
122 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0257.02 Imp. B (EP): 8-Chloro-5,6-dihydro-11H-
benzo[5.6]cyclohepta[1,2-b]pyridin-11-one
O
N
Cl
(A) 100 mg
MM 0257.08 Imp. C (EP): Ethyl 4-(4,8-Dichloro-5,6-dihydro-
11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-
ylidene)piperidine-1-carboxylate
N O
O
N
Cl
Cl
(D) 100 mg
MM 0257.01 Imp. D (EP): 8-Chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine (Descarboethoxyloratadine;
Desloratadine)
NH
N
Cl
(A) 50 mg
MM 0257.05 Imp. G (EP): 8-Chloro-11-(1-methylpiperidin-4-
ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta-
[1,2-b]pyridine
N
N
Cl
(A) 100 mg
MM 0257.07 Imp. H (EP): Ethyl 4-Oxopiperidine-1-carboxylate
N O
O
O
(A) 100 mg
MM 0257.06 (11RS)-8-Chloro-11-hydroxy-11-(1-methylpiperidin-4-yl)-
6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
N
N
Cl
OH
(A) 100 mg
Lorazepam
MM 0071.00 Lorazepam [Controlled Substance]
N
H
N
O
Cl
Cl
OH
(A) 100 mg
MM 0071.01 Imp. A (EP): (2-Amino-5-chlorophenyl)(2-chlorophenyl)methanone
(2-Amino-2',5-dichlorobenzophenone)
Cl
NH2
O
Cl
(B) 100 mg
MM 0071.07 Imp. B (EP): (3RS)-7-Chloro-5-(2-chlorophenyl)-
2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl Acetate
(Lorazepam Acetate)
[Controlled Substance]
N
H
N
O
Cl
Cl
O
O
(A) 100 mg
MM 0071.06 Imp. C (EP): 7-Chloro-5-(2-chlorophenyl)-
1,3-dihydro-2H-1,4-benzodiazepin-2-one
4-Oxide N
H
N
O
Cl
Cl
O
(A) 100 mg
MM 0071.03 Imp. D (EP): (5RS)-7-Chloro-5-(2-chlorophenyl)-
4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione
NH
H
N
O
Cl
Cl
O
(A) 100 mg
MM 0071.02 Imp. E (EP): 6-Chloro-4-(2-chlorophenyl)-
quinazoline-2-carbaldehyde
Cl
N
N
Cl
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 123
Code Product Price Unit
MM 0071.04 6-Chloro-4-(2-chlorophenyl)-2-quinazolinecarboxylic Acid
Cl
N
N
Cl
O
OH
(A) 100 mg
MM 0071.08 6-Chloro-4-(2-chlorophenyl)-2-quinazolinemethanol
Cl
N
N
Cl
OH
(A) 100 mg
MM 0071.09 6-Chloro-4-(2-chlorophenyl)-2(1H)-quinazolinone
N
H
N
Cl
O
Cl
(A) 100 mg
Losartan Potassium
MM 0168.00 Losartan
N
N
OH
Cl
NH
N N
N
on request
MM 0168.14 Imp. B (Pharmeuropa) : [2'-(1H-Tetrazol-5-yl)biphenyl-
4-yl]methanol
N
N N
HN
HO
(A) 50 mg
MM 0168.04 Imp. C (Pharmeuropa) : [2-Butyl-5-chloro-1-[[2'-(1H-
tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazol-
4-yl]methanol
N
N
Cl
N
N N
HN
HO
(D) 50 mg
MM 0168.08 Imp. D (EP) : 2-Butyl-4-chloro-1H-imidazole-5-carbaldehyde
NH
N
O
Cl
(A) 100 mg
MM 0168.05 Imp. E (EP): 5-(4'-Methylbiphenyl-2-yl)-1H-tetrazole
N
N N
HN
(A) 50 mg
MM 0168.15 Imp. F (EP) : 5-[4'[[2-Butyl-4-chloro-5-[[(1-
methylethyl)oxy]methyl]-1H-imidazol-1-yl]-
methyl]biphenyl-2-yl]-1H-tetrazole (Losartan
Isopropyl Ether)
N
N
O
Cl
N
N N
HN
(A) 100 mg
MM 0173.04 Imp. G (EP) : Triphenylmethanol
OH
(A) 100 mg
MM 0168.16 Imp. H (EP) : [2-Butyl-4-chloro-1-[[2'-[2-
(triphenylmethyl)-2H-tetrazol-5-yl]biphenyl-
4-yl]methyl]-1H-imidazol-5-yl]methanol
N
N
OH
Cl
N
N N
N
(A) 100 mg
Pharmaceutical impurities
124 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0168.18 Imp. J (EP) : [2-Butyl-4-chloro-1-[[2'-(1H-
tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-
imidazol-5-yl]methyl Acetate
N
N
O
Cl
N
N N
HN
O (A) 100 mg
MM 0168.12 Losartan Methyl Ether
N
N
O
Cl
N
N N
HN
(A) 100 mg
Lovastatin
MM 0050.00 Lovastatin
H
O O
O
O
OH
(A) 100 mg
MM 0377.00 Imp. A (EP): (1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-Hydroxy-
6-oxotetrahydro-2H-pyran-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-
hexahydronaphthalen-1-yl (2S)-2-Methylbutanoate (Mevastatin)
O
O
OH
O O
(A) 100 mg
MM 0050.01 Imp. B (EP) as Sodium Salt: (3R,5R)-7-[(1S,2S,6R,8S,8aR)-
2,6-Dimethyl-8-[[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-
hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic Acid Sodium
Salt (Lovastatin Hydroxy Acid Sodium Salt)
H
O O
OH
OH
O
ONa
(A) 100 mg
MM 0050.03 Imp. C (EP): (1S,3R,7S,8S,8aR)-3,7-Dimethyl-8-[2-[(2R)-6-oxo-
3,6-dihydro-2H-pyran-2-yl]ethyl]-1,2,3,7,8,8a-hexahydronaphthalen-
1-yl (2S)-2-Methylbutanoate (Dehydrolovastatin)
H
O O
O
O
(A) 100 mg
Malic Acid
New MM 1332.01 Imp. A (EP): (E)-Butenedioic Acid (Fumaric Acid)
OH
O
HO
O
(B) 100 mg
Maprotiline Hydrochloride
MM 0820.00 Maprotiline Hydrochloride
N
H
x HCl
(A) 250 mg
MM 0820.01 Imp. A (EP): 3-(9,10-Ethanoanthracen-9(10H)-yl)prop-2-enal
O
(A) 50 mg
MM 0820.02 Imp. B (EP) as Hydrochloride:
3-(9,10-Ethanoanthracen-9(10H)-yl)-N-
[3-(9,10-ethanoanthracen-9(10H)-yl)propyl]-N-
methylpropan-1-amine Hydrochloride
N
x HCl
(C) 10 mg
MM 0820.03 Imp. C (EP) as Hydrochloride: 3-(9,10-Ethanoanthracen-
9(10H)-yl)propan-1-amine Hydrochloride
NH
2
x HCl
(C) 10 mg
MM 0820.04 Imp. D (EP) as Hydrochloride: 3-(9,10-Ethanoanthracen-
9(10H)-yl)-N-methylprop-2-en-1-amine Hydrochloride
(Dehydromaprotiline Hydrochloride)
N
H
x HCl
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 125
Code Product Price Unit
MM 0820.05 Imp. E (EP) as Hydrochloride: 3-(9,10-Ethanoanthracen-
9(10H)-yl)-N,N-dimethylpropan-1-amine Hydrochloride
N
x HCl
(A) 100 mg
Mebendazole
MM 0882.02 Imp. B (EP): (2-Hydroxy-1H-benzimidazol-5-
yl)phenylmethanone
O
N
H
N
OH
(A) 50 mg
MM 0882.04 Imp. D (EP): Methyl (5-Benzoyl-1-methyl-1H-
benzimidazol-2-yl)carbamate
O
N
N
NH
O
O
(A) 50 mg
MM 0882.05 Imp. E (EP): Ethyl (5-Benzoyl-1H-benzimidazol-
2-yl)carbamate
O
N
H
N
NH
O
O
(A) 50 mg
MM 0882.06 Imp. F (EP): Methyl [5-(4-Methylbenzoyl)-1H-
benzimidazol-2-yl]carbamate
O
N
H
N
NH
O
O
(A) 50 mg
Mebeverine Hydrochloride
MM 0319.00 Mebeverine Hydrochloride
O
N
O
O
O
O
x HCl
(A) 100 mg
MM 0319.02 Imp. A (Pharmeuropa): 4-Methoxyphenylacetone
O
O
(B) 100 mg
MM 0319.03 Imp. B (Pharmeuropa) as Hydrochloride: N-[(1RS)-
1-[(4-Methoxyphenyl)methyl]ethyl]ethanamine
Hydrochloride
O
NH
x HCl
(A) 100 mg
MM 0319.01 Imp. D (Pharmeuropa): 3,4-Dimethoxybenzoic Acid (Veratric Acid)
O
HO
O
O
(B) 100 mg
Mechlorethamine Hydrochloride
MM 0823.00 Mechlorethamine Hydrochloride
N
Cl Cl
x HCl
(A) 500 mg
Meclofenoxate Hydrochloride
MM 0044.00 Meclofenoxate Hydrochloride
Cl
O
O
O
N
x HCl
(A) 500 mg
MM 0044.02 (4-Chlorophenoxy)acetic Acid
Cl
O
OH
O
(B) 100 mg
Meclozine Hydrochloride
MM 0586.00 Meclozine Dihydrochloride
N
Cl
N
x 2 HCl
(A) 500 mg
New MM 0586.06 3-Methylbenzaldehyde
O
(A) 100 mg
MM 0380.09 Imp. B (EP): (RS)-(4-Chlorophenyl)phenyl-
methanol (4-Chlorobenzhydrol)
OH
Cl
(B) 100 mg
Pharmaceutical impurities
126 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0380.10 Imp. C (EP): (4-Chlorophenyl)phenyl-
methanone (4-Chlorobenzophenone)
O
Cl
(B) 100 mg
New MM 0586.08 Imp. D (EP): 1,1'-(1,3-
Phenylenebismethylene)-
bis[4-[(4-
chlorophenyl)phenylmethyl]piperazine]
Cl
N
N
N
N
Cl
(A) 50 mg
New MM 0586.09 Imp. E (EP): 1-(Diphenylmethyl)-4-[(3-methyl-
phenyl)methyl]piperazine
N
N
(A) 50 mg
MM 0380.04 Imp. F (EP): 1,4-Bis[(4-chlorophenyl)phenyl-
methyl]-piperazine
N
N
Cl
Cl
(A) 100 mg
MM 0380.01
Imp. H (EP): 1-[(RS)-(4-Chlorophenyl)phenyl-
methyl]piperazine ((RS)-1-[(4-Chlorophenyl)-
phenylmethyl]piperazine)
N
NH
Cl
(A) 100 mg
MM 0586.05 Meclozine N-Oxide
N
Cl
N
O
(B) 10 mg
MM 0586.07 N-(3-Methylbenzyl)piperazine Dihydrochloride
N
HN
x 2 HCl
(A) 100 mg
Medroxyprogesterone
MM 0635.00 Medroxyprogesterone
O
O
OH
(A) 100 mg
Medroxyprogesterone Acetate
MM 0532.00 Medroxyprogesterone Acetate
O
O
O
O
(A) 100 mg
MM 0532.01 Imp. A (EP): 6-Hydroxy-6-methyl-3,20-dioxopregn-4-en-17-yl
Acetate (6-Hydroxymedroxyprogesterone Acetate)
O
O
O
O
OH
(D) 100 mg
MM 0635.00 Imp. B (EP):17-Hydroxy-6-methylpregn-4-ene-3,20-dione
(Medroxyprogesterone)
O
O
OH
(A) 100 mg
MM 0532.05 Imp. E (EP): 6-Methylidene-3,20-dioxopregn-4-en-17-yl
Acetate (6-Methylenehydroxyprogesterone Acetate)
O
O
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 127
Code Product Price Unit
MM 0532.06 Imp. F (EP): 6-Methyl-3,20-dioxo-5-pregnan-17-yl Acetate
(4,5-Dihydromedroxyprogesterone Acetate)
O
O
O
O
H
(D) 50 mg
MM 0532.07 Imp. G (EP): 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl
Acetate (Megestrol Acetate)
O
O
O
O
(A) 250 mg
MM 0532.09 Imp. H (EP): 3,20-Dioxopregn-4-en-17-yl Acetate
(Hydroxyprogesterone Acetate)
O
O
O
O
(A) 100 mg
Mefenamic Acid
MM 0327.00 Mefenamic Acid
OH
O
NH
(A) 500 mg
MM 0327.01 Imp. A (EP): 2,3-Dimethylaniline
NH
2
(B) 100 mg
MM 0327.02 Imp. B (EP): N-(2,3-Dimethylphenyl)-
2-[(2,3-dimethylphenyl)amino]benzamide
N
H
O
NH
(A) 100 mg
MM 0217.14 Imp. C (EP): 2-Chlorobenzoic Acid
OH
O
Cl
(A) 100 mg
MM 0278.01 Imp. D (EP): Benzoic Acid
OH
O
(B) 100 mg
Mefloquine Hydrochloride
MM 1198.01 2,8-Bis-(trifluoromethyl)-4-quinolinol
N
F
F F
OH
F
F
F
(A) 100 mg
Megestrol Acetate
MM 0532.07 Megestrol Acetate
O
O
O
O
(A) 250 mg
MM 0532.00 Imp. A (EP): 6-Methyl-3,20-dioxopregn-4-en-17-yl
Acetate (Medroxyprogesterone Acetate)
O
O
O
O
(A) 100 mg
New MM 0532.09 Imp. K (Pharmeuropa): 3,20-Dioxopregn-4-en-17-yl
Acetate
O
O
O
O
(A) 100 mg
Pharmaceutical impurities
128 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Meloxicam
MM 0246.00 Meloxicam
N
S
O O
OH O
H
N
S
N
(A) 500 mg
MM 0084.03 Imp. A (EP): Ethyl 4-Hydroxy-2-methyl-
2H-1,2-benzothiazine-3-carboxylate 1,1-Dioxide
N
S
O O
OH O
O
(A) 100 mg
MM 0246.01 Imp. B (EP): 5-Methylthiazol-2-amine
S
N
H
2
N
(A) 100 mg
MM 0246.16 Imp. C (EP): N-[(2Z)-3,5-Dimethylthiazol-2(3H)-
ylidene]-4-hydroxy-2-methyl-2H-1,2-benzothiazine-
3-carboxamide 1,1-Dioxide
N
S
OH O
N
S
N
O O
(A) 50 mg
MM 0246.17 Imp. D (EP): N-[(2Z)-3-Ethyl-5-methylthiazol-2(3H)-ylidene]-
4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide
1,1-Dioxide
N
S
OH O
N
S
N
O O
(A) 50 mg
MM 0084.02 Imp. E (EP): Methyl 4-Hydroxy-2-methyl-
2H-1,2-benzothiazine-3-carboxylate 1,1-Dioxide
N
S
O O
OH O
O
(A) 100 mg
MM 0084.12 Imp. F (EP): Isopropyl 4-Hydroxy-2-methyl-2H-
1,2-benzothiazine-3-carboxylate 1,1-Dioxide
(1-Methylethyl 4-Hydroxy-2-methyl-2H-1,2-
benzothiazine-3-carboxylate 1,1-Dioxide)
N
S
OH O
O
O O
(A) 100 mg
Melperone
MM 0321.00 Melperone
F
O
N
(A) 100 mg
Memantine Hydrochloride
MM 1045.01 1-Hydroxy-3,5-dimethyladamantane
OH
(A) 100 mg
MM 1045.04 1-Chloro-3,5-dimethyladamantane
Cl
(A) 100 mg
Mephenesin
MM 0810.00 Mephenesin
O
OH
OH
(A) 500 mg
Mephentermine Hemisulphate
MM 0740.00 Mephentermine Hemisulfate
H
N
x H
2
SO
4
(A) 500 mg
Mepivacaine Hydrochloride
MM 0368.00 Mepivacaine Hydrochloride
H
N
O
N
x HCl
(A) 500 mg
MM 0102.02 Imp. A (EP): 2,6-Dimethylaniline
NH2
(B) 100 mg
MM 0368.02 Imp. B (EP) as Hydrochloride: (RS)-N-(2,6-
Dimethylphenyl)piperidine-2-carboxamide
Hydrochloride
H
N
O
N
H
x HCl
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 129
Code Product Price Unit
MM 0368.03 Imp. C (EP): N-(2,6-Dimethylphenyl)pyridine-2-carboxamide
H
N
O
N
(A) 100 mg
New MM 0368.07 Imp. E (EP): (RS)-N-(4-Chloro-2,6-dimethyl-
phenyl)-1-methylpiperidine-2-carboxamide
H
N
O
N
Cl
(A) 50 mg
MM 0368.06 Mepivacaine N-Oxide
H
N
O
N
O
(A) 100 mg
Mepyramine Maleate
MM 0559.00 Mepyramine Maleate
O
OH
O
OH
x
N
N
O N
(A) 500 mg
MM 0559.02 Imp. A (EP): N-(4-Methoxybenzyl)pyridin-2-amine NH
O N
(A) 100 mg
MM 0164.03 Imp. B (EP): 4-Methoxybenzaldehyde (Anisaldehyde)
O
O (C) 100 mg
MM 0084.01 Imp. C (EP): Pyridin-2-amine
N
NH
2
(B) 100 mg
MM 0559.05 Mepyramine N-Oxide Dihydrochloride
N
N
O N
O
x 2 HCl
(A) 100 mg
Mequinol
MM 1131.00 Mequinol
HO
O
(A) 500 mg
Mesalazine
MM 0217.00 Mesalazine
OH
OH
H
2
N
O
(A) 500 mg
MM 0042.01 Imp. A (EP): 4-Aminophenol
H
2
N
OH
(B) 100 mg
MM 0042.07 Imp. B (EP): 3-Aminophenol
OH H
2
N
(B) 100 mg
MM 0217.06 Imp. C (EP): 2-Aminophenol
OH
NH
2
(A) 100 mg
MM 0217.07 Imp. D (EP): 3-Aminobenzoic Acid
OH
O
NH
2
(A) 100 mg
MM 0217.09 Imp. F (EP): 3-Amino-2-hydroxybenzoic
Acid (3-Aminosalicylic Acid) OH
O
OH
NH
2
(A) 100 mg
MM 0217.10 Imp. G (EP): 2,5-Dihydroxybenzoic Acid
OH
O
OH
HO
(A) 100 mg
MM 0045.00 Imp. H (EP): 2-Hydroxybenzoic Acid
(Salicylic Acid) OH
O
OH
(A) 500 mg
MM 0217.12 Imp. I (EP): 2-Hydroxy-5-(phenyldiazenyl)benzoic Acid
(Phenylazosalicylic Acid)
OH
O
OH
N
N
(A) 50 mg
Pharmaceutical impurities
130 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0093.17 Imp. K (EP) as Hydrochloride: Aniline Hydrochloride
H
2
N
x HCl
(B) 100 mg
MM 0217.14 Imp. L (EP): 2-Chlorobenzoic Acid
OH
O
Cl
(A) 100 mg
MM 0217.15 Imp. M (EP): 2-Chloro-5-nitrobenzoic Acid
OH
O
Cl
O
2
N
(A) 100 mg
MM 0217.16 Imp. N (EP): 2-Hydroxy-5-nitrobenzoic Acid
(5-Nitrosalicylic Acid) OH
O
OH
O
2
N
(A) 100 mg
MM 0227.04 Imp. O (Pharmeuropa): 4-Aminobenzene-
sulfonic Acid (Sulfanilic Acid)
H
2
N
S
OH
O O
(A) 100 mg
MM 0217.02 5-Acetaminosalicylic Acid
OH
O OH
N
H
O
(A) 100 mg
Metamizole Sodium
MM 0052.00 Metamizole Sodium Monohydrate
N
N
O
N S
O
O
ONa
x H
2
O
(A) 500 mg
MM 0052.02 Imp. A (EP): 4-Formylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-
pyrazol-3-one (4-Formylaminophenazone) N
N
O
H
N O
(A) 100 mg
MM 0052.04 Imp. B (EP): 4-Amino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-
3-one (Ampyrone) N
N
O
NH
2
(A) 100 mg
MM 0052.10 Imp. C (EP) as Hydrochloride: 4-Methylamino-1,5-dimethyl-
2-phenyl-1,2-dihydro-3H-pyrazol-3-one Hydrochloride
(4-Methylaminophenazone Hydrochloride)
N
N
O H
N
x HCl
(A) 100 mg
MM 0052.05 Imp. D (EP): 4-Dimethylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-
pyrazol-3-one (4,4-Dimethylaminophenazone) N
N
O
N
(A) 100 mg
MM 0052.01 4-Acetylaminophenazone
N
N
O
H
N O
(A) 100 mg
MM 0052.50 4-Benzylideneaminoantipyrine
N
N
O
N
(A) 100 mg
Metformin Hydrochloride
MM 0056.00 Metformin Hydrochloride
NH
H
2
N N
H
N
NH
x HCl
(A) 500 mg
MM 0056.01 Imp. A (EP): Cyanoguanidine
NH
H
2
N N
H
N
(B) 100 mg
MM 0056.07 Imp. B (EP) as Nitrate: (4,6-Diamino-1,3,5-
triazin-2-yl)guanidine Nitrate N N
N H
2
N N
H
NH
2
NH
NH
2
x HNO
3
(A) 100 mg
MM 0056.03 Imp. C (EP): N,N-Dimethyl-1,3,5-triazine-2,4,6-triamine
N N
N H
2
N N
NH2
(A) 100 mg
MM 0056.04 Imp. D (EP): 1,3,5-Triazine-2,4,6-triamine (Melamine)
N N
N H2N NH2
NH2
(B) 100 mg
MM 0056.05 Imp. E (EP) as Hydrochloride:1-Methylbiguanide Hydrochloride
NH
H2N N
H
N
H
NH
x HCl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 131
Code Product Price Unit
MM 0056.06 Imp. F (EP) as Hydrochloride: N-Methylmethanamine Hydrochloride
H
N
x HCl
(C) 100 mg
Methadone Hydrochloride
New MM 0531.04 Imp. C (EP) as Hydrochloride: (3RS)-4-(Dimethyl-
amino)-3-methyl-2,2-diphenylbutanenitrile Hydro-
chloride (Isodidiavalo Hydrochloride)
N
N
x HCl
(A) 50 mg
MM 0531.06 Imp. E (EP): Diphenylacetonitrile
N
(A) 100 mg
Methamphetamine Hydrochloride
MM 0964.00 Methamphetamine Hydrochloride
[Controlled Substance]
H
N
x HCl
(A) 100 mg
Methotrexate
MM 0040.00 Methotrexate
N
N
N
N
NH
2
H
2
N
N
N
H
O
O OH
O
OH
(A) 500 mg
MM 0040.08 Imp. A (EP) as Hydrochloride: (2,4-Diaminopteridin-
6-yl)methanol Hydrochloride
N
N
N
N
NH
2
H
2
N
OH x HCl
(A) 100 mg
Methoxsalen
MM 0555.00 Methoxsalen
O
O
O
O (A) 500 mg
MM 0555.01 5-Methoxypsoralen (Bergapten)
O
O
O
O
(A) 100 mg
Methoxyphenamine Hydrochloride
MM 0655.00 Methoxyphenamine Hydrochloride
O
H
N
x HCl
(A) 500 mg
Methyl Nicotinate
MM 0549.00 Methyl Nicotinate
N O
O
(A) 500 mg
MM 0553.00 Imp. A (EP): Nicotinic Acid
N OH
O
(A) 500 mg
Methyl Parahydroxybenzoate
MM 0431.00 Methyl Parahydroxybenzoate
HO
O
O
(A) 500 mg
MM 0045.01 Imp. A (EP): 4-Hydroxybenzoic Acid
HO
OH
O
(B) 100 mg
MM 0498.00 Imp. B (EP): Ethyl 4-Hydroxybenzoate
(Ethyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0432.00 Imp. C (EP): Propyl 4-Hydroxybenzoate
(Propyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
Pharmaceutical impurities
132 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0496.00 Imp. D (EP): Butyl 4-Hydroxybenzoate
(Butyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0431.01 Sodium Methyl Parahydroxybenzoate
NaO
O
O
(A) 500 mg
Methylphenidate Hydrochloride
MM 1031.04 Ritalinic Acid
H
N
OH O
(A) 100 mg
Methylprednisolone
MM 0190.00 Methylprednisolone
O
HO
O
OH
OH
(A) 100 mg
MM 0190.01
Imp. A (EP): 17,21-Dihydroxy-6-methylpregna-1,4-diene-
3,11,20-trione
O
O
O
OH
OH
(D) 50 mg
Methylprednisolone Acetate
MM 0191.00 Methylprednisolone Acetate
O
HO
O
O
OH
O
(D) 100 mg
MM 0190.00 Imp. B (EP): Methylprednisolone
O
HO
O
OH
OH
(A) 100 mg
MM 0194.00 Imp. E (EP): Prednisolone Acetate
O
HO
O
O
OH
O
(A) 500 mg
Methylprednisolone Hydrogen Succinate
MM 0192.00 Methylprednisolone Hydrogen Succinate Sodium Salt
O
HO
O
O
OH
O
ONa
O
on request
MM 0190.00 Imp. A (EP): Methylprednisolone
O
HO
O
OH
OH
(A) 100 mg
MM 0191.00 Imp. C (EP): Methylprednisolone Acetate
O
HO
O
O
OH
O
(D) 100 mg
Methyltestosterone
MM 0558.00 Methyltestosterone
O
OH
(A) 250 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 133
Code Product Price Unit
MM 0323.00 Testosterone
O
OH
(A) 500 mg
Metixene Hydrochloride
MM 0125.01 Imp. A (EP): 9H-Thioxanthene
S
(A) 100 mg
MM 0125.02 Imp. B (EP): 9H-Thioxanthen-9-one
(Thioxanthone)
S
O
(B) 100 mg
MM 0125.03 3-Chloromethyl-1-methylpiperidine Cl
N
on request
Metoclopramide
MM 0073.00 Metoclopramide Hydrochloride Monohydrate
O H2N
Cl
N
H
O
N
x HCl
x H2O
(A) 500 mg
MM 0073.03 Imp. A (EP): 4-(Acetylamino)-5-chloro-N-
[2-(diethylamino)ethyl]-2-methoxybenzamide
O N
H
Cl
N
H
O
N
O
(A) 100 mg
MM 0073.04 Imp. B (EP): Methyl 4-(Acetylamino)-5-chloro-2-methoxybenzoate
O N
H
Cl
O
O O
(A) 100 mg
MM 0073.02 Imp. C (EP): 4-Amino-5-chloro-2-methoxybenzoic Acid
O H2N
Cl
O
OH
(B) 100 mg
MM 0073.05 Imp. D (EP): Methyl 4-(Acetylamino)-2-methoxybenzoate
O N
H
O
O O
(A) 100 mg
MM 0073.01 Imp. E (EP): N,N-Diethylethane-1,2-diamine
H2N
N
(B) 100 mg
MM 0073.06 Imp. F (EP): 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-
2-hydroxybenzamide
OH H2N
Cl
N
H
O
N
(A) 100 mg
MM 0073.07 Imp. G (EP): N'-(4-Amino-5-chloro-2-methoxybenzoyl)-N,N-
diethylethane-1,2-diamine N-Oxide (Metoclopramide N-Oxide)
O H2N
Cl
N
H
O
N
O
(A) 100 mg
MM 0073.08 Imp. H (EP): 4-(Acetylamino)-2-hydroxybenzoic Acid
OH N
H
O
O OH
(A) 100 mg
MM 0073.09 Methyl 4-Amino-2-hydroxybenzoate
OH H2N
O
O
(A) 100 mg
MM 0073.10 Methyl 4-(Acetylamino)-2-hydroxybenzoate
OH N
H
O
O O
(A) 100 mg
Metoprolol Succinate
MM 0279.00 Metoprolol Succinate
O
O
OH
H
N
2
O
HO
OH
O
x
(A) 100 mg
Pharmaceutical impurities
134 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0027.04 Imp. A (EP): (2RS)-1-(Ethylamino)-3-[4-(2-methoxyethyl)-
phenoxy]propan-2-ol
O
O
OH
H
N
(A) 100 mg
MM 0027.01 Imp. B (EP): 4-(2-Methoxyethyl)phenol
O
OH
(A) 100 mg
MM 0027.24 Imp. C (EP) as Hydrochloride: 4-[(2RS)-2-
Hydroxy-3-[(1-methylethyl)amino]propoxy]-
benzaldehyde Hydrochloride
O
OH
H
N
O
x HCl
(A) 100 mg
MM 0027.06 Imp. D (EP): (2RS)-3-[4-(2-Methoxyethyl)phenoxy]propane-
1,2-diol
O
O
OH
OH
(A) 100 mg
MM 0027.07 Imp. E (EP): (2RS)-1-[2-(2-Methoxyethyl)phenoxy]-
3-[(1-methylethyl)amino]propan-2-ol
O
OH
H
N
O
(A) 100 mg
MM 0027.08 Imp. F (EP): (2RS)-1-[(1-Methylethyl)amino]-3-phenoxy-
propan2-ol
O
OH
H
N
(A) 100 mg
MM 0027.09 Imp. G (EP): 2-(4-Hydroxyphenyl)ethanol
HO
OH
(A) 100 mg
MM 0027.10 Imp. H (EP): (2RS)-1-[4-(2-Hydroxyethyl)phenoxy]-
3-[(1-methylethyl)amino]propan-2-ol
HO
O
OH
H
N
(A) 100 mg
MM 0027.11 (2RS)-1-(4-Ethenylphenoxy)-3-[(1-methylethyl)amino]-
propan-2-ol
O
OH
H
N
(A) 100 mg
MM 0027.12 Imp. J (EP): 1-[2-Hydroxy-
3-[(1-methylethyl)amino]propoxy]-
3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
O
O
OH
O
OH
H
N
(A) 50 mg
MM 0027.13 (2RS)-1-[4-[(EZ)-2-Methoxyethenyl]phenoxy]-
3-[(1methylethyl)amino]propan-2-ol
O
OH
H
N
O
(A) 100 mg
MM 0027.28 Imp. M (EP) as Dihydrochloride:
1,3-Bis[(1-methylethyl)amino]propan-2-ol Dihydrochloride
H
N
OH
H
N x 2 HCl
(A) 100 mg
MM 0027.16 Imp. N (EP): (2RS)-3-[(1-Methylethyl)amino]propane-1,2-diol
HO
OH
H
N
(A) 100 mg
MM 0027.03 Imp. O (EP): 1,1'-[(1-Methylethyl)imino]bis-
[3-[4-(2-methoxyethyl)phenoxy]propan-2-ol]
O
O
OH
N
O
O
OH (A) 100 mg
Metoprolol Tartrate
MM 0027.00 Metoprolol Tartrate
O
O
OH
H
N
2
O
HO
OH
O
x
OH
OH
(A) 500 mg
MM 0027.04 Imp. A (EP): (2RS)-1-(Ethylamino)-
3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
O
O
OH
H
N
(A) 100 mg
MM 0027.01 Imp. B (EP): 4-(2-Methoxyethyl)phenol
O
OH
(A) 100 mg
MM 0027.24 Imp. C (EP) as Hydrochloride: 4-[(2RS)-2-
Hydroxy-3-[(1-methylethyl)amino]propoxy]-
benzaldehyde Hydrochloride
O
OH
H
N
O
x HCl
(A) 100 mg
MM 0027.06 Imp. D (EP): (2RS)-3-[4-(2-Methoxyethyl)phenoxy]propane-
1,2-diol
O
O
OH
OH
(A) 100 mg
MM 0027.07 Imp. E (EP): (2RS)-1-[2-(2-Methoxyethyl)-
phenoxy]-3-[(1-methylethyl)amino]propan-2-ol
O
OH
H
N
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 135
Code Product Price Unit
MM 0027.08 Imp. F (EP): (2RS)-1-[(1-Methylethyl)amino]-
3-phenoxypropan-2-ol
O
OH
H
N
(A) 100 mg
MM 0027.09 Imp. G (EP): 2-(4-Hydroxyphenyl)ethanol
HO
OH
(A) 100 mg
MM 0027.10 Imp. H (EP): (2RS)-1-[4-(2-Hydroxyethyl)-
phenoxy]-3-[(1-methylethyl)amino]propan-2-ol
HO
O
OH
H
N
(A) 100 mg
MM 0027.11 (2RS)-1-(4-Ethenylphenoxy)-3-[(1-methylethyl)amino]propan-
2-ol
O
OH
H
N
(A) 100 mg
MM 0027.12 Imp. J (EP): 1-[2-Hydroxy-
3-[(1-methylethyl)amino]propoxy]-3-[4-
(2-methoxyethyl)phenoxy]propan-2-ol
O
O
OH
O
OH
H
N
(A) 50 mg
MM 0027.13 (2RS)-1-[4-[(EZ)-2-Methoxyethenyl]phenoxy]-
3-[(1methylethyl)amino]propan-2-ol
O
OH
H
N
O
(A) 100 mg
MM 0027.28 Imp. M (EP) as Dihydrochloride:
1,3-Bis[(1-methylethyl)amino]propan-2-ol Dihydrochloride
H
N
OH
H
N x 2 HCl
(A) 100 mg
MM 0027.16 Imp. N (EP): (2RS)-3-[(1-Methylethyl)amino]propane-1,2-diol
HO
OH
H
N
(A) 100 mg
MM 0027.03 Imp. O (EP): 1,1'-
[(1-Methylethyl)imino]bis-
[3-[4-(2-methoxyethyl)phenoxy]propan-
2-ol]
O
O
OH
N
O
O
OH (A) 100 mg
MM 0027.02 1-[4-(2-Methoxyethyl)phenoxy]-2,3-epoxypropane
O
O
O
(A) 100 mg
MM 0027.17 1-Chloro-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
O
O Cl
OH
(A) 100 mg
MM 0027.18 4,4'-(2-Hydroxy-1,3-propandiyldioxy)-
bis[(2-methoxyethyl)benzene)]
O
O O
OH
O
(A) 100 mg
MM 0027.22 3-Chloropropane-1,2-diol
OH
OH
Cl
(B) 100 mg
MM 0027.26 1-[2-(2-Methoxyethyl)phenyoxy]-2,3-epoxypropane
O
O
O
(C) 50 mg
Metronidazole
MM 0012.00 Metronidazole
N
N
O
2
N
OH
(A) 500 mg
MM 0012.02 Imp. A (EP): 2-Methyl-4-nitroimidazole
NH
N
O
2
N
(B) 100 mg
MM 0012.05 Imp. B (EP): 4-Nitroimidazole
NH
N
O
2
N
(C) 100 mg
MM 0012.06 Imp. C (EP): 2-(4-Nitro-1H-imidazol-1-yl)ethanol
N
N
OH
O
2
N
(A) 100 mg
MM 0012.07 Imp. D (EP): 2-(5-Nitro-1H-imidazol-1-yl)ethanol
N
N
OH
O
2
N
(A) 100 mg
MM 0012.01 Imp. E (EP): 2-(2-Methyl-4-nitro-1H-imidazol-1-yl)ethanol N
N
OH
O2N
(A) 100 mg
MM 0012.09 Imp. G (EP): 2-(2-Methyl-5-nitro-1H-
imidazol-1-yl)acetic Acid
N
N
OH
O
2
N
O
(A) 100 mg
MM 0012.04 1-(2-Hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole
(Hydroxymetronidazole)
N
N
O2N
OH
OH
(A) 100 mg
Pharmaceutical impurities
136 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Metronidazole Benzoate
MM 0278.00 Metronidazole Benzoate
N
N
O
2
N
O
O
(A) 100 mg
MM 0012.00 Imp. A (EP): Metronidazole
N
N
O
2
N
OH
(A) 500 mg
MM 0012.02 Imp. B (EP): 2-Methyl-5-nitroimidazole
(2-Methyl-4-nitroimidazole)
NH
N
O
2
N
(B) 100 mg
MM 0278.01 Imp. C (EP): Benzoic Acid
OH
O
(B) 100 mg
MM 0278.04 2-(2-Methyl-4-nitro-1H-imidazol-1-yl)ethyl Benzoate
N
N
O
O
O
2
N
(A) 100 mg
Mevastatin
MM 0377.00 Mevastatin
O
O
OH
O O
(A) 100 mg
Mexiletine Hydrochloride
MM 0146.00 Mexiletine Hydrochloride
O
NH
2
x HCl
(A) 500 mg
MM 0146.01 Imp. A (EP): 2,6-Dimethylphenol
OH
(A) 100 mg
MM 0146.02 Imp. B (EP): 1-(2,6-Dimethylphenoxy)propan-2-one
O
O
(A) 100 mg
New MM 0146.06 Imp. D (EP) as Hydrochloride: (2RS)-2-(2,6-Di-
methylphenoxy)propan-1-amine Hydrochloride
O
NH
2
x HCl
(A) 50 mg
Mianserin Hydrochloride
MM 0147.00 Mianserin Hydrochloride
N
N
x HCl
(A) 100 mg
MM 0147.01 Imp. A (EP): [2-[(2RS)-4-Methyl-2-phenyl-
piperazin-1-yl]phenyl]methanol
N
N
OH
(A) 100 mg
MM 0147.04 Imp. C (EP): (2-Aminophenyl)methanol
H
2
N
OH
(B) 100 mg
MM 0147.06 Mianserin N-Oxide
N
N
O
(D) 100 mg
Miconazole Nitrate
MM 0281.00 Miconazole Nitrate
O
x HNO
3
N
N
Cl
Cl
Cl Cl
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 137
Code Product Price Unit
MM 0074.00 Miconazole
O
N
N
Cl
Cl
Cl Cl
(A) 250 mg
MM 0281.01 Imp. A (EP): (1RS)-1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanol
HO
N
N
Cl
Cl
(A) 100 mg
MM 0524.00 Imp. B (EP) as Nitrate: 1-[(2RS)-2-[(4-Chlorobenzyl)oxy]-
2-(2,4-dichlorophenyl)ethyl]-1H-imidazole Nitrate
(Econazole Nitrate)
O
x HNO
3
N
N
Cl
Cl
Cl
(A) 500 mg
MM 0281.03 Imp. C (EP) as Nitrate: (2RS)-2-[(2,4-Dichlorobenzyl)oxy]-
2-(2,4-dichlorophenyl)ethanamine Nitrate
O
x HNO
3
NH
2
Cl
Cl
Cl Cl
(D) 100 mg
MM 0541.00 Imp. D (EP) as Nitrate: 1-[(2RS)-2-[(2,6-Dichlorobenzyl)oxy]-
2-(2,4-dichlorophenyl)ethyl]-1H-imidazole Nitrate
(Isoconazole Nitrate)
O
x HNO
3
N
N
Cl
Cl
Cl
Cl
(A) 100 mg
MM 0281.06 Imp. F (EP) as Nitrate: 1-[(2RS)-
2-[(3,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl]-
1H-imidazole Nitrate
O
x HNO
3
N
N
Cl
Cl
Cl
Cl
(A) 100 mg
MM 0281.07 Imp. G (EP) as Nitrate: 1-[(2RS)-
2-[(2,5-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl]-
1H-imidazole Nitrate
O
x HNO
3
N
N
Cl
Cl
Cl
Cl
(A) 100 mg
MM 0281.08 Imp. H (EP) as Nitrate: 1-[(2RS)-2-Benzyloxy-
2-(2,4-dichlorophenyl)ethyl]-1H-imidazole Nitrate
O
x HNO
3
N
N
Cl
Cl
(A) 100 mg
MM 0281.09 Imp. I (EP) as Nitrate: 1-[(2RS)-2-[(2-Chlorobenzyl)-
oxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole Nitrate
O
x HNO
3
N
N
Cl
Cl
Cl
(A) 100 mg
MM 0281.10 1-(2,4-Dichlorobenzoylmethyl)imidazole
O
N
N
Cl
Cl
(A) 100 mg
Pharmaceutical impurities
138 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Midazolam
MM 0070.02 Imp. F (EP): 7-Chloro-5-(2-fluorophenyl)-1,3-
dihydro-2H-1,4-benzodiazepin-2-one
(1-Des[(diethylamino)ethyl]flurazepam) N
H
N
O
Cl
F
(A) 100 mg
Minoxidil
MM 0521.00 Minoxidil
N
N N NH
2
NH2
O
(A) 500 mg
MM 0521.01 Imp. A (EP): 6-Chloropyrimidine-2,4-diamine 3-Oxide
N
N Cl NH
2
NH2
O
(A) 100 mg
MM 0521.02 Imp. B (EP): 6-Chloropyrimidine-2,4-diamine
N
N Cl NH
2
NH2
(C) 100 mg
MM 0521.05 Imp. E (EP): 6-(Piperidin-1-yl)pyrimidine-2,4-diamine
(Desoxyminoxidil)
N
N N NH
2
NH2
(A) 100 mg
Mirtazapine
New MM 1005.00 Mirtazapine
N
N
N
(A) 100 mg
MM 1005.02 Imp. A (EP): (14bRS)-2-Methyl-1,2,3,4,10-
14b-hexahydropyrazino[2,1-a]pyrido[2,3-
c][2]benzazepine 2-Oxide
N
N
N
O
(A) 100 mg
MM 1005.03 Imp. B (EP): [2-[(2RS)-4-Methyl-2-phenyl-
piperazin-1-yl]pyridin-3-yl]methanol
N
N
N
HO
(A) 100 mg
New MM 1005.09 Imp. D (EP) as Maleate: (14bRS)-1,2,3,4,10,14b-
Hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benz-
azepine Maleate
N
N
NH
x
O
OH
O
OH
(A) 50 mg
MM 1005.01 Imp. E (EP): (2RS)-4-Methyl-1-(3-methyl-
pyridin-2-yl)-2-phenylpiperazine
N
N
N
(A) 100 mg
MM 1005.07 1-Methyl-3-phenylpiperazine
HN
N
(A) 100 mg
Moclobemide
MM 0250.00 Moclobemide O
N
H
Cl
N
O (A) 100 mg
Modafinil
New MM 540.01 Imp. A (EP): [(RS)-(Diphenylmethyl)sulfinyl]acetic
Acid
S
OH
O O (A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 139
Code Product Price Unit
New MM 0540.02 Imp. B (EP): 2-[(Diphenylmethyl)sulfonyl]acetamide
S
NH
2
O
O O (A) 50 mg
New MM 0540.03 Imp. C (EP): Methyl [(RS)-(Diphenylmethyl)sulfinyl]-
acetate
S
O
O O (A) 50 mg
New MM 0599.14 Bis(diphenylmethyl) Ether
O
(A) 50 mg
New MM 0540.04 2-[(Diphenylmethyl)sulfenyl]acetamide
S
NH
2
O (A) 50 mg
New MM 540.06 Bis(diphenylmethyl)disulfide
S
S
(A) 50 mg
Molsidomine
MM 0267.00 Molsidomine
O
N
N
O
N
N
O
O
+
-
(A) 250 mg
MM 0267.02 Imp. A (EP) as Hydrochloride: 3-(Morpholin-4-yl)sydnonimine
Hydrochloride (Linsidomine Hydrochloride)
O
N
N
O
N
HN
+
-
x HCl
(A) 100 mg
MM 0267.03 Imp. B (EP): 4-Nitrosomorpholine
N
O
N
O
(A) 100 mg
MM 0267.01 Imp. C (EP): (2E)-(Morpholin-4-ylimino)acetonitrile
N
O
N
N
(A) 100 mg
MM 0267.06 Imp. E (EP): Morpholine
O
HN (A) 100 mg
Montelukast Sodium
MM 0698.00 Montelukast Sodium
N Cl S
ONa
O
HO
on request
Morphine Hydrochloride
MM 0037.00 Morphine Hydrochloride Trihydrate
[Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
MM 0442.00 Imp. A (EP) as Phosphate Hemihydrate:
Codeine Phosphate Hemihydrate
[Controlled Substance]
O OH O
N
x H
2
O
x H
3
PO
4
(A) 100 mg
Pharmaceutical impurities
140 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0037.01 Imp. B (EP): 7,7',8,8'-Tetradehydro-4,5:4',5'-diepoxy-
17,17'-dimethyl-2,2'-bimorphinanyl-3,3',6,6'-tetrol
(Pseudomorphine; 2,2'-Bimorphine)
O OH HO
N
O HO OH
N
(A) 100 mg
MM 0037.03
Imp. F (EP): (17S)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-
3,6-diol17-Oxide (Morphine N-Oxide) [Controlled Substance]
O OH HO
N
O
(A) 100 mg
MM 0037.02 7,7',8,8'-Tetradehydro-4,5a:4',5'a-diepoxy-3,3'-dimethoxy-
17,17'-dimethyl-2,2'-bimorphinanyl-6a,6'a-diol (Codeine
Dimer; Dimethyl Pseudomorphine)
O OH O
N
O HO O
N
(A) 100 mg
Morphine Sulphate
MM 0280.00 Morphine Hemisulphate Pentahemihydrate
[Controlled Substance]
O OH HO
N
x H
2
SO
4
2
x 5 H
2
O
(A) 250 mg
MM 0442.00 Imp. A (EP) as Phosphate Hemihydrate:
Codeine Phosphate Hemihydrate
[Controlled Substance]
O OH O
N
x H
2
O
x H
3
PO
4
(A) 100 mg
MM 0037.01 Imp. B (EP): 7,7',8,8'-Tetradehydro-4,5:4',5'-diepoxy-
17,17'-dimethyl-2,2'-bimorphinanyl-3,3',6,6'-tetrol
(Pseudomorphine;2,2'-Bimorphine)
O OH HO
N
O HO OH
N
(A) 100 mg
MM 0037.03 Imp. F (EP): (17S)-7,8-Didehydro-4,5-epoxy-
17-methylmorphinan-3,6-diol 17-Oxide (Morphine N-Oxide)
[Controlled Substance]
O OH HO
N
O
(A) 100 mg
Moxifloxacin Hydrochloride
MM 0885.00 Moxifloxacine Hydrochloride
N N
O
OH
O
F
O
HN
H
H
x HCl
(D) 100 mg
Moxonidine
MM 1278.02 Imp. B (EP): N-(Imidazolidin-2-ylidene)-4,6-
dimethoxy-2-methylpyrimidin-5-amine
(4-Methoxymoxonidine)
N
N O
O
N N
H
HN
(A) 100 mg
Mycophenolate Mofetil
MM 1001.00 Mycophenolate Mofetil
O
O
OH
O
O
O
N
O
(D) 100 mg
MM 1001.05 Imp. E (EP): Methyl (4E)-6-(4-Hydroxy-6-
methoxy-7-methyl-3-oxo-1,3-dihydroiso-
benzofuran-5-yl)-4-methylhex-4-enoate
O
O
OH
O
O
O
(A) 100 mg
MM 1001.06 Imp. F (EP): (4E)-6-(4-Hydroxy-6-methoxy-7-
methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-
4-methylhex-4-enoic Acid (Mycophenolic Acid)
O
O
OH
O
OH
O
(A) 100 mg
MM 1001.07 Imp. G (EP): 2-(Morpholin-4-yl)ethyl
(4E)-6-(4-Hydroxy-6-methoxy-7-methyl-
3-oxo-1,3-dihydroisobenzofuran-5-yl)-
4-methylhex-4-enoate N-Oxide
O
O
OH
O
O
O
N
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 141
Code Product Price Unit
MM 1001.08 Imp. H (EP): 7-Hydroxy-5-methoxy-4-methyl-
6-[2-[(2RS)-2-methyl-5-oxotetrahydrofuran-2-
yl]ethyl]isobenzofuran-1(3H)-one
O
O
OH
O
O
O
(A) 100 mg
Nabumetone
MM 0153.00 Nabumetone
O
O
(A) 500 mg
MM 0153.02 Imp. A (EP): 3-(6-Methoxynaphthalen-2-yl)-
5-methylcyclohexanone
O
O
(A) 100 mg
MM 0153.03 Imp. B (EP): (5RS)-5-(6-Methoxynaphthalen-2-yl)-
3-methylcyclohex-2-enone
O
O
(A) 100 mg
MM 0153.04 Imp. C (EP): (2RS)-4-(6-Methoxynaphthalen-2-yl)-butan-2-ol
O
OH
(A) 100 mg
MM 0153.05 Imp. D (EP): (E)-4-(6-Methoxynaphthalen-2-yl)-but-3-en-2-one
O
O
(A) 100 mg
New MM 0153.06 Imp. E (EP): 1,5-Bis(6-methoxynaphthalen-
2-yl)pentan-3-one
O
O
O
(A) 50 mg
MM 0153.07 Imp. F (EP): 6,6'-Dimethoxy-2,2'-binaphthalenyl
O
O
(A) 100 mg
MM 0152.01
(6-Methoxy-2-naphthyl)acetic Acid ((6-Methoxynaphthalen-
2-yl)acetic Acid, -Demethylnaproxen)
O
OH
O
(A) 100 mg
Nadolol
MM 0439.00 Nadolol
HO
OH
O
OH
H
N
and enantiomers
on request
MM 0439.06 Imp. F (EP) as Hydrochloride: (2RS)-1-[(1,1-
Dimethylethyl)amino]-3-(naphthalen-1-yloxy)-
propan-2-ol Hydrochloride
O
OH
H
N
x HCl
(A) 50 mg
MM 0439.07 Imp. G (EP) as Hydrochloride: (2RS)-1-[(1,1-
Dimethylethyl)amino]-3-[(5,6,7,8-tetrahydro-
naphtalen-1-yl)oxy]-propan-2-ol Hydrochloride
O
OH
H
N
x HCl
(A) 50 mg
Nafcillin Sodium
MM 0392.00 Nafcillin Sodium
N
S
ONa
O
H
O
NH
O
O
on request
MM 0392.02 Penilloic Acids of Nafcillin
H
N
O
S
HN
O
HO
O
(D) 100 mg
MM 0026.04 6-Aminopenicillanic Acid
N
S
H
O
H
2
N
O
OH
(B) 100 mg
MM 0392.04 2-Ethoxynaphthoic Acid
OH O
O
(B) 100 mg
Pharmaceutical impurities
142 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Naftidrofuryl Hydrogen Oxalate
MM 0373.00 Naftidrofuryl Hydrogen Oxalate
O
O
O
N O OH
OH O
x
(A) 500 mg
Naloxone Hydrochloride Dihydrate
MM 0272.00 Naloxone Hydrochloride Dihydrate
O O HO
N
OH
x HCl
x 2 H2O
(A) 250 mg
Naltrexone
MM 0233.00 Naltrexone Hydrochloride
O O HO
N
x HCl
HO
(A) 100 mg
Nandrolone
MM 0660.00 Nandrolone
H
O
OH
(A) 250 mg
MM 0660.01 19-Norandrost-4-ene-3,17-dione (Estr-4-ene-3,17-dione)
H
O
O
(A) 100 mg
Nandrolone Decanoate
MM 0982.00 Nandrolone Decanoate
H
O
O
O
(A) 100 mg
MM 0660.00 Imp. D (EP): 17-Hydroxyestr-4-en-3-one (Nandrolone)
H
O
OH
(A) 250 mg
Naphazoline Hydrochloride
MM 0075.00 Naphazoline Hydrochloride
N
HN
x HCl
(A) 500 mg
MM 0075.06 Imp. A (EP) as Hydrochloride: N-(2-Aminoethyl)-
2-(naphthalen-1-yl)acetamide Hydrochloride
(Naphthylacetylethylenediamine Hydrochloride)
O
N
H
NH
2
x HCl
(A) 100 mg
MM 0075.02 Imp. B (EP): (Naphthalen-1-yl)acetic Acid
(1-Naphthylacetic Acid)
O
OH
(B) 100 mg
MM 0075.04 Imp. C (EP): (Naphthalen-1-yl)acetonitrile
(1-Naphthylacetonitrile)
N
(B) 100 mg
MM 0075.05 Ethyl (1-Naphthyl)acetate
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 143
Code Product Price Unit
MM 0075.07 (Naphthalen-1-y)lacetamide (1-Naphthylacetamide)
O
NH
2
(A) 100 mg
Naphazoline Nitrate
MM 0286.00 Naphazoline Nitrate
N
HN
x HNO3
(A) 500 mg
MM 0075.06 Imp. A (EP) as Hydrochloride:
N-(2-Aminoethyl)-2-(naphthalen-1-yl)acetamide
Hydrochloride (Naphthylacetylethylenediamine
Hydrochloride)
O
N
H
NH
2
x HCl
(A) 100 mg
MM 0075.02 Imp. B (EP): (Naphthalen-1-yl)acetic Acid
(1-Naphthylacetic Acid)
O
OH
(B) 100 mg
MM 0075.04 Imp. C (EP): (Naphthalen-1-yl)acetonitrile (1-Naphthylacetonitrile)
N
(B) 100 mg
MM 0075.05 Ethyl (1-Naphthyl)acetate
O
O
(A) 100 mg
MM 0075.07 (Naphthalen-1-yl)acetamide
(1-Naphthylacetamide)
O
NH
2
(A) 100 mg
Naproxen
MM 0152.00 Naproxen
O
OH
O
(A) 500 mg
MM 0152.06 Imp. A (EP): (2S)-2-(6-Hydroxynaphthalen-2-yl)-
propanoic Acid (O-Demethylnaproxen)
HO
OH
O
(A) 100 mg
MM 0152.09 Imp. B (EP): (2S)-2-(5-Chloro-6-methoxy-
naphthalen-2-yl)propanoic Acid
(5-Chloronaproxen)
O
OH
O
Cl
(A) 100 mg
MM 0152.10 Imp. C (EP): (2S)-2-(5-Bromo-6-methoxy-
naphthalen-2-yl)propanoic Acid
(5-Bromonaproxen)
O
OH
O
Br
(A) 100 mg
MM 0152.11 Imp. D (EP): (2S)-2-(5-Iodo-6-methoxy-
naphthalen-2-yl)propanoic Acid
(5-Iodonaproxen)
O
OH
O
I
(A) 100 mg
MM 0152.02 Imp. E (EP): Methyl (2S)-2-(6-Methoxy-
naphthalen-2-yl)propanoate
(Naproxen Methyl Ester)
O
O
O
(A) 100 mg
MM 0152.12 Imp. F (EP): Ethyl (2S)-2-(6-Methoxy-
naphthalen-2-yl)propanoate
(Naproxen Ethyl Ester)
O
O
O
(A) 100 mg
MM 0152.14 Imp. H (EP): 6-Methoxynaphthalen-2-ol (Hydroxynerolin)
O
OH
(A) 100 mg
MM 0152.01 Imp. I (EP):(6-Methoxynaphthalen-2-yl)acetic Acid
(-Demethylnaproxen)
O
OH
O
(A) 100 mg
MM 0152.18 Imp. J (EP): 2-Ethyl-6-methoxynaphthalene (Ethylnerolin)
O
(A) 100 mg
Pharmaceutical impurities
144 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0152.16 Imp. K (EP): (1RS)-1-(6-Methoxynaphthalen-2-yl)ethanol
O
OH
(A) 100 mg
MM 0152.07 Imp. L (EP): 1-(6-Methoxynaphthalen-2-yl)ethanone (Acetylnerolin)
O
O
(B) 100 mg
MM 0152.08 Imp. M (EP): 2-Methoxynaphthalene (Nerolin)
O
(B) 100 mg
MM 0152.17 Imp. N (EP): 2-Bromo-6-methoxynaphthalene
O
Br
(C) 100 mg
MM 0152.04 Naproxen Sodium
O
ONa
O
(A) 500 mg
MM 0152.15 2-Carboxy-6-methoxynaphthalene
O
OH
O
(A) 100 mg
Nateglinide
MM 0847.00 Nateglinide
H
N
O
OH
O
on request
New MM 0847.03 Imp. B (Pharmeuropa): N-[[trans-4-(Propan-
2-yl)cyclohexyl]carbonyl]-L-phenylalanine
H
N
OH
O
O
(A) 50 mg
New MM 0314.03 Imp. C (EP): Phenylalanine
H
2
N
OH
O
(B) 100 mg
MM 0847.04 Imp. E (Pharmeuropa): N-[(trans-4-Ethyl-
cyclohexyl)carbonyl]-D-phenylalanine
(Nateglinide Ethyl Analog)
H
N
OH
O
O
(A) 50 mg
MM 0847.06 Imp. G (Pharmeuropa): Ethyl N-[[trans-4-(Propan-
2-yl)cyclohexyl]carbonyl]-D-phenylalaninate
(Nateglinide Ethyl Ester)
H
N
O
O
O
(A) 50 mg
Nevirapine Anhydrous
MM 1146.01 Imp. A (EP): 11-Ethyl-4-methyl-5,11-dihydro-
6H-dipyrido [3,2-b:2',3'-e][1,4]diazepin-6-one
NH
N
N N
O
(A) 100 mg
MM 1146.02 Imp. B (EP): 4-Methyl-5,11-dihydro-6H-
dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
NH
H
N
N N
O
(A) 100 mg
MM 1146.03 Imp. C (EP): 4-Methyl-11-propyl-5,11-dihydro-
6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
NH
N
N N
O
(D) 100 mg
MM 1146.04 3-Amino-2-chloro-4-methylpyridine
N Cl
H
2
N
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 145
Code Product Price Unit
Nicardipine Hydrochloride
MM 0465.00 Nicardipine Hydrochloride
H
N
O
O
O
O
N
NO
2
x HCl
(A) 250 mg
MM 0465.01 3-Methyl 5-[Methyl(phenylmethyl)amino]-
ethyl 2,6-Dimethyl-4-(3-nitrophenyl)pyridine-
3,5-dicarboxylate Dihydrochloride
N
O
O
O
O
N
NO
2
x 2 HCl
(A) 100 mg
Nicergoline
MM 0115.00 Nicergoline
N
O
O
N
N
O
H
Br
(A) 100 mg
MM 0115.02 Imp. A (EP): [(6aR,9R,10aS)-10a-Methoxy-
4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydro-
indolo[4,3-fg]quinolin-9-yl]methyl 5-Chloro-
pyridine-3-carboxylate (Chloronicergoline)
N
O
O
N
N
O
H
Cl
(D) 50 mg
MM 0115.04 Imp. C (EP): [(6aR,9R,10aS)-10a-Methoxy-4,7-dimethyl-
4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-
9-yl]methanol (Methylmethoxylumilysergol)
N
OH
N
O
H (D) 100 mg
MM 0115.06 Imp. D (EP): 5-Bromopyridine-3-carboxylic Acid
HO
O
N
Br
(B) 100 mg
MM 0115.03 5-Debromonicergoline
N
O
O
N
N
O
H on request
Nicorandil
MM 0924.00 Nicorandil
N
N
H
O
O
NO
2
(A) 100 mg
Nicotinamide
MM 0552.00 Nicotinamide
N NH2
O
(A) 500 mg
MM 0552.01 Isonicotinamide
N
NH2
O
(A) 100 mg
Nicotine
MM 0517.00 Nicotine
N N
(A) 500 mg
MM 0517.03 Imp. C (EP): (5S)-1-Methyl-5-(pyridin-3-yl)pyrrolidin-2-one (Cotinine)
N N
O
(A) 100 mg
MM 0517.01 Imp. G (EP): 3-[(2S)-Piperidin-2-yl]pyridine (Anabasine)
N N
H
(A) 100 mg
Nicotinic Acid
MM 0553.00 Nicotinic Acid
N OH
O
(A) 500 mg
Pharmaceutical impurities
146 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
New MM 0553.06 Imp. B (EP): 2,2'-Bipyridine-5,5'-dicarboxylic
Acid (6,6'-Dinicotinic Acid) N OH
O
N HO
O
(A) 100 mg
MM 0553.03 Imp. E (EP): Pyridine-4-carboxylic Acid
(Isonicotinic Acid)
N
OH
O
(A) 100 mg
MM 0549.00 Methyl Nicotinate
N O
O
(A) 500 mg
MM 0104.00 Benzyl Nicotinate
N O
O
(A) 500 mg
Nifedipine
MM 0003.00 Nifedipine
O
O
O
O
H
N
NO
2
(A) 500 mg
MM 0003.02 Imp. A (EP): Dimethyl 2,6-Dimethyl-4-(2-nitrophenylpyridine-
3,5-dicarboxylate (Nitrophenylpyridine Analogue of Nifedipine)
O
O
O
O
N
NO
2
(A) 100 mg
MM 0003.01 Imp. B (EP): Dimethyl 2,6-Dimethyl-4-(2-nitrosophenylpyridine-
3,5-dicarboxylate (Nitrosophenylpyridine Analogue of Nifedipine)
O
O
O
O
N
NO
(A) 100 mg
MM 0003.07 Imp. C (EP) as E/Z-Mixture: Methyl (E/Z)-2-(2-Nitrobenzylidene)-
3-oxobutanoate
NO
2
O
O
O
(A) 100 mg
MM 0003.08 Imp. D (EP): Methyl 3-Aminobut-2-enoate
O
O
H
2
N
(C) 100 mg
MM 0003.03 2-Nitrobenzaldehyde
O
NO
2
(B) 100 mg
Niflumic Acid
MM 0850.00 Niflumic Acid
N
OH
O
NH
F
F F
(A) 250 mg
MM 0915.01 Imp. A (EP): 2-Chloropyridine-3-carboxylic
Acid (2-Chloronicotinic Acid)
N
OH
O
Cl
(A) 100 mg
MM 0850.05 Imp. B (EP): 2-Hydroxy-N-[3-(trifluoro-
methyl)phenyl]pyridine-3-carboxamide
H
N
F
F F
O
N OH
(A) 100 mg
MM 0161.06 Imp. C (EP): 3-(Trifluoromethyl)aniline
NH
2
F
F F
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 147
Code Product Price Unit
MM 0850.01 Imp. F (EP): Methyl 2-[[3-(Trifluoromethyl)-
phenyl]amino]pyridine-3-carboxylate
(Niflumic Acid Methyl Ester)
N
O
O
NH
F
F F
(A) 100 mg
Nifuroxazide
MM 0574.00 Nifuroxazide
O
N
H
N
OH
O
O2N
(A) 500 mg
MM 0574.01 Imp. A (EP): 4-Hydroxybenzohydrazide
(p-Hydroxybenzohydrazide)
H
2
N
H
N
OH
O
(C) 100 mg
MM 0431.00 Imp. B (EP): Methyl 4-Hydroxybenzoate
(Methyl Parahydroxybenzoate) O
OH
O
(A) 500 mg
MM 0943.02 Imp. C (EP): (5-Nitrofuran-2-yl)methylidene
Diacetate ((5-Nitrofuran-2-yl)methylene Diacetate)
O
O
O
2
N
O
O
O
(A) 100 mg
Nifursol
MM 0444.00 Nifursol
OH
O
2
N
NO
2
N
H
O
N
O
NO2
(A) 100 mg
MM 0444.01 5-Nitro-2-furfural
O
NO
2
O (C) 100 mg
MM 0444.02 5-Nitrofurfural Hydrazone
O
NO2
N
H
2
N
(A) 100 mg
MM 0444.03 3,5-Dinitrosalicylic Acid Hydrazide
OH
O
2
N
NO
2
N
H
O
NH
2
(A) 100 mg
Nikethamide
MM 0627.00 Nikethamide
N N
O
(A) 500 mg
Nimesulide
MM 0378.00 Nimesulide
O O
2
N
H
N
S
O O
(A) 250 mg
MM 0378.01 Imp. A (EP): N-(2,4-Dinitro-6-phenoxyphenyl)methanesulphonamide
O O
2
N
H
N
S
O O
NO2
(A) 100 mg
MM 0378.02 Imp. B (EP): N-(2-Phenoxyphenyl)methanesulphonamide
O
H
N
S
O O
(A) 100 mg
MM 0378.03 Imp. C (EP): 2-Phenoxyaniline
O
NH
2
(A) 100 mg
Pharmaceutical impurities
148 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0378.04 Imp. D (EP): 4-Nitro-2-phenoxyaniline
O
NH
2
O
2
N
(A) 100 mg
MM 0378.05 Imp. E (EP): N,N-Bis(methylsulphonyl)-2-
phenoxyaniline
O
N
S
S
O
O
O O
(A) 100 mg
MM 0378.06 Imp. F (EP): N,N-Bis(methylsulphonyl)-4-
nitro-2-phenoxyaniline
O
N
S
S
O
2
N
O O
O
O
(A) 100 mg
MM 0378.07 Imp. G (EP): 4-Nitro-2-phenoxyphenol
O
OH
O
2
N
(A) 50 mg
Nimodipine
MM 0416.00 Nimodipine
H
N
O
O
O
O
O
NO
2
(A) 100 mg
MM 0416.01 Imp. A (EP): 2-Methoxyethyl 1-Methylethyl 2,6-Dimethyl-
4-(3-nitrophenyl)pyridine-3,5-dicarboxylate
N
O
O
O
O
O
NO
2
(A) 100 mg
MM 0416.02 Imp. B (EP): Bis(1-methylethyl) 2,6-Dimethyl-4-(3-nitrophenyl)-
1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
O
O
NO
2
(A) 100 mg
MM 0416.03 Imp. C (EP): Bis(2-methoxyethyl) 2,6-Dimethyl-
4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
H
N
O
O
O
O
O
NO
2
O
(A) 100 mg
Nitrazepam
MM 0078.00 Nitrazepam [Controlled Substance]
N
H
N
O
O2N
(A) 100 mg
MM 0078.02 Imp. A (EP): 3-Amino-6-nitro-4-phenylquinolin-2(1H)-one
O2N
H
N
NH2
O
(A) 100 mg
MM 0078.01 Imp. B (EP): (2-Amino-5-nitrophenyl)phenylmethanone
(2-Amino-5-nitrobenzophenone)
O2N
NH2
O
(B) 100 mg
MM 0078.03 Imp. C (EP): 2-Bromo-N-[4-nitro-2-(phenyl-
carbonyl)phenyl]acetamide NH
O
O
Br
O
2
N
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 149
Code Product Price Unit
MM 0078.05 Imp. D (EP): 2-(1,3-Dioxo-1,3-dihydro-2H-
isoindol-2-yl)-N-[4-nitro-2-(phenylcarbonyl)-
phenyl]acetamide
NH
O
O
N
O
O
O
2
N
(A) 50 mg
MM 0078.07 7-Aminonitrazepam
N
H
N
O
H
2
N
(A) 100 mg
Nitrendipine
MM 0092.00 Nitrendipine
H
N
NO2
O
O
O
O
(A) 500 mg
MM 0092.03 Imp. A (EP): Ethyl Methyl 2,6-Dimethyl-4-(3-nitrophenyl)pyridine-
3,5-dicarboxylate (Photolysis Product)
N
NO2
O
O
O
O
(A) 100 mg
MM 0092.01 Imp. B (EP): Dimethyl 2,6-Dimethyl-4-(3-nitrophenyl)-
1,4-dihydropyridine-3,5-dicarboxylate
H
N
NO2
O
O
O
O
(A) 100 mg
MM 0092.02 Imp. C (EP): Diethyl 2,6-Dimethyl-4-(3-nitrophenyl)-
1,4-dihydropyridine-3,5-dicarboxylate
H
N
NO2
O
O
O
O
(A) 100 mg
MM 0092.04 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic
Acid Methyl Ester
H
N
NO2
OH
O
O
O
(A) 50 mg
MM 0092.05 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylic
Acid Ethyl Ester
H
N
NO2
OH
O
O
O
(A) 50 mg
Nitrofural
MM 0943.00 Nitrofural O
O
2
N
N
H
N NH
2
O
(A) 500 mg
MM 0943.02 Imp. B (EP): (5-Nitrofuran-2-yl)methylene Diacetate
O
O
2
N
O
O
O
O
(A) 100 mg
Nitrofurantoin
MM 0506.00 Nitrofurantoin
O
O
2
N
N
N
H
N
O
O
(A) 500 mg
Nizatidine
MM 0220.00 Nizatidine
NO
2
N
H
N
H
S
N
S
N
(A) 500 mg
MM 0220.01 Imp. A (EP): N,N-Dimethyl-2-nitroethene-1,1-diamine
NO
2
N
H
N
H
(A) 100 mg
Pharmaceutical impurities
150 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0220.09 Imp. B (EP): (EZ)-N-Methyl-1-methylsulphanyl)-2-nitroethen-1-amine
NO
2
S N
H
(A) 100 mg
MM 0220.02 Imp. C (EP): (EZ)-N-[2-[[[2-[(Dimethylamino)methyl]thiazol-
4-yl]methyl]sulphinyl]ethyl]-N-methyl-2-nitroethene-
1,1-diamine
NO
2
N
H
N
H
S
N
S
N
O
(C) 50 mg
MM 0220.04 Imp. D (EP) as Dioxalate: 2-[[[2-[(Dimethyl-
amino)methyl]thiazol-4-yl]methyl]sulphanyl]-
ethanamine Dioxalate
NH
2
S
N
S
N HO O
O HO
x 2
(A) 50 mg
MM 0220.10 Imp. G (EP): N,N'-Bis[2-[[[2-[(dimethylamino)-
methyl]thiazol-4-yl]methyl]sulphanyl]ethyl]-2-
nitroethene-1,1-diamine
N
H
N
H
S
N
S
N
NO
2
S
S
N
N
(A) 50 mg
MM 0220.11 Imp. H (EP) as Hydrochloride: 2-(Dimethylamino)thioacetamide
Hydrochloride
S
NH
2
N
x HCl
(A) 100 mg
MM 0086.07 Imp. K (EP): 3-(Methylamino)-5,6-dihydro-2H-1,4-thiazin-2-one Oxime
N
S
N
H
N
OH
(A) 100 mg
Nonivamide
MM 1033.00 Nonivamide
HO
O
N
H
O
(A) 500 mg
MM 1033.01 4-(Aminomethyl)-2-methoxyphenol Hydrochloride (Vanillylamine
Hydrochloride)
HO
O
NH
2
x HCl
(A) 100 mg
MM 1033.02 N-[(4-Hydroxy-3-methoxyphenyl)methyl]octanamide
(N-Vanillyloctanamide)
HO
O
N
H
O
(A) 100 mg
MM 1033.03 N-[(4-Hydroxy-3-methoxyphenyl)methyl]-
decanamide (N-Vanillyldecanamide)
HO
O
N
H
O
(A) 100 mg
MM 1033.04 N,O-Dinonanoylvanillylamine
O
O
N
H
O
O
(A) 100 mg
Noradrenaline Tartrate
MM 0614.02 Imp. A (EP): Adrenaline (L-Adrenaline)
HO
HO
H
N
OH
(A) 500 mg
MM 0384.00 Imp. C (EP) as Hydrochloride: Dopamine Hydrochloride
HO
HO
NH
2
x HCl
(A) 500 mg
Norethisterone
MM 0218.00 Norethisterone
O
OH
(A) 250 mg
MM 0218.04 Imp. A (EP): 17-Hydroxy-19-nor-17-pregna-4,6-dien-20-yn-3-one
(6,7-Didehydronorethisterone)
O
OH
(D) 100 mg
MM 0660.01 Imp. B (EP): Estr-4-ene-3,17-dione (Norandrostenedione)
O
O
(A) 100 mg
MM 0218.01 Imp. H (EP): 6,17-Dihydroxy-19-nor-17-pregn-4-en-20-yn-3-one
(6-Hydroxynorethisterone)
O
OH
OH
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 151
Code Product Price Unit
MM 0218.02 6-Hydroxynorethisterone
O
OH
OH
(D) 50 mg
MM 0218.03 6-Ketonorethisterone
O
OH
O
(D) 100 mg
Norethisterone Acetate
MM 0219.00 Norethisterone Acetate
O
O
O
(A) 100 mg
MM 0218.00 Imp. A (EP): Norethisterone
O
OH
(A) 250 mg
MM 0219.10 Imp. B (EP): 3-Oxo-19-nor-17-pregn-5(10)-en-20-yn-17-yl
Acetate
O
O
O
on request
MM 0219.01 Imp. F (EP): 6-Hydroxy-3-oxo-19-nor-17-pregn-4-en-20-yn-17-yl
Acetate (6-Hydroxynorethisterone Acetate)
O
O
O
OH
(D) 100 mg
MM 0219.03 Imp. G (EP): 3,6-Dioxo-19-nor-17-pregn-4-en-20-yn-17-yl
Acetate (6-Ketonorethisterone Acetate)
O
O
O
O
(D) 100 mg
MM 0219.02
6-Hydroxynorethisterone Acetate
O
O
O
OH
(D) 50 mg
MM 0219.04 6,7-Didehydronorethisterone Acetate
O
O
O
(D) 100 mg
Norfenefrine Hydrochloride
MM 0973.00 Norfenefrine Hydrochloride
HO
OH
NH
2
x HCl
(A) 500 mg
Norfloxacin
MM 0350.00 Norfloxacin
N N
O
F
OH
O
HN (A) 250 mg
MM 0350.01 Imp. A (EP): 7-Chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-
3-carboxylic Acid
N Cl
O
OH
O
F
(A) 100 mg
MM 0350.03 Imp. D (EP): 1-Ethyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one
N N
O
HN
F
(D) 100 mg
Pharmaceutical impurities
152 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0350.04 Imp. G (EP): 1-Ethyl-6-fluoro-7-(4-formyl-piperazin-1-yl)-
4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
N N
O
OH
O
N
F
O (D) 100 mg
Nortriptyline Hydrochloride
MM 0079.00 Nortriptyline Hydrochloride
x HCl
N
H
(A) 500 mg
MM 0062.01 Imp. A (EP): 10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-one
(Dibenzosuberone)
O
(B) 100 mg
MM 0079.01 Imp. B (EP) as Hydrochloride: 3-(5H-Dibenzo-
[a,d][7]annulen-5-ylidene)-N-methylpropan-1-
amine Hydrochloride (Norcyclobenzaprine
Hydrochloride)
N
H
x HCl
(A) 50 mg
MM 0062.03 Imp. D (EP): 5-[3-(Dimethyl-amino)propyl]-
10,11-dihydro-5H-dibenzo-[a,d][7]annulen-5-ol
OH
N
(A) 100 mg
MM 0062.02 Imp. E (EP) as Hydrochloride: 3-(5H-
Dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethyl-
propan-1-amine Hydrochloride (Cyclobenzaprine
Hydrochloride)
N
x HCl
(A) 100 mg
MM 0062.00 Imp. F (EP) as Hydrochloride:
Amitriptyline Hydrochloride
N
x HCl
(A) 500 mg
MM 0062.12 Imp. J (EP) as Hydrochloride: [3-(10,11-
Dihydro-5H-dibenzo[a,d][7]annulen-
5-ylidene)propyl]-dimethylamine Oxide Hydrochloride
(Amitriptyline N-Oxide Hydrochloride)
N
x HCl
O
(B) 10 mg
Nucleosides
New MM 1316.01 Cytidine
O
OH
HO N
N
O
NH
2
OH
(A) 100 mg
New MM 1316.02 2'-Deoxycytidine
O
OH
HO N
N
O
NH
2
(A) 100 mg
Ofloxacin
MM 0228.00 Ofloxacin
N
O
N
O
F
N
OH
O
(A) 500 mg
MM 0228.04 Imp. A (EP): (RS)-9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid (FPA)
N
O
F
O
F
OH
O
(A) 100 mg
MM 0228.05 Imp. B (EP): (RS)-9-Fluoro-3-methyl-10-(4-
methylpiperazin-1-yl)-2,3-dihydro-7H-pyrido-
[1,2,3-de]-1,4-benzoxazin-7-one
N
O
N
O
F
N (A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 153
Code Product Price Unit
MM 0228.08 Imp. E (EP): (RS)-9-Fluoro-3-methyl-7-oxo-10-(piperazin-
1-yl)-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-
6-carboxylic Acid
N
O
N
O
F
HN
OH
O
(A) 100 mg
MM 0228.10 Imp. F (EP) as Hydrochloride: 4-[(RS)-6-Carboxy-
9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-10-yl]-
1-methylpiperazine 1-Oxide Hydrochloride (Ofloxacin
N-Oxide Hydrochloride)
N
O
N
O
F
N
OH
O
O
x HCl
(A) 100 mg
Olanzapine
New MM 0329.00 Olanzapine
N
N
N
HN
S
on request
MM 0329.08 Imp. A (EP): 5-Methyl-2-[(2-nitrophenyl)-
amino]thiophene-3-carbonitrile
HN
S
N
O
2
N
(A) 50 mg
MM 0329.02 Imp. B (EP): 2-Methyl-5,10-dihydro-4H-
thieno[2,3-b][1,5]benzodiazepin-4-one
(Olanzapine Lactame)
O
H
N
HN
S
(A) 50 mg
MM 0329.07 Imp. C (EP): 1-(Chloromethyl)-1-methyl-4-(2-
methyl-10H-thieno[2,3-b][1,5]benzodiazepin-
4-yl)piperazin-1-ium Chloride (Olanzapine-N-
Chloromethyl Chloride)
N
N
+
N
HN
S
Cl
Cl
-
(A) 100 mg
New MM 0329.03 Imp. D (EP): 1-Methyl-4-(2-methyl-10H-thieno-
[2,3-b][1,5]benzodiazepin-4-yl)piperazin-1-oxide
(Olanzapine N-Oxide)
N
N
N
HN
S
O
(A) 50 mg
Omeprazole
MM 0095.00 Omeprazole
N
O
S
O
H
N
N
O
(A) 500 mg
MM 0095.03 Imp. A (EP): 5-Methoxy-1H-benzimidazole-2-thiol
SH
H
N
N
O
(A) 100 mg
MM 0095.04 Imp. B (EP): 2-[(RS)-[(3,5-Dimethylpyridin
-2-yl)methyl]sulphinyl]-5-methoxy-1H-
benzimidazole
N S
O
H
N
N
O
(A) 100 mg
MM 0095.06 Imp. C (EP): 5-Methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-
2-yl)methyl]sulphanyl]-1H-benzimidazole (Ufiprazole)
N
O
S
H
N
N
O
(A) 100 mg
MM 0095.05 Imp. D (EP): 5-Methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-
2-yl) methyl]sulphonyl]-1H-benzimidazole (Omeprazole
Sulphone)
N
O
S
H
N
N
O
O
O
(A) 100 mg
MM 0095.07 Imp. E (EP): 4-Methoxy-2-[[(RS)-(5-methoxy-1H-
benzimidazol-2-yl)sulphinyl]methyl]-3,5-dimethylpyridine
1-Oxide (Omeprazole N-Oxide)
N
O
S
O
NH
N
O
O
(A) 100 mg
MM 0095.01 Imp. F (EP): 8-Methoxy-1,3-dimethyl-
12-thioxopyrido[1',2':3,4]imidazo[1,2-a]-benzimidazol-2(12H)-
one N
N
N
S
O
O
(D) 50 mg
MM 0095.02 Imp. G (EP): 9-Methoxy-1,3-dimethyl-
12-thioxopyrido[1',2':3,4]imidazo[1,2-a]-benzimidazol-2(12H)-
one N
N
N
S
O
O (D) 50 mg
Pharmaceutical impurities
154 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0095.15 Imp. H (EP): 2-[(RS)-[(4-Chloro-3,5-dimethylpyridin-
2-yl)methyl]sulfinyl]-5-methoxy-1H-benzimidazole
N
S
O
NH
N
O
Cl
(D) 100 mg
MM 0095.16 Imp. I (EP): 4-Methoxy-2-[[(5-methoxy-1H-benzimidazol-
2-yl)sulphonyl]methyl]-3,5-dimethylpyridine 1-Oxide
(Omeprazole Sulphone N-Oxide)
N
O
S
NH
N
O
O
O O
(A) 100 mg
MM 0095.08 5-Methoxy-2-[[(3,5-dimethylpyridin-2-yl)methyl]sulphanyl]-
1H-benzimidazole
N
S
NH
N
O
(A) 100 mg
MM 0095.19 5-Methoxy-2-[[(4-chloro-3,5-dimethylpyridin-2-yl)
methyl]sulphanyl]-1H-benzimidazole
N
Cl
S
NH
N
O
(D) 100 mg
MM 0095.20 5-Methoxy-1,3-dihydrobenzimidazol-2-one
O
NH
N
H
O
(A) 100 mg
MM 0095.23 2-[[(4-Methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphinyl]-1H-
benzimidazole
N
O
S
O
NH
N
(A) 100 mg
MM 0095.24 5-Methoxy-2-(4-methoxy-3,5-dimethylpyridin-2-yl)-1H-
benzimidazole
NH
N
O
N
O
(A) 100 mg
Ondansetron Hydrochloride Dihydrate
MM 0252.00 Ondansetron Hydrochloride Dihydrate
N
O
N
N
x HCl
x 2 H
2
O
(A) 100 mg
MM 0252.09 Ondansetron
N
O
N
N
(A) 100 mg
MM 0252.03 Imp. A (EP): (3RS)-3-(Dimethylamino)methyl-9-methyl-
1,2,3,9-tetrahydro-4H-carbazol-4-one
N
O
N
(A) 100 mg
MM 0252.02 Imp. B (EP): 6,6'-Methylene bis[(3RS)-
9-methyl-3-[(2-methyl-1H-imidazol-
1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-
4-one]
N N
N N
N N
O O
(D) 50 mg
MM 0252.01 Imp. C (EP): 9-Methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one
N
O
(A) 100 mg
MM 0252.04 Imp. D (EP): 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-
4-one
N
O
(A) 100 mg
MM 0015.02 Imp. E (EP): 1H-Imidazole (Imidazole)
N
N
H
(B) 100 mg
MM 0252.06 Imp. F (EP): 2-Methyl-1H-imidazole
N
N
H
(B) 100 mg
MM 0252.07 Imp. G (EP): (3RS)-3-[(1H-Imidazol-1-yl)methyl]-9-methyl-
1,2,3,9-tetrahydro-4H-carbazol-4-one
(C-Demethylondansetron)
N
O
N
N
(A) 100 mg
MM 0252.08 Imp. H (EP): (3RS)-3-[(2-Methyl-1H-imidazol-1-yl)methyl]-
1,2,3,9-tetrahydro-4H-carbazol-4-one
(N-Demethylondansetron)
H
N
O
N
N
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 155
Code Product Price Unit
Opipramol Dihydrochloride
MM 0422.01 5-(3-Piperazin-1-yl-propyl)-5H-dibenzo[b,f]azepine
Dihydrochloride
N
N
NH
x 2 HCl
(A) 100 mg
Ornidazole
MM 0948.00 Ornidazole
N
N
O
2
N
Cl
OH
(A) 500 mg
MM 0012.02 2-Methyl-4-nitroimidazole
NH
N
O
2
N
(B) 100 mg
MM 0948.02 3-(2-Methyl-5-nitro-1H-imidazol-1-yl)propane-1,2-diol
N
N
O
2
N
OH
OH
(A) 100 mg
MM 0948.03 3-(2-Methyl-5-nitro-1H-imidazol-1-yl)-1,2-epoxypropane
N
N
O
2
N
O
(A) 100 mg
MM 0948.04 1-(3-Chloro-2-hydroxypropyl)-2-methyl-4-nitroimidazole N
N
Cl
OH
O
2
N
(A) 100 mg
Orphenadrine Hydrochloride
MM 0801.00 Orphenadrine Hydrochloride
O
N
x HCl
(A) 500 mg
MM 0801.01 Imp. A (EP): (RS)-(2-Methylphenyl)phenylmethanol
(2-Methylbenzhydrol)
OH
(A) 100 mg
MM 0801.02 Imp. B (EP): (2-Methylphenyl)phenylmethanone (2-Methylbenzophenone)
O
(A) 100 mg
MM 0801.03 Imp. C (EP) as Hydrochloride: (RS)-2-[(2-Methyl-
phenyl)phenylmethoxy]ethanamine Hydrochloride
O
NH
2
x HCl
(A) 50 mg
MM 0490.00 Imp. D (EP) as Hydrochloride: Diphenhydramine
Hydrochloride
O
N
x HCl
(A) 500 mg
MM 0801.05 Imp. E (EP) as Hydrochloride: (RS)-N,N-Dimethyl-
2-[(3-methylphenyl)phenylmethoxy]ethanamine Hydrochloride
(meta-Methylbenzyl Isomer Hydrochloride)
O
N
x HCl
(A) 100 mg
MM 0490.04 Imp. F (EP) as Hydrochloride: (RS)-N,N-Dimethyl-
2-[(4-methylphenyl)phenylmethoxy]ethanamine
Hydrochloride (para-Methylbenzyl Isomer Hydro-
chloride; 4-Methyldiphenhydramine Hydrochloride)
O
N
x HCl
(A) 100 mg
MM 0801.07 N-Desmethylorphenadrine Hydrochloride
O
H
N
x HCl
(A) 100 mg
Pharmaceutical impurities
156 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Oxacillin Sodium
MM 0686.00 Oxacillin Sodium Monohydrate
O
N N
H
O N
S
O
O
ONa
H
x H
2
O
(A) 250 mg
MM 0026.04 Imp. A (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-
7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylic Acid (6-Aminopenicillanic Acid)
N
S
O
O
OH
H
H
2
N
(B) 100 mg
MM 0682.00 Imp. E (EP) as Sodium Salt Monohydrate:
Cloxacillin Sodium Monohydrate
N
S
O
O
ONa
H
x H
2
O H
N
O
N
O
Cl
(A) 500 mg
Oxalic Acid Dihydrate
MM 0928.00 Oxalic Acid Dihydrate
OH O
O OH
x 2 H
2
O
(A) 500 mg
MM 0928.01 Oxalic Acid
OH O
O OH
(A) 500 mg
Oxaliplatin
MM 0928.00 Imp. A (EP) as Dihydrate: Ethanedioic Acid
Dihydrate (Oxalic Acid Dihydrate)
OH O
O OH
x 2 H
2
O
(A) 500 mg
Oxazepam
MM 0080.00 Oxazepam [Controlled Substance]
N
H
N
O
Cl
OH
(D) 100 mg
MM 0028.03 Imp. D (EP): (2-Amino-5-chlorophenyl)phenylmethanone
(2-Amino-5-chlorobenzophenone)
Cl
NH2
O
(B) 100 mg
MM 0028.02 Imp. E (EP): 7-Chloro-5-phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one 4-Oxide
(Demoxepam) N
H
N
O
Cl
O
(A) 100 mg
MM 0080.03 6-Chloro-4-phenyl-3,4-dihydroquinazoline-2-carboxylic Acid
Cl
N
NH
O
OH
(A) 100 mg
Oxcarbazepine
MM 0076.17 Oxcarbazepine
N
O NH
2
O
(A) 100 mg
MM 0076.10 10-Hydroxy-10,11-dihydrocarbamazepine
N
O NH
2
HO
(A) 100 mg
Oxeladin Hydrogen Citrate
MM 0547.00 Oxeladin Hydrogen Citrate
O
O
N
O
x
OH
O
OH
O
OH
OH
O
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 157
Code Product Price Unit
MM 0547.02 Imp. A (EP): 2-[2-(Diethylamino)ethoxy]ethanol
HO
O
N
(A) 100 mg
MM 0547.01 Oxeladin N-Oxide
O
O
N
O
O
(B) 10 mg
Oxfendazole
MM 0518.02 Imp. B (EP): Methyl [5-(Phenylsulphonyl)-
1H-benzimidazol-2-yl]carbamate (Fenbendazole Sulphone)
S
N
H
N
NH
O
O
O O
(A) 100 mg
Oxolinic Acid
MM 0898.00 Oxolinic Acid
O
O
N
OH
O O
(A) 250 mg
Oxomemazine
MM 0957.00 Oxomemazine
S
N
N
O O
(A) 100 mg
MM 0958.00 Trimeprazine Tartrate
HO
OH
OH
OH
O
O
N
S
N
x
2
(A) 500 mg
MM 0958.02 Trimeprazine Sulphoxide Hydrochloride
S
N
N
O
x HCl
(A) 100 mg
MM 0958.04 Oxomemazine N-Oxide Hydrochloride (Trimeprazine Sulphone
N-Oxide Hydrochloride)
S
N
N
O
O O
x HCl
(A) 100 mg
Oxprenolol Hydrochloride
MM 0129.00 Oxprenolol Hydrochloride
O
O
OH
H
N
x HCl
(A) 500 mg
New MM 0129.01 1-(2-Hydroxyphenoxy)-3-(isopropylamino)-2-propanol
Hydrochloride
OH
O
OH
H
N
x HCl
(A) 50 mg
Oxybuprocaine Hydrochloride
MM 0543.00 Oxybuprocaine Hydrochloride
O
O
H
2
N
O
N
x HCl
(A) 500 mg
MM 0094.03 Imp. A (EP): 4-Aminobenzoic Acid
OH
O
H2N
(B) 100 mg
MM 0543.02 Imp. B (EP): 4-Amino-3-butoxybenzoic Acid
OH
O
H
2
N
O
(A) 100 mg
MM 0543.03 Imp. C (EP): 4-Amino-3-hydroxybenzoic Acid
OH
O
H
2
N
OH
(A) 100 mg
Pharmaceutical impurities
158 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0543.05 Oxybuprocaine N-Oxide Dihydrochloride
O
O
H
2
N
O
N
x 2 HCl
O
(A) 100 mg
Oxybutynin Hydrochloride
MM 0047.00 Oxybutynin Hydrochloride (A) 250 mg
MM 0047.06 Imp. B (EP): 4-(Diethylamino)but-2-ynyl
2-Hydroxy-2,2-diphenylacetate
(Diphenyl analogue of Oxybutynin)
O
N
O
HO
(A) 100 mg
MM 0047.04 Imp. C (EP) as Hydrochloride: 4-(Ethylmethylamino)but-
2-ynyl (RS)-2-Cyclohexyl-2-hydroxy-2-phenylacetate
Hydrochloride (Methylethyl analogue of Oxybutynin
Hydrochloride)
O
N
O
x HCl
HO
(D) 100 mg
MM 0047.01 Imp. D (EP): (RS)-2-Cyclohexyl-2-hydroxy-2-phenylacetic Acid
(Phenylcyclohexylglycolic Acid)
OH
O
HO
(A) 100 mg
MM 0047.07 Imp. E (EP): 4-(Ethylpropylamino)but-2-ynyl (RS)-
2-Cyclohexyl-2-hydroxy-2-phenylacetate (Ethylpropyl
analogue of Oxybutynin)
O
N
O
HO
(A) 100 mg
MM 0047.02 Methyl (RS)-2-Cyclohexyl-2-hydroxy-2-
phenylacetate (Phenylcyclohexylglycolic
Acid Methyl Ester)
O
O
OH
(A) 100 mg
MM 0047.03 4-Diethylaminobut-2-yn-1-ol N
HO
(A) 100 mg
MM 0047.11 Desethyloxybutynin Hydrochloride
O
N
H
O
HO
x HCl
(D) 100 mg
MM 0047.50 Propargyl (RS)-2-Cyclohexyl-2-hydroxy-2-phenylacetate
(Phenylcyclohexylglycolic Acid Propargyl Ester)
O
O
HO
(B) 10 mg
Oxycodone Hydrochloride
MM 0672.00 Oxycodone Hydrochloride
[Controlled Substance]
O O O
N
HO x HCl
(A) 100 mg
MM 0672.03 Imp. C (EP) as Hydrochloride: 4,5-Epoxy-14-hydroxy-
3-methoxymorphinan-6-one Hydrochloride (Noroxycodone
Hydrochloride)
O O O
H
N
HO
x HCl
(D) 50 mg
MM 0672.05 4,5-Epoxy-3-methoxy-17-methylmorphinan-6,14-diol
Hydrochloride (6-Oxycodol Hydrochloride)
[Controlled Substance]
O OH O
N
HO x HCl
on request
MM 0672.06 Oxycodone N-Oxide
O O O
N
HO
O
(D) 50 mg
Oxymetazoline Hydrochloride
MM 0177.00 Oxymetazoline Hydrochloride
HN
N
HO
x HCl
(A) 250 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 159
Code Product Price Unit
MM 0177.01 Imp. A (EP) as Hydrochloride: N-(2-Aminoethyl)-
2-[4-(1,1-dimethylethyl)-3-hydroxy-
2,6-dimethylphenyl)]acetamide Hydrochloride
HO
H
N
O
NH
2 x HCl
(A) 100 mg
MM 0089.00 Imp. B (EP) as Hydrochloride: Xylometazoline
Hydrochloride
x HCl
N
H
N
(A) 500 mg
MM 0177.07 Imp. C (EP): 2-[4-(1,1-Dimethylethyl)-3-
hydroxy-2,6-dimethylphenyl]acetamide
OH
NH
2
O
(A) 100 mg
MM 0177.04
Imp. D (EP): [4-(1,1-Dimethylethyl)-3-hydroxy-
2,6-dimethylphenyl]acetic Acid
OH
OH
O
(A) 100 mg
MM 0177.05 Imp. E (EP): [4-(1,1-Dimethylethyl)-3-hydroxy-
2,6-dimethylphenyl]acetonitrile
OH
N
(D) 100 mg
Oxyphenbutazone
MM 0933.00 Oxyphenbutazone Monohydrate
N
N
O
O
OH
x H
2
O
(A) 250 mg
Oxytetracycline Hydrochloride
MM 0554.00 Oxytetracycline Hydrochloride
OH O OH O
NH
2
O
OH
OH
N OH
HO
H H x HCl
(A) 500 mg
MM 0452.00 Imp. B (EP) as Hydrochloride: Tetracycline Hydrochloride
OH O OH O
NH
2
O
OH
OH
N
H H x HCl
HO
(A) 500 mg
Pantoprazole Sodium Sesquihydrate
MM 0099.00 Pantoprazole Sodium
N
O
O
S
O
NNa
N
O
F
F
(D) 100 mg
MM 0099.01 Pantoprazole
N
O
O
S
O
NH
N
O
F
F
(D) 100 mg
MM 0099.02 Imp. A (EP): 5-(Difluoromethoxy)-2-[[(3,4-
dimethoxypyridin-2-yl)methyl]sulphonyl]-
1H-benzimidazole (Pantoprazole Sulphone)
S
NH
N
O
F
F O
O
N
O
O
(A) 100 mg
MM 0099.03 Imp. B (EP): 5-(Difluoromethoxy)-2-[[(3,4-
dimethoxypyridin-2-yl)methyl]sulphanyl]-
1H-benzimidazole
N
O
O
S
NH
N
O
F
F
(A) 100 mg
MM 0099.04 Imp. C (EP): 5-(Difluoromethoxy)-1H-benzimidazole-2-thiol
SH
NH
N
O
F
F
(A) 100 mg
MM 0099.11 Mixture of Imp. D and F (EP): 5- and 6-(Di-
fluoromethoxy)-2-[(RS)-[(3,4-dimethoxypyridin-
2-yl)methyl]sulphinyl]-1-methyl-1H-benzimidazole
N
O
O
S
O
N
N
O
F
F
N
O
O
S
O
N
N
O
F
F
+
(D) 100 mg
Pharmaceutical impurities
160 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0099.05 2-Chloromethyl-3,4-dimethoxypyridine Hydrochloride
Cl
N
O O
x HCl
(A) 100 mg
MM 0099.06 Pantoprazole N-Oxide
N
O
O
S
O
NH
N
O
F
F
O
(D) 100 mg
MM 0099.07 Pantoprazole Sulphone N-Oxide
N
O
O
S
NH
N
O
F
F
O
O O
(A) 100 mg
Paracetamol
MM 0042.00 Paracetamol
H
N
O
HO
(A) 500 mg
MM 0042.08 Imp. A (EP): N-(2-Hydroxyphenyl)acetamide
(2-Acetamidophenol)
OH
O
H
N
(B) 100 mg
MM 0042.05 Imp. B (EP): N-(4-Hydroxyphenyl)propanamide
(N-Propionyl-4-aminophenol)
H
N
O
HO
(A) 100 mg
MM 0042.09 Imp. C (EP): N-(3-Chloro-4-hydroxyphenyl)acetamide
(3-Chloro-4-hydroxyacetanilide)
HO
H
N
O
Cl
(A) 100 mg
MM 0042.10 Imp. D (EP): N-Phenylacetamide (Acetanilide)
H
N
O
(B) 100 mg
MM 0042.11 Imp. E (EP): 1-(4-Hydroxyphenyl)ethanone
(4-Hydroxyacetophenone)
HO
O
(B) 100 mg
MM 0042.03 Imp. F (EP): 4-Nitrophenol
NO2
HO
(B) 100 mg
MM 0042.12 Imp. G (EP): 1-(4-Hydroxyphenyl)ethanone Oxime
(4-Hydroxyacetophenone Oxime)
N
HO
HO
(A) 100 mg
MM 0042.04 Imp. H (EP): 4-(Acetylamino)phenyl Acetate
(N,O-Diacetyl-4-aminophenol)
H
N
O
O
O
(A) 100 mg
MM 0042.13 Imp. I (EP): 1-(2-Hydroxyphenyl)ethanone
(2-Hydroxyacetophenone)
O
OH
(B) 100 mg
MM 0042.02 Imp. J (EP): N-(4-Chlorophenyl)acetamide
(4-Chloroacetanilide)
H
N
O
Cl
(B) 100 mg
MM 0042.01 Imp. K (EP): 4-Aminophenol
NH2
HO
(B) 100 mg
MM 0042.07 3-Aminophenol
NH
2
HO
(B) 100 mg
Paroxetine Hydrochloride Anhydrous
MM 1032.02 Imp. B (EP): 1,3-Benzodioxol-5-ol (Sesamol)
O
O
OH
(A) 100 mg
MM 1032.07 Imp. G (EP) as Hydrochloride: 4-(4-Fluorophenyl)-
1-methyl-1,2,3,6-tetrahydropyridine Hydrochloride
x HCl
N
F
(A) 100 mg
MM 1032.12 [(3S,4R)-4-(4-Fluorophenyl)-1-methylpiperidin-3-yl]methanol
HO N
F
(A) 100 mg
Pentetrazol
MM 0692.00 Pentetrazol N
N
N
N
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 161
Code Product Price Unit
Pentoxifylline
MM 0761.00 Pentoxifylline
N
N
N
N
O
O O
(A) 500 mg
MM 0577.00 Imp. A (EP): Theobromine
HN
N
N
N
O
O
(A) 500 mg
MM 0176.03 Imp. B (EP): 3-Methyl-3,7-dihydro-1H-purine-
2,6-dione (3-Methylxanthine) HN
N
N
H
N
O
O
(A) 100 mg
MM 0176.00 Imp. C (EP): Theophylline
N
N
N
H
N
O
O
(A) 500 mg
MM 0494.00 Imp. F (EP): Caffeine
N
N
N
N
O
O
(A) 500 mg
Pentoxyverine Hydrogen Citrate
MM 1268.01 Imp. A (EP): 1-Phenylcyclopentanecarboxylic Acid
OH
O (A) 100 mg
Peppermint Oil
MM 0388.00 (-)-Menthol (Levomenthol)
OH
(A) 500 mg
MM 0163.12 (+)-(R)-Pulegone
O
(A) 100 mg
Perazine Dimaleate
MM 0815.00 Perazine Dimaleate
S
N
N
N O
HO
HO
O
x 2
(A) 100 mg
Perazine Dimalonate
MM 0157.00 Perazine Dimalonate
S
N
N
N
O
OH
O
HO
x 2
on request
MM 0157.01 Perazine Sulphoxide
S
N
N
N
O
(A) 100 mg
MM 0157.02 Phenothiazine
S
H
N
(B) 100 mg
MM 0157.03 1-(3-Chloropropyl)-4-methylpiperazine
N
N
Cl
on request
Perphenazine
MM 0826.00 Perphenazine
S
N
Cl
N
N
OH
(A) 100 mg
Pharmaceutical impurities
162 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0826.01 Imp. A (EP): 2-[4-[3-(2-Chloro-5-oxido-10H-
phenothiazin-10-yl)propyl]piperazin-1-yl]-
ethanol (Perphenazine Sulphoxide)
S
N
Cl
N
N
OH O
(A) 100 mg
New MM 0826.02 Imp. B (EP): 2-[4-[3-(10H-Phenothiazin-10-
yl)propyl]piperazin-1-yl]ethanol
S
N N
N
OH
(A) 50 mg
Phenacetin
MM 0551.00 Phenacetin
O
H
N
O
(A) 100 mg
MM 0042.00 Paracetamol
H
N
O
HO
(A) 500 mg
MM 0042.01 4-Aminophenol
NH2
HO
(B) 100 mg
Phenethyl Alcohol
MM 0953.00 Phenylethyl Alcohol
OH
(A) 500 mg
Pheniramine Maleate
MM 0059.00 Pheniramine Maleate O
OH
O
OH
x
N
N
(A) 100 mg
MM 0059.02 Imp. A (EP): 2-Benzylpyridine N (C) 100 mg
MM 0059.03 Imp. B (EP): 4-Benzylpyridine N (C) 100 mg
MM 0059.09 Imp. C (EP) as Sesquifumarate: (3RS)-N,N-
Dimethyl-3-phenyl-3-(pyridin-4-yl)propan-
1-amine Sesquifumarate
N
N
x
OH
O
HO
O
1,5
(A) 100 mg
MM 0059.08 Imp. D (EP) as Dihydrochloride: N,N,N',N'-Tetramethyl-
3-phenyl-3-(pyridin-2-yl)pentane-1,5-diamine Dihydrochloride
N
N
N
x 2 HCl
(D) 100 mg
MM 0059.01 Pheniramine
N
N (A) 100 mg
MM 0059.05 Pheniramine N-Oxide Dihydrochloride
N
N
O
x 2 HCl
(A) 100 mg
MM 0059.06 Norpheniramine Maleate
H
N
N
OH
O
OH
O
x
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 163
Code Product Price Unit
Phentolamine Mesilate
MM 0171.04 Imp. B (EP) as Hydrochloride: 2-(Chloromethyl)-
4,5-dihydro-1H-imidazole Hydrochloride
Cl
N
H
N
x HCl
100 mg
Phenobarbital
MM 0265.07 Imp. B (EP): (5RS)-5-Ethyl-6-imino-5-
phenyldihydropyrimidine-2,4(1H,3H)-
dione
NH
H
N O
NH
O
(A) 50 mg
MM 0265.08 Imp. C (EP): 5-Methyl-5-phenylpyrimidine-
2,4,6(1H,3H,5H)-trione
NH
H
N O
O
O
(A) 50 mg
MM 0265.01 Phenylethylacetylurea
(2-Phenylbutyrylurea)
N
H
O
NH2
O
(A) 100 mg
MM 0265.02 N-Benzoyl-N'-(2-phenyl)butanoylurea
N
H
O
N
H
O O
(A) 100 mg
MM 0265.03 Barbituric Acid
NH
H
N O
O
O
(C) 100 mg
Phenoxyethanol
MM 0952.00 Phenoxyethanol
O
OH
(A) 500 mg
Phenoxymethylpenicillin Potassium
MM 0026.00 Phenoxymethylpenicillin Potassium
N
S
H
O
O
OK
H
N
O
O
(A) 250 mg
MM 0160.00 Imp. A (EP) as Potassium Salt: Benzylpenicillin
Potassium
N
S
H
O
O
OK
H
N
O
(A) 250 mg
MM 0026.03 Imp. B (EP): Phenoxyacetic Acid
O
OH
O
(B) 100 mg
MM 0026.04 Imp. C (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid
(6-Aminopenicillanic Acid)
N
S
H
O
H
2
N
O
OH
(B) 100 mg
MM 0026.02 Imp. D (EP): (2S,5R,6R)-3,3-Dimethyl-7-oxo-
6-[[2-(4-hydroxyphenoxy)acetyl]amino]-4-thia-
1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
(4-Hydroxyphenoxymethylpenicillin)
N
S
H
O
O
OH
H
N
O
O
HO
(A) 100 mg
MM 0026.01 Imp. E (EP): (4S)-2-[Carboxy[(phenoxyacetyl)
amino]methyl]-5,5-dimethylthiazolidine-4-
carboxylic Acid
(Penicilloic Acids of Phenoxymethylpenicillin)
HN
S
O
OH
H
N
O
O OH
O
(A) 100 mg
MM 0026.05 Imp. F (EP): (2RS,4S)-5,5-Dimethyl-2-
[[(phenoxyacetyl)amino]methyl]thiazolidine-
4-carboxylic Acid
(Penilloic Acids of Phenoxymethylpenicillin)
HN
S
O
OH
NH
O
O
(A) 100 mg
Pharmaceutical impurities
164 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Phenylbutazone
MM 0548.00 Phenylbutazone
N
N
O
O
(A) 500 mg
MM 0548.01 Imp. A (EP): (2RS)-2-[(1,2-Diphenyldiazanyl)-
carbonyl]hexanoic Acid
N
NH
O
OH O
(D) 100 mg
MM 0548.02 Imp. B (EP): 4-Butyl-4-hydroxy-1,2-diphenylpyrazolidine-3,5-dione
N
N
O
O
OH
(A) 50 mg
MM 0548.03 Imp. C (EP): 1,2-Diphenyldiazane
(1,2-Diphenylhydrazine)
H
N
N
H
(A) 100 mg
MM 0548.04 Imp. D (EP): 1,2-Diphenyldiazene
N
N
(C) 100 mg
MM 0548.05 Imp. E (EP) as Dihydrochloride: Biphenyl-4,4'-diamine
Dihydrochloride (Benzidine Dihydrochloride)
H
2
N NH
2
x 2 HCl
(A) 100 mg
Phenylephrine Hydrochloride
MM 0081.00 Phenylephrine Hydrochloride
HO
H
N
OH
x HCl
(A) 500 mg
MM 0081.03 Imp. C (EP) as Hydrochloride: 1-(3-Hydroxyphenyl)-
2-(methylamino)ethanone Hydrochloride (Phenylephrone
Hydrochloride)
HO
H
N
O
x HCl
(D) 100 mg
MM 0081.08 Imp. E (EP) as Hydrochloride: 2-(Benzyl-
methylamino)-1-(3-hydroxyphenyl)ethanone
Hydrochloride (Benzylphenylephrone Hydrochloride)
HO N
O
x HCl
(D) 100 mg
MM 0081.05 1,2,3,4-Tetrahydro-4,6-dihydroxy-2-methylisoquinoline
Hydrochloride
HO
OH
N
x HCl
(A) 100 mg
MM 0081.06 1,2,3,4-Tetrahydro-4,8-dihydroxy-2-methylisoquinoline
Hydrochloride
OH
N
OH
x HCl
(A) 50 mg
Phenylpropanolamine Hydrochloride
MM 0656.00 Phenylpropanolamine Hydrochloride [Drug Precursor]
NH
2
OH
and enatiomere
x HCl
(A) 500 mg
Phenyltoloxamine Citrate
MM 0770.00 Phenyltoloxamine Citrate
x
O
N
OH
O
OH
O
OH
O
OH
(A) 500 mg
Phenytoin
MM 0630.00 Phenytoin
NH
H
N
O
O
(A) 500 mg
MM 0630.01 Imp. A (EP): Diphenylmethanone (Benzophenone)
O
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 165
Code Product Price Unit
MM 0630.02 Imp. B (EP): Diphenylethanedione (Benzil)
O
O (B) 100 mg
MM 0630.04 Imp. C (EP): Amino(diphenyl)acetic Acid (2,2-Diphenylglycine)
O
OH
NH
2
(A) 100 mg
MM 0630.06 Imp. E (EP): (Carbamoylamino)(diphenyl)acetic Acid
HN
O
NH
2
O
OH
(A) 50 mg
MM 0630.08 Imp. F (EP): 5-(4-Methylphenyl)-5-phenylimidazolidine-2,4-dione
NH
H
N
O
O
(A) 100 mg
MM 0630.07 1-Methyl-5,5-diphenylimidazolidine-2,4-dione
NH
N
O
O
(D) 100 mg
MM 0630.03 5-(4-Methylphenyl)hydantoin
NH
H
N
O
O
(A) 100 mg
Phenytoin Sodium
MM 0622.00 Phenytoin Sodium
N
H
N
ONa
O
(A) 500 mg
MM 0630.01 Imp. A (EP): Diphenylmethanone (Benzophenone)
O
(B) 100 mg
MM 0630.02 Imp. B (EP): Diphenylethanedione (Benzil) O
O
(B) 100 mg
MM 0630.04
Imp. C (EP): Amino(diphenyl)acetic
Acid (2,2-Diphenylglycine)
O
OH
NH
2
(A) 100 mg
MM 0630.08 Imp. F (EP): 5-(4-Methylphenyl)-5-
phenylimidazolidine-2,4-dione
NH
H
N
O
O
(A) 100 mg
MM 0630.07 1-Methyl-5,5-diphenylimidazolidine-2,4-dione
NH
N
O
O
(D) 100 mg
MM 0630.03 5-(4-Methylphenyl)hydantoin
NH
H
N
O
O
(A) 100 mg
Pholcodine
MM 0037.00 Imp. A (EP) as Hydrochloride Trihydrate:
Morphine Hydrochloride Trihydrate
[Controlled Substance]
O OH HO
N
x HCl
x 3 H
2
O
(A) 250 mg
MM 0280.00 Imp. A (EP) as Hemisulphate Pentahemihydrate: Morphine
Hemisulphate Pentahemihydrate [Controlled Substance]
O OH HO
N
2
x H
2
SO
4
x 5 H
2
O
(A) 250 mg
Pharmaceutical impurities
166 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0442.00 Imp. B (EP) as Phosphate Hemihydrate:
Codeine Phosphate Hemihydrate
[Controlled Substance]
O OH O
N
x H
3
PO
4
x 1/2 H
2
O
(A) 100 mg
MM 0004.00 Imp. B (EP) as Monohydrate: Codeine Monohydrate
[Controlled Substance]
O OH O
N
x H
2
O
(A) 100 mg
Pilocarpine Hydrochloride
MM 0338.00 Pilocarpine Hydrochloride
x HCl
O
O N
N
(A) 500 mg
MM 0338.01 Imp. A (EP) as Hydrochloride: (3R,4R)-3-Ethyl-4-
[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-
2(3H)-one Hydrochloride (Isopilocarpine
Hydrochloride)
x HCl
O
O N
N
(A) 100 mg
MM 0338.02 Imp. B (EP) as Sodium Salt: (2S,3R)-2-Ethyl-3-
(hydroxymethyl)-4-(1-methyl-1H-imidazol-5-
yl)butanoic Acid Sodium Salt (Pilocarpic Acid
Sodium Salt)
N
N ONa
O
OH
(A) 100 mg
MM 0338.03 Imp. C (EP) as Sodium Salt: (2R,3R)-2-Ethyl-3-
(hydroxymethyl)-4-(1-methyl-1H-imidazol-5-
yl)butanoic Acid Sodium Salt (Isopilocarpic
Acid Sodium Salt)
N
N ONa
O
OH
(A) 100 mg
Pindolol
MM 0082.00 Pindolol
N
H
O N
H
OH
(A) 250 mg
MM 0082.08 Imp. B (EP): 1-[4-[2-Hydroxy-3-[(1-methyl-
ethyl)amino]propoxy]-1H-indol-1-yl]-3-[(1-
methylethyl)amino]propan-2-ol
O
H
N
OH
N
OH
H
N
(D) 100 mg
MM 0082.06 Imp. C (EP): 1,1'-[(1-Methylethyl)imino]bis[3-
(1H-indol-4-yloxy)propan-2-ol]
O N
OH
HN
OH
O
NH
(A) 100 mg
MM 0082.02 Imp. D (EP): (2RS)-3-(1H-Indol-4-yloxy)propane-
1,2-diol
O OH
OH
HN
(A) 100 mg
MM 0082.01 Imp. E (EP): 1H-Indol-4-ol
N
H
OH
(A) 100 mg
Pioglitazone Hydrochloride
New MM 0616.06 Imp. C (Pharmeuropa): (5RS)-5-[4-[2-
(5-Ethylpyridin-2-yl)ethoxy]benzyl]-3-
[2-(5-ethylpyridin-2-yl)ethyl]-1,3-
thiazolidine-2,4-dione
N O
N
S
O
O
N
(A) 50 mg
New MM 0616.08 Imp. E (Pharmeuropa): Ethyl 3-[4-[2-(5-
Ethylpyridin-2-yl)ethoxy]phenyl]propanoate
N O
O
O
(A) 50 mg
New MM 0616.04 5-[4-[2-(5-Ethylpyridin-2-yl)ethoxy]benzyl]-
2-iminothiazolidin-4-one
N O
NH
S
NH
O
(A) 100 mg
Pipazetate Hydrochloride
MM 0486.06 Bis-(2-piperidinoethyl)ether Dihydrochloride (BPEE
Dihydrochloride)
O
N N
x 2 HCl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 167
Code Product Price Unit
MM 0486.02 1,2-Dipiperidinoethane (DPE)
N
N
(A) 100 mg
MM 0486.05 2-(2-Piperidinoethoxy)ethanol Hydrochloride
HO
O
N
x HCl
(A) 100 mg
Pipemidic Acid Trihydrate
MM 0401.00 Pipemidic Acid Trihydrate
N
N N
O
OH
O
N
HN
x 3 H
2
O
(A) 250 mg
Pipenzolate Bromide
MM 0783.00 Pipenzolate Bromide
O
O
OH
N
+
Br
-
(A) 500 mg
MM 0630.01 Diphenylmethanone (Benzophenone)
O
(B) 100 mg
MM 0783.09 Benzilic Acid O
HO
OH
(B) 100 mg
Piperacillin
MM 0295.00 Piperacillin
N
S
OH
O
H
O
H
N
NH
O
O N
N
O
O
(A) 100 mg
Piperacillin Sodium
MM 0296.00 Piperacillin Sodium
N
S
O
NaO
H
O
H
N
NH
O
O N
N
O
O
(A) 100 mg
MM 0253.00 Imp. A (EP) as Sodium Salt: Ampicillin Sodium
N
S
O
NaO
H
O
H
N
NH
2
O
(A) 500 mg
MM 0296.05 Imp. E (EP): 1-Ethylpiperazine-2,3-dione
NH
O
O
N (A) 100 mg
MM 0296.07 Imp. G (EP): (2R)-2-[[(4-Ethyl-2,3-dioxopiperazin-1-yl)-
carbonyl]amino]-2-phenylacetic Acid
OH
NH
O
O N
N
O
O
(A) 100 mg
MM 0026.04 Imp. H (EP): (2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid (6-Aminopenicillanic
Acid)
N
S
H
O
H
2
N
O
OH
(B) 100 mg
Piprinhydrinate
MM 0155.00 Piprinhydrinate
O
N
N
N
N
H
N
Cl
O
O
on request
Pharmaceutical impurities
168 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0155.01 Diphenylpyraline
O
N
(A) 100 mg
MM 0155.02 8-Chlorotheophylline
N
N
N
H
N
Cl
O
O
(B) 100 mg
MM 0490.02 Diphenylmethanol (Benzhydrol)
OH
(B) 100 mg
Piracetam
MM 0083.00 Piracetam
NH
2
O
N
O
(A) 500 mg
MM 0083.05 Imp. A (EP): Pyrrolidin-2-one (2-Pyrrolidone)
NH
O
(B) 100 mg
MM 0083.04 Imp. B (EP): Methyl (2-Oxopyrrolidin-1-yl)acetate
O
O
N
O
(A) 100 mg
MM 0083.02 Imp. C (EP): Ethyl (2-Oxopyrrolidin-1-yl)acetate
O
O
N
O
(A) 100 mg
MM 0083.01 Imp. D (EP): (2-Oxopyrrolidin-1-yl)acetic Acid
OH
O
N
O
(A) 100 mg
MM 0083.03 N-Vinyl-2-pyrrolidone
N
O
(A) 100 mg
MM 0083.06 2-Chloroacetamide
O
NH2
Cl
(C) 100 mg
Piroxicam
MM 0084.00 Piroxicam
N
S
O O
OH O
H
N N
(A) 500 mg
MM 0084.01 Imp. A (EP): Pyridin-2-amine (2-Pyridylamine)
NH2 N
(B) 100 mg
MM 0084.08 Imp. B (EP): 4-Hydroxy-N-(pyridin-2-yl)-2H-1,2-benzothiazine-
3-carboxamide 1,1-Dioxide
NH
S
O O
OH O
H
N N
(A) 100 mg
MM 0084.09 Imp. C (EP): 4-Hydroxy-2-methyl-2H-1,2-benzothiazine-
3-carboxamide1,1-Dioxide
N
S
O O
OH O
NH
2
(A) 100 mg
MM 0084.07 Imp. D (EP): Methyl (1,1-Dioxido-3-oxo-1,2-benzisothiazol-2(3H)-
yl)acetate N
S
O
O
O
O
O
(A) 100 mg
MM 0084.05 Imp. E (EP): Ethyl (1,1-Dioxido-3-oxo-1,2-benzisothiazol-2(3H)-
yl)acetate N
S
O
O
O
O
O
(A) 100 mg
MM 0084.10 Imp. F (EP): 1-Methylethyl (1,1-Dioxido-3-oxo-1,2-benzisothiazol-
2(3H)-yl)acetate N
S
O
O
O
O
O
(A) 100 mg
MM 0084.04 Imp. G (EP): Methyl 4-Hydroxy- 2H-1,2-benzothiazine-3-carboxylate
1,1-Dioxide
NH
S
O O
OH O
O
(A) 100 mg
MM 0084.06 Imp. H (EP): Ethyl 4-Hydroxy- 2H-1,2-benzothiazine-3-carboxylate
1,1-Dioxide
NH
S
O O
OH O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 169
Code Product Price Unit
MM 0084.11 Imp. I (EP): 1-Methylethyl 4-Hydroxy-2H-1,2-benzothiazine-
3-carboxylate 1,1-Dioxide
NH
S
O O
OH O
O
(A) 100 mg
MM 0084.02 Imp. J (EP): Methyl 4-Hydroxy-2-methyl-2H-1,2-benzothiazine-
3-carboxylate 1,1-Dioxide
N
S
O O
OH O
O
(A) 100 mg
MM 0084.03 Imp. K (EP): Ethyl 4-Hydroxy-2-methyl-2H-1,2-benzothiazine-
3-carboxylate 1,1-Dioxide
N
S
O O
OH O
O
(A) 100 mg
MM 0084.12 Imp. L (EP): 1-Methylethyl 4-Hydroxy-2-methyl-2H-
1,2-benzothiazine-3-carboxylate 1,1-Dioxide
N
S
O O
OH O
O
(A) 100 mg
MM 0084.13 N-Methylsaccharin
N
S
O
O
O
(A) 100 mg
MM 0084.15
4-Isopropoxy-2-methyl-N-(2-pyridinyl)-2H-
1,2-benzothiazine-3-carboxamide 1,1-Dioxide
N
S
O O
O O
H
N N
(A) 100 mg
MM 0084.16 N,N'-Di-(2-pyridinyl)oxamide
H
N N
O
N
H
O
N
(C) 50 mg
MM 0084.17 N-(2-Pyridinyl)oxamic Acid Hydrochloride H
N N
O
OH
O
x HCl
on request
MM 0084.20 2-(1,1-Dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)acetamide
N
S
O
O
O
NH2
O
(A) 100 mg
MM 0084.21 N-(6-Methyl-2-pyridyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazine-
3-carboxamide-1,1-Dioxide
N
S
O O
OH O
H
N N
(B) 10 mg
MM 0084.22 4-Methoxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-
3-carboxamide-1,1-Dioxide
N
S
O O
O O
H
N N
(C) 10 mg
MM 0084.23 2-Methyl-N-2-(1-methylpyridinium)-2H-1,2-benzothiazine-
3-carboxamide-4-olate 1,1-Dioxide
N
S
O O
O O
H
N N
(B) 10 mg
MM 0084.24 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-Dioxide
NH
S
O O
OH O
NH2
(B) 10 mg
Potassium Sorbate
MM 0955.00 Potassium Sorbate
O
OK
(A) 500 mg
Povidone
MM 0083.03 Imp. A (EP): 1-Ethenylpyrrolidin-2-one
(1-Vinylpyrrolidin-2-one, N-Vinyl-2-pyrrolidone)
N
O
(A) 100 mg
MM 0083.05 Imp. B (EP): Pyrrolidin-2-one (2-Pyrrolidone)
H
N
O
(B) 100 mg
MM 0537.01 Vinyl Acetate
O
O
(B) 100 mg
Pralidoxime Methyl Sulphate
MM 0689.00 Pralidoxime Methyl Sulphate
N
N
OH
O
S
O
O O
(A) 100 mg
MM 0689.01 2-Carboxy-N-methylpyridinium Iodide
N
OH
O
I
-
(A) 100 mg
Pharmaceutical impurities
170 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0689.02 2-Carbamoyl-N-methylpyridinium Methanesulfonate
N
NH
2
O
S
O O
O
(A) 100 mg
Prasterone
MM 0651.00 Prasterone
O
HO
(A) 500 mg
MM 0651.02 16-Dehydropregnenolone Acetate Oxime
O
N
OH
O
(A) 100 mg
Pravastatin Sodium
MM 0503.00 Pravastatin Sodium
OH
O O
H
O
ONa
OH
OH
(A) 100 mg
MM 0503.04 Imp. D (EP): (1S,3S,7S,8S,8aR)-3-Hydroxy-8-[2-[(2R,4R)-
4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl]-7-methyl-
1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-Methylbutanoate
(Pravastatin Lactone)
OH
O O
H
OH
O
O
(D) 100 mg
Prazepam
MM 0023.02 Imp. A (EP): 7-Chloro-5-phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one (Nordazepam)
[Controlled Substance] N
H
N
O
Cl
(A) 100 mg
MM 0028.03 Imp. C (EP): (2-Amino-5-chlorophenyl)phenyl-
methanone
Cl
NH
2
O
(B) 100 mg
Praziquantel
MM 0615.00 Praziquantel
O
N
N
O
H
(A) 250 mg
MM 0615.02 Imp. B (EP): 2-(Cyclohexylcarbonyl)-
2,3,6,7-tetrahydro-4H-pyrazino[2,1-a]-
isoquinolin-4-one
O
N
N
O
on request
Prazosin Hydrochloride
MM 0085.00 Prazosin Hydrochloride
N
N
N
N
O
O
NH
2
O
O
x HCl
(A) 100 mg
MM 0085.04 Imp. A (EP): 2-Chloro-6,7-dimethoxyquinazoline-4-amine
N
N
O
O
NH2
Cl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 171
Code Product Price Unit
MM 0085.05 Imp. B (EP): 1,4-Bis(furan-2-ylcarbonyl)piperazine
N
N
O
O
O
O
(A) 100 mg
MM 0085.01 Imp. C (EP): 6,7-Dimethoxy-2-(piperazin-1-yl)quinazolin-4-amine
N
NH
N
N
O
O
NH2
(A) 100 mg
MM 0085.02 Imp. D (EP): 1-(Furan-2-ylcarbonyl)piperazine
HN
N
O
O
(A) 100 mg
MM 0085.03 Imp. E (EP): 2,2'-(Piperazin-1,4-diyl)bis-
(6,7-dimethoxyquinazolin-4-amine)
N N
N
O
O
NH
2
N
N
O
O
NH
2
N
(D) 100 mg
MM 0085.06 2,4-Dichloro-6,7-dimethoxyquinazoline
N
N
O
O
Cl
Cl
(A) 100 mg
MM 0085.07 6,7-Dimethoxyquinazoline-2,4(1H,3H)-dione
NH
H
N O
O
O
O
(C) 100 mg
Prednisolone
MM 0193.00 Prednisolone
O
HO
OH
O
OH
(A) 500 mg
MM 0185.00 Imp. A (EP): Hydrocortisone
O
HO
OH
O
OH
(A) 500 mg
MM 0482.00 Imp. B (EP): 17,21-Dihydroxypregna-1,4-
diene-3,11,20-trione (Prednisone)
O
O
OH
O
OH
(A) 250 mg
MM 0194.00 Imp. C (EP): 11 ,17-Dihydroxy-3,20-dioxo-
pregna-1,4-dien-21-yl Acetate (Prednisolone
Acetate)
O
HO
OH
O
O
O
(A) 500 mg
MM 0193.01 (20R)-Hydroxyprednisolone
O
HO
OH
HO
OH
(C) 10 mg
MM 0193.02 (20S)-Hydroxyprednisolone
O
HO
OH
HO
OH
(D) 50 mg
Prednisolone Acetate
MM 0194.00 Prednisolone Acetate
O
HO
O
O
OH
O
(A) 500 mg
MM 0187.00 Imp. A (EP): Hydrocortisone Acetate
O
HO
O
O
OH
O
(A) 500 mg
Pharmaceutical impurities
172 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0193.00 Imp. B (EP): Prednisolone
O
HO
OH
O
OH
(A) 500 mg
MM 0194.04 Prednisolone 17-Acetate
O
HO
O
O
OH
O
(C) 50 mg
MM 0194.07 Prednienic Acid
O
HO
OH
OH
O
(A) 100 mg
Prednisolone Pivalate
MM 0304.00 Prednisolone Pivalate
O
HO
OH
O
O
O
(D) 250 mg
Prednisolone Sodium Phosphate
MM 0305.00 Prednisolone Sodium Phosphate
O
HO
OH
O
O
P
ONa
O ONa
(A) 100 mg
Prednisolone Sodium Sulfobenzoate
MM 0484.01 Sodium 3-Sulfobenzoate
HO
O
S
ONa
O O
(C) 100 mg
Prednisone
MM 0482.00 Prednisone
O
O
OH
OH O
(A) 250 mg
Prednisone Acetate
MM 0196.00 Prednisone Acetate
O
O
O
OH
O
O
(A) 250 mg
Prilocaine Hydrochloride
MM 0563.00 Prilocaine Hydrochloride
H
N
O
N
H
x HCl
(A) 500 mg
New MM 0563.01 Imp. A (EP): (RS)-2-Chloro-N-(2-methylphenyl)-
Propanamide
H
N
O
Cl
(A) 100 mg
MM 0563.02 Imp. B (EP): 2-Methylbenzenamine
(o-Toluidine)
NH
2
(A) 100 mg
New MM 0563.03 Imp. C (EP) as Hydrochloride: (RS)-2-Ethylamino-
N-(2-methylphenyl)propanamide Hydrochloride
H
N
O
N
H
x HCl
(A) 50 mg
New MM 0563.04 Imp. D (EP) as Hydrochloride: (RS)-N-(3-Methyl-
phenyl)-2-(propylamino)propanamide Hydrochloride
H
N
O
N
H x HCl
(A) 50 mg
New MM 0563.05 Imp. E (EP) as Hydrochloride: (RS)-N-(4-Methylphenyl)-
2-(propylamino)propanamide Hydrochloride
H
N
O
N
H
x HCl
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 173
Code Product Price Unit
Primidone
MM 1030.01 Imp. A (EP) as Hydrate: 2-Ethyl-2-phenylpropane-
diamide Hydrate (Ethylphenylmalonamide Hydrate) NH
2
NH
2
O
O
x H
2
O
(A) 100 mg
MM 1030.03 Imp. C (EP): (2RS)-2-Phenylbutanamide
NH
2
O
(A) 100 mg
MM 1030.04
Imp. D (EP): (2RS)-2-Cyano-2-phenylbutanamide
NH
2
O
N
(A) 50 mg
MM 1030.05 Imp. E (EP): (2RS)-2-Phenylbutanoic Acid
OH
O
(A) 100 mg
Probenecid
MM 0657.00 Probenecid
OH
O
S
N
O O
(A) 500 mg
Procainamide Hydrochloride
MM 0550.00 Procainamide Hydrochloride
H2N
N
H
O
N
x HCl
(A) 500 mg
MM 0550.02 Procainamide N-Oxide Dihydrochloride
H
2
N
N
H
O
N
x 2 HCl
O
(A) 100 mg
Procaine Hydrochloride
MM 0596.00 Procaine Hydrochloride
O
N
O
H2N
x HCl
(A) 500 mg
MM 0094.03 4-Aminobenzoic Acid
OH
O
H
2
N
(B) 100 mg
Progesterone
MM 0222.00 Progesterone
O
O
(A) 500 mg
MM 0222.03 Imp. C (EP): (20R)-20-Hydroxypregn-4-en-3-one
O
HO
(A) 100 mg
MM 0222.01 Imp. E (EP): (20R)-3-Oxopregn-4-en-20-yl Acetate
O
O
O
(D) 100 mg
MM 0222.08 11-Hydroxyprogesterone
O
O
HO
(A) 100 mg
MM 0222.12 11-Ketoprogesterone
O
O
O
(A) 100 mg
Pharmaceutical impurities
174 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0222.14 Pregnanediol (5-Pregnane-3,20(S)-diol)
HO
HO
H
(A) 100 mg
MM 0222.15 Pregnanetriol (5-Pregnane-3,17,20(S)-triol)
HO
HO
H
OH
on request
Proguanil Hydrochloride
MM 0162.05 Imp. B (EP): 4-Chloroaniline
Cl
NH
2
(B) 100 mg
Prolintane Hydrochloride
MM 0663.00 Prolintane Hydrochloride
N x HCl
(A) 100 mg
Promazine Hydrochloride
MM 0290.00 Promazine Hydrochloride
S
N
N
x HCl
(A) 500 mg
MM 0290.01 Imp. A (EP): 3-(10H-Phenothiazin-10-yl)-N,N-dimethylpropan-1-amine
S-Oxide (Promazine Sulphoxide)
S
N
N
O
(A) 100 mg
MM 0290.02 N,N-Dimethyl-3-chloropropylamine Hydrochloride
N Cl
x HCl
(B) 100 mg
MM 0157.02 Phenothiazine
S
H
N
(B) 100 mg
Promethazine Hydrochloride
MM 0412.00 Promethazine Hydrochloride
S
N
N
x HCl
(A) 500 mg
MM 0157.02 Imp. A (EP): Phenothiazine
S
NH
(B) 100 mg
MM 0412.02 Imp. B (EP) as Hydrochloride: (2RS)-N,N-
Dimethyl-2-(10H-phenothiazin-10-yl)propan-
1-amine Hydrochloride (Isopromethazine
Hydrochloride)
S
N
N
x HCl
(A) 100 mg
New MM 0412.03 Imp. C (EP) as Hydrochloride: (2RS)-N-Methyl-
1-(10H-phenothiazin-10-yl)propan-2-amine
Hydrochloride (Norpromethazine Hydrochloride)
S
N
H
N
x HCl
(A) 50 mg
MM 0412.04 Imp. D (EP): (2RS)-N,N-Dimethyl-1-(10H-phenothiazin-10-yl)propan-
2-amine S-Oxide (Promethazine Sulphoxide)
S
N
O
N
(A) 100 mg
MM 0412.05 Promethazine Sulphoxide N-Oxide Hydrochloride
S
N
N
x HCl
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 175
Code Product Price Unit
MM 0412.06 (2RS)-N-Methyl-2-(10H-phenothiazin-10-yl)propan-1-amine
Hydrochloride (Norisopromethazine Hydrochloride)
S
N
H
N
x HCl
(A) 100 mg
Propafenone Hydrochloride
MM 0405.00 Propafenone Hydrochloride O O
OH
N
H
x HCl
(A) 500 mg
MM 0405.02 Imp. A (EP): 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one
OH O
(A) 100 mg
MM 0405.03 Imp. B (EP) as Hydrochloride: (2E)-1-[2-[(2RS)-
2-Hydroxy-3-(propylamino)propoxy]phenyl]-
3-phenylprop-2-en-1-one Hydrochloride
O
OH
N
H
O
x HCl
(A) 50 mg
MM 0405.04 Imp. C (EP): 1-[2-[[(2RS)-Oxiranyl]methoxy]phenyl]-
3-phenylpropan-1-one
O
O
O (A) 50 mg
New MM 0405.05 Imp. D (EP): 1-[2-[(2RS)-2,3-Dihydroxy-propoxy]phenyl]-
3-phenylpropan-1-one
O
OH
OH O (A) 50 mg
MM 0405.06 Imp. E (EP): 1-[2-[(2RS)-3-Chloro-2-hydroxy-
propoxy]phenyl]-3-phenylpropan-1-one
O
OH
Cl O (A) 50 mg
MM 0405.07 Imp. F (EP): 1,1'-[2-Hydroxypropane-
1,3-diylbis(oxy-2,1-phenylene)]bis(3-
phenylpropan-1-one)
O O
OH
O O (A) 50 mg
MM 0405.09 Imp. H (EP): (2RS)-2-Phenyl-2,3-dihydro-4H-1-benzopyran-4-one
O
O
(A) 100 mg
MM 0405.01 5-Hydroxypropafenone Hydrochloride
OH
O O
OH
N
H
x HCl
(A) 100 mg
Propentofylline
MM 0875.01 3-Methyl-7-propylxanthine
HN
N
N
N
O
O
(A) 100 mg
MM 0875.02 1-(3-Hydroxypropyl)-3-methyl-7-propylxanthine
N
N
N
N
O
O
HO
(A) 100 mg
MM 0875.03 1,7-Bis-(5-oxohexyl)-3-methylxanthine
N
N
N
N
O
O
O
O
(A) 100 mg
Propofol
MM 0461.00 Propofol
OH
(A) 250 mg
MM 0461.03 Imp. A (EP): 2,4-Bis(1-methylethyl)phenol
OH
(A) 100 mg
Pharmaceutical impurities
176 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0461.04 Imp. C (EP): 2-(1-Methylethyl)phenol
OH
(C) 100 mg
MM 0461.02 Imp. E (EP): 3,3',5,5'-Tetrakis(1-
Methylethyl)bisphenyl-4,4'-diol
OH HO
(A) 100 mg
MM 0461.05 Imp. F (EP): 3-(1-Methylethyl)phenol
HO
(C) 100 mg
MM 0461.08 Imp. G (EP): 2-(1-Methylethoxy)-1,3-bis(1-methylethyl)benzene
O
(A) 100 mg
MM 0461.06 Imp. H (EP): 4-(1-Methylethyl)phenol
HO
(C) 100 mg
MM 0461.07 Imp. I (EP): Oxydibenzene
O
(B) 100 mg
MM 0461.13 Imp. J (EP): 2,6-Bis(1-methylethyl)benzene-1,4-dione
O
O
(A) 50 mg
MM 0461.11 Imp. K (EP): 1-(1-Methylethoxy)-2-(1-methylethyl)benzene
O
(A) 100 mg
MM 0461.15 Imp. M (Pharmeuropa): 2,6-Diisopropylbenzoic Acid
O OH
(A) 50 mg
Propranolol Hydrochloride
MM 0043.00 Propranolol Hydrochloride
O
OH
H
N
x HCl
(A) 500 mg
MM 0043.01 Imp. A (EP): (2RS)-3-(Naphthalen-1-
yloxy)propane-1,2-diol (Diol Derivative)
O
OH
OH
(A) 100 mg
MM 0043.03 Imp. B (EP) as Hydrochloride: 1,1'-[(1-
Methylethyl)imino]bis[3-(naphthalen-1-
yloxy)propan-2-ol] Hydrochloride
(Tertiary Amine Derivative Hydrochloride)
O
OH
O
OH
N
x HCl
(A) 100 mg
New MM 0043.02 Imp. C (EP): 1,3-Bis(naphthalen-1-yloxy)-
propan-2-ol (Bis-ether Derivative)
O
OH
O
(A) 50 mg
MM 0043.04 1-Naphthol
OH
(B) 100 mg
MM 0043.05 1-(1-Naphtyloxy)-2,3-epoxypropane O
O
(A) 100 mg
Propyl Gallate
MM 1037.00 Propyl Gallate
HO
HO
OH
O
O
(A) 500 mg
Propyl Parahydroxybenzoate
MM 0432.00 Propyl Parahydroxybenzoate
HO
O
O
(A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 177
Code Product Price Unit
MM 0045.01 Imp. A (EP): 4-Hydroxybenzoic Acid
HO
OH
O
(B) 100 mg
MM 0431.00 Imp. B (EP): Methyl 4-Hydroxybenzoate
(Methyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0498.00 Imp. C (EP): Ethyl 4-Hydroxybenzoate (Ethyl Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0496.00 Imp. D (EP): Butyl 4-Hydroxybenzoate (Butyl
Parahydroxybenzoate)
HO
O
O
(A) 500 mg
MM 0432.01 Sodium Propyl Parahydroxybenzoate
NaO
O
O
(B) 100 mg
Propylhexidrine Hydrochloride
MM 0664.00 Propylhexidrine Hydrochloride
NH
x HCl
(A) 100 mg
Propyphenazone
MM 0036.00 Propyphenazone
N
N
O
(A) 500 mg
MM 0036.05 Imp. A (EP): Phenazone
N
N
O
(A) 100 mg
MM 0036.04 Imp. C (EP): 4-[(1RS)-1,3-Dimethylbutyl]-
1,5-dimethyl-2-phenyl-1,2-dihydro-3H-
pyrazol-3-one
N
N
O
(A) 50 mg
Protionamide
New MM 0844.01 Protionamide Sulphoxide
N
NH
2
S
O
(A) 50 mg
Proxymetacaine Hydrochloride
MM 0404.00 Proxymetacaine Hydrochloride
H
2
N
O
O
O
N
x HCl
(A) 500 mg
MM 0404.01 3-Amino-4-propoxybenzoic Acid Hydrochloride
H
2
N
O
OH
O
x HCl
(A) 100 mg
MM 0404.02 Proxymetacaine N-Oxide Dihydrochloride
H
2
N
O
O
O
N
x 2 HCl
O
(C) 50 mg
Proxyphylline
MM 1284.00 Proxyphylline
N
N
N
N
O
O
OH
(A) 250 mg
Pseudoephedrine Hydrochloride
MM 2115.01 Methcathinone Hydrochloride
(2-Methylamino-1-phenylpropan-1-one Hydrochloride)
[Controlled Substance]
NH
O
x HCl
(A) 100 mg
MM 2115.04 (1S,2S)-N-Acetylpseudoephedrine
N
OH
O
(A) 100 mg
Pharmaceutical impurities
178 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 2115.05 (1S,2S)-N,O-Diacetylpseudoephedrine
N
O
O
O
(A) 100 mg
New MM 0652.00 Imp. A (EP) as Hydrochloride: Ephedrine
Hydrochloride [Drug Precursor]
H
N
OH
x HCl
(A) 500 mg
New MM 1147.00 Imp. A (EP) as Sulphate: Ephedrine Sulphate [Drug
Precursor]
H
N
OH
2
x H
2
SO
4
(A) 250 mg
New MM 2115.03 (1S,2S)-O-Acetylpseudoephedrine Hydrochloride
NH
O
O
x HCl
(A) 50 mg
Pyrazinamide
MM 0385.00 Pyrazinamide
N
N
NH
2
O
on request
MM 0385.01 Imp. A (EP): Pyrazine-2-carboxylic Acid
N
N
OH
O
(A) 100 mg
Pyridostigmine Bromide
New MM 0429.00 Pyridostigmine Bromide
Br
-
N
+
O N
O (A) 100 mg
MM 0429.02 Imp. B (EP) as Iodide: 3-Hydroxy-1-methyl-
pyridinium Iodide
I
-
N
+
HO
(A) 100 mg
Pyridoxine Hydrochloride
MM 0021.00 Pyridoxine Hydrochloride
N
HO
OH
OH
x HCl
(A) 500 mg
MM 0021.01 Imp. A (EP) as Hydrochloride: 6-Methyl-
1,3-dihydrofuro[3,4-c]pyridin-7-ol
Hydrochloride
N
HO
O
x HCl
(D) 100 mg
MM 0021.02 Imp. B (EP) as Hydrochloride: 5-(Hydroxymethyl)-
2,4-dimethylpyridin-3-ol Hydrochloride
N
HO
OH
x HCl
(A) 100 mg
MM 0021.03 Pyridoxine Diacetate
N
HO
O
O
O
O
(A) 100 mg
MM 0021.05 Pyridoxal Hydrochloride
N
HO
O
OH
x HCl
(A) 100 mg
MM 0021.06 Pyridoxamine Dihydrochloride
N
HO
NH
2
OH
x 2 HCl
(A) 100 mg
MM 0021.07 4-Pyridoxic Acid
N
HO
OH
OH
O
(D) 50 mg
Quetiapine Fumarate
MM 1130.01 Imp. B (Pharmeuropa) as Dihydrochloride:
11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine
Dihydrochloride
N
NH
N
S
x 2 HCl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 179
Code Product Price Unit
MM 1130.09 Imp. G (Pharmeuropa): Dibenzo[b,f][1,4]thiazepin-
11(10H)-one
O
H
N
S
(A) 100 mg
New MM 1130.10 Imp. H (Pharmeuropa): 2-[2-[4-(Dibenzo[b,f][1,4]-
thiazepin-11-yl)-1-oxidopiperazin-1-yl]ethoxy]-
ethanol (Quetiapine N-Oxide)
N
N
O
OH
N
S
O
(A) 50 mg
Quinapril Hydrochloride
MM 0011.01 4-Amino-6-chlorobenzene-1,3-disulphonamide (Salamide)
S
Cl NH
2
H
2
N
S
NH2
O O O O
(B) 100 mg
MM 0010.05 Imp. B (Pharmeuropa): (2S)-2-[[(1S)-1-
(Ethoxycarbonyl)-3-phenylpropyl]amino]-
propanoic Acid
H
N
O O
OH
O (A) 100 mg
Quinine Dihydrochloride
MM 0458.00 Quinine Dihydrochloride
N
O
HO
N
H
H
x 2 HCl
(A) 500 mg
Quinuclidinyl Benzilate
MM 0783.09 Benzilic Acid
HO
O
OH
(B) 100 mg
MM 0825.02 3-Quinuclidinol
N
OH
(A) 100 mg
Rabeprazole Sodium
MM 0618.01 Rabeprazole Sodium
N
O
S
O
Na
N
N
O
on request
MM 0618.00 Rabeprazole
N
O
S
O
H
N
N
O
on request
MM 0618.02 2-[[[4-(3-Methoxypropoxy)-3-methyl-
2-pyridinyl]methyl]thio]-1H-benzimidazole
N
O
S
H
N
N
O
(A) 100 mg
MM 0618.03 Rabeprazole Sulphone
N
O
S
H
N
N
O
O
O
(A) 100 mg
MM 0618.04 Rabeprazole N-Oxide
N
O
S
O
H
N
N
O
O
(D) 100 mg
MM 0618.05 Rabeprazole Sulphone N-Oxide
N
O
S
H
N
N
O
O
O
O
(A) 100 mg
Pharmaceutical impurities
180 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0618.07 2-Chloromethyl-3-methyl-4-(3-methoxypropoxy)pyridine
Hydrochloride
N
O
Cl
O
x HCl
(A) 100 mg
Raloxifene Hydrochloride
MM 0738.00 Raloxifene Hydrochloride
S
HO
OH
O
O
N
x HCl
(A) 100 mg
New MM 0738.01 Imp. C (EP): [6-Hydroxy-2-(4-hydroxyphenyl)-1-
benzothiophen-3-yl][4-[2-(piperidin-1-yl)ethoxy]-
phenyl]methanone N-Oxide (Raloxifene N-Oxide)
O
N
O
S
HO
OH
O
(A) 50 mg
Ramipril
MM 0448.05 Imp. D (EP): Ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-
Methyl-1,4-dioxodecahydro-2H-cyclopenta[4,5]-
pyrrolo[1,2-a]pyrazin-2-yl]-4-phenylbutanoate
(Ramipril Diketopiperazine)
N
O O
O
O
N
H
H
H
(A) 100 mg
MM 0010.05 Imp. F (EP): (2S)-2-[[(1S)-1-(Ethoxycarbonyl)-
3-phenylpropyl]amino]propanoic Acid
H
N
OH
O
O O
(A) 100 mg
MM 0291.04 Imp. G (EP): Methylbenzene (Toluene) (C) 100 mg
MM 0448.04 Imp. M (EP): (2R,3R)-2,3-Bis(benzoyloxy)-
butanedioic Acid (Dibenzoyltartric Acid)
O
O
O OH
O
O HO
O
(A) 100 mg
New MM 0448.11 (2S,3aS,6aS)-Octahydro-cyclopenta[b]pyrrole-2-carboxylic
Acid Phenylmethyl Ester Hydrochloride
HN
H H
O O
x HCl
(A) 100 mg
Ranitidine Hydrochloride
MM 0086.00 Ranitidine Hydrochloride O
S N
H
N
H
N
x HCl
NO
2
(A) 500 mg
MM 0086.02 Imp. A (EP): N,N'-
Bis[2-[[[5-[(dimethylamino)methyl]furan-2-yl]-
methyl]sulphanyl]ethyl]-2-nitroethene-
1,1-diamine
O
S N
H
N
NO2
H
N O
S N
(A) 100 mg
MM 0086.01 Imp. B (EP): 2-[[[5-[(Dimethylamino)methyl]-
furan-2-yl]methyl]sulphanyl]ethanamine
O
S N
NH
2 (A) 100 mg
MM 0086.03 Imp. C (EP): N-[2-[[[5-[(Dimethylamino)-
methyl]furan-2-yl]methyl]sulphinyl]ethyl]-N'-
methyl-2-nitroethene-1,1-diamine
(Ranitidine Sulphoxide)
O
S N
H
N
H
N
O
NO
2
(A) 100 mg
MM 0086.06 Imp. D (EP) as Sodium Salt: N-[2-[[[5-
[(Dimethylamino)methyl]furan-2-yl]-
methyl]sulphanyl]ethyl]-2-nitroacetamide
Sodium Salt
O
S N
H
N ONa
NO
2
(A) 100 mg
MM 0086.05 Imp. E (EP): N-[2-[[[5-[(Dimethyloxidoamino)-
methyl]furan-2-yl]methyl]sulphanyl]ethyl]-
N'-methyl-2-nitroethene-1,1-diamine
(Ranitidine N-Oxide)
O
S N
H
N
H
N
O
NO
2
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 181
Code Product Price Unit
MM 0086.17 Imp. F (EP) as Hydrochloride: [5-[(Dimethyl-
amino)methyl]furan-2-yl]methanol Hydrochloride
O
OH N x HCl
(A) 100 mg
MM 0086.07 Imp. G (EP): 3-(Methylamino)-5,6-dihydro-2H-1,4-thiazin-2-one Oxime
N
S
N
H
N
OH
(A) 100 mg
MM 0086.08 Imp. H (EP): N-Methyl-2-nitroacetamide
N
H
O
NO
2
(A) 100 mg
MM 0086.10 Imp. I (EP): 2,2'-Methylenebis[N-[2-[[[5-[(dimethyl-
amino)methyl]furan-2-yl]methyl]sulphanyl]ethyl]-N'-
methyl-2-nitroethene-1,1-diamine]
O
S N
N
H
N
H
O
S N
H
N
H
N
NO
2
NO
2
(A) 100 mg
MM 0220.09 Imp. K (EP): N-Methyl-1-methylthio-2-
nitroethenamine ((EZ)-N-Methyl-1-(methyl-
sulphanyl)-2-nitroethen-1-amine) N
H
S
NO
2
(A) 100 mg
Ranolazine Dihydrochloride
New MM 1320.01 2-[(2-Methoxyphenoxy)methyl]oxirane
O
O
O
(A) 100 mg
Reagents
MM 0334.01 Diethylhexylphthalate (Bis-(2-ethylhexyl) Phthalate)
O
O
O
O
(C) 500 mg
MM 0334.02 3-(N-Morpholino)propane Sulfonic Acid (MOPS)
O
N S
OH
O O
(C) 500 mg
MM 0334.03 3-(N-Morpholino)ethane Sulfonic Acid (MES)
O
N
S
OH
O O
(C) 500 mg
MM 0334.08 Salicylaldehyde Azine
N N
HO
OH
(A) 100 mg
Repaglinide
New MM 0944.00 Repaglinide
N
H
N O OH
O
O
(A) 100 mg
New MM 0944.02 Imp. B (EP): [3-Ethoxy-4-(ethoxycarbonyl)-
phenyl]acetic Acid
HO
O O
O
O
(A) 100 mg
New MM 0944.01 Imp. C (EP) as N-Acetyl-L-glutamate: (1S)-
3-Methyl-1-[2-(piperidin-1-yl)phenyl]butan-
1-amine N-Acetyl-L-glutamate
NH
2
N
O
HO OH
O
HN
O
x
(A) 100 mg
Ribavirin
MM 0542.00 Ribavirin
O
OH OH
HO
N
N
N
H
2
N
O
(A) 250 mg
MM 0542.01 Imp. A (EP): 1--D-Ribofuranosyl-1H-1,2,4-
triazole-3-carboxylic Acid
O
OH OH
HO
N
N
N
HO
O
(D) 100 mg
MM 0542.03 Imp. C (EP): 1H-1,2,4-Triazole-3-carboxylic Acid
N
N
H
N HO
O
(D) 100 mg
Pharmaceutical impurities
182 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0542.04 Imp. D (EP): 1H-1,2,4-Triazole-3-carboxamide
N
N
H
N H2N
O
(D) 100 mg
MM 0542.05 1-(5-O-Benzoyl- -D-ribofuranosyl)-1H-1,2,4-
triazole-3-carboxamide (5'-O-Benzoylribavirin)
O
OH OH
O
N
N
N
O
H
2
N
O
(D) 100 mg
MM 0542.06 Imp. F (EP): 1-(5-O-Acetyl--D-ribofuranosyl)-1H-1,2,4-triazole-
3-carboxamide (5'-O-Acetylribavirin)
O
OH OH
O
N
N
N
O
H
2
N
O
(D) 100 mg
Riboflavin
MM 0030.00 Riboflavin
N
N
NH
N
O
O
HO OH
OH
OH
(A) 500 mg
Rifampicin
MM 0514.02 3-Formylrifamycin Isonicotinylhydrazone
O
OH
OH
O
O
HN
O
O
OH
O
O
N
H
N
OH
OH
O
N
on request
Risedronate Sodium 2.5 Hydrate
New MM 0777.00 Risedronate Sodium 2.5 Hydrate
N
P
O
P
O
HO
OH
x 2,5 H
2
O
OH
OH
ONa
(A) 100 mg
Risperidone
MM 0491.00 Risperidone
N
N
O
N
N O
F
(A) 100 mg
MM 0491.01 Imp. A (EP): 3-[2-[4-[(E)-(2,4-Difluorophenyl)-
(hydroxyimino)methyl]piperidin-1-yl]ethyl]-2-
methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]-
pyrimidin-4-one
N
N
O
N
N
F
F
HO
(D) 100 mg
MM 0491.02 Imp. B (EP): 3-[2-[4-[(Z)-(2,4-Difluorophenyl)-
(hydroxyimino)methyl]piperidin-1-yl]ethyl]-2-
methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]-
pyrimidin-4-one
N
N
O
N
N
F
F
OH
(A) 100 mg
MM 0491.03 Imp. C (EP): (9RS)-3-[2-[4-(6-Fluoro-
1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-
2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-
4-one (9-Hydroxyrisperidone)
N
N
O
N
N O
F
OH
(D) 100 mg
MM 0491.04 Imp. D (EP): 3-[2-[4-(5-Fluoro-1,2-benzisoxazol-
3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-
tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
N
N
O
N
N O
F (D) 100 mg
MM 0491.05 Imp. E (EP): (6RS)-3-[2-[4-(6-Fluoro-1,2-
benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2,6-
dimethyl-6,7,8,9-tetrahydro-4H-pyrido-
[1,2-a]pyrimidin-4-one
N
N
O
N
N O
F
(D) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 183
Code Product Price Unit
MM 0491.08 Imp. F (EP): 2-[2-Methyl-4-oxo-6,7,8,9-tetrahydro-
4H-pyrido[1,2-a]pyrimidin-3-yl]ethyl 4-(6-Fluoro-
1,2-benzisoxazol-3-yl)piperidin-1-carboxylate
O N
N O
F
O
N
N
O
(A) 100 mg
MM 0491.10 Imp. H (EP): 3-[2-[4-(2,4-Difluorobenzoyl)piperidin-
1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido-
[1,2-a]pyrimidin-4-one
N
N
O
N
O
F
F
(A) 100 mg
MM 0491.09 3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-
1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido-
[1,2-a]pyrimidin-4-one
N
N
O
N
O
F
OH
(A) 100 mg
MM 0491.13 Imp. L (EP) as Hydrochloride: 3-(2-Chloroethyl)-
2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]-
pyrimidin-4-one Hydrochloride (Risperidone
Piperidopyrimidinone Intermediate Hydrochloride)
N
N
O
Cl
x HCl
(A) 100 mg
New MM 0491.18 3-[2-[4-[2-Fluoro-4-[4-(6-fluoro-
1,2-benzisoxazol-3-yl)piperidin-
1-yl]benzoyl]piperidin-1-yl]ethyl]-2-methyl-
6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-
pyrimidin-4-one
N
N
O
N
O
N
F
N
O
F
(D) 50 mg
Ritodrine Hydrochloride
MM 0063.06 Imp. A (BP): Tyramine
HO
NH
2
(B) 100 mg
Ritonavir
New MM 1034.00 Ritonavir
O
N N
H
N
S
H
N
O
N
H
O
O
N
S
OH
on request
Ronidazole
MM 1026.01 (1-Methyl-5-nitroimidazol-2-yl)methanol
N
N
O
2
N
OH
(A) 100 mg
Rosiglitazone Maleate
MM 0522.01 Rosiglitazone Maleate N
N
O
NH
S
O
O
O
OH
OH
O
x
(D) 100 mg
Rosuvastatin Calcium
New MM 0936.01 4-(4-Fluorophenyl)-6-isopropyl-
2-[methyl(methylsulfonyl)amino]pyrimidine-5-carbaldehyde
N N
N
S
O O
F O
(A) 100 mg
New MM 0936.02 4-(4-Fluorophenyl)-6-isopropyl-
2-[methyl(methylsulfonyl)amino]pyrimidine-5-methanol
N N
N
S
O O
F HO
(A) 100 mg
Pharmaceutical impurities
184 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Roxatidine Acetate Hydrochloride
New MM 0597.03 N-[3-[3-[(Piperidin-1-yl)methyl]phenoxy]propan-
1-yl]phthalimide Hydrochloride
O N
N
O
O
x HCl
(A) 50 mg
Rutoside Trihydrate
MM 0109.03 Imp. C (EP) as Dihydrate: 2-(3,4-Dihydroxyphenyl)-
3,5,7-trihydroxy-4H-1-benzopyran-4-one Dihydrate
(Quercetin Dihydrate)
O
HO OH
O
OH
OH
HO x 2 H
2
O
(A) 100 mg
Saccharin Sodium
MM 0818.00 Saccharin Sodium
NNa
S
O
O
O
(A) 500 mg
Salbutamol Sulphate
MM 0381.00 Salbutamol Sulphate
x H
2
SO
4
HO
OH
OH
H
N
2
(A) 500 mg
MM 0381.02 Imp. B (EP): (1RS)-2-[(1,1-Dimethylethyl)-
amino]-1-(4-hydroxyphenyl)ethanol
HO
OH
H
N
(A) 50 mg
MM 0381.03 Imp. C (EP): (1RS)-2-[(1,1-Dimethylethyl)amino]-1-(4-hydroxy-
3-methylphenyl)ethanol
HO
OH
H
N
(A) 50 mg
MM 0381.05 Imp. E (EP): (1RS)-2-[Benzyl(1,1-dimethyl-
ethyl)amino]-1-[4-hydroxy-3-(hydroxymethyl)-
phenyl]ethanol
HO
OH
OH
N
(A) 100 mg
MM 0381.07 Imp. G (EP) as Hydrochloride:
2-[Benzyl(1,1-dimethylethyl)amino]-1-[4-hydroxy-
3-(hydroxymethyl)phenyl]ethanone Hydrochloride
HO
OH
O
N
x HCl
(D) 50 mg
MM 0381.08 4-[2-[(1,1-Dimethylethyl)amino]ethyl]-2-
methylphenol
HO
H
N
(A) 100 mg
MM 0381.10 Imp. J (EP) as Hydrochloride: 2-[(1,1-Dimethyl-
ethyl)amino]-1-[4-hydroxy-3-(hydroxymethyl)-
phenyl]ethanone Hydrochloride (Salbutamone
Hydrochloride)
HO
OH
O
H
N
x HCl
(D) 50 mg
MM 0381.17 4-[(1RS)-2-(tert-Butylamino)-1-hydroxyethyl]-2-
ethylphenol Hydrobromide
HO
OH
H
N
x HBr
(A) 50 mg
Salicylic Acid
MM 0045.00 Salicylic Acid
OH
OH
O
(A) 500 mg
MM 0045.01 Imp. A (EP): 4-Hydroxybenzoic Acid
HO
O
OH
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 185
Code Product Price Unit
MM 0045.02 Imp. B (EP): 4-Hydroxyisophthalic Acid
HO
OH
O
OH
O
(A) 100 mg
MM 0045.11 Imp. C (EP): Phenol
OH
(B) 100 mg
MM 0045.12 Imidazole Salicylate
OH
O
O
N
H
H
N
(A) 100 mg
MM 0045.13 Choline Salicylate
OH
O
O
N
OH
on request
MM 0045.14 N,N-Diethylsalicylamide
OH
N
O
(A) 100 mg
Salmeterol Xinafoate
New MM 0536.03 Imp. B (EP): (1RS)-1-[4-Hydroxy-3-(hydroxy-
methyl)phenyl]-2-[[6-(2-phenylethoxy)hexyl]-
amino]ethanol
HO
OH
OH
H
N
O
(A) 100 mg
New MM 0536.07 Imp. F (EP): (1RS)-1-(4-Hydroxy-3-methylphenyl)-
2-[[6-(4-phenylbutoxy)hexyl]amino]ethanol
HO
OH
H
N
O
(A) 50 mg
Secnidazole
MM 0119.00 Secnidazole
N
N
O2N
OH
(A) 100 mg
MM 0012.02 2-Methyl-4-nitroimidazole
NH
N
O
2
N
(B) 100 mg
Selegiline Hydrochloride
MM 0656.00 Imp. C (EP) as Hydrochloride: (1RS, 2SR)-2-
Amino-1-phenylpropan-1-ol Hydrochloride
(Phenylpropanolamine Hydrochloride)
NH
2
OH
and enatiomer
x HCl
(A) 500 mg
Sertraline Hydrochloride
MM 0317.01 Sertraline Hydrochloride HN
Cl
Cl
x HCl
(A) 100 mg
MM 0317.00 Sertraline HN
Cl
Cl
(A) 100 mg
MM 0317.05 Imp. B (EP) as Hydrochloride: (1RS,4RS)-N-
Methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-
1-amine Hydrochloride
HN
and enantiomer
x HCl
(A) 100 mg
Pharmaceutical impurities
186 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0317.06 Imp. C (EP) as Hydrochloride: (1RS,4RS)-4-
4-Chlorophenyl)-N-methyl-1,2,3,4-tetrahydro-
naphthalen-1-amine Hydrochloride
HN
Cl
and enantiomer
x HCl
(D) 100 mg
MM 0317.10 Imp. E (EP): (2R)-Hydroxyphenylacetic Acid
((R)-Mandelic Acid)
OH
OH
O (A) 100 mg
MM 0792.03 Imp. E (EP) as Racemate: Hydroxyphenylacetic Acid (Mandelic Acid)
OH
OH
O (A) 100 mg
MM 0317.09 Imp. F (EP) as Racemate: 4-(3,4-Dichlorophenyl)-
3,4-dihydronaphthalen-1(2H)-one (Sertraline
Tetralone Derivative)
Cl
Cl
O
(A) 100 mg
Sibutramine Hydrochloride
New MM 0991.04 Imp. A (Pharmeuropa) as Hydrochloride: (1RS)-
1-[1-(2-Chlorophenyl)cyclobutyl]-N,N,3-trimethyl-
butan-1-amine Hydrochloride
N
Cl
x HCl
(A) 50 mg
New MM 0991.05 Imp. B (Pharmeuropa) as Hydrochloride: (1RS)-
1-[1-(3-Chlorophenyl)cyclobutyl]-N,N,3-trimethyl-
butan-1-amine Hydrochloride N
Cl
x HCl
(A) 50 mg
New MM 0991.06 Imp. C (Pharmeuropa) as Hydrochloride: (1RS)-
1-[1-(4-Chlorophenyl)cyclobutyl]-N,N-dimethyl-
pentan-1-amine Hydrochloride
Cl
N
x HCl
(A) 50 mg
MM 0991.02 Imp. D (Pharmeuropa) as Hydrochloride: (1RS)-
1-[1-(4-Chlorophenyl)cyclobutyl]-
N,3-dimethylbutan-1-amine Hydrochloride
(N-Monodesmethylsibutramine Hydrochloride)
Cl
HN
x HCl
(A) 100 mg
New MM 0991.07 Imp. E (Pharmeuropa): (4-Chlorophenyl)acetonitrile
Cl
N
(A) 50 mg
MM 0991.03 Imp. G (Pharmeuropa) as Hydrochloride: (1RS)-
1-[1-(4-Chlorophenyl)cyclobutyl]-3-methylbutan-
1-amine Hydrochloride (N,N-Didesmethyl-
sibutramine Hydrochloride)
Cl
NH
2
x HCl
(A) 100 mg
MM 0991.09 Imp. H (Pharmeuropa): 2-(4-Chlorophenyl)-2-(prop-
2-en-1-yl)pent-4-enenitrile
Cl
N
(A) 50 mg
MM 0991.10 Imp. I (Pharmeuropa): (1RS)-1-[1-(4-Chlorophenyl)-
cyclobutyl]-3-methylbutan-1-ol
Cl
OH
(A) 50 mg
New MM 0991.11 Imp. J (Pharmeuropa): 1-[1-(4-Chlorophenyl)cyclo-
butyl]-3-methylbutan-1-one
Cl
O
(A) 50 mg
Sibutramine Hydrochloride Monohydrate
New MM 0991.00 Sibutramine Hydrochloride Monohydrate
Cl
N
x HCl
x H
2
O
(A) 100 mg
Sildenafil Citrate
MM 0254.00 Sildenafil Citrate
O
S
N
O O
N
N
HN
N
N
O
HO
O
OH
O
HO
O
HO
x
(D) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 187
Code Product Price Unit
MM 0254.09 Sildenafil
O
S
N
O O
N
N
HN
N
N
O
(D) 100 mg
MM 0254.04 Imp. B (Pharmeuropa): 5-[2-Ethoxy-5-[(4-
methyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl]-
1-methyl-3-propyl-6,7-dihydro-1Hpyrazolo-
[4,3-d]pyrimidin-7-one (Sildenafil N-Oxide)
O
S
N
O O
N
N
HN
N
N
O
O
(A) 100 mg
MM 0254.22 Imp. C (Pharmeuropa): 5-[2-Hydroxy-5-[(4-
methylpiperazin-1-yl)sulfonyl]phenyl]-1-
methyl-3-propyl-6,7-dihydro-1H-pyrazolo-
[4,3-d]pyrimidin-7-one (Desethylsildenafil)
OH
S
N
O O
N
N
HN
N
N
O
(D) 100 mg
MM 0254.06 Imp. D (Pharmeuropa): 4-Ethoxy-3-(1-methyl-
7-oxo-3-propyl-6,7-dihydro-1Hpyrazolo[4,3-d]-
pyrimidin-5-yl)benzenesulfonic Acid
(3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-
benzenesulfonic Acid)
O
S
HO
O O
N
HN
N
N
O
on request
MM 0254.01 4-[[2-Ethoxy-5-[(4-methyl-1-piperazinyl)-
sulfonyl]benzoyl]amino]-1-methyl-3-propyl-1H-
pyrazole-5-carboxamide
O
S
N
O O
N
N
H
H
2
N
N
N
O
O
(A) 100 mg
MM 0254.02 2-Ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoic Acid
O
S
N
O O
N
OH
O
(A) 100 mg
MM 0254.05 4-Amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide
H
2
N
H
2
N
N
N
O
(A) 100 mg
MM 0254.08 1-[[3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl)-
4-ethoxyphenyl]sulfonyl]piperazine
(Desmethylsildenafil)
O
S
N
O O
HN
N
HN
N
N
O
(D) 100 mg
MM 0254.11 3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-
pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-N-
[2-(methylamino)ethyl]-
benzenesulfonamide
S
N
H
O O
NH
O
N
HN
N
N
O
on request
MM 0254.21 2-Ethoxy-5-(4-methylpiperazine-1-sulfonyl)benzaldehyde
(1-[(4-Ethoxy-3-formylphenyl)sulfonyl]-4-methylpiperazine)
O
S
N
O O
N
O
(A) 100 mg
New MM 0254.29 5-(2-Ethoxyphenyl)-1-methyl-3n-propyl-1,6-dihydro-7H-
pyrazolo[4,3-d]pyrimidin-7-one
O
N
HN
N
N
O
(A) 100 mg
Silybin
MM 0472.00 Silybin
O HO
OH O
OH
O
O
OH
O
OH
on request
Simvastatin
MM 0158.00 Simvastatin
H
O O
O
O
OH
(A) 100 mg
Pharmaceutical impurities
188 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0158.01 Imp. A (EP) as Sodium Salt: (3R,5R)-7-
[(1S,2S,6R,8S,8aR)-8-[(2,2-Dimethylbutanoyl)oxy]-
2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-
1-yl]-3,5-dihydroxyheptanoic Acid Sodium Salt (Tenivastatin
Sodium Salt; Simvastatin Hydroxy Acid Sodium Salt)
H
O O
OH
OH
O
ONa
(A) 100 mg
MM 0158.02 Imp. B (EP): (1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-(Acetyloxy)-
6-oxotetrahydro-2H-pyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-
hexahydronaphthalen-1-yl 2,2-Dimethylbutanoate (Simvastatin
Acetate Ester)
H
O O
O
O
O
O
(A) 100 mg
MM 0158.03 Imp. C (EP): (1S,3R,7S,8S,8aR)-3,7-Dimethyl-8-[2-[(2R)-6-oxo-
3,6-dihydro-2H-pyran-2-yl]ethyl]-1,2,3,7,8,8a-hexahydronaphthalen-
1-yl 2,2-Dimethylbutanoate (Anhydrosimvastatin)
H
O O
O
O
(A) 100 mg
MM 0050.00 Imp. E (EP): Lovastatin
H
O O
O
O
OH
(A) 100 mg
Sodium Benzoate
MM 0730.00 Sodium Benzoate
ONa
O
(A) 500 mg
Sodium Cromoglicate
MM 0039.00 Sodium Cromoglicate
O O
OH
O O
O O
NaO
O
ONa
O
(A) 500 mg
MM 0039.03 Imp. A (EP): 1-(2,6-Dihydroxyphenyl)ethanone
(2',6'-Dihydroxyacetophenone)
OH
OH
O
(B) 100 mg
MM 0039.04 Imp. B (EP): Diethyl 5,5'-[(2-hydroxypropane-
1,3-diyl)dioxy]bis(4-oxo-4H-1-benzopyran-2-
carboxylate) (Ethyl Cromoglicate)
O O
OH
O O
O O
O
O
O
O
(A) 100 mg
MM 0039.01 Succinophenone; Diphenacyl O
O
(A) 100 mg
MM 0039.02 1,3-Bis(2-acetyl-3-hydroxyphenoxy)-2-propanol
O O
OH
HO OH
O O
(A) 100 mg
Sodium Cyclamate
MM 0678.05 Cyclamic Acid
H
N
S
OH
O O
(A) 100 mg
MM 0093.17 Imp. B (EP) as Hydrochloride: Aniline Hydrochloride
(Phenylamine Hydrochloride)
NH
2
x HCl
(B) 100 mg
MM 0678.03 Imp. C (EP): Cyclohexanamine
NH
2
(C) 100 mg
MM 0678.04 Imp. D (EP): N-Cyclohexylcyclohexanamine
H
N
(C) 100 mg
Sodium Fluoride
MM 0734.00 Sodium Fluoride NaF (A) 500 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 189
Code Product Price Unit
Sodium Picosulfate
MM 0054.00 Sodium Picosulfate
N
O O
S S
NaO ONa
O O O O
(A) 500 mg
MM 0054.01 Imp. A (EP): 4-[(RS)-(4-Hydroxyphenyl)-
(pyridin-2-yl)methyl]phenyl Sodium Sulphate
(4-[(Pyridin-2-yl)(4-hydroxyphenyl)methyl]-
phenyl Sodium Sulphate)
N
HO O
S
ONa
O O
(A) 100 mg
MM 0031.01 Imp. B (EP): 4,4'-[(Pyridin-2-yl)methylene]-
diphenol (4,4'-(Pyridin-2-ylmethylene)di-
phenol)
N
HO OH
(A) 100 mg
MM 0054.02 Imp. C (EP): 2-[(RS)-(Pyridin-2-yl)[4-(sulphonato-
oxy)phenyl]methyl]phenyl Disodium Sulphate
(2,4'-[(Pyridin-2-yl)-methylene]bisphenyl Bis-
(Sodium Sulphate))
N
O
O
S
S
ONa
NaO
O O
O O
(D) 50 mg
MM 0031.04 2,4'-[(Pyridin-2-yl)methylene]bisphenol (2-[(RS)-
(4-Hydroxyphenyl)(pyridin-2-yl)methyl]phenol)
N
HO
OH
(A) 50 mg
Sodium Thiophene-2-carboxylate
MM 1081.00 Sodium Thiophene-2-carboxylate
S
ONa
O
(A) 250 mg
Sorbic Acid
MM 0954.00 Sorbic Acid
O
OH
(A) 500 mg
Sotalol Hydrochloride
MM 0046.00 Sotalol Hydrochloride
N
H
H
N
S
O O
OH
x HCl
(A) 100 mg
MM 0046.01 Imp. A (EP) as Hydrochloride: N-[4-[2-
[(1-Methylethyl)amino]ethyl]phenyl]-
methanesulphonamide Hydrochloride
N
H
H
N
S
O O x HCl
(A) 100 mg
MM 0046.02 Imp. B (EP) as Hydrochloride: N-[4-[[(1-
Methylethyl)amino]acetyl]phenyl]-
methanesulphonamide Hydrochloride
N
H
H
N
S
O O
O
x HCl
(A) 100 mg
MM 0046.03 Imp. C (EP):N-(4-Formylphenyl)methanesulphonamide
N
H
S
O O
O
(A) 100 mg
Spironolactone
MM 0197.00 Spironolactone
O S
O
O
O
(A) 500 mg
New MM 0197.01 Imp. F (EP): (2'R)-3',4'-Dihydro-5'H-spiro[androst-
4,6-diene-17,2'-furan]-3,5'-dione (Canrenone)
O
O
O
(A) 100 mg
Pharmaceutical impurities
190 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Stavudine
New MM 0534.00 Stavudine
O
HO
N
HN
O
O
(A) 100 mg
MM 0534.01 Imp. A (EP): 5-Methylpyrimidine-2,4(1H,3H)-dione (Thymine)
N
H
HN
O
O
(A) 100 mg
MM 0534.03 Imp. C (EP): 1-(2-Deoxy--D-erythro-pentofuranosyl)-
5-methylpyrimidine-2,4(1H,3H)-dione (Thymidine)
O
HO
N
HN
O
O
OH
(A) 100 mg
Strychnine Nitrate
MM 0658.00 Strychnine Nitrate
N
N
O O
H
H
H
x HNO3
(A) 500 mg
MM 0658.02 Strychnine N-Oxide Hydrochloride
N
N
O O
H
H
H
x HCl
O
on request
Sulfacetamide
MM 0579.00 Sulfacetamide
H2N
S
N
H
O O O
(A) 500 mg
Sulfacetamide Sodium
MM 1087.00 Sulfacetamide Sodium Monohydrate
H
2
N
S
N
O O
x H
2
O
O
Na
(A) 500 mg
MM 0227.05 Imp. A (EP): Sulfanilamide
S
NH
2
O O
H
2
N
(A) 100 mg
Sulfadiazine
MM 0623.00 Sulfadiazine
S
H2N
N
H
O O
N
N (A) 500 mg
MM 0623.03 Imp. A (Pharmeuropa): Pyrimidin-2-amine
H
2
N N
N (A) 100 mg
MM 0227.04 Imp. B (Pharmeuropa): 4-Aminobenzenesulfonic Acid (Sulphanilic
Acid)
S
H
2
N
OH
O O
(A) 100 mg
MM 0227.05 Imp. D (Pharmeuropa): 4-Aminobenzenesulfonamide
(Sulfanilamide)
S
H
2
N
NH
2
O O
(A) 100 mg
MM 0623.02 Imp. E (Pharmeuropa): N-[4-(Pyrimidin-2-ylsulfamoyl)-
phenyl]acetamide (Acetylsulfadiazine)
S
N
H
O O
N
N
N
H
O
(A) 50 mg
New MM 0623.07 N-[(4-Aminophenyl)sulfonyl]-N-(pyrimidin-2-yl)acetamide
(Acetylsulfadiazine)
S
H
2
N
N
O O
N
N
O
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 191
Code Product Price Unit
Sulfadimidine
MM 0581.00 Imp. A (Pharmeuropa): 4-Amino-N-(4-methyl-2-
pyrimidyl)benzenesulphonamide (Sulfamerazine)
H
2
N
S
N
H
O O
N
N
(A) 500 mg
MM 623.00 Imp. B (Pharmeuropa): 4-Amino-N-pyrimidin-2-
ylbenzenesulphonamide (Sulfadiazine)
H
2
N
S
N
H
O O
N
N (A) 500 mg
MM 0883.00 Imp. C (Pharmeuropa): (4-Aminophenylsulphonyl)-
guanidine (Sulfaguanidine)
H
2
N
S
N
H
O O
NH
2
NH
(A) 100 mg
MM 0227.05 Imp. D (Pharmeuropa): 4-Aminobenzenesulphonamide
(Sulfanilamide)
H
2
N
S
NH
2
O O
(A) 100 mg
MM 0579.00 Imp. E (Pharmeuropa): N-[(4-Aminophenyl)sulfonyl]-
acetamide (Sulfacetamide)
H
2
N
S
N
H
O O
O
(A) 500 mg
MM 0227.04 Imp. F (Pharmeuropa): 4-Aminobenzenesulphonic
Acid (Sulphanilic Acid)
H
2
N
S
OH
O O
(A) 100 mg
Sulfadimethoxine Sodium
MM 1020.00 Sulfadimethoxine Sodium
S
H
2
N
N
Na
O O
N N
O
O
(A) 500 mg
Sulfafurazole
MM 0583.00 Sulfafurazole
H2N
S
N
H
O O
O
N
(A) 500 mg
Sulfaguanidine
MM 0883.00 Sulfaguanidine
H
2
N
S
N
H
O O
NH
2
NH
(A) 100 mg
MM 0227.05 Imp. A (EP): 4-Aminobenzenesulphonamide (Sulphanilamide)
H
2
N
S
NH
2
O O
(A) 100 mg
MM 0883.02 Imp. B (EP): N-[(4-Aminophenyl)sulphonyl]urea
(Sulphacarbamide)
H
2
N
S
N
H
O O
NH
2
O
(A) 50 mg
Sulfamerazine
MM 0581.00 Sulfamerazine
N
N N
H
S
H2N
O O
(A) 500 mg
MM 0227.05 Sulphanilamide
NH
2
S
H
2
N
O O
(A) 100 mg
Sulfamethoxazole
MM 0227.00 Sulfamethoxazole
N
H
S
H
2
N
O O
N
O
(A) 500 mg
Pharmaceutical impurities
192 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0227.01 Imp. A (EP): N-[4-[(5-Methylisoxazol-3-yl)-
sulphamoyl]phenyl]acetamide
N
H
S
O O
N
O
N
H
O
(A) 100 mg
MM 0227.03 Imp. B (EP): 4-[[(4-Aminophenyl)sulphonyl]amino]-N-
(5-methylisoxazol-3-yl)benzenesulphonamide
N
H
S
N
O
N
H
S
H
2
N
O O
O O
(A) 100 mg
MM 0227.02 Imp. C (EP): 5-Methylisoxazol-3-amine
H
2
N N
O
(B) 100 mg
MM 0227.04 Imp. D (EP): 4-Aminobenzenesulphonic Acid
(Sulphanilic Acid)
OH
S
H
2
N
O O
(A) 100 mg
MM 0227.05 Imp. E (EP): 4-Aminobenzenesulphonamide (Sulphanilamide)
NH
2
S
H
2
N
O O
(A) 100 mg
Sulfamethylphenazole
MM 1108.00 Sulfamethylphenazole
N
H
S
H
2
N
N
N
O O
(A) 100 mg
Sulfaquinoxaline Sodium
MM 0702.00 Sulfaquinoxaline Sodium
N
N
Na
N
S
O O
NH
2
on request
Sulfasalazine
MM 0045.00 Imp. H (EP): Salicylic Acid
HO
O OH
(A) 500 mg
Sulfathiazole
MM 0578.00 Sulfathiazole
N
S N
H
S
O O
H
2
N
(A) 500 mg
Sulindac
MM 0624.00 Sulindac
OH
F
S
O
O
(A) 500 mg
Sulpiride
MM 0051.00 Sulpiride
N
N
H
O
S
O
O
H
2
N
O
(A) 500 mg
MM 0051.01 Imp. A (EP): [(2RS)-1-Ethylpyrrolidin-2-yl]methanamine
N
H2N
(A) 100 mg
MM 0051.02 Imp. B (EP): Methyl 2-Methoxy-5-sulphamoylbenzoate
O
O
S
O
O
H
2
N
O
(A) 100 mg
MM 0051.03 Imp. C (EP): Ethyl 2-Methoxy-5-sulphamoylbenzoate
O
O
S
O
O
H
2
N
O
(A) 100 mg
MM 0051.04 Imp. D (EP): 2-Methoxy-5-sulphamoylbenzoic Acid
OH
O
S
O
O
H
2
N
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 193
Code Product Price Unit
MM 0051.05 Imp. E (EP): 2-Methoxy-5-sulphamoylbenzamide
NH
2
O
S
O
O
H
2
N
O
(A) 100 mg
MM 0051.06 Imp. F (EP): 1-Ethyl-2-[[(2-methoxy-5-
sulphamoylbenzoyl)amino]methyl]pyrrolidine
1-Oxide (Sulpiride N-Oxide)
N
N
H
O
S
O
O
NH
2
O
O
(A) 100 mg
MM 0051.07 Imp. G (EP): (RS)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-
2-hydroxy-5-sulphamoylbenzamide
N
N
H
O
S
O
O
H
2
N
OH
(A) 100 mg
MM 0051.08 5-Sulphamoylsalicylic Acid
OH
O
S
O
O
H
2
N
OH
(A) 100 mg
MM 0051.09 5-Sulphosalicylic Acid Dihydrate
OH
O
S
O
O
HO
OH
x 2 H
2
O
(C) 100 mg
Sumatriptan Succinate
New MM 0310.04 Imp. D (EP) as Maleate: N,N-Dimethyl-
2-[5-[(methylsulfamoyl)methyl]-1H-indol-
3-yl]ethanamine N-Oxide Maleate
H
N
S
N
H
N
O
O O
O
OH
O
OH
x
(A) 100 mg
New MM 0310.05 Imp. E (EP): [3-(2-Aminoethyl)-1H-indol-5-yl]-
N-methylmethanesulfonamide
H
N
S
N
H
NH
2
O O
(A) 100 mg
Suplatast Tosilate
MM 0722.01 Methyl Toluene-4-sulphonate
S
O
O O
(B) 100 mg
Tamoxifen Citrate
MM 0053.00 Tamoxifen Citrate
O
N
O
HO
O
HO
O
OH
HO x
(A) 100 mg
MM 0053.02 Imp. B (EP): 1-[4-(2-Dimethylaminoethoxy)phenyl]-
1,2-diphenylbutan-1-ol
O
N
OH
(A) 100 mg
MM 0053.14 Imp. C (EP) Z-Isomer: 2-[4-[(Z)-1,2-Diphenyl-
ethenyl]phenoxy]-N,N-dimethylethanamine
O
N
on request
MM 0053.15 Imp. C (EP) E-Isomer: 2-[4-[(E)-
1,2-Diphenylethenyl]phenoxy]-N,N-dimethylethanamine
O
N
(A) 50 mg
MM 0053.16 Imp. D (EP) Z-Isomer: 2-[4-[(Z)-1,2-Diphenylprop-
1-enyl]phenoxy]-N,N-dimethylethanamine
O
N
(A) 50 mg
Pharmaceutical impurities
194 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0053.17 Imp. D (EP) E-Isomer: 2-[4-[(E)-1,2-Diphenylprop-
1-enyl]phenoxy]-N,N-dimethylethanamine
O
N
on request
MM 0053.05 Imp. E (EP):2-[2-[(EZ)-1,2-Diphenylbut-1-enyl)phenoxy]-N,N-
dimethylethanamine
O
N
(A) 100 mg
MM 0053.12 Imp. F (EP) as Hydrochloride: 2-[4-[(Z)-1,2-Diphenylbut-
1-enyl]phenoxy]-N-methylethanamine Hydrochloride
O
N
H
x HCl
(A) 100 mg
MM 0053.07 Imp. G (EP): (2RS)-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-
2-phenylbutan-1-one
O
N
O
(A) 100 mg
MM 0053.08 1,2-Diphenylbutan-1-one
O
(A) 100 mg
MM 0053.09 1-(4-Methoxyphenyl)-1,2-diphenylbutan-1-ol
O
OH
(A) 100 mg
MM 0053.10 (EZ)-1-(4-Hydroxyphenyl)-1,2-diphenylbut-1-ene
OH
(C) 50 mg
MM 0053.18 Tamoxifen N-Oxide
O
N
O
(A) 100 mg
Tamsulosin Hydrochloride
MM 0938.00 Tamsulosin Hydrochloride
O
O
H
N
O
S
NH
2
O O
x HCl
(D) 100 mg
MM 0938.02 Imp. A (EP) as Hydrochloride: 5-[(2R)-2-
[Bis[2-(2-ethoxyphenoxy)ethyl]amino]-
propyl]-2-methoxybenzenesulfonamide
Hydrochloride
O
O
N
O
S
NH
2
O O
x HCl
O
O
(A) 100 mg
MM 0938.03 Imp. B (EP): 5-[(2R)-2-Aminopropyl]-
2-methoxybenzenesulfonamide
H
2
N
O
S
NH
2
O O
(A) 100 mg
MM 0938.04 Imp. C (EP) as Hydrochloride: 2-Methoxy-5-[(2R)-
2-[(2-phenoxyethyl)amino]propyl]benzene-
sulfonamide Hydrochloride
O
H
N
O
S
NH
2
O O
x HCl
(A) 100 mg
MM 0938.05 Imp. D (EP) as Hydrochloride: 2-Methoxy-
5-[(2R)-2-[[2-(2-methoxyphenoxy)ethyl]-
amino]propyl]benzenesulfonamide
Hydrochloride
O
O
H
N
O
S
NH
2
O O
x HCl
(A) 100 mg
MM 0938.06 Imp. E (EP): 5-Formyl-2-methoxybenzene-
Sulfonamide O
O
S
NH
2
O O
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 195
Code Product Price Unit
MM 0938.07 Imp. F (EP) as Hydrochloride: 2-(2-Ethoxy-
phenoxy)ethanamine Hydrochloride
O
O
NH
2 x HCl
(A) 100 mg
New MM 0938.10 Imp. G (EP) as Racemate Hydrochloride:
5-[(2RS)-2-[[2-(2-Ethoxyphenoxy)ethyl]-
amino]propyl]-2-methoxybenzenesulfonamide
Hydrochloride (Tamsulosin Racemate
Hydrochloride)
O
O
H
N
O
S
NH
2
O O
x HCl
(A) 50 mg
MM 0938.01 Imp. H (EP) as Racemate Hydrochloride:
(2RS)-N-[2-(2-Ethoxyphenoxy)ethyl]-
1-(4-methoxyphenyl)propan-
2-amine Hydrochloride
O
O
H
N
O
x HCl
(A) 100 mg
MM 0938.09 Imp. I (EP): 1-(2-Bromoethoxy)-2-ethoxybenzene
O
O
Br
(A) 100 mg
Telmisartan
New MM 0939.01 Imp. A (EP): 4-Methyl-6-(1-methyl-1H-benz-
imidazol-2-yl)-2-propyl-1H-benzimidazole
NH
N
N
N
(A) 100 mg
New MM 0939.10 Methyl 4'-(Bromomethyl)biphenyl-2-carboxylate
Br
O O
(A) 100 mg
Temazepam
MM 0087.00 Temazepam [Controlled Substance]
N
N
O
Cl
OH
on request
MM 0023.01 Imp. A (EP): [5-Chloro-2-(methylamino)-
phenyl]phenylmethanone
(5-Chloro-2-(methylamino)benzophenone)
Cl
NH
O
(B) 100 mg
MM 0080.00 Imp. B (EP): Oxazepam [Controlled Substance]
N
H
N
O
Cl
OH
(D) 100 mg
Tenofovir Disoproxil Fumarate
New MM 1329.00 Tenofovir Disoproxil Fumarate
N
N
N
N
NH
2
O
P
O
O
O
O
O
O
O
O
O
OH
HO
O
O
x
on request
Tenoxicam
MM 0084.01 Imp. A (EP): Pyridin-2-amine
H
2
N
N
(B) 100 mg
MM 0247.01 Imp. B (EP): Methyl 4-Hydroxy-2-methyl-2H-thieno[2,3-e]1,2-thiazine-
3-carboxylate 1,1-Dioxide
N
S
OH O
O
S
O O
(A) 100 mg
Pharmaceutical impurities
196 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0247.04 Imp. C (EP): N-Methylthiophene-2-carboxamide
H
N
S
O
(A) 100 mg
MM 0247.06 Imp. E (EP): 2-Methylthieno[2,3-d]isothiazol-3(2H)-one 1,1-Dioxide
S
N
S
O
O
O
(A) 100 mg
New MM 0247.10 2-(Methoxycarbonyl)-3-thiophenesulfonyl Chloride
O
Cl
S
O
S
O O
(A) 100 mg
Terazosin Hydrochloride Dihydrate
MM 0843.00 Terazosin Hydrochloride Dihydrate
N
N O
O
NH
2
N
N
O
O
x HCl
x 2 H
2
O
(A) 100 mg
MM 0085.04 Imp. A (EP): 2-Chloro-6,7-
dimethoxyquinazolin-4-amine N
N O
O
NH
2
Cl
(A) 100 mg
MM 0843.02 Imp. B (EP): 1-(4-Hydroxy-
6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-
tetrahydrofuran-2-yl]carbonyl]piperazine
N
N O
O
OH
N
N
O
O
(A) 100 mg
MM 0085.01 Imp. C (EP): 6,7-Dimethoxy-
2-(piperazin-1-yl)quinazolin-4-amine
N
N O
O
NH
2
N
NH (A) 100 mg
MM 0843.04 Imp. D (EP) as Hydrochloride: 1-(4-Amino-6,7-
dimethoxyquinazolin-2-yl)-4-formylpiperazine
Hydrochloride
N
N O
O
NH
2
N
N
O
x HCl
(A) 100 mg
MM 0085.03 Imp. E (EP): 2,2'-(Piperazine-1,4-diyl)bis(6,7-
dimethoxyquinazolin-4-amine)
N
N O
O
NH
2
N
N N
N
NH
2
O
O
(D) 100 mg
MM 0085.00 Imp. K (EP) as Hydrochloride:
Prazosin Hydrochloride
N
N O
O
NH
2
N
N
O
O
x HCl
(A) 100 mg
MM 0085.02 Imp. L (EP): 1-(Furan-2-ylcarbonyl)piperazine
HN
N
O
O
(A) 100 mg
MM 0085.05 Imp. M (EP): 1,4-Bis(furan-2-
ylcarbonyl)piperazine
N
N
O
O
O
O
(A) 100 mg
MM 0843.15 Imp. N (EP): 1-[[(2RS)-Tetrahydrofuran-2-yl]carbonyl]piperazine
HN
N
O
O
(A) 100 mg
MM 0843.16 Imp. O (EP): 1,4-Bis[(tetrahydrofuran-2-yl)carbonyl]piperazine
N
N
O
O
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 197
Code Product Price Unit
Terbinafine Hydrochloride
MM 0696.00 Terbinafine Hydrochloride
x HCl
N
(A) 100 mg
MM 0696.02 Imp. A (EP) as Hydrochloride: N-Methyl-C-(naphthalen-
1-yl)methanamine Hydrochloride (Secundary Amine
Hydrochloride)
x HCl
NH
(A) 100 mg
MM 0696.03 Imp. B (EP) as Hydrochloride: (2Z)-N,6,6-Trimethyl-
N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
Hydrochloride (cis-Terbinafine Hydrochloride)
x HCl
N
(D) 100 mg
MM 0696.04 Imp. C (EP) as Hydrochloride: (2E)-
N,6,6-Trimethyl-N-(naphthalen-2-ylmethyl)hept-
2-en-4-yn-1-amine Hydrochloride (trans-iso-
Terbinafine Hydrochloride)
N
x HCl
(D) 100 mg
MM 0696.05 Imp. D (EP) as Hydrochloride: (2E)-N,6,6-Trimethyl-
N-[(4-methylnaphthalen-1-yl)methyl]hept-2-en-4-yn-
1-amine Hydrochloride (4-Methylterbinafine
Hydrochloride
x HCl
N
(D) 100 mg
MM 0696.07 N-Demethylterbinafine Hydrochloride
x HCl
N
H
(D) 50 mg
New MM 0696.10 Imp. F (EP) as Hydrochloride: (2Z)-
N,6,6-Trimethyl-N-(naphthalen-2-ylmethyl)hept-
2-en-4-yn-1-amine Hydrochloride (cis-Iso-
terbinafine Hydrochloride)
x HCl
N
(D) 50 mg
Terbutaline Sulphate
MM 0708.01 Imp. A (EP): 3,5-Dihydroxybenzoic Acid (-Resorcylic Acid)
HO
OH
OH
O
(B) 100 mg
MM 0708.03 Imp. B (EP) as Hemisulphate: (4RS)-
2-(1,1-Dimethylethyl)-1,2,3,4-tetrahydroisoquinoline-
4,6,8-triol Hemisulphate
HO
OH
OH
x 1/2 H
2
SO
4
N
(D) 100 mg
Terfenadine
MM 0055.00 Terfenadine
OH
N
OH
(A) 500 mg
MM 0055.04 Imp. A (EP): 1-[4-(1,1-Dimethylethyl)phenyl]-
4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-
1-one (Terfenadone)
OH
N
O
(A) 100 mg
MM 0055.07 Imp. B (EP): (1RS)-1-[4-(1,1-Dimethylethyl)phenyl]-
4-[4-(diphenylmethyl)piperidin-1-yl]butan-1-ol
N
OH
(A) 100 mg
MM 0055.12 Imp. E (EP) as Hydrochloride: 1-[(4RS)-
4-[4-(1,1-Dimethylethyl)phenyl]-
4-hydroxybutyl]piperidine-4-carboxylic Acid
Hydrochloride HO
N
OH
O
x HCl
(A) 100 mg
Pharmaceutical impurities
198 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0055.09 Imp. G (EP): [1-[4-[4-(1,1-Dimethylethyl)-
phenyl]but-3-enyl]piperidin-4-
yl]diphenylmethanol
OH
N
(A) 100 mg
MM 0055.10 Imp. H (EP):
[1-[4-[4-(1,1-Dimethylethyl)phenyl]butyl]piperidin-
4-yl]diphenylmethanol
OH
N
(A) 100 mg
MM 0055.02 Imp. I (EP): Diphenyl(piperidin-4-yl)methanol (Azacyclonol)
OH
NH (B) 100 mg
MM 0055.03 Imp. J (EP): Ethyl 1-[(4RS)-
4-[4-(1,1-Dimethylethyl)phenyl]-4-hydroxybutyl]-
piperidine-4-carboxylate
O
N
OH
O
(A) 100 mg
Testosterone
MM 0323.00 Testosterone
O
OH
(A) 500 mg
MM 0323.01 Imp. A (EP): Androst-4-ene-3,17-dione (Androstenedione)
O
O
(A) 100 mg
MM 0323.02 Imp. B (EP): 3-Ethoxyandrosta-3,5-dien-17-one (Androstenedione
Ethylenolether)
O
O
(A) 100 mg
MM 0323.03 Imp. C (EP): 17-Hydroxyandrost-4-en-3-one (Epitestosterone)
O
OH
(A) 100 mg
MM 0323.04 Imp. D (EP): Androst-4-ene-3,17-diol
(4-Androstenediol)
HO
OH
(A) 100 mg
MM 0323.05 Imp. E (EP): 3-Oxoandrost-4-en-17-yl Acetate (Testosterone
Acetate)
O
O
O
(A) 100 mg
MM 0565.00 Imp. F (EP): 17-Hydroxy-5-androstan-3-one (Androstanolone,
Stanolone)
O
OH
H
(A) 250 mg
MM 0323.07 Imp. G (EP): Androsta-1,4-diene-3,17-dione (Androstadienedione)
O
O
(A) 100 mg
MM 0864.00 Imp. H (EP): 17-Hydroxyandrosta-1,4-dien-3-one (Boldenone)
O
OH
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 199
Code Product Price Unit
MM 0323.12 Imp. I (EP): 17-Hydroxyandrosta-4,6-dien-3-one
(6-testosterone)
O
OH
(A) 100 mg
MM 0323.13 Imp. J (EP): 3-Methoxyandrosta-3,5-dien-
17-one (Androstenedione Methylenolether)
O
O
(A) 100 mg
Testosterone Benzoate
MM 0493.00 Testosterone Benzoate
O
O
O
(D) 250 mg
MM 0323.00 Testosterone
O
OH
(A) 500 mg
MM 0278.01 Benzoic Acid
OH
O
(B) 100 mg
Testosterone Enantate
MM 1119.00 Testosterone Enantate
O
O
O
(A) 100 mg
MM 0863.08 Imp. B (EP): 3-Oxoandrost-4-en-17-yl Hexanoate
(Testosterone Caproate)
O
O
O
(A) 100 mg
MM 0323.00 Imp. D (EP): 17-Hydroxyandrost-4-en-3-one (Testosterone)
O
OH
(A) 500 mg
Testosterone Isocaproate
MM 0863.00 Testosterone Isocaproate
O
O
O
(A) 100 mg
MM 0323.00 Imp. A (EP): Testosterone
O
OH
(A) 500 mg
MM 0323.05 Imp. B (EP): 3-Oxoandrost-4-en-17-yl Acetate
(Testosterone Acetate)
O
O
O
(A) 100 mg
MM 0897.00 Imp. C (EP): Testosterone Propionate
O
O
O
(A) 100 mg
Pharmaceutical impurities
200 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0863.07 Imp. D (EP): 3-Oxoandrost-4-en-17-yl 2-Methylpropanoate
(Testosterone Isobutyrate)
O
O
O
(A) 100 mg
MM 0863.08 Imp. E (EP): 3-Oxoandrost-4-en-17-yl
Hexanoate (Testosterone Caproate)
O
O
O
(A) 100 mg
MM 1119.00 Imp. F (EP): Testosterone Enantate
O
O
O
(A) 100 mg
MM 0863.09 Imp. G (EP): 3-Oxoandrost-4-en-17-yl
4-Methylpentanoate
(Epitestosterone Isocaproate)
O
O
O
(A) 100 mg
Testosterone Propionate
MM 0897.00 Testosterone Propionate
O
O
O
(A) 100 mg
MM 0323.05 Imp. A (EP): 3-Oxoandrost-4-en-17-yl Acetate (Testosterone
Acetate) O
O
O
(A) 100 mg
MM 0863.07 Imp. B (EP): 3-Oxoandrost-4-en-17-yl 2-Methyl-
propanoate (Testosterone Isobutyrate) O
O
O
(A) 100 mg
MM 0323.00 Imp. C (EP): Testosterone
OH
O
(A) 500 mg
MM 0897.04 Imp. D (EP): 3-Oxoandrosta-1,4-dien-17-yl Propanoate
O
O
O
(C) 50 mg
MM 0897.05 Imp. E (EP): 3-Oxoandrosta-4,6-dien-17-yl
Propanoate O
O
O
(A) 100 mg
Tetracaine Hydrochloride
MM 0504.00 Tetracaine Hydrochloride
x HCl
O
O
N
H
N
(A) 500 mg
MM 0094.03 Imp. A (EP): 4-Aminobenzoic Acid
OH
O
H
2
N
(B) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 201
Code Product Price Unit
MM 0504.01 Imp. B (EP): 4-(Butylamino)benzoic Acid
OH
O
N
H
(A) 100 mg
MM 0504.04 Imp. C (EP): Methyl 4-(Butylamino)benzoate
O
O
N
H
(A) 100 mg
MM 0504.02 Tetracaine N-Oxide
O
O
N
H
N
O
(A) 100 mg
Tetracycline Hydrochloride
MM 0452.00 Tetracycline Hydrochloride
OH O OH O
NH
2
O
OH
OH
N
H H x HCl
HO
(A) 500 mg
Tetramisole Hydrochloride
MM 0703.00 Tetramisole Hydrochloride
N
N S
x HCl
(A) 500 mg
Tetrazepam
MM 0091.00 Tetrazepam [Controlled Substance]
N
N
O
Cl
(A) 100 mg
MM 0091.06 Imp. B (EP): 7-Chloro-5-cyclohexyl-1,3-dihydro-2H-
1,4-benzodiazepin-2-one
N
H
N
O
Cl
(A) 100 mg
MM 0091.07 Imp. C (EP): 7-Chloro-5-cyclohexyl-1-methyl-
1,3-dihydro-2H-1,4-benzodiazepin-2-one
N
N
O
Cl
(A) 100 mg
MM 0091.03 Imp. E (EP): 7-Chloro-5-(cyclohex-1-enyl)-1,3-
dihydro-2H-1,4-benzodiazepin-2-one
(Nortetrazepam) N
H
N
O
Cl
(A) 100 mg
MM 0091.04 6-Chloro-2-methyl-4-oxo-4H-3,1-benzoxazine
Cl
N
O
O
(A) 100 mg
MM 0091.52 2-Bromo-4'-chloro-2'-(cyclohexylcarbonyl)acetanilide
Cl
NH
O
O
Br
on request
Tetryzoline Hydrochloride
MM 0088.00 Tetryzoline Hydrochloride
N HN
x HCl
(A) 100 mg
MM 0088.03 Imp. A (EP): (1RS)-1,2,3,4-Tetrahydronaphthalene-1-carbonitrile
(-Cyanotetraline)
N
(A) 100 mg
MM 0088.02 1,2,3,4-Tetrahydro-1-naphthalenecarboxylic Acid
O OH
(A) 100 mg
Pharmaceutical impurities
202 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0088.04 Methyl 1,2,3,4-Tetrahydro-1-naphthalenecarboxylate
O O
(A) 100 mg
MM 0088.05 N-(2-Aminoethyl)-1,2,3,4-tetrahydro-
naphthalene-1-yl-carboxamide Hydrochloride
((1,2,3,4-Tetrahydro-1-naphthyl)formyl-
ethylenediamine Hydrochloride)
O
H
N
NH
2
x HCl
(A) 100 mg
MM 0088.06 2-(1,2,3,4-Tetrahydro-1-naphthalenyl)-1H-imidazole Hydrochloride
N HN
x HCl
(A) 100 mg
Thalidomide
MM 0940.00 Thalidomide
N
O
O
NH
O
O
(A) 100 mg
Theobromine
MM 0577.00 Theobromine
HN
N
N
N
O
O
(A) 500 mg
Theophylline
MM 0176.00 Theophylline
N
N
N
H
N
O
O
(A) 500 mg
MM 0494.00 Imp. A (EP): Caffeine
N
N
N
N
O
O
(A) 500 mg
MM 0176.03 Imp. B (EP): 3-Methyl-3,7-dihydro-1H-purine-2,6-dione
(3-Methylxanthine) HN
N
N
H
N
O
O
(A) 100 mg
MM 0176.02 Imp. C (EP): N-(6-Amino-1,3-dimethyl-2,4-
dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)formamide N
N O
O
NH
2
H
N
O
(A) 100 mg
MM 0176.01 Imp. D (EP): N-Methyl-5-(methylamino)-1H-imidazole-
4-carboxamide (Theophyllidine) N
H
HN
N
H
N
O
(A) 100 mg
MM 0603.00 Imp. F (EP): Etofylline
N
N
N
N
O
O
OH
(A) 500 mg
MM 0176.04 1-Methylxanthine
N
N
H
N
H
N
O
O
on request
MM 0176.05 7-Methylxanthine
HN
N
H
N
N
O
O
(A) 100 mg
Theophylline-Ethylenediamine
MM 0494.00 Imp. A (EP): Caffeine
N
N
N
N
O
O
(A) 500 mg
MM 0176.03 Imp. B (EP): 3-Methyl-3,7-dihydro-1H-purine-2,6-dione
(3-Methylxanthine) HN
N
N
H
N
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 203
Code Product Price Unit
MM 0176.02 Imp. C (EP): N-(6-Amino-1,3-dimethyl-2,4-
dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)form-
amide
N
N O
O
NH
2
H
N
O
(A) 100 mg
MM 0176.01 Imp. D (EP): N-Methyl-5-(methylamino)-1H-
imidazole-4-carboxamide (Theophyllidine) N
H
HN
N
H
N
O
(A) 100 mg
MM 0603.00 Imp. F (EP): Etofylline
N
N
N
N
O
O
OH
(A) 500 mg
MM 0577.00 Imp. G (EP): Theobromine
HN
N
N
N
O
O
(A) 500 mg
Thiamazole
MM 0889.00 Thiamazole
N
NH
S
(A) 500 mg
MM 0889.02 Imp. B (EP): 1-Methyl-1H-imidazole
N
N
(B) 100 mg
MM 0889.03 Imp. C (EP): 1-Methyl-2-(methylsulphanyl)-1H-imidazole
N
N
S
(A) 100 mg
MM 0889.04 Imp. C (EP) as Hydrochloride: 1-Methyl-2-(methylsulphanyl)-1H-
imidazole Hydrochloride
N
N
S
x HCl
(A) 100 mg
Thiamine Hydrochloride
MM 0049.00 Thiamine Hydrochloride (Vitamin B1)
N
+
N
N
NH
2
S
HO
Cl
-
x HCl
(A) 500 mg
MM 0049.05 Imp. E (EP): 3-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-
5-(2-hydroxyethyl)-4-methylthiazol-2(3H)-thione
(Thioxothiamine)
N N
N
NH
2
S
HO
S
(A) 100 mg
MM 0049.02 5-(2-Hydroxyethyl)-4-methylthiazole
N
S OH
(A) 100 mg
MM 0049.04 4-Amino-5-hydroxymethyl-2-methylpyrimidine Hydrochloride N
N NH
2
OH
x HCl
(A) 100 mg
Thiamphenicol
MM 0737.00 Thiamphenicol
Cl
N
H
O
Cl OH
S OH
O O
(A) 500 mg
Thioctic Acid
MM 0127.00 Thioctic Acid
S S
OH
O
(A) 500 mg
Thioridazine Hydrochloride
MM 0116.05 2-Methylthiophenothiazine
NH
S
S
(A) 100 mg
Tiabendazole
MM 0602.00 Tiabendazole
N
H
N
N
S
(A) 500 mg
MM 0602.01 Imp. A (EP): Benzene-1,2-diamine
NH2
NH
2 (C) 100 mg
Pharmaceutical impurities
204 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Tiamulin Hydrogen Fumarate
MM 0394.00 Tiamulin Hydrogen Fumarate
O
H
HO
O
O
S
N
OH
O
O
HO
x
(A) 100 mg
MM 0460.10 Fumaric Acid
OH
HO
O
O
(B) 100 mg
MM 0394.04 Imp. A (EP): (3aS,4R,5S,6S,8R,9R,9aR,10R)-
6-Ethenyl-5,8-dihydroxy-4,6,9,10-tetramethyl-
octahydro-3a,9-propano-3aH-cyclopentacyclo-
octen-1(4H)-one (Mutilin)
O
H
HO
HO
(A) 100 mg
New MM 0394.06 Imp. C (EP) as Dihydrochloride: 2,2'-(Disulfane-
1,2-diyl)bis(N,N-diethylethanamine)
Dihydrochloride
S
S
N
N
x 2 HCl
(A) 50 mg
New MM 0394.13 Imp. J (EP): (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-Ethenyl-
5-hydroxy-4,6,9,10-tetramethyl-1-oxo-decahydro-3a,9-propano-3aH-
cyclopentacyclo-octen-8-yl Acetate (Mutilin 14-Acetate)
O
H
HO
O
O
(A) 50 mg
MM 0394.18 Imp. P (EP): (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-
Ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-
decahydro-3a,9-propano-3aH-cyclopentacyclo-
octen-8-yl [(Phenylsulphonyl)oxy]acetate
O
H
HO
O
O
O
S
O O
(A) 50 mg
Tiapride Hydrochloride
New MM 0073.01 Imp. C (EP): N,N-Diethylethane-1,2-diamine
H
2
N
N
(B) 100 mg
New MM 1331.04 N-[2-(Diethylamino)ethyl]-2-hydroxy-
5-(methylsulfonyl)benzamide
S
O O
OH
N
H
O
N
(A) 100 mg
Ticlopidine Hydrochloride
MM 0150.00 Ticlopidine Hydrochloride
N
S
x HCl
Cl
(A) 500 mg
MM 0150.12 Imp. A (EP): Thieno[3,2-c]pyridine
N
S
(A) 100 mg
MM 0150.06 Imp. B (EP): 6,7-Dihydrothieno[3,2-c]pyridin-4(5H)-one
HN
S
O
(A) 100 mg
MM 0150.01 Imp. C (EP) as Hydrochloride: (2-Chloro-
phenyl)methanamine Hydrochloride
NH
2
x HCl
Cl
(A) 100 mg
MM 0150.07 Imp. D (EP) as Hydrochloride: 5-Benzyl-
4,5,6,7-tetrahydrothieno[3,2-c]pyridine Hydrochloride
N
S
x HCl
(A) 100 mg
MM 0150.13 Imp. E (EP) as Chloride: 5-(2-Chlorobenzyl)-
thieno[3,2-c]pyridinium Chloride
N
+
S
Cl
-
Cl
(A) 50 mg
New MM 0150.14 Imp. F (EP) as Hydrochloride: 6-(2-Chloro-
benzyl)-4,5,6,7-tetrahydrothieno[2,3-c]-
pyridine Hydrochloride
N
S
Cl
x HCl
(A) 50 mg
MM 0150.08 Imp. G (EP) as Hydrochloride: 5-(3-Chlorobenzyl)-
4,5,6,7-tetrahydrothieno[3,2-c]pyridine Hydrochloride
N
S
Cl
x HCl
(A) 100 mg
MM 0150.09 Imp. H (EP) as Hydrochloride: 5-(4-Chlorobenzyl)-
4,5,6,7-tetrahydrothieno[3,2-c]pyridine Hydrochloride
N
S
Cl
x HCl
(C) 50 mg
MM 0150.11 Imp. I (EP) as Hydrochloride: N-(2-Chlorobenzyl)-
2-(thiophen-2-yl)ethanamine Hydrochloride
NH
S
x HCl
Cl
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 205
Code Product Price Unit
MM 0150.10 Imp. J (EP) as Dihydrochloride: N,N'-
Bis(2-chlorobenzyl)ethane-1,2-diamine Dihydrochloride
NH
N
H
Cl
x 2 HCl
Cl
(A) 100 mg
MM 0150.15 Imp. L (EP): 5-(2-Chlorobenzyl)-6,7-dihydrothieno[3,2-c]pyridin-
4(5H)-one
N
S
O Cl
(A) 50 mg
MM 0150.04 5-(2-Chlorobenzoyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
N
S
O Cl
(A) 100 mg
Tilidine Hydrochloride Hemihydrate
MM 0134.00 Tilidine Hydrochloride Hemihydrate
[Controlled Substance]
x HCl
x 1/2 H
2
O
O O
N
and enantiomer
(A) 100 mg
MM 0134.01 Imp. A (EP): Ethyl (1RS,2RS)-2-(Dimethylamino)-1-phenylcyclohex-
3-enecarboxylate (cis-Tilidine)
[Controlled Substance]
O O
N
and enantiomer
(D) 100 mg
MM 0134.03 Imp. D (EP) as Hydrochloride: Ethyl (2RS)-3-Dimethylamino-
2-phenylpropanoate Hydrochloride
x HCl
N
O
O
(A) 100 mg
MM 0134.05 Tilidine [Controlled Substance]
O O
N
and enantiomer
(A) 100 mg
Timolol Maleate
MM 0440.00 Timolol Maleate
O
OH
O
OH
x
N
S
N
N
O
OH
H
N
O
(A) 250 mg
MM 0440.04 Imp. D (EP): 4-(Morpholin-4-yl)-1,2,5-thiadiazol-
3-ol
N
S
N
N
OH
O
(A) 100 mg
MM 0440.03 N-Benzyl-tert-butylamine
HN
(B) 100 mg
MM 0440.05 3-Hydroxy-4-morpholino-1,2,5-thiadiazole 1-Oxide
N
S
N
N
OH
O
O
(A) 100 mg
MM 0440.02 (S)-Isotimolol
N
S
N
N
O
O
HO N
H
(A) 100 mg
Tinidazole
MM 0012.02 Imp. A (EP): 2-Methyl-5-nitro-1H-imidazole
(2-Methyl-4-nitroimidazole) NH
N
O
2
N
(B) 100 mg
Tioconazole
New MM 0281.01 Imp. D (EP): (1RS)-1-(2,4-Dichlorophenyl)-2-
(1H-imidazol-1-yl)ethanol
N
N
HO
Cl
Cl
(A) 100 mg
Pharmaceutical impurities
206 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Tiotropium Bromide Monohydrate
New MM 1293.05 Imp. E (EP): Methyl 2-Hydroxy-2,2-dithiophen-2-ylacetate
O
O
OH
S
S
(A) 100 mg
MM 1293.06 Imp. F (EP): Dithiophen-2-ylmethanone
S
S
O
(A) 100 mg
Tizanidine Hydrochloride
New MM 0887.04 N-Acetyltizanidine
N
S
N
Cl
NH
N
N
O
(A) 50 mg
New MM 0887.05 1-Acetylimidazolidine-2-thione
N
H
N
S
O
(A) 50 mg
Tolazoline Hydrochloride
MM 0585.00 Tolazoline Hydrochloride
HN
N
x HCl
(A) 500 mg
Tolbutamide
MM 0325.01 Imp. A (EP): (4-Methylphenyl)sulfonamide
(Toluenesulfonamide; 4-Methylbenzene-
sulfonamide)
S
NH
2
O O
(C) 100 mg
Tolnaftate
MM 0731.01 Imp. A (EP): Naphthalen-2-ol (-Naphthol)
HO
(A) 100 mg
MM 0731.04 Imp. D (EP): N,3-Dimethylaniline (N-Methyl-m-toluidine)
NH
(A) 100 mg
New MM 0731.03 O-Naphthalen-2-yl Chlorothioformate
Cl O
S (A) 100 mg
Tolmetin Sodium Dihydrate
MM 0571.00 Tolmetin Sodium Dihydrate
N ONa
O
O
x 2 H
2
O
on request
Tolterodine Tartrate
New MM 0900.00 Tolterodine Tartrate
N
OH
OH
OH
OH
O
HO
O
x
(A) 100 mg
Topiramate
New MM 1348.00 Topiramate
O
O
O
O
O
O
S
NH
2
O O
(A) 100 mg
Torasemide, Anhydrous
New MM 1283.02 Imp. B (EP): 4-[(3-Methylphenyl)amino]-
pyridine-3-Sulfonamide N
NH
S
NH
2
O O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 207
Code Product Price Unit
New MM 1283.03 Imp. C (EP): 1-Ethyl-3-[[4-[(3-methylphenyl)amino]-
pyridin-3-yl]sulfonyl]urea N
NH
S
N
H
O O
N
H
O
(A) 50 mg
New MM 1283.04 Imp. D (EP): 1-Butyl-3-[[4-[(3-methylphenyl)amino]-
pyridin-3-yl]sulfonyl]urea N
NH
S
N
H
O O
N
H
O
(A) 50 mg
Tramadol Hydrochloride
MM 0007.00 Tramadol Hydrochloride
OH
O
N
x HCl
and enantiomer
(A) 500 mg
MM 0007.01 Imp. A (EP) as Hydrochloride: (1RS,2SR)-
2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)-
cyclohexanol Hydrochloride
OH
O
N
x HCl
and enantiomer
(A) 100 mg
MM 0007.03 Imp. B (EP) as Hydrochloride:
[2-(3-Methoxyphenyl)cyclohex-1-enyl]-N,N-
dimethylmethanamine Hydrochloride
N
x HCl
O
(A) 100 mg
MM 0007.04 Imp. C (EP) as Hydrochloride: (1RS)-[2-(3-Methoxy-
phenyl)cyclohex-2-enyl]-N,N-dimethylmethanamine
Hydrochloride
N
x HCl
O
(A) 100 mg
MM 0007.06 Imp. D (EP) as Hydrochloride: (1RS,2RS)-2-
[(Dimethylamino)methyl]-1-(3-hydroxyphenyl)-
cyclohexanol Hydrochloride
OH
HO
N
x HCl
and enantiomer
(A) 100 mg
MM 0007.02 Imp. E (EP) as Hydrochloride: (2RS)-
2-[(Dimethylamino)methyl]-
cyclohexanone Hydrochloride
N
x HCl
O
(A) 100 mg
MM 0007.05 3-Bromoanisole
O Br
(B) 100 mg
MM 0007.07 N-Desmethyltramadol Hydrochloride
OH
O
NH
and enantiomer
x HCl
(A) 100 mg
MM 0007.08 N,O-Didesmethyltramadol Hydrochloride
OH
HO
N
H
x HCl
and enantiomer
(A) 100 mg
MM 0007.09 3-Methoxyphenol
O OH
(B) 100 mg
MM 0007.11 Tramadol N-Oxide
OH
O
N
and enantiomer
O
(A) 100 mg
MM 0007.50 [2-(3-Hydroxyphenyl)cyclohex-1-enyl]-N,N-dimethylmethanamine
Hydrochloride
N
x HCl
HO
(A) 100 mg
Tranexamic Acid
MM 0330.00 Tranexamic Acid
OH
O
H2N
(A) 500 mg
Pharmaceutical impurities
208 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0330.04 Imp. D (EP): 4-Aminomethylbenzoic Acid
OH
O
H
2
N
(B) 100 mg
Trazodone Hydrochloride
MM 0421.00 Trazodone Hydrochloride
Cl N
N N
N
N
O
x HCl
(A) 100 mg
MM 0421.13 Imp. A (BP) as Hydrochloride:
4-(3-Chloro-phenyl)-1-[3-(3-oxo-2,3-
dihydro-1,2,4-triazolo[4,3-a]pyridin-2-
yl)propyl]piperazine N
1-
oxide Hydrochloride
(Trazodone N-Oxide Hydrochloride)
Cl N
N N
N
N
O
x HCl
O
(A) 50 mg
New MM 0421.02 Imp. B (BP): 2-[3-(4-Phenylpiperazin-1-yl)-
propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one
N
N N
N
N
O
(A) 50 mg
MM 0421.03
Imp. C (BP) as Dihydrochloride:
2-[3-[4-(4-Chlorophenyl)piperazin-1-yl]propyl]-
1,2,4-triazolo[4,3-a]pyridin-3(2H)-one
Dihydrochloride
N
N N
N
N
O
Cl
x 2 HCl
on request
New MM 0421.04 Imp. D (BP) as Hydrochloride: 2-3-
[4-(3-Bromo-phenyl)piperazin-1-yl]-
propyl-1,2,4-triazolo[4,3-a]-pyridin-
3(2H)-one Hydrochloride
N
N N
N
N
O
Br x HCl
(A) 50 mg
MM 0421.06 Imp. F (BP) as Hydrochloride: 1-(3-Chlorophenyl)-
4-(3-chloropropyl)piperazine Hydrochloride N
N Cl
Cl
x HCl
(A) 100 mg
New MM 0421.07 Imp. G (BP) as Hydrochloride: 3-[4-(3-
Chlorophenyl)piperazin-1-yl]propyl
Isobutyl Ether Hydrochloride
N
N O
Cl
x HCl
(D) 50 mg
MM 0421.08 Imp. H (BP) as Dihydrochloride: 1,3-Bis-[4-(3-chloro-
phenyl)piperazin-1-yl]propane Dihydrochloride N
N N
Cl N Cl
x 2 HCl
(A) 100 mg
MM 0421.10 3-[4-(3-Chlorophenyl)piperazin-1-yl]propanol
Cl N
N HO
(A) 100 mg
MM 0421.11 1,2,4-Triazolo-[4,3-a]pyridine-3(2H)-one
N
NH
N
O
(A) 100 mg
MM 0421.12 1,4-Bis-3-chlorophenylpiperazine
Cl N
N Cl
on request
Triacetin
MM 0966.00 Triacetin
O
O
O
O
O
O
(A) 500 mg
Triamcinolone
MM 0198.01 Triamcinolone
O
F
OH
OH
OH
O
HO
(A) 250 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 209
Code Product Price Unit
MM 0198.02 Imp. A (EP): 9-Fluoro-11,17-dihydroxy-3,20-
dioxopregna-1,4-diene-16,21-diyl Diacetate
(Triamcinolone 16,21-Diacetate)
O
F
O
O
OH
O
HO
O
O
(A) 100 mg
MM 0508.03 Imp. C (EP): 9-Fluoro-11,16,17,21-tetrahydroxypregn-
4-ene-3,20-dione (Pretriamcinolone)
O
F
OH
OH
OH
O
HO
on request
Triamcinolone Acetonide
MM 0198.00 Triamcinolone Acetonide
O
HO
F
O
O
O
OH
(A) 250 mg
MM 0198.01 Imp. A (EP): Triamcinolone
O
HO
F
OH
OH
O
OH
(A) 250 mg
MM 0198.05 Imp. C (Pharmeuropa): 9-Fluoro-11 ,21,21-
trihydroxy-16 ,17-(1-methylethylidenedioxy)-
pregna-1,4-diene-3,20-dione (Triamcinolone
Acetonide 21-Aldehyde Hydrate)
O
HO
F
O
O
O
OH
OH
(A) 100 mg
MM 0198.02 Triamcinolone 16,21-Diacetate
O
HO
F
OH
O
O
O
O
O
(A) 100 mg
Triamcinolone Hexacetonide
MM 0306.00 Triamcinolone Hexacetonide
O
HO
F
O
O
O
O
O
(A) 100 mg
MM 0198.00 Imp. A (EP): Triamcinolone Acetonide
O
HO
F
O
O
O
OH
(A) 250 mg
MM 0198.01 Triamcinolone
O
HO
F
OH
OH
O
OH
(A) 250 mg
Triamterene
MM 0269.00 Triamterene
N
N N
N
NH2
NH
2
H2N
(A) 500 mg
MM 0269.02 Imp. A (EP): 5-Nitrosopyrimidine-2,4,6-triamine
(Nitrosotriaminopyrimidine) N
N
NO
NH
2
NH
2
H
2
N
(B) 100 mg
Pharmaceutical impurities
210 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0269.01 Sodium Hydroxytriamterene Sulphate
N
N N
N
NH
2
NH
2
H
2
N
O
S
NaO
O O
(B) 10 mg
Tributyl Acetylcitrate
MM 0499.00 Tributyl Acetylcitrate
O O
O O
O
O
O
O
on request
MM 0499.01 Imp. A (EP): Tributyl 2-Hydroxypropane-
1,2,3-tricarboxylate (Tributyl Citrate)
O O
O O
O
O
HO
(C) 100 mg
MM 0499.02 Imp. B (EP) (E-Isomer): Tributyl (E)-Propene-
1,2,3-tricarboxylate (Tributyl (E)-Aconitate)
O O
O
O
O O
(A) 100 mg
Triclabendazole
MM 0313.00 Triclabendazole
O
N
H
N
Cl
Cl
Cl
S
(D) 100 mg
Triclosan
MM 0610.00 Triclosan
O
Cl
Cl OH
Cl
(A) 500 mg
Trihexyphenidyl Hydrochloride
MM 0237.00 Trihexyphenidyl Hydrochloride
N
OH
x HCl
(A) 500 mg
MM 0237.03 Imp. A (EP) as Hydrochloride: 1-Phenyl-3-
(piperidin-1-yl)propan-1-one Hydrochloride
O
N
x HCl
(A) 100 mg
MM 0237.01 Acetophenone
O
(B) 100 mg
MM 0237.04 Trihexyphenidyl N-Oxide
N
OH
O
(C) 50 mg
Trimebutine
MM 0417.00 Trimebutine
O
O
O
O
O
N
(A) 500 mg
MM 0417.05 Trimebutine Maleate
O
O
O
O
O
N
OH
O
x
O
OH
(A) 500 mg
MM 0417.01 Imp. A (EP) as Hydrochloride: (2RS)-2-
(Dimethylamino)-2-phenylbutanol Hydro-
chloride
OH
N x HCl
(A) 100 mg
MM 0093.13 Imp. B (EP): 3,4,5-Trimethoxybenzoic
Acid
O
O
O
OH
O
(B) 100 mg
MM 0093.11 Imp. C (EP): Methyl 3,4,5-Trimethoxybenzoate
O
O
O
O
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 211
Code Product Price Unit
MM 0417.11 Imp. D (EP): (1RS)-1-[(Dimethylamino)-methyl]-
1-phenylpropyl 3,4,5-Trimethoxybenzoate
O
O
O
O
O
N (A) 50 mg
MM 0417.07 Imp. E (EP) as Hydrochloride: (2RS)-2-(Methyl-
amino)-2-phenylbutyl 3,4,5-Trimethoxy-benzoate
Hydrochloride (N-Desmethyltrimebutine Hydro-
chloride)
x HCl
O
O
O
O
O
H
N
(A) 50 mg
MM 0417.10 1-Dimethylaminomethyl-1-phenyl-1-propanol Hydrochloride (alpha-
[(Dimethylamino)methyl]-alpha-ethyl-benzenemethanol
Hydrochloride)
x HCl
HO
N
(A) 100 mg
Trimeprazine Tartrate
MM 0958.00 Trimeprazine Tartrate
HO
OH
OH
OH
O
O
N
S
N
x
2
(A) 500 mg
MM 0957.00 Trimeprazine Sulphone (Oxomemazine)
S
N
N
O O
(A) 100 mg
MM 0958.02 Trimeprazine Sulphoxide Hydrochloride
S
N
N
O
x HCl
(A) 100 mg
MM 0958.04 Trimeprazine Sulphone N-Oxide Hydrochloride
(Oxomemazine N-Oxide Hydrochloride)
S
N
N
O
O O
x HCl
(A) 100 mg
Trimetazidine Dihydrochloride
MM 0539.00 Trimetazidine Dihydrochloride
N
HN
O
O
O
x 2 HCl
(A) 100 mg
MM 0539.01 Imp. A (EP) as Dihydrochloride: 1-(3,4,5-
Trimethoxybenzyl)piperazine Dihydrochloride
N
HN
O
O
O
x 2 HCl
(A) 100 mg
MM 0539.02 Imp. B (EP): 1,4-Bis(2,3,4-trimethoxy-
benzyl)piperazine
N
N
O
O
O
O
O
O
(A) 100 mg
MM 0539.03 Imp. C (EP): 2,3,4-Trimethoxybenzaldehyde
O
O
O
O
(B) 100 mg
MM 0539.04 Imp. D (EP): (2,3,4-Trimethoxyphenyl)methanol
HO
O
O
O
(A) 100 mg
MM 0539.05 Imp. E (EP) as Dihydrochloride: 1-(2,4,5-
Trimethoxybenzyl)piperazine Dihydrochloride
N
HN
O
O
O
x 2 HCl
(A) 100 mg
MM 0539.06 Imp. F (EP) as Dihydrochloride: 1-(2,4,6-Tri-
methoxybenzyl)piperazine Dihydrochloride
N
HN
O
O
O
x 2 HCl
(A) 100 mg
MM 0539.07 Imp. G (EP) as Hexahydrate: Piperazine Hexahydrate NH
HN
x 6 H
2
O
(B) 100 mg
Pharmaceutical impurities
212 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0539.09 Imp. H (EP): Ethyl 4-(2,3,4-Trimethoxybenzyl)-
piperazine-1-carboxylate
N
N
O
O
O
O
O
(A) 100 mg
MM 0539.10 Imp. I (EP) as Dihydrochloride: 1-Methyl-4-
(2,3,4-trimethoxybenzyl)piperazine
Dihydrochloride (N-Methyltrimetazidine
Dihydrochloride)
N
N
O
O
O
x 2 HCl
(A) 100 mg
MM 0539.08 1-Formyl-4-(2,3,4-trimethoxybenzyl)piperazine
Hydrochloride
N
N
O
O
O
x HCl
O
(A) 100 mg
Trimethoprim
MM 0093.00 Trimethoprim O
O
O
N
N NH
2
NH2
(A) 500 mg
MM 0093.06 Imp. A (EP): N
2-
Methyl-5-(3,4,5-trimethoxybenzyl)pyrimidine-
2,4-diamine
O
O
O
N
N NH
NH2
(A) 100 mg
MM 0093.01 Imp. B (EP): (2,4-Diaminopyrimidin-5-yl)-(3,4,5-trimethoxy-
phenyl)methanone
O
O
O
N
N NH
2
NH2 O
(A) 100 mg
MM 0093.08 Imp. C (EP): (RS)-(2,4-Diaminopyrimidin-5-yl)(3,4,5-trimethoxy-
phenyl)methanol
O
O
O
N
N NH
2
NH2 OH
(A) 100 mg
MM 0093.04 Imp. D (EP): 2-Amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-4-ol O
O
O
N
N NH
2
OH
(A) 100 mg
MM 0093.03 Imp. E (EP): 4-Amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-2-ol O
O
O
N
N OH
NH2
(A) 100 mg
MM 0093.09 Imp. F (EP): 5-(3-Bromo-4,5-dimethoxybenzyl)pyrimidine-
2,4-diamine
O
O
Br
N
N NH
2
NH2
(A) 100 mg
MM 0093.10 Imp. G (EP): 5-(4-Ethoxy-3,5-dimethoxybenzyl)pyrimidine-
2,4-diamine
O
O
O
N
N NH
2
NH2
(A) 100 mg
MM 0093.11 Imp. H (EP): Methyl 3,4,5-Trimethoxybenzoate O
O
O
O
O
(A) 100 mg
MM 0093.12 Imp. I (EP): 3-(Phenylamino)-2-(3,4,5-trimethoxy-
benzyl)prop-2-enenitrile (E/Z-mixture)
O
O
O
H
N
N
(A) 100 mg
MM 0093.13 Imp. J (EP): 3,4,5-Trimethoxybenzoic Acid O
O
O
OH
O
(B) 100 mg
MM 0093.17 Imp. K (EP) as Hydrochloride: Aniline
Hydrochloride
NH
2
x HCl
(B) 100 mg
MM 0093.02 5-(3,4,5-Trimethoxybenzyl)pyrimidin-2,4-diol O
O
O
N
N OH
OH
(B) 10 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 213
Code Product Price Unit
MM 0093.05 2-Amino-5-(4-hydroxy-3,5-dimethoxybenzyl)pyrimidin-4-ol O
HO
O
N
N NH
2
OH
(A) 100 mg
MM 0093.07 N
4-
Methyl-5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine O
O
O
N
N NH
2
NH
(C) 50 mg
Trimipramine Maleate
MM 0240.00 Trimipramine Maleate
O
OH
O
OH
N N
x
(A) 500 mg
MM 0240.01 Trimipramine
N N
(A) 100 mg
MM 0240.04 Imp. A (EP): (2RS)-3-(10,11-Dihydro-5H-dibenzo-
[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine
N-oxide (Trimipramine N-Oxide)
N N
O
(A) 100 mg
MM 0240.02 Imp. B (EP) as Hydrochloride: (2RS)-3-(10,11-
Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,2-di-
methylpropan-1-amine Hydrochloride
(Desmethyltrimipramine Hydrochloride)
N
H
N
x HCl
(A) 100 mg
MM 0240.05 Imp. C (EP) as Hydrochloride: (2RS)-3-(5H-
Dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-
1-amine Hydrochloride
N N
x HCl
(A) 50 mg
MM 0077.00 Imp. D (EP) as Hydrochloride: Imipramine
Hydrochloride
N
x HCl
N
(A) 500 mg
MM 0076.06 Imp. F (EP): 10,11-Dihydro-5H-dibenzo[b,f]azepine (Iminodibenzyl)
NH
(B) 100 mg
Tropicamide
MM 0601.00 Tropicamide
N
N
O
OH
(A) 250 mg
MM 0601.01 Imp. A (EP): N-(Pyridin-4-ylmethyl)ethanamine
N
HN (A) 100 mg
MM 0601.03 Imp. C (EP): (2RS)-3-Hydroxy-2-
phenylpropanoic Acid (Tropic Acid)
OH
O
OH
(A) 100 mg
MM 0160.03 Imp. D (Pharmeuropa): Phenylacetic Acid [Drug Precursor]
OH
O (B) 100 mg
Tropisetron Hydrochloride
MM 0763.01 Imp. A (EP): (1R,3r,5S)-8-Methyl-8-
azabicyclo[3.2.1]oct-3-ol (Tropine)
HO
N
H
H
H
(A) 100 mg
MM 0763.02 Imp. B (EP): 1H-Indole-3-carboxylic Acid
OH
HN
O
(A) 100 mg
Pharmaceutical impurities
214 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Trospium Chloride
MM 0783.09 Imp. A (EP): Hydroxydiphenylacetic Acid
(Benzilic Acid)
OH
O
OH
(B) 100 mg
Tryptophan
MM 0172.00 L-Tryptophan
H
N
O
OH
NH
2
(A) 500 mg
MM 0172.09 Imp. A (EP): 3,3'-[Ethylidenebis(1H-indole-
1,3-diyl)]bis[(2S)-2-aminopropanoic] Acid
(1,1'-Ethylidenebistryptophan)
N
O
OH
NH
2
N
NH
2
O
HO
(D) 100 mg
MM 0172.03 Imp. D (EP): (S)-2-Amino-3-(5-hydroxy-1H-indol-3-yl)propanoic
Acid (5-Hydroxytryptophan)
H
N
O
OH
NH
2
HO
(A) 100 mg
MM 0172.13 N-Acetyltryptophan
H
N
O
OH
HN
O
(A) 100 mg
Tyrosine
MM 0634.00 Tyrosine
HO
OH
O
NH
2
(A) 100 mg
Valaciclovir Hydrochloride, Anhydrous
MM 0061.02 Imp. A (EP): 2-Amino-1,9-dihydro-6H-
purin-6-one (Guanine) HN
N
N
H
N
O
H
2
N
(B) 100 mg
MM 0061.00 Imp. B (EP): 2-Amino-9-[(2-hydroxy-
ethoxy)methyl]-1,9-dihydro-6H-purin-6-
one (Aciclovir)
HN
N
N
N
O
H
2
N
O
OH
(A) 500 mg
MM 0619.07 Imp. G (EP): N,N-Dimethylpyridin-4-amine
N
N (A) 100 mg
MM 0061.01 Imp. I (EP): 2-[(2-Amino-6-oxo-1,6-dihydro-
9H-purin-9-yl)methoxy]ethyl Acetate HN
N
N
N
O
H
2
N
O
O
O
(A) 100 mg
Valproic Acid
MM 0751.00 Valproic Acid
O
OH
(A) 500 mg
MM 0751.11 Sodium Valproate
O
ONa
(A) 500 mg
MM 0751.01 Imp. A (EP): Pentanoic Acid (Valeric Acid)
OH
O
(C) 100 mg
MM 0751.02 Imp. B (EP): (2RS)-2-Ethylpentanoic Acid
OH
O
(A) 100 mg
MM 0751.03 Imp. C (EP): (2RS)-2-(1-Methylethyl)pentanoic Acid
OH
O
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 215
Code Product Price Unit
MM 0751.04 Imp. D (EP): 2,2-Dipropylpentanoic Acid
OH
O
(A) 100 mg
MM 0751.05 Imp. E (EP): Pentanamide (Valeramide)
NH
2
O
(A) 100 mg
MM 0751.06 Imp. F (EP): 2-Propylpentanamide
NH
2
O
(A) 100 mg
MM 0751.07 Imp. G (EP): 2,2-Dipropylpentanamide
NH
2
O
(A) 100 mg
MM 0751.08 Imp. H (EP): Pentanenitrile (Valeronitrile)
N
(C) 100 mg
MM 0751.09 Imp. I (EP): 2-Propylpentanenitrile
N
(A) 100 mg
MM 0751.10 Imp. J (EP): 2,2-Dipropylpentanenitrile
N
(A) 100 mg
Vancomycin Hydrochloride
MM 0239.00 Vancomycin Hydrochloride
O
HO
NH
2
O
OH
HO
HO
O
O
Cl
HO
N
H
O
NH
OH
OH
HN O
NH
O
HN
NH
2
O
O
H
N
O
NH OH
Cl
O
O
OH
x HCl
O
O OH
(A) 100 mg
Venlafaxine Hydrochloride
MM 0393.00 Venlafaxine Hydrochloride
O
N
OH
x HCl
(D) 100 mg
MM 0393.02 Imp. A (EP) as Hydrochloride: 2-(4-
Methoxyphenyl)-N,N-dimethylethanamine
Hydrochloride
O
N
x HCl
(A) 100 mg
MM 0393.07 Imp. B (EP) as Hydrochloride: Ethyl (2RS)-3-
(Dimethylamino)-2-(4-methoxyphenyl)propanoate
Hydrochloride
O
N
O O
x HCl
(A) 100 mg
MM 0393.08 Imp. C (EP) as Hydrochloride: 1-[(1RS)-2-Amino-
1-(4-methoxyphenyl)ethyl]cyclohexanol Hydrochloride
O
NH
2
OH
x HCl
(A) 100 mg
MM 0393.04 Imp. D (EP) as Hydrochloride: 1-[(1RS)-1-(4-
Methoxyphenyl)-2-(methylamino)ethyl]cyclo-
hexanol Hydrochloride
O
H
N
OH
x HCl
(A) 100 mg
MM 0393.09 Imp. E (EP) as Hydrochloride: (5RS)-5-(4-
Methoxyphenyl)-3-methyl-1-oxa-3-azaspiro-
[5.5]undecane Hydrochloride
O
N
O
x HCl
(A) 100 mg
Pharmaceutical impurities
216 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0393.10 Imp. F (EP) as Hydrochloride: (2RS)-2-
(Cyclohex-1-enyl)-2-(4-methoxyphenyl)-
N,N-dimethylethanamine Hydrochloride
O
N
x HCl
(A) 100 mg
MM 0393.03 Imp. G (EP) as Hydrochloride: (2RS)-2-
Cyclohexyl-2-(4-methoxyphenyl)-N,N-
dimethylethanamine Hydrochloride
O
N
x HCl
(A) 100 mg
MM 0393.11 Imp. H (EP): 1-[(1RS)-1-(4-Methoxyphenyl)-
2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]-
Cyclohexanol
O
H
N
OH
O
(A) 50 mg
MM 0393.01 O-Desmethylvenlafaxine
HO
N
OH
(A) 100 mg
Verapamil Hydrochloride
MM 0022.00 Verapamil Hydrochloride
O
O N
O
x HCl
O
N
(A) 500 mg
MM 0022.07 Imp. A (EP) as Dihydrochloride: N,N'-
Bis[2-(3,4-dimethoxyphenyl)ethyl]-
N,N'-dimethylpropane-1,3-diamine
Dihydrochloride
O
O N N O
O
x 2 HCl
(A) 100 mg
MM 0022.08 Imp. B (EP) as Hydrochloride: 2-(3,4-Dimethoxyphenyl)-N-
methylethanamine Hydrochloride
O
O NH
x HCl
(A) 100 mg
MM 0022.09 Imp. C (EP) as Hydrochloride: 2-(3,4-
Dimethoxyphenyl)-N,N-dimethylethan-
amine Hydrochloride
O
O N
x HCl
(A) 100 mg
MM 0022.02 Imp. D (EP): 3-Chloro-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-
methylpropan-1-amine
O
O N Cl
(A) 100 mg
MM 0022.05 Imp. E (EP): (3,4-Dimethoxyphenyl)methanol
O
O
OH
(B) 100 mg
MM 0022.10 Imp. F (EP) as Hydrochloride: (2RS)-
2-(3,4-Dimethoxyphenyl)-5-(methylamino)-
2-(1-methylethyl)pentanenitrile
Hydrochloride
HN
O
x HCl
O
N
(A) 100 mg
MM 0022.04 Imp. G (EP): 3,4-Dimethoxybenzaldehyde
O
O
O (B) 100 mg
MM 0022.11 Imp. H (EP) as Hydrochloride: (2RS)-
2-(3,4-Dimethoxyphenyl)-
5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-
2-ethylpentanenitrile Hydrochloride
O
O N
O
x HCl
O
N
(A) 100 mg
MM 0022.12 Imp. I (EP) as Hydrochloride: (2RS)-
2-(3,4-Dimethoxyphenyl)-2-[2-[[2-(3,4-dimethoxy-
phenyl)ethyl](methyl)amino]ethyl]-3-methyl-
butanenitrile Hydrochloride
N
O
O
O
O
x HCl
N
(A) 50 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 217
Code Product Price Unit
MM 0022.21 Imp. J (EP) as Maleate: (2RS)-
2-(3,4-Dimethoxyphenyl)-
5-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-
2-(1-methylethyl)pentanenitrile Maleate
(N-Norverapamil Maleate)
O
O N
H
O
O
N
OH
O
O
OH
x
(A) 100 mg
MM 0022.03 Imp. K (EP): (2RS)-2-(3,4-Dimethoxyphenyl)-3-methylbutylnitrile
O
N
O (A) 100 mg
MM 0022.13 Imp. L (EP): 1-(3,4-Dimethoxyphenyl)-2-
methylpropan-1-one
O
O
O (A) 100 mg
MM 0022.15 Imp. N (EP) as Hydrochloride: 5,5'-
(Methylimino)bis[2-(3,4-dimethoxy-
phenyl)-2-(1-methylethyl)pentanenitrile]
Hydrochloride
N
O
O
O
x HCl
O
N N
(A) 50 mg
MM 0022.16 Imp. O (EP) as Hydrochloride: (2RS)-
2-(3,4-Dimethoxyphenyl)-
5-[2-[2-(3,4-dimethoxy-
phenyl)ethyl](methyl)amino]-
2-propylpentanenitrile Hydrochloride
O
O N
O
x HCl
O
N
(A) 100 mg
MM 0022.06 Diisopropylhomoveratylcyanide
O
N
O (D) 100 mg
MM 0022.18 3,4-Dimethoxyphenylacetonitrile
O
O
N
(A) 100 mg
MM 0022.19 Verapamil N-Oxide Hydrochloride
O
O N
O
x HCl
O
N
O
(C) 50 mg
Vincamine
MM 0519.00 Vincamine
N
N
H
O
O
HO
(A) 100 mg
Vinpocetine
MM 0406.00 Vinpocetine
N
N
O
O
H
(D) 100 mg
MM 0406.02 Imp. A (EP): Ethyl (12RS,13aSR,13bSR)-13a-
Ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octa-
hydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]-
naphthyridine-12-carboxylate (Ethyl Vincaminate)
N
N
H
O
O
HO
and enantiomer
(D) 100 mg
MM 0406.01 Imp. B (EP): Methyl (13aS,13bS)-13a-Ethyl-
2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-
de]pyrido[3,2,1-ij][1,5]naphthyridine-12-
carboxylate (Apovincamine)
N
N
O
O
H
(D) 100 mg
Pharmaceutical impurities
218 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
Voriconazole
New MM 1094.04
Imp. A (EP): 1-(2,4-Difluorophenyl)-2-
(1H-1,2,4-triazol-1-yl)ethanone
N
N
N
O
F
F
(A) 100 mg
Warfarin Sodium
MM 0732.01 Imp. A (EP): (5RS)-3-(2-Hydroxyphenyl)-5-phenylcyclohex-
2-enone
OH
O
(A) 100 mg
MM 0732.02 Imp. B (EP): 4-Hydroxy-2H-1-benzopyran-
2-one (4-Hydroxycoumarin)
O O
OH
(A) 100 mg
MM 0732.03 Imp. C (EP): (3E)-4-Phenylbut-3-en-2-one
(Benzalacetone)
O
(A) 100 mg
Xylazine Hydrochloride
MM 0515.00 Xylazine Hydrochloride
H
N S
N
x HCl
(A) 500 mg
MM 0102.02 Imp. A (EP): 2,6-Dimethylaniline (2,6-Xylidine)
H
2
N
(B) 100 mg
Xylometazoline Hydrochloride
MM 0089.00 Xylometazoline Hydrochloride
N
N
H
x HCl
(A) 500 mg
MM 0089.07 Imp. A (EP) as Hydrochloride: N-(2-Aminoethyl)-2-
[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]acetamide
Hydrochloride
O
N
H
NH
2
x HCl
(A) 100 mg
MM 0089.04 Imp. B (EP): 2-(Chloromethyl)-5-(1,1-dimethylethyl)-
1,3-dimethylbenzene
Cl
(A) 100 mg
MM 0089.03 Imp. C (EP): [4-(1,1-Dimethylethyl)-2,6-dimethylphenyl]acetonitrile
N
(A) 100 mg
MM 0089.05 Imp. D (EP): 1-(1,1-Dimethylethyl)-3,5-dimethylbenzene (C) 100 mg
MM 0089.02 Imp. F (EP): [4-(1,1-Dimethylethyl)-2,6-dimethylphenyl]acetic Acid
O
OH
(A) 100 mg
Zaleplon
New MM 1322.02 N-[3-[3-(Dimethylamino)-1-oxo-2-propenyl]phenyl]-N-ethylacetamide
O
N
O
N
(A) 100 mg
Pharmaceutical impurities
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 219
Code Product Price Unit
Zidovudine
MM 0534.00 Imp. A (EP): 1-[(2R,5S)-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl)-
5-methylpyrimidine-2,4(1H,3H)-dione (Stavudine)
O
HO
N
HN
O
O
(A) 100 mg
MM 0173.02 Imp. B (EP): 1-(3-Chloro-2,3-dideoxy--D-
erythro-pentofuranosyl)-5-methylpyrimidine-
2,4(1H,3H)-dione
O
HO
N
HN
O
O
Cl
(A) 100 mg
MM 0534.01 Imp. C (EP): 5-Methylpyrimidine-2,4(1H,3H)dione (Thymine)
N
H
HN
O
O
(A) 100 mg
MM 0173.04 Imp. D (EP): Triphenylmethanol
OH
(A) 100 mg
New MM 0534.03
Imp. E (Pharmeuropa): 1-(2-Deoxy- -D-erythro-
pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-
dione (Thymidine)
O
HO
N
HN
O
O
OH
(A) 100 mg
Zileuton
MM 1297.03 1-Benzo-[b]thien-2-ylethanone
S
O
(A) 100 mg
New MM 1297.02 2-(Benzo[b]thien-2-oyl)benzo[b]thiophene
O
S S
(A) 50 mg
Ziprasidone Hydrochloride Monohydrate
New MM 1273.00 Ziprasidone Hydrochloride Monohydrate
N
N
N
S
HN
Cl
O
x HCl x H
2
O
on request
Zolpidem Tartrate
MM 0333.01 Imp. A (EP): N,N-Dimethyl-2-[7-methyl-
2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
N
N
N
O
(D) 100 mg
MM 0333.02 2-[6-Methyl-2-(4-methylphenyl)imidazo-[1,2-a]pyridin-3-yl]acetamide
N
N
NH
2
O
(A) 100 mg
MM 0333.03 2-[6-Methyl-2-(4-methylphenyl)imidazo-[1,2-a]pyridin-3-yl]acetic
Acid
N
N
OH
O
(A) 100 mg
MM 0333.04 Methyl 2-[6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-
3-yl]acetate
N
N
O
O
(D) 50 mg
MM 0333.05 6-Methyl-2-(4-methylphenyl)imidazo-[1,2-a]pyridine-3-acetonitrile
N
N
N
(A) 100 mg
Pharmaceutical impurities
220 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Price Unit
MM 0333.06 Oxozolpidem (N,N,6-Trimethyl-2-(4-methylphenyl)--oxo-
imidazo [1,2-a]pyridine-3-acetamide)
N
N
N
O
O
(D) 100 mg
MM 0333.07 Zolpaldehyde (6-Methyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-
3-carboxaldehyde)
N
N
O
(A) 100 mg
MM 0333.08 Zolpyridine (4-Methyl-N-(5-methyl-2-pyridinyl)-benzamide)
H
N
O N
(A) 100 mg
MM 0333.09 6-Methyl-2-(4-methylphenyl)--oxo-imidazo[1,2-
a]pyridine-3-acetamide
N
N
NH
2
O
O
(A) 100 mg
MM 0333.10 Methyl -Hydroxy-6-methyl-2-(4-methylphenyl)-
imidazo[1,2-a]pyridine-3-acetate
N
N
O
O
HO
(A) 100 mg
Zopiclone
MM 0149.00 Zopiclone
N
Cl
N
N
N
O
O
O
N
N
(D) 100 mg
MM 0149.01 Imp. A (EP): (5RS)-6-(5-Chloropyridin-2-yl)-7-oxo-
6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-Methylpiperazine-
1-carboxylate 4-Oxide (Zopiclone Oxide)
N
Cl
N
N
N
O
O
O
N
N O
(D) 100 mg
MM 0149.02 Imp. B (EP): (7RS)-6-(5-Chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-
5H-pyrrolo[3,4-b]pyrazin-5-one
N
Cl
N
N
N
O
HO
(D) 100 mg
New MM 0149.03
Imp. C (EP): 6-(5-Chloropyridin-2-yl)-6,7-
dihydro-5H-pyrrolo[3,4-b]pyrazin-5-one
N
Cl
N
N
N
O
(A) 50 mg
MM 0149.04 2-Amino-5-chloropyridine
N
Cl
H
2
N
(A) 250 mg
MM 0149.05 3-(5-Chloropyridine-2-carbamoyl)-2-pyrazinecarboxylic Acid
N
Cl
N
H
O
N
N
OH
O
(A) 100 mg
MM 0149.06 6-(5-Chloropyridin-2-yl)- 6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-
5,7-dione
N
Cl
N
N
N
O
O
(A) 100 mg
MM 0149.07 5-(Chloropyridine-2-yl-carbamoyl)pyrazine
N
N
N
H
O
N
Cl
(A) 100 mg
MM 0149.50 2-Acetylamino-5-chloropyridine
N
H
O
N
Cl
(A) 100 mg
European
Pharmacopoeia
Certifed liquids
for viscosity
measurements
International
commission on
pharmaceutical
enzymes
European
pharmacopoeia
reagents
WHO International
Standards for
Antibiotics
From Atorvastatin to Zopiclone:
Over 2,700 pharmaceutical impurities
LGC Standards offers over 2,700 reference standards for
impurities to support the pharmaceutical industry worldwide.
Acknowledged by regulation authorities worldwide
Impurities linked to the European Pharmacopoeia (EP) whereever possible
Customised pharmaceutical impurities created on request
Detailed certifcates of analysis provided
Additional documentation on request
Assistance in fnding the right material to suit your analyses
Atorvastatin
Bupropion
Clopidogrel
Esomeprazol
Ibuprofen
Naproxen
Omeprazole
Risperidone
Sildenafl
Steroid hormones
Venlafaxine
Zopiclone
Over 20 new products per month: Check out our new impurities
on www.lgcstandards.com/newimpurities
LGC Limited, 2011. All rights reserved. 2297/NLh/0811
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 223
European Pharmacopoeia
Background
The European Pharmacopoeia (EP) Commission includes in its membership delegates from nations who
have adopted the European Pharmacopoeia.
The EP Commission is in charge of judging the suitability of monographs. Prior to release, a new monograph
must be adopted by the EP Commission, and then published in the annual Fascicule. Member States then
officially adopt the new monograph on 1
st
January of the following year.
To support the monographs of the European Pharmacopoeia, a collection of reference substances has been
made available which includes:
1. Current, official, European Pharmacopoeia Chemical Reference Substances (EP CRS) and
Biological Reference Preparations (BRP)
2. Reference Spectra
3. Other reference preparations, including Enzymes and Substrates from the
International Commission on Pharmaceutical Enzymes and Certified Viscosity Standards
from Van Swinden Laboratories.
4. With supplement 4.3, the revised EP general method 2.2.6 replaces CRS reference liquids with
certified reference materials available from suppliers of chemical reagents or materials certified
for metrology. Ten liquid CRMs, certified by the Physical Chemistry Division of the Central Office
of Measures (GUM), Warsaw in Poland, cover the wide range of refractive index from 1,333
(water) to 1,657 (1-bromonaphthalene). More detailed information is given in
the chapter "Dyes and refractive index CRMs" of this catalogue.
5. European Pharmacopoeia Reagents.
The European Pharmacopoeia have discontinued the publication of lot lists in printed formate. Therefore
LGC Standards will collect available information of the European Pharmacopoeia and provide you with a
non-official lot list, which includes all new official batches and changes of the European Pharmacopoeia. Of
course you can continue to send us queries about actual lot numbers anytime, as usual. Please contact your
local offices. We are happy to help then.
Relationship with other pharmacopoeias in Europe
Any reference substance, spectra or preparation required for a new EP monograph, is made available as
soon as the monograph comes into force.
Many of the member countries of the European Pharmacopoeia Commission have adopted the EP in full,
and their monographs require only EP CRS/BRP. When an EP monograph is adopted by the pharmacopoeia
of a member state of the Council of Europe then any reference material that may have been available from a
national pharmacopoeia, e.g. BP or PF, will usually be discontinued in favour of the EP reference substance.
However, a number of member countries of the EP Commission maintain national pharmacopoeial
monographs, especially for finished dosage forms, which require the use of separate reference substances.
A separate chapter in this catalogue includes lists of the reference substances produced for the British,
French, Swiss and International pharmacopoeia monographs. The International Pharmacopoeia (IP)
reference substances are described in the section referring to the WHO (World Health Organization).
Production and certification
European Pharmacopoeia reference substances and preparations are selected and verified by the EP
laboratories as being suitable for the use as prescribed in the relevant monograph of the European
Pharmacopoeia.
Since CRS and BRP are officially certified by the European Pharmacopoeia Commission, it should be noted
that neither certificates of analysis nor data not relevant to the use of the products as defined by the EP
monograph are provided with the reference product or substance.
European Pharmacopoeia
224 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Storage, shelf life and expiry dates
European Pharmacopoeia CRS/BRP are subject to regular inspection and repeated analysis by EP scientific
staff. Each EP CRS/BRP is, on receipt by the customer, fit for the intended use.
No expiry date is indicated on the reference materials because the products or substances comply with the
requirements of the corresponding monograph and are monitored regularly. When batches are to be
changed, LGC Standards can provide you with the date on which the previous lot will no longer be official.
In specific cases for reasons related to filling or labeling, sub-batches are obtained from the same batch of
bulk material. However, all the necessary precautions are taken in order to guarantee that the quality and
specifications of the sub-batches do not differ from one to another. The EP changed the labeling structure of
the sub-batches recently. Sub-batches are now labeled for example as 2.1, 2.2, 2.3 instead of 2a, 2b, 2c.
The EP is also currently over-labelling all its reference standards vials with a secondary label. This new
secondary label is useful for customs purposes as it can be peeled off. It can also be stuck onto your
laboratory book to prove the use of the reference standard. All the required information to perform the tests
described in the European Pharmacopoeia monographs are stated on the primary label.
EP recommends only sufficient material should be purchased for immediate use and that unopened vials
should be stored in the dark unless otherwise stated. Whilst most EP CRS/BRP can be shipped at ambient
temperature, certain items have to be maintained at controlled temperatures at all times and are subject to
special shipping charges and storage conditions (details are available on request).
Where no drying conditions are stated, the substance is to be used as received.
Once opened, EP can no longer guarantee the stability of the material and any of the CRS/BRP not used
should be disposed of and not kept for future use.
Validation of secondary standards
All secondary in-house working standards have to be validated against the corresponding EP CRS/BRP.
Please make sure that the secondary material is used only for the same official purposes for which the
primary pharmacopoeial material was designed.
Proper use
EP discontinued their use code number system as of January 2006.
For information on the use of the substances please refer to the monograph or contact your local LGC
Standards office.
Opening
For reference substances and preparations supplied in sealed glass ampoules the following technique is
suitable for opening the ampoule: tap gently to collect the material at the lower end, score the ampoule with a
file, heat a glass rod to white heat and apply firmly to the file mark. If the glass does not crack, deepen and
extend the file mark, and repeat the process. Eye and hand protection MUST be used.
Many reference substances are supplied as lyophilised material in a septum vial. No attempt should be made
to open the vial and weigh out the powder. It is important to strictly follow the monograph instructions,
reconstitute the material in a buffer solvent and handle the resultant solution volumetrically.
Toxicity
The potential toxicity of certain reference substances is such that special precautions should be taken to
avoid contact.
Such substances should be manipulated in a glove box. If this is not possible, gloves, eye protection and a
mask should be worn.
Following the guidelines suggested by the EP does not replace the need to carry out a full hazard
assessment.
Biological and blood products should be regarded as potentially hazardous to health and therefore used and
disposed of according to established laboratory safety procedures.
Controlled Substances
The EPs product range contains substances subject to Controlled Substance regulations schedules.
Special ordering procedures apply, so please contact LGC Standards for details and costs.
Code Product Unit
EPY0000055 Acamprosate calcium - Reference Spectrum unit
EPY0000116 Acamprosate impurity A
3-aminopropane-1-sulphonic acid
50 mg
EPY0000500 Acarbose 94.7 mg
EPY0000354 Acarbose for identification 10 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 225
Code Product Unit
EPY0000427 Acarbose for peak identification 40 mg
EPA0040000 Acebutolol hydrochloride 50 mg
EPY0000359 Acebutolol impurity B
N-[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)
amino]propoxy]phenyl]acetamide (diacetolol)
10 mg
EPY0000127 Acebutolol impurity C
N-(3-acetyl-4-hydroxyphenyl)butanamide
20 mg
EPY0000128 Acebutolol impurity I
N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl)
butanamide
0.004 mg
EPY0000056 Aceclofenac - Reference Spectrum unit
EPY0001094 Aceclofenac for peak identification 10 mg
EPY0000085 Aceclofenac impurity F
benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
20 mg
EPY0000086 Aceclofenac impurity H
[[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl]oxy]acetyl]oxy]acetic acid
10 mg
EPY0000810 Acemetacin 100 mg
EPY0000811 Acemetacin impurity A
4-chlorobenzoic acid
10 mg
EPY0000842 Acemetacine impurity mixture 0.06 mg
EPA0070000 Acesulfame potassium 50 mg
EPA0070020 Acesulfame potassium impurity B
5-chloro-6-methyl-1,2,3-oxathiazin-4(3H)-one 2,2-dioxide
50 mg
EPA0100000 Acetazolamide 100 mg
EPY0001084 Acetazolamide for system suitability 0.0068 mg
EPY0000002 Acetylcholine chloride 50 mg
EPA0150000 Acetylcysteine 50 mg
EPA0152000 Acetylcysteine impurity C
N,N'-diacetyl-L-cystine
10 mg
EPA0153000 Acetylcysteine impurity D
N,S-diacetyl-L-cysteine
10 mg
EPY0000565 -Acetyldigoxin 50 mg
EPY0000642 -Acetyldigoxin for peak identification 10 mg
EPA0200000 Acetylsalicylic acid 100 mg
EPA0208000 N-Acetyltryptophan 125 mg
EPA0202000 N-Acetyltyrosine 200 mg
EPY0000693 Acholeplasma laidlawii BRP 1 mL
EPA0220000 Aciclovir 75 mg
EPY0001264 Aciclovir for system suitability 10 mg
EPY0001271 Aciclovir for peak identification 1 0.3 mg
EPY0001269 Aciclovir for peak identification 2 0.003 mg
EPA0225000 Acitretin 100 mg
EPY0001121 Adapalene 100 mg
EPY0001120 Adapalene impurity C
1-[2-(methyloxy)phenyl]tricyclo[3.3.1.1]decane
6 mg
EPY0001119 Adapalene for peak identification 2.022 mg
EPA0230000 Adenine 50 mg
EPA0230200 Adenosine 50 mg
EPY0000110 Adipic acid 50 mg
EPY0000882 Adrenaline 5 mg
EPY0000883 Adrenaline with impurity F 10 mg
EPA0300000 Adrenaline tartrate 100 mg
EPY0000740 Adrenaline impurity mixture 0.005 mg
EPY0000707 Adrenaline tartrate with impurity A 15 mg
EPY0000728 Agnus castus fruit standardised dry extract 200 mg
European Pharmacopoeia
226 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPA0325000 Alanine 60 mg
EPA0325100 Albendazole 50 mg
EPA0325200 Alcuronium chloride 50 mg
EPA0325450 Alfacalcidol 5 mg
EPA0325451 Alfacalcidol - Reference Spectrum unit
EPA1225000 Alfadex 150 mg
EPA0325500 Alfentanil hydrochloride - Reference Spectrum unit
EPA0325800 Alfuzosin hydrochloride 10 mg
EPY0000832 Alfuzosin for system suitability 10 mg
EPA0349000 Allantoin 60 mg
EPA0350000 Allopurinol 50 mg
EPA0350010 Allopurinol impurity A
5-amino-1H-pyrazole-4-carboxamide
10 mg
EPA0350020 Allopurinol impurity B
5-formylamino-1H-pyrazole-4-carboxamide
10 mg
EPA0350030 Allopurinol impurity C
N-(4H-1,2,4-triazol-4-yl)1H-pyrazole-4-carboxamide
10 mg
EPA0350040 Allopurinol impurity D
ethyl 5-amino-1H-pyrazole-4-carboxylate
10 mg
EPA0350050 Allopurinol impurity E
ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate
20 mg
EPA0351000 Allylstrychnine bromide 10 mg
EPY0000235 Almagate 25 mg
EPY0000255 Almagate - Reference Spectrum unit
EPA0357000 Alprazolam Controlled Substance 100 mg
EPA0360000 Alprenolol hydrochloride 100 mg
EPY0000054 Alprostadil 50 mg
EPY0000606 Altizide 150 mg
EPY0000843 Altizide impurity B
3-[(2,2-dimethoxyethyl)sulphanyl]prop-1-ene
15 mg
EPY0000687 Alverine citrate 5 mg
EPY0000595 Alverine for peak identification 0.125 mg
EPY0000607 Alverine impurity D
N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine
10 mg
EPA0363000 Amantadine hydrochloride 100 mg
EPA0363700 Ambroxol hydrochloride 125 mg
EPA0900000 Amfetamine sulphate - Reference Spectrum unit
EPA0365000 Amidotrizoic acid dihydrate 100 mg
EPA0368000 Amikacin 200 mg
EPA0365900 Amikacin sulphate 200 mg
EPY0001117 Amikacin for system suitability 20 mg
EPA0370000 Amiloride hydrochloride 100 mg
EPY0000020 Amiloride impurity A
methyl-3,5-diamino-6-chloropyrazine-2-carboxylate
10 mg
EPY0000173 4-Aminobenzoic acid 60 mg
EPA0420000 Aminocaproic acid 50 mg
EPA0460000 7-Aminodesacetoxycephalosporanic acid 20 mg
EPA0496000 Aminoglutethimide 125 mg
EPA0496005 Aminoglutethimide impurity A
(3RS)-3-(3-aminophenyl)-3-ethylpiperidine-2,6-dione;
(3-aminoglutethimide)
20 mg
EPA0496020 Aminoglutethimide impurity D
3,3'-[diazenediyldi(4,1-phenylene)]bis(3-ethylpiperidine-2,6-dione) (azoglutethimide)
10 mg
EPA0575000 Amiodarone hydrochloride 100 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 227
Code Product Unit
EPY0000129 Amiodarone impurity D
(2-butyl-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)methanone
20 mg
EPY0000130 Amiodarone impurity E
(2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone
20 mg
EPA0590000 Amisulpride 50 mg
EPA0590004 Amisulpride impurity B
4-amino-N-[[(2RS )-1-ethylpyrrolidin-2-yl] methyl]-5-(ethylsulphonyl)-2-hydroxybenzamine
10 mg
EPY0000563 Amitriptyline hydrochloride 10 mg
EPY0000049 Amlodipine besilate 150 mg
EPY0001067 Amlodipine for peak identification 10 mg
EPY0001068 Amlodipine impurity A
3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-2-[[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-
yl)ethoxy]methyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
10 mg
EPY0001069 Amlodipine impurity B
3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-6-methyl-2-[[2-[[2-
(methylcarbamoyl)benzoyl]amino]ethoxy]methyl]-1,4-dihydropyridine-3,5-dicarboxylate
10 mg
EPY0001070 Amlodipine impurity G
dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
10 mg
EPY0000302 Ammonio methacrylate copolymer (type A) - Reference Spectrum unit
EPY0000303 Ammonio methacrylate copolymer (type B) - Reference Spectrum unit
EPA0650000 Amobarbital Controlled Substance 500 mg
EPA0700000 Amobarbital sodium Controlled Substance 500 mg
EPA0800000 Amoxicillin trihydrate 100 mg
EPY0000005 Amphotericin B 100 mg
New EPY0001361 Amphotericin B for microbiological assay 100 mg
EPY0001014 Amphotericin B for peak identification 10 mg
EPA1000000 Ampicillin (anhydrous) 250 mg
EPA1100000 Ampicillin trihydrate 150 mg
New EPY0001244 Amylmetacresol 285 mg
New EPY0001245 Amylmetacresol for peak identification 10 mg
New EPY0001386 Angelica dahuria root 160 mg
EPA1200000 Anhydrotetracycline hydrochloride 15 mg
EPA1210000 Antazoline hydrochloride 50 mg
EPY0000172 Apomorphine hydrochloride - Reference Spectrum unit
EPA1220000 Alpha-apo-oxytetracycline 20 mg
EPA1230000 Beta-apo-oxytetracycline 20 mg
EPA1250000 Aprotinin solution BRP 0.5 mL
EPY0001154 Aprotinin for system suitability 2.7 mg
EPA1269000 L-Arabinitol 10 mg
EPY0000806 Arbutin 100 mg
EPA1270000 Arginine 50 mg
EPY0000304 Arginine aspartate 20 mg
EPA1271000 Arginine hydrochloride 50 mg
EPY0001185 Aristolochic acid I 11 mg
EPY0001175 Aristolochic acid for system suitability 1 mg
EPY0000079 Articaine hydrochloride 100 mg
EPY0000080 Articaine impurity A
methyl3-[[2-(propylamino)acetyl]amino]-4-methylthiophene-2-carboxylate
15 mg
EPY0000081 Articaine impurity E
methyl 4-methyl-3-[[(2RS)-2-[(1-methylethyl)amino]propanoyl]
amino]thiophene-2-carboxylate
10 mg
EPA1300000 Ascorbic acid (Vitamin C) 100 mg
EPY0001024 Ascorbic acid impurity C
D-sorbosonic acid
20 mg
EPY0001170 Ascorbic acid impurity D
Methyl D-sorbosonate
10 mg
European Pharmacopoeia
228 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000800 Ascorbyl palmitate 10 mg
EPY0000305 Asparagine monohydrate 60 mg
EPA1320000 Aspartame 40 mg
EPA1321000 Aspartame impurity A
2-(5-benzyl-3,6-dioxopiperazin-2-yl)acetic acid (diketopiperazine)
10 mg
EPA1330000 Aspartic acid 50 mg
EPY0001171 Astragaloside IV 40 mg
EPA1340000 Atenolol 100 mg
EPY0001089 Atenolol for system suitability 5 mg
New EPY0001327 Atorvastatine calcium trihydrate 150 mg
New EPY0001328 Atorvastatin impurity A
desfluoroatorvastatin
10 mg
New EPY0001329 Atorvastatin impurity B
3-epi-atorvastatin
10 mg
New EPY0001330 Atorvastatin impurity C
fluoroatorvastatin
10 mg
New EPY0001331 Atorvastatin impurity D
3-[(4-fluorophenyl)carbonyl]-2-(2-methylpropanoyl)-N,3-diphenyloxirane-2-carboxamide
10 mg
New EPY0001332 Atorvastatin impurity E
ent-atorvastatin
10 mg
EPY0000424 Atracurium besilate 120 mg
EPY0000503 Atracurium for impurity F identification 5 mg
EPY0000504 Atracurium for peak identification 5 mg
EPY0000878 Atropine 30 mg
EPY0000845 Atropine for peak identification 0.25 mg
EPY0000816 Atropine impurity B
(1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl (2RS)-3-hydroxy-2-phenylpropanoate (noratropine)
10 mg
EPA1400000 Atropine sulphate 50 mg
EPY0000029 Azaperone 50 mg
EPA1500000 Azathioprine 100 mg
EPY0001240 Azathioprine impurity A
1-methyl-4-nitro-1H-imidazol-5-amine
10 mg
EPY0001246 Azathioprine impurity G
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purin-2-amine (thiamiprine)
5 mg
EPY0000326 Azelastine hydrochloride 25 mg
EPY0000327 Azelastine impurity B
1-benzoyl-2-[(4RS)-1-methylhexahydro-1H-azepin-4-yl]diazane
5 mg
EPY0000328 Azelastine impurity D
4-(4-chlorobenzyl)phthalazin-1(2H)-one
5 mg
EPY0000329 Azelastine impurity E
3-(4-chlorobenzilidene)isobenzofuran-1(3H)-one
5 mg
EPY0000306 Azithromycin 200 mg
EPY0000637 Azithromycin for peak identification 15 mg
EPY0000641 Azithromycin for system suitability 0.05 mg
EPY0000307 Azithromycin impurity A
6-demethylazithromycin
10 mg
EPY0000285 B19 virus DNA for NAT testing BRP 150 mg
EPB0070000 Bacampicillin hydrochloride 120 mg
EPB0100000 Bacitracin zinc 150 mg
EPB0200000 Baclofen 50 mg
EPB0200050 Baclofen impurity A
(RS)-4-amino-3-(4-chlorophenyl)butyric acid lactam
50 mg
EPY0001273 Baicalin 10 mg
EPB0250000 Bambuterol hydrochloride 100 mg
EPB0300000 Barbital Controlled Substance 500 mg
EPY0000295 Basic butylated methacrylate copolymer - Reference Spectrum unit
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 229
Code Product Unit
EPB0305000 Beclometasone dipropionate anhydrous 150 mg
EPY0000351 Beclometasone dipropionate monohydrate 10 mg
EPY0000352 Beclometasone dipropionate for system suitability 10 mg
EPY0000469 Beclometasone dipropionate for peak identification 10 mg
EPY0001073 Beclometasone dipropionate impurities F and N 0.052 mg
EPY0001025 Benazepril hydrochloride 160 mg
EPY0001038 Benazepril for system suitability 0.016 mg
EPY0001026 Benazepril impurity A
[(3R)-3-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2-oxo-2,3,4,5-tetrahydro-1H-1-
benzazepin-1-yl]acetic acid
10 mg
EPB0400000 Bendroflumethiazide 100 mg
EPY0000564 Bendroflumethiazide impurity A
4-amino-6-(trifluoromethyl)benzene-1,3-disulphonamide
5 mg
EPY0000044 Benfluorex hydrochloride 50 mg
EPY0000043 Benfluorex hydrochloride for system suitability 360 mg
EPB0470000 Benperidol 100 mg
EPB0477000 Benserazide hydrochloride 50 mg
EPB0477010 Benserazide impurity A
(RS)-2-amino-3-hydroxypropanohydrazide
20 mg
EPY0001071 Benserazide impurity C
(2RS)-2-amino-3-hydroxy-2'-[(1EZ)-(2,3,4-trihydroxybenzylidene)]propanohydrazide
10 mg
EPY0001079 Benserazide for peak identification 10 mg
EPY0001064 Benzaldehyde 150 mg
EPY0001060 Benzalkonium chloride for system suitability 20 mg
EPB0500000 Benzathine benzylpenicillin 125 mg
EPY0000775 Benzbromarone 10 mg
EPB0550000 Benzethonium chloride 100 mg
EPB0600000 Benzocaine 50 mg
EPY0000647 Benzophenone 40 mg
EPY0000167 Benzyl alcohol 50 mg
EPB0670000 Benzyl benzoate - Reference Spectrum unit
EPB0680000 S-Benzylmercaptoacetyltriglycin 10 mg
EPB0700000 Benzylpenicillin potassium 50 mg
EPB0900000 Benzylpenicillin sodium 200 mg
EPY0001149 Berberine chloride 20 mg
EPB0950000 Betadex 200 mg
EPY0000391 Betahistine dihydrochloride 50 mg
EPB0990000 Betahistine mesilate 100 mg
EPB1000000 Betamethasone 75 mg
EPB1030000 Betamethasone acetate 100 mg
EPB1040000 Betamethasone diproprionate 100 mg
EPB1045000 Betamethasone sodium phosphate 100 mg
EPB1054000 Betamethasone-17-valerate 100 mg
EPB1055000 Betamethasone-21-valerate 15 mg
EPY0001027 Betamethasone valerate for system suitability 25 mg
EPY0001065 Betamethasone valerate impurity mixture 0.018 mg
New EPY0001360 Betaxolol for peak identification 15 mg
EPB1103000 Betaxolol hydrochloride 60 mg
EPB1103100 Betaxolol impurity A
(RS)-3-(4-ethylphenoxy)-1-[(1-methylethyl)-amido]propan-2-ol
10 mg
New EPY0001354 Betaxolol impurity C
2-[[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]methyl]oxirane
5 mg
EPB1115000 Bezafibrate 100 mg
EPY0001078 Bicisate labelling kit 1024 mg
European Pharmacopoeia
230 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPB1110000 Bifonazole 100 mg
EPB1110004
Bifonazole impurity B
4-[(RS)-(biphenyl-4-yl)phenylmethyl]-1H-imidazole trifluoroacetate
10 mg
EPY0001059 Bilberry dry extract 250 mg
EPB1116000 Biotin (Vitamin H) 20 mg
EPB1120000 Biperiden hydrochloride 60 mg
EPB1121000 Biperiden impurity A
(1RS)-1-[(1SR,2SR,4SR)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl-3-(piperidin-1-yl)propan-1-ol
(endo form)
20 mg
EPB1130000 1,3-bis(2-acetyl-3-hydroxyphenoxy)-2-propanol 50 mg
EPB1140000 Bisacodyl 50 mg
EPY0000608 Bisacodyl for peak identification 10 mg
EPY0000694 Bisacodyl for system suitability 5 mg
EPY0000812 Bisoprolol fumarate 50 mg
EPY0000877 Bisoprolol for system suitability method A 1 mg
EPY0000813 Bisoprolol for system suitability method B 1 mg
EPB1141000 Bleomycin sulphate 7 mg
EPY0000434 Boldine 30 mg
EPB1142000 Bordetella pertussis mouse antiserum BRP 0.5 mg
EPB1143000 Bromazepam Controlled Substance 60 mg
EPY0000645 Bromazepam for system suitability Controlled Substance 10 mg
EPB1145000 Bromhexine hydrochloride 100 mg
EPY0000200 Bromhexine impurity C
N-(2-aminobenzyl)-N-methylcyclohexanamine
10 mg
EPB1150000 Bromocriptine mesilate 30 mg
EPY0000677 Bromocriptine mesilate for system suitability 5 mg
EPB1152000 Bromperidol 100 mg
EPB1152050 Bromperidol decanoate 60 mg
EPB1153000 Brompheniramine maleate 100 mg
EPY0000468 Brotizolam Controlled Substance 10 mg
EPY0000470 Brotizolam impurity B
2-bromo-4-(2-chlorophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
(demethylbrotizolam)
10 mg
EPB1155000 Brucella melitensis Rev. 1 strain BRP 1 mL
EPB1157300 Budesonide 110 mg
EPY0001148 Budesonide for system suitability 10 mg
EPB1156000 Bufexamac 100 mg
EPB1157400 Buflomedil hydrochloride 100 mg
EPB1157410 Buflomedil impurity B
4-(pyrrolidin-1-yl)-1-(4-hydroxy-2,6-dimethoxyphenyl)butan-1-one
20 mg
EPB1158000 Bumetanide 150 mg
EPY0000309 Bumetanide impurity A
3-nitro-4-phenoxy-5-sulphamoylbenzoic acid
5 mg
EPY0000310 Bumetanide impurity B
3-amino-4-phenoxy-5-sulphamoylbenzoic acid
5 mg
EPB1160000 Bupivacaine hydrochloride 100 mg
EPY0000088 Bupivacaine impurity B
(2RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
20 mg
EPY0000089 Bupivacaine impurity E
6-(butylamino)-N-(2,6-dimethylphenyl)hexanamide
20 mg
EPY0001108 Buprenorphine Controlled Substance 10 mg
EPY0001109 Buprenorphine hydrochloride Controlled Substance 10 mg
EPY0001122 Buprenorphine for system suitability Controlled Substance 10 mg
EPB1168000 Buserelin 2 mg
EPB1168020 D-His-Buserelin 0.5 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 231
Code Product Unit
EPY0000131 Buspirone hydrochloride 5 mg
EPY0000471 Buspirone for system suitability 2 mg
EPB1170000 Busulfan 50 mg
EPB1217000 Butyl parahydroxybenzoate 100 mg
EPB1212000 Butylhydroxyanisole 50 mg
EPB1215000 Butylhydroxytoluene
Plastic additive 07
50 mg
New EPY0001304 Butyl methanesulfonate 30 l
New EPY0001357 Butyl parahydroxybenzoate impurity E
2-methylpropyl 4-hydroxybenzoate (iso-butyl parahydroxybenzoate)
15 mg
EPY0000472 Cabergoline 100 mg
EPC0100000 Caffeine 70 mg
EPY0000787 Caffeine for system suitability 20 mg
EPC0166000 Calcifediol 5 mg
EPC0166001 Calcifediol - Reference Spectrum unit
EPY0000499 Calcipotriol (anhydrous) - Reference Spectrum unit
EPY0000473 Calcipotriol monohydrate 5 mg
EPY0000474 Calcipotriol monohydrate - Reference Spectrum unit
EPC0200000 Calcitonin (salmon) 2x0.98 mg
EPY0000632 Calcitonin-Gly 0.4 mL
EPC0200010 N-acetyl-cys1-calcitonin 20 mg
EPC0225000 Calcitriol 10 mg
EPC0226000 Calcitriol - Reference Spectrum unit
EPC0250000 Calcium folinate 100 mg
EPC0299000 Calcium glucoheptonate 60 mg
EPC0300000 Calcium gluconate 100 mg
EPC0340000 Calcium levulinate dihydrate 250 mg
EPC0350000 Calcium oxalate monohydrate 500 mg
EPC0400000 Calcium pantothenate 60 mg
EPC0405000 Camphor (racemic) 50 mg
New EPY0001388 Candesartan cilexetil 60 mg
New EPY0001389 Candesartan for system suitability 10 mg
EPC0410000 Canrenone 50 mg
EPC0426000 Caprylic acid 200 mg
EPY0000671 Capsaicin 50 mg
EPC0430000 Captopril 10 mg
EPY0001182 Captopril for system suitability 20 mg
New EPY0001219
Captopril impurity B
(2S) 1-[(2S)-3-bromo-2-methylpropanoyl]pyrrolidine-2-carboxylic acid
250 mg
EPY0001220 Captopril impurity C
(2RS)-2-methyl-3-sulphanylpropanoic acid
10 mg
EPY0001221 Captopril impurity D
(2RS)-3-bromo-2-methylpropanoic acid
10 mg
EPY0000435 Captopril impurity E
(2S)-1-isobutyryl-pyrrolidine-2-carboxylic acid
10 mg
EPY0000113 Carbachol 50 mg
EPC0450000 Carbamazepine 200 mg
EPY0000033 Carbamazepine impurity A
10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide(10,11-dihydrocarbamazepine)
10 mg
EPC0451000 Carbasalate calcium - Reference Spectrum unit
EPY0001161 Carbasalate impurity B
2-[[2-(acetyloxy)benzoyl]oxy]benzoic acid (acetylsalicylsalicylic acid)
5 mg
EPC0455000 Carbenicillin sodium 50 mg
EPC0460000 Carbidopa 50 mg
European Pharmacopoeia
232 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPC0465000 Carbimazole 100 mg
EPC0470000 Carbocisteine 60 mg
EPC0499900 Carbon dioxide - Reference Spectrum unit
EPC0550000 Carboplatin - Reference Spectrum unit
EPY0000475 Carboprost trometamol 40 mg
EPY0000536 Carboprost trometamol - Reference Spectrum unit
EPY0000035 Carisoprodol 50 mg
EPY0000036 Carisoprodol impurity A
(2RS)-2-(hydroxymethyl)-2-methylpentyl(1-methylethyl)carbamate
10 mg
EPY0001214 Carmellose 10 mg
EPC0580004 Carmustine - Reference Spectrum unit
EPC0580010 Carmustine impurity A
1,3-bis(2-chloroethyl)urea
20 mg
EPY0000846 Carprofen for veterinary use 30 mg
EPY0000884 Carprofen for system suitability 5 mg
EPY0000192 Carteolol hydrochloride - Reference Spectrum unit
EPY0000193 Carteolol for system suitability 30 mg
EPY0000075 Carvedilol - Reference Spectrum unit
EPY0000103 Carvedilol impurity C
(2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H-carbazol-4-yloxy) propan-2-ol
10 mg
EPC0600000 Casein BRP 100 g
EPC0630000 Cefaclor 450 mg
EPC0640000 Delta-3-Cefaclor 20 mg
EPC0650000 Cefadroxil 250 mg
EPC0675000 Cefalexin monohydrate 150 mg
EPC0682000 Cefalotin sodium 100 mg
EPY0000505 Cefalotin for impurity B identification 10 mg
EPC0682300 Cefamandole nafate 125 mg
EPY0000240 Cefapirin sodium 100 mg
EPC0682400 Cefatrizine propylene glycol 150 mg
EPC0682410 Cefatrizine impurity A
7-amino-(6R,7R)-3-[(2H-1,2,3-triazol-4-yl)sulfanyl]-methyl-8-oxo-5-thia-1-
azabicyclo[4.2.O]oct-2-ene-2-carboxylic acid(7-ACA triazole)
60 mg
EPC0682800 Cefazolin 150 mg
EPY0000633 Cefepime dihydrochloride monohydrate 150 mg
EPY0000634 Cefepime dihydrochloride monohydrate for system suitability 15 mg
New EPY0001336 Cefepime impurity E
(6R,7R)-7-amino-3-[(1-methylpyrrolidinio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-
2-carboxylate
10 mg
EPC0684000 Cefixime 200 mg
EPC0684750 Cefoperazone dihydrate 100 mg
EPC0684800 Cefoperazone sodium - Reference Spectrum unit
EPY0000420 Cefotaxime acid 80 mg
EPC0685000 Cefotaxime sodium 30 mg
EPY0000506 Cefotaxime sodium for peak identification 10 mg
EPC0688000 Cefoxitin sodium 100 mg
New EPY0001305 Cefpodoxime proxetil 70 mg
New EPY0001306 Cefpodoxime proxetil for peak identification 10 mg
New EPY0001318 Cefpodoxime proxetil for impurity H identification 10 mg
EPC0690000 Cefradine 300 mg
EPY0001111 Ceftazidime for peak identification 10 mg
EPY0000568 Cefradine for peak identification 6 mg
EPY0001174 Cefradine impurity mixture 0.04 mg
EPC0690500 Ceftazidime 200 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 233
Code Product Unit
EPC0690510 Ceftazidime impurity A
(6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)
imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)-methyl]-5-thia-1-azabicyclo
[4.2.O]oct-3-ene-2-carboxylate (delta-2-ceftazidime)
15 mg
EPC0691000 Ceftriaxone sodium 80 mg
EPC0692000 Ceftriaxone impurity A
E-isomer
10 mg
EPC0694990 Cefuroxime axetil 60 mg
EPC0695000 Cefuroxime sodium 150 mg
EPY0000311 Celiprolol hydrochloirde 10 mg
EPY0000312 Celiprolol impurity I
1-acetyl-1-(4-ethoxyphenyl)-3,3-diethylurea
0.02 mg
EPY0000239 Celiprolol for peak identification 20 mg
EPY0000784 Cellulose acetate 40 mg
EPC0698005 Cellulose acetate butyrate - Reference Spectrum unit
EPY0001054 Cellulose acetate phthalate 10 mg
EPC0700000 Cephaeline hydrochloride 15 mg
EPC0980650 Cetirizine dihydrochloride 100 mg
EPY0001197 Cetirizine for peak identification 1.01 mg
EPC0980651 Cetirizine impurity A
(RS)-1-[(4-chlorophenyl)phenylmethyl]piperazine
10 mg
EPC0984100 Cetostearyl isononanoate - Reference Spectrum unit
EPC0990000 Cetyl alcohol 250 mg
EPY0000073 Cetyl palmitate 15 60 mg
EPY0000074 Cetyl palmitate 95 50 mg
EPC1000000 Cetylpyridinium chloride 50 mg
EPC1050000 Chenodeoxycholic acid 125 mg
EPY0000104 Chitosan hydrochloride 30 mg
EPC1100000 Chlorambucil 100 mg
New EPY0001298 Chlorambucil for system suitability 10 mg
New EPY0001299 Chlorambucil with impurity G 10 mg
EPC1200000 Chloramphenicol 500 mg
EPC1300000 Chloramphenicol dipalmitate 100 mg
EPC1350000 Chloramphenicol disodium disuccinate 25 mg
EPC1400000 Chloramphenicol palmitate isomer 100 mg
EPC1425000 Chloramphenicol sodium succinate 1500 mg
EPC1435000 Chlorcyclizine hydrochloride 100 mg
EPC1450000 Chlordiazepoxide Controlled Substance 2x50 mg
EPC1500000 Chlordiazepoxide hydrochloride Controlled Substance 100 mg
EPY0000476 Chlordiazepoxide impurity A
7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 4-oxide
10 mg
EPC1510000 Chlorhexidine 50 mg
EPC1520000 Chlorhexidine diacetate 10 mg
EPC1540000 Chlorhexidine dihydrochloride 50 mg
EPC1530000 Chlorhexidine for performance test 50 mg
EPY0000569 Chlorogenic acid 20 mg
EPC2223030 1-(4-Chlorophenyl)-1-phenylethanol
Clemastine fumarate impurity C
20 mg
EPC1650000 Chloroquine sulphate 200 mg
EPC1700000 Chlorothiazide 100 mg
EPC1800000 Chlorphenamine maleate 100 mg
EPY0000436 Chlorphenamine impurity A
2-(4-chlorophenyl)-4-(dimethylamino)-2-[2-(dimethylamino)ethyl]butanenitrile
0.01 mg
EPY0000437 Chlorphenamine impurity C
(3RS)-3-(4-chlorophenyl)-N-methyl-3-(pyridin-2-yl)propan-1-amine
10 mg
European Pharmacopoeia
234 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPC1900000 Chlorpromazine hydrochloride 200 mg
EPY0000507 Chlorpromazine impurity A
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1- amine S-oxide
(chlorpromazine sulphoxide)
10 mg
EPY0000479 Chlorpromazine impurity D
3-(2-chloro-10H-phenothiazin-10-yl)-N-methypropan-1-amine (demethylchlorpromazine)
10 mg
EPY0000508 Chlorpromazine impurity E
2-chloro-10H-phenothiazine
10 mg
EPC1905000 Chlorpropamide 100 mg
EPC1905020 Chlorpropamide impurity B
1,3-Dipropylurea
50 mg
EPC1915000 Chlorprothixene hydrochloride 50 mg
EPC1950000 Chlortalidone 150 mg
EPY0000779 Chlortalidone for peak identification 1.017 mg
EPC2000000 Chlortetracycline hydrochloride 100 mg
EPC2100000 Cholecalciferol 500 mg
EPC2150000 Cholecalciferol for system suitability 1 mL
EPC2155000 Cholesterol 60 mg
EPC2158000 Cholic acid 60 mg
EPY0000280 Chondroitin sulphate sodium 250 mg
EPY0000593 Chondroitin sulphate sodium (marine) 100 mg
EPC2160000 Chymotrypsin BRP 100 mg
EPY0000040 Ciclopirox 100 mg
EPC2162701 Ciclopirox impurity A
(RS)-2-(3-cyclohexyl-5-methyl-4,5-dihydroisoxazol-5-yl)acetic acid
20 mg
EPC2162702 Ciclopirox impurity B
6-cyclohexyl-4-methyl-2H-pyran-2-one
20 mg
EPC2162700 Ciclopirox olamine 150 mg
EPC2163000 Ciclosporin 120 mg
EPY0000361 Ciclosporin for system suitability 5 mg
EPC2170000 Cilastatin sodium 10 mg
EPC2174000 Cilazapril 50 mg
EPC2174002 Cilazapril impurity A
1,1-dimethylethyl(1S,9S)-9-[[(S)-1-ethoxycarbonyl-3-phenylpropyl]amino]-
10-oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-caboxylate
25 mg
EPC2174005 Cilazapril impurity D
(1S,9S)-9-[[(R)-1-ethoxycarbonyl-3-phenylpropyl]amino]-10-oxo-octahydro-6H-
pyridazino[1,2a][1,2]diazepine-1-carboxylic acid
10 mg
EPC2175000 Cimetidine 50 mg
EPC2175500 Cimetidine hydrochloride 100 mg
EPY0001130 Cimetidine for peak identification 10 mg
EPY0001146 Cimetidine for system suitability 0.5085 mg
EPC2177000 Cinchocaine hydrochloride 60 mg
EPY0000176 Cineole 180 mg
EPC2180000 Cinnarizine 100 mg
EPY0000362 Ciprofibrate 5 mg
EPY0000363 Ciprofibrate for system suitability 5 mg
EPY0000198 Ciprofloxacin 20 mg
EPC2190000 Ciprofloxacin hydrochloride 100 mg
EPY0000199 Ciprofloxacin hydrochloride for peak identification 10 mg
EPC2190050 Ciprofloxacin impurity A
7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
(fluoroquinolonic acid)
10 mg
EPC2210000 Cisplatin 100 mg
EPY0001018 Cisplatin impurity A
trans-diamminedichloroplatinium (II)
10 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 235
Code Product Unit
EPY0001019 Cisplatin impurity B
amminetrichloroplatinate (-)
10 mg
EPY0001007 Citalopram hydrochloride 5 mg
EPY0001008 Citalopram hydrobromide 5 mg
EPY0000855 Citalopram for system suitability 0.06 mg
EPA1202000 Citric acid (anhydrous) 50 mg
EPC2219000 Citric acid monohydrate 50 mg
EPY0000639 Cladribine 50 mg
EPY0000609 Cladribine for peak identification 10 mg
EPY0000610 Cladribine impurity C
2-chloro-7H-purin-6-amine
5 mg
EPY0000320 Clarithromycin 160 mg
EPY0000321 Clarithromycin for peak identification 30 mg
EPY0000269 Clazuril for system suitability 10 mg
EPC2221000 Clebopride malate 100 mg
EPC2223000 Clemastine fumarate 100 mg
EPC2248000 Clenbuterol hydrochloride 30 mg
EPC2248010 Clenbuterol impurity B
1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanone (clenbuterol ketone)
10 mg
EPC2250000 Clindamycin hydrochloride 200 mg
EPC2269000 Clindamycin phosphate 250 mg
EPY0000364 Clioquinol 5 mg
EPY0000205 Clobazam - Reference Spectrum unit
EPY0000241 Clobazam impurity A
7-chloro-5-phenyl-1,5-dihydro-1,5-dihydro-3H-1,5-benzodiazepine-2,4-dione
10 mg
EPY0000559 Clobetasol propionate 40 mg
EPY0000570 Clobetasol for peak identification 2 mg
EPY0000571 Clobetasol impurity J
(17R)-4'-chloro-5'-ethyl-9-fluoro-11-hydroxy-16-methylspiro[androsta-1,4-diene-17,2'(3'H)-
furan]-3,3'-dione (17 alpha-spiro compound)
0.4 mg
EPC2285000 Clobetasone butyrate 50 mg
EPY0001137 Clobetasone butyrate for system suitability 30 mg
EPY0000888 Clodronate disodium tetrahydrate 5 mg
EPY0000885 Clodronate impurity D
(chloromethylene)bis(phosphonic acid)
5 mg
EPY0000313 Clofazimine 150 mg
EPY0000358 Clofazimine for system suitability 10 mg
EPC2300000 Clofibrate 0.5 mL
EPC2320000 Clomifene citrate 50 mg
EPC2332000 Clomifene citrate for performance test 50 mg
EPC2360000 Clomipramine hydrochloride 100 mg
EPY0000132 Clomipramine impurity C
3-(3-chloro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
10 mg
EPY0000133 Clomipramine impurity D
3-(3,7-dichloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)
N,N-dimethylpropan-1-amine
10 mg
EPY0000134 Clomipramine impurity F
3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
5 mg
EPC2385000 Clonazepam Controlled Substance 50 mg
EPC2385015 Clonazepam impurity B
3-Amino-4-(2-chlorophenyl)-6-nitro-1H-quinolin-2-one
25 mg
EPY0000286 Clonazepam - Reference Spectrum unit
EPC2400000 Clonidine hydrochloride 100 mg
EPY0000801 Clonidine impurity B
1-acetyl-2-[(2,6-dichlorophenyl)amino]-4,5-dihydro-1H-imidazole
20 mg
EPY0000833 Clopamide 40 mg
European Pharmacopoeia
236 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000848 Clopamide for system suitability 10 mg
New EPY0001333 Clopidogrel hydrogen sulfate 60 mg
New EPY0001334 Clopidogrel for system suitability 100 mg
New EPY0001335 Clopidogrel impurity A
(2S)-(2-chlorophenyl)[6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]acetic acid
10 mg
EPY0000392 Closantel sodium dihydrate 20 mg
EPY0000393 Closantel for system suitability 20 mg
EPC2424400 Clostridia (multi-component) rabbit antiserum
(for vaccines-vet.use) BRP
1 mg
EPC2424550 Clostridium tetani guinea pig antiserum
(for vaccines-human use) BRP
3x1 mL
EPC2424500 Clostridium tetani guinea pig antiserum
(for vaccines - vet.use) BRP
1 mg
EPC2425600 Clostridium tetani rabbit antiserum
(for vaccines - vet.use) BRP
1 mg
EPC2430000 Clotrimazole 100 mg
EPY0000818 Clotrimazole impurity E
(2-chlorophenyl)phenylmethanone (2-chlorobenzophenone)
15 mg
EPY0000849 Clotrimazole for peak identification 1 mg
EPC2450000 Cloxacillin sodium 200 mg
EPC2460000 Clozapine 60 mg
EPY0000758 Clozapine for peak identification 0.41 mg
EPY0000162 Cocaine hydrochloride - Reference Spectrum unit
EPC2480000 Cocoyl caprylocaprate 40 mg
EPY0000722 Codeine Controlled Substance 20 mg
EPC2500000 Codeine - Reference Spectrum unit
EPY0000334 Codeine impurity A
7,8-didehydro-4,5-epoxy-3,6-dimethoxy-17-methylmorphinan
(o-methylcodeine) Controlled Substance
10 mg
EPC2500100 Codeine hydrochloride dihydrate - Reference Spectrum unit
EPC2510000 Codergocrine mesilate 60 mg
EPC2580000 Colchicine 50 mg
EPY0000209 Colchicine for system suitability 10 mg
EPY0000374 Colestyramine 10 mg
EPC2600000 Colistimethate sodium 20 mg
EPY0000277 Colistin sulphate 25 mg
EPC2700000 Colistin sulphate for microbiological assay 25 mg
EPC2725000 Copovidone - Reference Spectrum unit
EPC2800000 Cortisone acetate 250 mg
EPY0000438 Coumarin 80 mg
EPC2900000 Cotton wool standard for neps 1000 mg
EPY0001053 Crospovidone 5 mg
EPC2970000 Crotamiton 100 mg
EPC2970005 Crotamiton impurity A
N-ethyl-N-(2-methylphenyl)but-3-enamide
30 mg
EPY0001061 Cyanidin chloride 20 mg
EPC3000000 Cyanocobalamin 20 mg
EPC3090000 Cyclizine hydrochloride 50 mg
EPY0000886 Cyclizine impurity A
1-methylpiperazine
15 mg
EPY0000887 Cyclizine impurity B
diphenylmethanol (benzhydrol)
10 mg
EPC3200000 Cyclobenzaprine hydrochloride 100 mg
EPC3230000 Cyclohexa-1,4-dienylglycine 20 mg
EPC3245000 Cyclopentolate hydrochloride 2x50 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 237
Code Product Unit
EPY0001088 Cyclopentolate for system suitability 60 mg
EPC3250000 Cyclophosphamide 50 mg
EPC3280000 Cyproheptadine hydrochloride 30 mg
EPY0001095 Cyproheptadine impurity C
5-(1-methylpiperidin-4-yl)-5H-dibenzo[a,d][7]annulen-5-ol
5 mg
EPC3283000 Cyproterone acetate 30 mg
New EPY0001390 Cyproterone acetate for peak identification 5 mg
EPY0001223 Cyproterone impurity mixture 0.01 mg
EPC3290000 Cysteine hydrochloride monohydrate 50 mg
EPC3300000 Cystine 100 mg
EPC3350000 Cytarabine 150 mg
EPY0000733 Dacarbazine 20 mg
EPY0000734 Dacarbazine impurity A
3,7-dihydro-4H-imidazo[4,5-d]-1,2,3-triazin-4-one (2-azahypoxanthine)
10 mg
EPY0000735 Dacarbazine impurity B
5-amino-1H-imidazole-carboxamide
10 mg
EPD0070000 Dalteparin sodium 250 mg
EPY0000600 Danaparoid sodium 10 mg
EPD0100000 Dapsone 100 mg
EPD0125000 Daunorubicin hydrochloride 100 mg
EPD0120000 Daunorubicinone
Daunorubicin aglycone
10 mg
EPD0160000 Deferoxamine mesilate 30 mg
EPD0201000 Dehydrohexetidine 50 mg
EPY0000611 Dembrexine hydrochloride monohydrate 10 mg
EPD0300000 Demeclocycline hydrochloride 100 mg
EPD0350000 N-Demethylerythromycin A 10 mg
EPY0000228 Demethylflumazenil - Reference Spectrum unit
EPD0406000 Deoxyminoxidil 0.25 mg
EPD0406200 Deptropine citrate 60 mg
EPD0430000 Dequalinium chloride 50 mg
EPD0431000 Dequalinium chloride for performance test 50 mg
EPY0001321 Dermatan sulfate and oversulfated chondroitin sulfate 1 mL
EPD0480000 Desacetylvinblastine 2x1 mg
EPY0000879 Desflurance - Reference Spectrum unit
EPY0000807 Desflurane impurity A
1,1'-oxybis(1,2,2,2-tetrafluoroethane)
1 mL
EPD0500000 Desipramine hydrochloride 100 mg
EPD0600000 Deslanoside 150 mg
EPD0630000 Desmethylmetrifonate 30 mg
EPD0650000 Desmopressin 0.98 mg
EPY0000509 Desogestrel 50 mg
EPY0000510 Desogestrel for system suitability 10 mg
EPD0400000 Desoxycortone acetate 100 mg
EPY0000001 Detomidine hydrochloride 100 mg
EPD0660020 Detomidine impurity B
(RS)-(1-benzyl-1H-imidazol-5-yl)(2,3-dimethylphenyl)methanol
20 mg
EPD0700000 Dexamethasone 60 mg
EPY0001177 Dexamethasone for system suitability 10 mg
EPD0710000 Dexamethasone acetate 100 mg
EPY0001169 Dexamethasone acetate impurity E
9-fluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregn-4-en-21-yl acetate
0.013 mg
EPY0000538 Dexamethasone isonicotinate 10 mg
EPY0000511 Dexamethasone isonicotinate for impurity C identification 10 mg
European Pharmacopoeia
238 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPD0718000 Dexamethasone pivalate 50 mg
EPD0720000 Dexamethasone sodium phosphate 100 mg
EPD0720800 Dexchlorpheniramine maleate 60 mg
EPD0730000 Dexpanthenol 5 mg
EPD0731000 Dextran 25 mg
EPD0731005 Dextran 1 50 mg
EPD0732000 Dextran Vo 10 mg
EPD0733000 Dextran 4 for calibration 50 mg
EPD0734000 Dextran 10 for calibration 50 mg
EPD0735000 Dextran 40 for calibration 50 mg
EPD0736000 Dextran 70 for calibration 50 mg
EPD0737000 Dextran 250 for calibration 50 mg
EPD0738000 Dextran 40 for performance test 50 mg
EPD0739000 Dextran 60/70 for performance test 50 mg
EPY0000744 Dextranomer 50 mg
EPD0740000 Dextromethorphan hydrobromide 100 mg
EPY0000261 Dextromethorphan impurity A
ent-3-methoxymorphinan
5 mg
EPY0001058 Dextropropoxyphene hydrochloride Controlled Substance 10 mg
EPY0001150 Dextropropoxyphene for system suitability Controlled Substance 5 mg
EPD0940000 Diazepam Controlled Substance 30 mg
EPY0000596 Diazepam for system suitability Controlled Substance 0.5 mg
EPD0950000 Diazoxide 50 mg
EPD0970000 Dibenzocycloheptene 20 mg
EPD1000000 Dibenzosuberone 100 mg
EPY0000480 Dibrompropamidine diisetionate 10 mg
EPY0000481 Dibrompropamidine for system suitability 20 mg
EPD1010000 Dibutyl phthalate 1 mL
EPY0000275 Dichlorodiaminocyclohexaneplatinum 10 mg
EPY0000259 Diclazuril for system suitability 20 mg
EPY0000264 Diclazuril for veterinary use - Reference Spectrum unit
EPD1039990 Diclofenac potassium 100 mg
EPD1040000 Diclofenac impurity A
1-(2,6-dichlorophenyl)-indolin-2-one
0.005 mg
EPD1050000 Dicloxacillin sodium 250 mg
EPD1060000 Dicycloverine hydrochloride 100 mg
EPY0000439 Didanosine 10 mg
EPY0000440 Didanosine for system suitability 10 mg
EPY0000441 Didanosine impurity A
1,7-dihydro-6H-purin-6-one (hypoxanthine)
10 mg
EPY0000442 Didanosine impurity G
9-(2,3-dideoxy--D-glycero-pentofuranosyl)-9H-purin-6-amine
(2',3'-dideoxyadenosine)
10 mg
EPD1200000 Dienestrol 150 mg
EPD1250000 Diethanolamine fusidate 50 mg
EPD1300000 Diethylcarbamazine citrate 250 mg
EPY0000217 Diethylene glycol (monoethyl ether) - Reference Spectrum unit
EPD1410000 Diethyl phthalate 1 mL
EPD1500000 Diethylstilbestrol 100 mg
EPD1600000 Diethylstilbestrol dimethyl ether 10 mg
EPD1700000 Diethylstilbestrol monomethyl ether 10 mg
EPD1750000 Diflunisal 30 mg
EPD1800000 Digitoxin 250 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 239
Code Product Unit
EPY0000640 Digoxigenin 5 mg
EPD1900000 Digoxin 30 mg
EPY0000554 Digoxin for peak identification 10 mg
EPD1940001 Dihydralazine sulphate (hydrated) - Reference Spectrum unit
EPY0000232 Dihydralazine for system suitability 10 mg
EPY0000216 Dihydrocodeine hydrogen tartrate - Reference Spectrum unit
EPY0000053 17 alpha-dihydroequilin 10 mg
EPD1945000 Dihydroergocristine mesilate 250 mg
EPD1950000 Dihydroergotamine mesilate 100 mg
EPY0000831 Dihydroergotamine for peak identification 10 mg
EPD1952000 Dihydroergotamine tartrate 150 mg
EPD1954000 Dihydrostreptomycin sulphate (for LC assay) 25 mg
EPY0000544 Dihydrotachysterol 30 mg
EPY0000482 Dihydrotachysterol for system suitability 5 mg
EPD1980000 Diltiazem hydrochloride 300 mg
EPY0001141 Diltiazem for system suitability 10 mg
EPD2000000 Dimenhydrinate 100 mg
EPY0000234 N,N-Dimethylacetamide - Reference Spectrum unit
EPY0001103 Dimenhydrinate for peak identification 1 mg
EPD2050000 Dimethyl sulfoxide 1 mL
EPD2200000 Dimeticone 200 mg
EPD2205000 Dimetindene maleate 50 mg
EPD2255000 Dinoprost trometamol 60 mg
EPD2250000 Dinoprostone 100 mg
EPD2250015 Dinoprostone impurity C
(E)-7-[(1S,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]-
5-oxocyclopentyl]-hept-5-enoic acid (5-trans-PGE2;(5E)-PGE2)
10 mg
EPY0000094 Diosmin 50 mg
EPY0000095 Diosmin for system suitability 5 mg
EPD2600000 Diphenhydramine hydrochloride 100 mg
EPY0000135 Diphenhydramine impurity A
2-(diphenylmethoxy)-N-methylethanamine
10 mg
EPD2630000 Diphenoxylate hydrochloride - Reference Spectrum unit
EPY0000258 Diphtheria toxin BRP 1 mL
EPD2700000 Diphtheria vaccine (absorbed) BRP 32 mg
EPY0000376 Dipivefrine hydrochloride 100 mg
EPY0000394 Dipivefrine for system suitability 10 mg
EPD2750100 Dipotassium clorazepate - Reference Spectrum unit
EPD2800000 Diprophylline 100 mg
EPD2850000 Dipyridamole 50 mg
EPY0000802 Dipyridamole for peak identification 2 mg
EPD2880000 Dirithromycin 100 mg
EPD2900000 Disodium edetate 100 mg
EPD2920000 Disopyramide 100 mg
EPD2922000 Disopyramide phosphate 100 mg
EPD2950000 Disulfiram 100 mg
EPD2953000 Dithranol 125 mg
EPD2953025 Dithranol impurity C
Dithranol-dimer 4,4',5,5'-tetrahydroxy-9,9'-bianthracenyl-10,10'(9H,9'H)-dione
20 mg
EPD2953050 Dithranol impurity D
1-hydroxyanthracen-9(10H)-one
20 mg
EPD2954000 Dobutamine hydrochloride 100 mg
EPY0001239 Dobutamine impurity mixture 0.1 mg
European Pharmacopoeia
240 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0001133 Docetaxel trihydrate 160 mg
EPY0001155 Docetaxel for system suitability 10 mg
EPD2954600 Docosahexaenoic acid ethyl ester 150 mg
EPD2954500 Docusate sodium - Reference Spectrum unit
EPY0000365 Dodecyl gallate 30 mg
EPD2955000 Domperidone 150 mg
EPD2957000 Domperidone maleate 150 mg
EPD2960000 Dopamine hydrochloride 50 mg
EPY0000612 Dopexamine dihydrochloride 10 mg
EPY0000613 Dopexamine impurity B
2-methoxy-4-[2-[[6-[(2-phenylethyl)hexyl]amino]ethyl]phenol
10 mg
EPY0000614 Dopexamine impurity F
4-Chloro-5-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]benzene-1,2-diol
10 mg
EPY0000726 Dorzolamide hydrochloride 50 mg
EPY0000727 Dorzolamide impurity A
(4R,6R)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]
thiopyran-2-sulphonamide 7,7-dioxide
5 mg
EPY0000750 Dorzolamide for system suitability 5 mg
EPD2962000 Dosulepin hydrochloride 100 mg
EPD2962005 Dosulepin impurity A
(E)-3-(6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-
N,N'-dimethylpropan-1-amine S-oxide
50 mg
New EPY0001385 Doubleteeth pubescent angelica root 500 mg
EPD2963000 Doxapram hydrochloride 50 mg
EPY0000208 Doxapram impurity B
(4RS)-1-ethyl-4-[2-[(2-hydroxyethyl)amino]ethyl]-3,3-diphenylpyrolidin-2-one
10 mg
EPY0000553 Doxazosin mesilate 60 mg
EPY0000551 Doxazosin impurity D
6,7-dimethoxyquinazoline-2,4(1H,3H)-dione
10 mg
EPY0000552 Doxazosin impurity F
2-chloro-6,7-dimethoxyquinazolin-4-amine
10 mg
EPY0000838 Doxepin hydrochloride 5 mg
EPY0000851 Doxepin for system suitability 1 mg
EPD2975000 Doxorubicin hydrochloride 150 mg
EPD3000000 Doxycycline hyclate 50 mg
EPY0000163 Doxylamine hydrogen succinate - Reference Spectrum unit
EPY0000160 Doxylamine impurity A
N,N-dimethyl-2-[1(RS)-1-phenyl-1-(pyridin-4-yl)ethoxy]ethanamine
50 mg
EPD3100000 Droperidol 150 mg
EPY0001105 Drospirenone 60 mg
EPY0001115 Drospirenone impurity E
3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-3'H,3''H-dicyclopropa
[6,7:15,16]pregn-4-ene-21,17-carbolactone (17-epidrospirenone)
0.06 mg
EPY0001004 Dydrogesterone 50 mg
EPY0001005 Dydrogesterone impurity A
9,10-pregna-4,6,8(14)-triene-3,20-dione
6 mg
EPY0001006 Dydrogesterone impurity B
pregna-4,6-diene-3,20-dione
5 mg
EPY0000249 Ebastine - Reference Spectrum unit
EPY0000247 Ebastine impurity C
4-(diphenylmethoxy)piperidine
10 mg
EPY0000248 Ebastine impurity D
1-[4-(1,1-dimethylethyl)phenyl]-4-(4-hydroxypiperidin-1-yl)butan-1-one
10 mg
EPY0001236 Econazole 10 mg
EPY0000254 Econazole for system suitability 20 mg
EPE0050000 Econazole nitrate 100 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 241
Code Product Unit
EPE0085000 Eicosapentaenoic acid ethyl ester 200 mg
EPY0000537 Emedastine difumarate 10 mg
EPY0000512 Emedastine impurity E
1-(2-ethoxyethyl)-2-(hexahydro-1H-1,4-diazepin-1yl)benzimidazole
10 mg
EPE0100000 Emetine hydrochloride 100 mg
EPE0110000 Enalapril for system suitability 20 mg
EPE0109000 Enalapril maleate 50 mg
EPY0001211 Enalapril impurity mixture 0.06 mg
EPY0000615 Enalaprilat dihydrate 100 mg
EPY0000629 Enalaprilat for system suitability 10 mg
EPY0000678 Enalaprilat impurity G
(2SR)-2-[(3SR,8aRS)-3-methyl-1,4-dioxohexahydropyrrolo
[1,2-a]pyrazin-2(1H)-4-phenylbutanoic acid
0.005 mg
EPY0000136 Enilconazole 60 mg
EPY0000137 Enilconazole impurity E
(1RS)-1-(2,4-dichlorophenyl)-2-(-1H-imidazol-1-yl)ethanol
20 mg
EPE0150000 Endotoxin standard BRP 11 mg
EPE0180000 Enoxaparin sodium 200 mg
EPE0180500 Enoxolone 100 mg
EPY0001259 Enrofloxacin 5 mg
EPY0001160 Enrofloxacin for system suitability 10 mg
New EPY0001249 Entacapone 160 mg
New EPY0001250 Entacapone impurity A
Z isomer of entacapone
10 mg
EPE0200000 Enterokinase BRP 500 mg
EPE0305000 Ephedrine hydrochloride (racemic) Drug Precursor 50 mg
EPE0300000 Ephedrine hydrochloride Drug Precursor 150 mg
EPE0400000 4-Epianhydrotetracycline hydrochloride 15 mg
EPE0430000 4-Epichlortetracycline hydrochloride 20 mg
EPE0440000 4-Epidemeclocycline hydrochloride 20 mg
EPE0500000 6-Epidoxycycline hydrochloride 50 mg
EPY0001139 Epinastine hydrochloride 20 mg
EPY0001128 Epinastine hydrochloride for system suitability 10 mg
EPE0530000 4-Epioxytetracycline 40 mg
EPE0550000 Epirubicin hydrochloride 100 mg
EPE0600000 4-Epitetracycline hydrochloride 30 mg
EPY0000052 Equilin 15 mg
EPE0850010 Eq influenza Subtype 1 Strain A/eq/Newmarket/77 Horse Antiserum BRP 3x1 mg
EPE0850021 Eq influenza Subtype 2 American-like/Newmarket Horse Antiserum BRP 3x1 mg
EPE0850022 Eq Influenza Subtype 2 European-like/Newmarket Horse Antiserum BRP 3x1 mg
EPY0000712 Eq Influenza Subtype 2 American-like/South Africa Horse Antiserum BRP 3x1 mg
EPE0900000 Ergocalciferol 500 mg
EPE1000000 Ergometrine maleate Drug Precursor 50 mg
EPE1100000 Ergosterol 20 mg
EPE1200000 Ergotamine tartrate Drug Precursor 100 mg
EPY0000051 Erysipelas ELISA coating antigen BRP 0.4 mg
EPY0000177 Erythritol 1000 mg
EPE1300000 Erythromycin for microbiological assay 250 mg
EPE1305000 Erythromycin A 250 mg
EPE1310000 Erythromycin B 50 mg
EPE1320000 Erythromycin C 50 mg
EPE1400000 Erythromycin estolate 100 mg
EPE1500000 Erythromycin ethylsuccinate 10 mg
European Pharmacopoeia
242 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPE1500800 Erythromycin stearate 50 mg
EPE1515000 Erythropoietin BRP 37.5 mg
EPY0000324 Esketamine hydrochloride - Reference Spectrum unit
EPY0000338 Esketamine impurity D
(2R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone ((R)-ketamine)
10 mg
EPY0001028 Esomeprazole magnesium trihydrate 10 mg
EPY0000749 Essential oil 1000 mg
EPE1600000 Estradiol benzoate 250 mg
EPY0000852 Estradiol benzoate for system suitability 10 mg
EPY0000045 Estradiol butyrate 10 mg
EPE1620000 Estradiol hemihydrate 100 mg
EPY0000314 Estradiol for peak identification 10 mg
EPY0000046 Estradiol valerate 50 mg
EPE1680000 Estriol 50 mg
EPE1680005 Estriol impurity A
9,11-didehydroestriol
20 mg
EPE1700000 Estrone 15 mg
EPE1800000 Etacrynic acid 100 mg
EPY0001263 Etacrynic acid for system suitability 10 mg
EPE1830000 Etamsylate 30 mg
EPE1840000 Ethacridine lactate monohydrate 50 mg
EPE1850000 Ethambutol hydrochloride 250 mg
EPY0000803 Ethambutol for system suitability 10 mg
EPA1202800 Ethanol (anhydrous) - Reference Spectrum unit
EPE1860100 Ethanol 96% - Reference Spectrum unit
EPE1900000 Ethinylestradiol 100 mg
EPY0001124 Ethinylestradiol for system suitability 25.3 mg
EPE2000000 Ethionamide 100 mg
EPE2150000 Ethosuximide 30 mg
EPE2250000 Ethosuximide impurity A
2-Ethyl-2-methylsuccinic acid
15 mg
EPE2195000 Ethyl acetate - Reference Spectrum unit
EPE2195900 Ethylcellulose - Reference Spectrum unit
EPE2202000 1-N-Ethylgaramin sulphate 50 mg
EPE2205500 1,1'-Ethylidenebistryptophan 2x0.00167 mg
EPY0000617 Ethyl indole-3-carboxylate 10 mg
EPE2300000 Ethylmorphine hydrochloride - Reference Spectrum unit
EPE2400000 Ethylnicotinamide 150 mg
EPE2425000 Ethyl parahydroxybenzoate 150 mg
EPE2450000 Etifenin 25 mg
EPE2451000 Etilefrine hydrochloride 75 mg
EPE2451010 Etilefrine impurity A
2-ethylamino-1-(3-hydroxyphenyl)ethanone
20 mg
EPY0000572 Etidronate disodium 10 mg
EPE2470000 Etodolac 60 mg
EPE2470050 Etodolac impurity H
2-(7-ethylindol-3-yl)ethanol
10 mg
EPY0000768 Etodolac for peak identification 10 mg
EPE2499900 Etofenamate 40 mg
EPE2499901 Etofenamate for peak identification 15 mg
EPE2499914 Etofenamate impurity G
2-hydroxyethyl 2-[[3-(trifluoromethyl)phenyl]amino]-benzoate
20 mg
EPE2500000 Etofylline 100 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 243
Code Product Unit
EPE2503000 Etomidate 50 mg
EPE2503004 Etomidate impurity B
methyl-1-[(1RS)-1-phenylethyl]-1H-imidazole-5-carboxylate
25 mg
EPE2600000 Etoposide 150 mg
New EPY0001365 Etoposide for system suitability 10 mg
EPE5000000 Eugenol 500 L
EPF0005000 Famotidine 100 mg
EPY0000382 Famotidine for system suitability 10 mg
EPF0007000 Famotidine impurity B
3,5-bis[2-[[[2-[(diaminomethylene)amino] thiazol-4-yl]methyl]thio]-ethyl]-
4H-1,2,4,6-thiatriazine1,1-dioxide
10 mg
EPY0000409 Famotidine impurity D
3-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]sulphanyl]propanamide
10 mg
EPY0000556 Febantel 110 mg
EPY0000660 Febantel for system suitability 10 mg
EPY0000731 Felbinac 10 mg
EPY0000732 Felbinac impurity A
4-acetyl biphenyl
20 mg
EPF0030000 Felodipine 120 mg
EPY0000415 Felypressin 0.994 mg
EPF0040000 Fenbendazole 150 mg
EPF0040010 Fenbendazole impurity A
methyl(1H-benzimidazol-2-yl)carbamate
20 mg
EPF0040020 Fenbendazole impurity B
methyl[5(6)-chlorobenzimidazol-2-yl]carbamate
20 mg
EPF0041000 Fenbufen 100 mg
EPF0048000 Fenofibrate 100 mg
EPF0048005 Fenofibrate impurity A
(4-chlorophenyl)(4-hydroxyphenyl)methanone
20 mg
EPF0048010 Fenofibrate impurity B
2[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid (fenofibric acid)
10 mg
EPF0048035 Fenofibrate impurity G
1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl]
oxy]-2-methylpropanoate
25 mg
EPY0000756 Fenoterol for peak identification 1.2 mg
EPF0050000 Fenoterol hydrobromide 100 mg
EPF0054990 Fentanyl - Reference Spectrum unit
EPF0055000 Fentanyl citrate - Reference Spectrum unit
EPF0060000 Fenticonazole nitrate 50 mg
EPF0060040 Fenticonazole impurity D
(RS)-1-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]-3-
[4-(phenylsuphanyl)benzyl]imidazolium nitrate
20 mg
EPF0100000 Ferrous gluconate 100 mg
EPY0001013 Ferulic acid 20 mg
EPY0000789 Fexofenadine hydrochloride 60 mg
EPY0000751 Fexofenadine impurity A
2-[4-[4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]
butanoyl]phenyl]-2-methylpropanoic acid
5 mg
EPY0000752 Fexofenadine impurity B
2-[3-[(1RS)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl]phenyl]-2-
methylpropanoic acid
0.01 mg
EPY0000753 Fexofenadine impurity C
(1RS)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]-1-[4-(1-methylethyl)phenyl]butan-1-ol
5 mg
EPY0001173 Filgrastim 0.2 mL
EPY0000090 Finasteride 60 mg
EPY0000091 Finasteride for system suitability 100 mg
EPY0000736 Flavoxate hydrochloride 10 mg
European Pharmacopoeia
244 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000737 Flavoxate impurity A
3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid
10 mg
EPY0000738 Flavoxate impurity B
ethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate
10 mg
EPF0120000 Flecainide acetate 200 mg
EPF0120005 Flecainide impurity A
3-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-1,5,6,7,8,8a-
hexahydroimidazo[1,5-a]pyridine
50 mg
EPY0001274 Flecainide for system suitability 10 mg
EPF0120010 Flecainide impurity B
(piperidin-2-yl)methanamine
25 mg
EPY0000138 Flubendazole 25 mg
EPY0000139 Flubendazole for system suitability 20 mg
EPY0000892 Flucloxacillin magnesium octahydrate 5 mg
EPY0000889 Flucloxacillin impurity C
6-aminopenicillanic acid
5 mg
EPY0000890 Flucloxacillin impurity D
3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid
5 mg
EPY0000891 Flucloxacillin impurity E
6-aminopenicillanic acid flucloxacillin amide
5 mg
EPF0150000 Flucloxacillin sodium 250 mg
EPY0000557 Fluconazole 50 mg
EPY0000558 Fluconazole for peak identification 10 mg
EPY0000573 Fluconazole impurity B
2-[2-fluro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
10 mg
EPY0000574 Fluconazole impurity C
1,1-(1,3-phenylene)di-1H-1,2,4-triazole
5 mg
EPF0175000 Flucytosine 100 mg
EPY0001262 Flucytosine for system suitability 0.3 mg
EPY0000419 Fludarabine phosphate 100 mg
EPF0180000 Fludrocortisone acetate 100 mg
EPF0188000 Flumazenil - Reference Spectrum unit
EPY0000335 Flumazenil impurity B
ethyl 8-hydroxy-5-methyl-6-oxo-5,6-dihydro-4H-imidazo
[1,5-a][1,4]benzodiazepine-3-carboxylate
5 mg
EPF0189000 Flumequine 60 mg
EPF0189020 Flumequine impurity B
ethyl(RS)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-benzo[i,j]
quinolizine-2-carboxylate (flumequine ethyl ester)
0.1 mg
EPF0188500 Flumetasone pivalate 100 mg
EPF0189900 Flunarizine dihydrochloride 100 mg
EPY0000265 Flunarizine dihydrochloride - Reference Spectrum unit
EPY0000266 Flunarizine dihydrochloride for system suitability 20 mg
EPF0190000 Flunitrazepam Controlled Substance 100 mg
EPY0000169 Flunitrazepam - Reference Spectrum unit
EPY0000443 Flunixin meglumine 10 mg
EPY0000444 Flunixin impurity B
2-methyl-3-(trifluoromethyl)aniline
10 mg
EPY0000445 Flunixin impurity C
ethyl 2-chloropyridine-3-carboxylate
50 mg
EPF0200000 Fluocinolone acetonide 100 mg
EPF0230000 Fluocortolone pivalate 100 mg
EPY0000796 Fluorescein 120 mg
EPY0000804 Fluorescein impurity C
2-(2,4-dihydroxybenzoyl)benzoic acid
0.01 mg
EPY0000454 Diacetylfluorescein 100 mg
EPF0245000 Fluoresceine sodium - Reference Spectrum unit
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 245
Code Product Unit
EPF0250000 Fluorouracil 40 mg
EPY0000762 Fluorouracil impurity A
pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid)
10 mg
EPY0000763 Fluorouracil impurity B
dihydropyrimidine-2,4,5(3H)-trione (isobarbituric acid or 5-hydroxyuracil)
10 mg
EPY0000764 Fluorouracil impurity C
pyrimidine-2,4(1H,3H)-dione (uracil)
10 mg
EPY0000765 Fluorouracil impurity F
2-ethoxy-5-fluoropyrimidin-4(1H)-one (2-ethoxy-5-fluorouracil)
10 mg
EPY0000791 Fluorouracil impurity mixture 0.0002 mg
EPF0253000 Fluoxetine hydrochloride 250 mg
EPF0253020 Fluoxetine impurity B
methyl(3-phenylpropyl)amine Controlled Substance
10 mg
EPF0253030 Fluoxetine impurity C
(RS)-methyl-[3-phenyl-3-(3-trifluoromethylphenoxy)-propyl]amine
5 mg
EPY0000064 Flupentixol dihydrochloride 100 mg
EPY0000067 Flupentixol impurity D
2-[2-[4-[3-[(EZ)-2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]
piperazin-1-yl]ethoxy]ethanol
15 mg
EPY0000078 Flupentixol impurity F
2-[4-[(EZ)-3-[(9RS)-2-(trifluoromethyl)-9H-thioxanthen-9-yl)prop-2-enyl]-
piperazin-1-yl]ethanol
25 mg
EPF0260000 Fluphenazine decanoate 60 mg
EPY0000009 Fluphenazine enantate 100 mg
EPF0280000 Fluphenazine dihydrochloride 50 mg
EPY0000708 Fluphenazine impurity mixture 0.07 mg
EPY0000298 Fluphenazine octanoate 10 mg
EPY0000299 Fluphenazine sulphoxide 10 mg
EPY0000211 Flurazepam monohydrochloride - Reference Spectrum unit
EPF0285200 Flurbiprofen 50 mg
EPF0285202 Flurbiprofen impurity A
(2RS)-2-(biphenyl-4-yl)propanoic acid
20 mg
EPY0000236 Fluspirilene 20 mg
EPY0000375 Fluspirilene impurity C
8-[4,4-bis((4-fluorophenyl)butyl]-3-(hydroxymethyl)-1-
phenyl-1,3,8-triazaspiro[4.5]decan-4-one
10 mg
EPF0285600 Flutamide 50 mg
EPF0285603 Flutamide impurity C
N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
20 mg
EPY0000284 Fluticasone propionate 100 mg
EPY0000221 Fluticasone impurity D
S-methyl 6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-
diene-17-carbothioate (S-methyl derivative)
10 mg
EPF0290000 Flutrimazole 100 mg
EPF0290010 Flutrimazole impurity B
(RS)-(2-fluorophenyl)(4-fluorophenyl)phenylmethanol
60 mg
EPY0001090 Fluvastatin sodium 110 mg
EPY0001082 Fluvastatin for system suitability 0.5 mg
EPY0000854 Fluvoxamine maleate 5 mg
EPY0000853 Fluvoxamine for system suitability 1.004 mg
EPY0000916 Fluvoxamine impurity D
5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one
10 mg
EPY0000386 Foeniculin for peak identification
Star anise oil
100 mg
EPF0300000 Folic acid 150 mg
EPY0001242 Folic acid impurity A (2S)-2-[(4-aminobenzoyl)amino]pentanedioic acid
(N-(4-aminobenzoyl)-l-glutamic acid)
15 mg
European Pharmacopoeia
246 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0001243 Folic acid impurity D
4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic acid (pteroic acid)
70 mg
EPF0372000 Formoterol fumarate dihydrate 10 mg
EPY0000339 Formoterol for impurity I identification 10 mg
EPY0000340 Formoterol fumarate for system suitability 10 mg
EPF0380000 Formylfolic acid
10-Formylfolic acid
30 mg
EPF0389000 Foscarnet sodium hexahydrate 50 mg
EPF0389004 Foscarnet impurity B
disodium(ethoxyoxydophosphanyl)formate
10 mg
EPY0001222 Foscarnet impurity D
Ethyl (diethoxyphosphinyl)formate
50 mg
EPY0001213 Foscarnet impurity mixture 0.012 mg
EPY0000782 Fosfomycin calcium 10 mg
EPF0399900 Fosfomycin calcium - Reference Spectrum unit
EPF0399950 Fosfomycin sodium - Reference Spectrum unit
EPF0400000 Fosfomycin trometamol 1500 mg
EPY0001227 Fosinopril sodium 60 mg
EPY0001228 Fosinopril impurity A
(2S,4S)-4-cyclohexyl-1-[[(R)-hydroxy(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-
carboxylic acid
5 mg
EPY0001229 Fosinopril impurity B
(2RS,4RS)-4-cyclohexyl-1-[[(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy)propoxy](4-
phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
5 mg
EPY0001230 Fosinopril impurity C
mixture of (2S,4S)-4-cyclohexyl-1-[[(S)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4-
phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid and (2S,4S)-4-cyclohexyl-1-[[(R)-
[(1R)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-
carboxylic acid
10 mg
EPY0001231 Fosinopril impurity D
(2S,4R)-4-cyclohexyl-1-[[(R)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4-
phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
10 mg
EPY0001232 Fosinopril impurity I
[(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl]acetic acid
5 mg
EPY0001233 Fosinopril impurity K
(2S,4S)-4-cyclohexyl-1-(2,2-dimethyl-1-oxopropyl)pyrrolidine-2-carboxylic acid
5 mg
EPY0001212 Fosinopril impurity mixture 0.02 mg
EPF0450000 Framycetin sulphate 2x25 mg
EPF0550000 Fructose 100 mg
EPF0600000 Fumaric acid 100 mg
EPF0700000 Furosemide 100 mg
EPF0702000 Furosemide impurity A
2-chloro-4-(furfurylamino)-5-sulphamoylbenzoic acid
5 mg
EPF1000000 Fusidic acid - Reference Spectrum unit
New EPY0001280 Gabapentin 300 mg
New EPY0001281 Gabapentin impurity A
2-azaspiro[4.5]decan-3-one
20 mg
New EPY0001348 Gabapentin impurity B
(1-cyanocyclohexyl)acetic acid
20 mg
New EPY0001349 Gabapentin impurity D
[1-[(3-oxo-2-azaspiro[4.5]dec-2-yl)methyl]cyclohexyl]acetic acid
10 mg
EPG0049000 Galactitol 50 mg
EPG0050000 Galactose 60 mg
EPY0001279 Galantamine hydrobromide 10 mg
EPY0001190 Galantamine natural for system suitability 10 mg
EPY0001201 Galantamine racemic mixture 10 mg
EPY0001191 Galantamine synthetic for system suitability 5 mg
EPG0100000 Gallamine triethiodide 100 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 247
Code Product Unit
EPG0150000 Gammacyclodextrin 50 mg
EPY0001129 Ganciclovir 220 mg
EPY0001144 Ganciclovir impurity mixture 0.005 mg
EPY0000675 Gemcitabine hydrochloride 50 mg
EPY0000676 Gemcitabine impurity A
4-aminopyrimidin-2(1H)-one (Cytosine)
20 mg
EPY0000513 Gemfibrozil 5 mg
EPY0000514 Gemfibrozil for system suitability 0.196 mg
EPG0200000 Gentamicin sulphate 2x25 mg
New EPY0001363 Gentamicin for peak identification 10 mg
EPY0001112 Gestodene 100 mg
EPY0001110 Gestodene for system suitability 10 mg
EPY0001116 Gestodene impurity I
13-ethyl-17-hydroxy-5-methoxy-18,19-dinor-5alpha,17alpha-pregn-15-en-20-yn-3-one
0.01 mg
EPY0001012 Ginkgo dry extract for peak identification 150 mg
EPY0001010 Ginkgolic Acid 20 mg
EPG0300000 Gitoxin 30 mg
EPG0325000 Glibenclamide 100 mg
EPG0325010 Glibenclamide impurity A
4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulphonamide
10 mg
EPY0000242 Glibenclamide impurity B
methyl [[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl] sulphonyl]carbamate
10 mg
EPG0326000 Gliclazide 20 mg
EPG0326004 Gliclazide impurity B
2-nitroso-octahydrocyclopenta[c]pyrrole
25 mg
EPG0326012 Gliclazide impurity F
1-(hexahydrocyclopenta[c]pyrrol-2-(1H)-yl-3-[(2-methylphenyl)sulphonyl]urea
30 mg
EPY0000515 Glimepiride 60 mg
EPY0000516 Glimepiride for system suitability 0.012 mg
EPG0340000 Glipizide 50 mg
EPG0342000 Glipizide impurity A
4-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzene sulphonamide
10 mg
EPY0000523 Glipizide impurity C
ethyl 2-[4-[(cyclohexylcarbamoyl)sulphamoyl]phenyl]ethyl]carbamate
10 mg
EPY0000643 Glipizide impurity D
6-methyl-N-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide
10 mg
EPY0001140 Glipizide impurity mixture 0.002 mg
EPY0000191 Human glucagon 2x0.952 mg
EPG0350500 Glucose 100 mg
EPG0355000 Glutamic acid 50 mg
EPY0000517 Glutathione 10 mg
EPG0360000 Glutethimide Controlled Substance 50 mg
EPG0400000 Glycerol (85 per cent) - Reference Spectrum unit
EPG0400002 Glycerol dibehenate 2000 mg
EPG0400004 Glycerol distearate 2000 mg
EPY0000794 Glycerol monocaprylate 400 mg
EPY0000795 Glycerol monocaprylocaprate 500 mg
EPG0400006 Glycerol monolinoleate 2000 mg
EPG0400007 Glycerol mono-oleate 2000 mg
EPG0400008 Glycerol monostearate 40-55 2000 mg
EPG0400101 Glyceryl trinitrate - Reference Spectrum unit
EPG0400100 Glyceryl trinitrate solution 0.5 mL
EPG0450000 Glycine 50 mg
New EPY0001308 Glycopyrronium bromide 10 mg
European Pharmacopoeia
248 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0001309 Glycopyrronium for peak identification 10 mg
New EPY0001358 Glycopyrronium impurity N
N(3RS)-3-[(2RS)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium
10 mg
EPY0000433 Ammonium glycyrrhizate 70 mg
EPG0460000 Glycyrrhizate (monoammonium) 300 mg
EPG0525000 Gonadorelin 5 mg
EPY0000125 Goserelin 2 mg
EPY0000126 Gosereline - Reference Spectrum unit
EPY0000019 4-D-Ser-goserelin 0.1 mg
EPY0000194 Goserelin validation mixture 1 mg
EPG0550000 Gramicidin 250 mg
EPY0000396 Granisetron hydrochloride 120 mg
EPY0000477 Granisetron impurity A
2-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2H-indazole-3-carboxamide
1 mg
EPY0000478 Granisetron impurity B
N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
1 mg
EPY0000395 Granisetron impurity E
(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine
2x10 mg
EPG0600000 Griseofulvin 50 mg
EPY0000619 Guaiacol 2200 mg
EPG0700000 Guaifenesin 100 mg
EPY0000117 Halofantrine hydrochloride 125 mg
EPY0000118 Halofantrine impurity C
[1,3-dichloro-6-(trifluoromethyl)phenantren-9-yl]methanol
10 mg
EPH0100000 Haloperidol 50 mg
EPH0100100 Haloperidol decanoate 60 mg
EPH0150000 Halothane - Reference Spectrum unit
EPY0000673 Harpagoside 1.03 mg
EPY0001287 Heparin calcium for NMR identification 30 mg
EPY0001282 Heparin for Physio-Chemical Analysis 300 mg
EPH0185000 Heparin Low-Molecular-Mass for assay BRP 5x10 mg
EPH0190000 Heparin Low-Molecular-Mass for calibration CRS 25 mg
EPH0200000 Heparin sodium BRP 2 mL
EPY0001283 Heparin sodium for NMR identification 30 mg
EPH0205010 Hepatitis A vaccine (inactivated,absorbed) Type B BRP 3x0.5 mL
EPY0001192 Hepatitis A Vaccine (Inactivated, Non-Adsorbed) 0.8 ml
EPY0000389 Hepatitis B vaccine (rDNA) BRP method A (thiomersal free) 2x0.5 mL
EPH0210010 Hepatitis B vaccine (rDNA) BRP method B 2x1 mL
EPH0215000 Hepatitis C Virus RNA for NAT testing BRP 5x40 mg
EPH0220000 Heptadecanol 2x600 mg
EPY0000063 Heptaminol hydrochloride 150 mg
EPY0000057 Heptaminol impurity A
(2RS)-6-methylhept-5-en-2-amine
20 mg
EPH0250000 alpha-Hexachlorocyclohexane 10 mg
EPH0330000 Hexamidine diisetionate 50 mg
EPH0325000 Hexetidine 100 mg
EPH0400000 Hexobarbital 500 mg
EPH0420000 Hexylresorcinol 100 mg
EPH0500000 Hide Powder 500 mg
EPH0600000 Histamine dihydrochloride 250 mg
EPH0700000 Histamine phosphate 250 mg
EPH0750000 Histidine 100 mg
EPH0755000 Histidine hydrochloride monohydrate 100 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 249
Code Product Unit
EPH0800000 Homatropine hydrobromide 100 mg
EPH0830000 Homatropine methylbromide 25 mg
EPH0837000 L-Homocycsteine thiolactone hydrochloride - Reference Spectrum unit
EPH0900000 Human albumin for electrophoresis BRP 1 mL
EPY0000219 Human anti-D immunoglobulin BPR unit
EPY0000667 Human coagulation factor VII concentrate BRP 2x26 mg
EPH0920000 Human coagulation factor VIII concentrate BRP 5x34 mg
EPH0920500 Human coagulation factor IX concentrate BRP 5x30 mg
EPH0950000 Human hepatisis A immunoglobulin BRP 3x10 mg
EPH0990000 Human immunoglobulin BRP 15800 mg
EPH1000000 Human immunoglobulin for electrophoresis BRP 96 mg
EPY0000488 Human immunoglobulin (molecular size) BRP 3x700 mg
EPH1005000 Human Plasma Pools for NAT Validation 3502 mg
EPH1100000 Human rabies immunoglobulin BRP 3x170 mg
EPH1110000 Human tetanus immunoglobulin BRP 87 mg
EPY0000502 Human vaccinia immunoglobulin 3x1 mL
EPH1115000 Hyaluronidase BRP 50 mg
EPH1120000 Hydralazine hydrochloride 20 mg
EPY0001151 Hydrastine hyrochloride 20 mg
EPH1200000 Hydrochlorothiazide 150 mg
EPY0000646 Hydrocodone hydrogen tartrate 2.5-hydrate Controlled Substance 10 mg
EPY0000710 Hydrocodone for peak identification Controlled Substance 10 mg
EPH1300000 Hydrocortisone 100 mg
EPY0001092 Hydrocortisone for peak identification 5 mg
EPH1400000 Hydrocortisone acetate 125 mg
EPH1425000 Hydrocortisone hydrogen succinate 100 mg
EPH1426000 Hydrogenated wool fat 250 mg
EPY0000446 Hydromorphone hydrochloride Controlled Substance 10 mg
EPB0650000 Hydrous benzoyl peroxide - Reference Spectrum unit
EPH1428000 Hydroxocobalamin 10 mg
EPY0000119 Hydroxycarbamide 175 mg
EPH1429400 Hydroxyethyl salicylate 125 mg
New EPY0001322 Hydroxyethyl starch (high Mw) 800 mg
EPY0001277 Hydroxyethyl starch (medium MW) 1200 mg
EPH1429700 4-Hydroxyphenoxymethylpenicillin potassium 20 mg
EPH1430000 D-alpha-(4-Hydroxy-phenyl)glycine 50 mg
EPY0000186 Hydroxypropylbetadex 10 mg
EPH1435000 Hydroxyzine hydrochloride 600 mg
EPY0000011 Hymecromone 100 mg
EPY0000012 Hymecromone impurity A
Resorcinol
25 mg
EPY0000013 Hymecromone impurity B
7-hydroxy-2-methyl-4H-1-benzopyran-4-one
25 mg
EPY0000483 Hyoscine 10 mg
EPY0000484 Hyoscine impurity A
(1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2S)-3-hydroxy-2-
phenylpropanoate (norhyoscine)
10 mg
EPH1450000 Hyoscine butylbromide 20 mg
EPY0000447 Hyoscine butylbromide impurity E
(1R,2R,4S,5S,7S)-9-butyl-7-[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-3-oxa-9-azoni
atricyclo[3.3.1.02,4]nonane
10 mg
EPH1500000 Hyoscine hydrobromide 50 mg
European Pharmacopoeia
250 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000448 Hyoscine hydrobromide impurity B
(1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-
3-hydroxy-2-phenylpropanoate
10 mg
EPH1600000 Hyoscyamine sulphate 100 mg
EPY0000449 Hyoscyamine impurity E
(1R,3s,5S)-8-azabicyclo[3.2.1] oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate
10 mg
EPY0000915 Hypromellose phthalate 10 mg
EPI0020000 Ibuprofen 160 mg
EPB1220000 Ibuprofen impurity B
(2RS)-2-(4-Butylphenyl)propionic acid (0,06% solution in Acetonitrile)
1.15 mL
EPY0000140 Ibuprofen impurity F
3-[4-(2-methylpropyl)phenyl]propanoic acid
5 mg
EPY0000881 Ibuprofen for peak identification 0.09 mg
EPI0050000 Idoxuridine 50 mg
EPI0060000 Ifosfamide 50 mg
EPI0060100 Ifosfamide - Reference Spectrum unit
EPI0060002 Ifosfamide impurity A
3-[(2-chloroethyl)amino]propyl dihydrogen phosphate
30 mg
EPI0060004 Ifosfamide impurity B
bis[3-[(2-chloroethyl)amino]propyl]dihydrogen diphosphate
20 mg
EPI0060010 Ifosfamide impurity E
3-chloro-N-(2-chloroethyl)propan-1-amine
10 mg
EPI0060012 Ifosfamide impurity F
(RS)-2-chloro-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide
10 mg
EPI0086000 Imidazole 100 mg
New EPY0001205 Imperatorin 20 mg
EPI0090000 Imipenem 100 mg
EPI0100000 Imipramine hydrochloride 50 mg
EPY0000893 Imipramine for system suitability 10 mg
EPY0001153 Immunoglobulin for anti-A, anti-B antibodies limit test 45 mg
EPY0000540 Immunoglobulin panel for anti-D antibodies test BRP 2000 mg
EPI0150000 Indapamide 150 mg
EPI0150020 Indapamide impurity B
4-chloro-3-sulphamoyl-N-(2-methyl-1H-indol-1-yl)benzamide
5 mg
EPY0000788 Indinavir 100 mg
EPY0000880 Indinavir sulphate - Reference Spectrum unit
EPY0000746 Indinavir for system suitability 20 mg
EPI0200000 Indometacin 50 mg
EPY0000349 Insulin aspart 3.89 mg
EPI0305000 Insulin (bovine) 7.99 mg
EPI0310000 Insulin (human) 7.03 mg
EPY0000348 Insulin lispro 5.93 mg
EPI0320000 Insulin (porcine) 8.61mg
EPI0320300 Interferon alfa-2a 1 mg
EPI0320301 Interferon alfa-2b 0.2 mL
EPY0001101 Interferon beta-1a 0.5 mL
EPI0320330 Interferon gamma 1b 2x0.6 mL
EPI0320331 Interferon gamma-1b validation solution 0.2 mL
EPI0328000 Iobenguane sulphate 25 mg
EPY0000839 Iobenguane sulphate - Reference Spectrum unit
EPY0001294 Iodixanol 60 mg
EPY0001292 Iodixanol impurity C
5-[acetyl[3-[[3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]amino]-2-
hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
10 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 251
Code Product Unit
EPY0001291 Iodixanol impurity E
5-[acetyl[3-[acetyl[3-carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-
triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-
triiodobenzene-1,3-dicarboxamide
10 mg
EPY0001293 Iodixanol impurity H
5-[acetyl[3-[acetyl[3-[[3-[3-[acetyl[3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-
triiodophenyl]amino]-2-hydroxypropoxy]-2-hydroxypropyl]carbamoyl]-5-[(2,3-
dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-
dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
10 mg
EPI0320800 Iohexol 150 mg
EPI0320810 Iohexol impurity A
5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodobenzene-1,3- dicarboxamide
50 mg
EPI0320820 Iohexol impurity J
5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodobenzene-1,3-dicarboxamide
125 mg
EPY0000672 Iohexol for peak identification 10 mg
EPI0329000 Iopamidol 50 mg
EPI0329010 Iopamidol impurity A
N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethy]-
5-amino-2,4,6-tri-iodoisophthalamide
10 mg
EPY0000406 Iopamidol impurity H
4-chloro-N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(2-hydroxypropanoyl)amino)2,6-
diiodobenzenz-1,3-dicarboxamide
10 mg
EPI0330000 Iopanoic acid 100 mg
EPY0001297 Iopentol 10 mg
EPY0001020 Iopromide 100 mg
EPY0001077 Iopromide impurity A
5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methylbenzene-1,3- dicarboxamide
0.125 mg
EPY0001021 Iopromide for system suitability 1 5 mg
EPY0001022 Iopromide for system suitability 2 5 mg
EPI0340000 Iotalamic acid 100 mg
EPA0560000 Iotalamic acid impurity A
5-Amino-2,4,6-tri-iodo-N-methylisophthalamic acid
20 mg
EPY0000555 Iotrolan 100 mg
EPY0000658 Iotrolan for system suitability 5 mg
EPY0000141 Ioxaglic acid 125 mg
EPY0000142 Ioxaglic acid impurity A
3-amino-5[[(2-hydroxyethyl)amino]carbonyl]-2,4,6-trioiodobenzoic acid
20 mg
EPI0360000 Ipratropium bromide 120 mg
EPY0000276 Ipratropium bromide impurity A
(1R,3r,5S,8r)-3-hydroxy-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane
10 mg
EPI0361000 Ipratropium bromide impurity B
(1R,3r,5S,8s)-3-[[(2RS)-3-hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)-8-
azonia- bicyclo[3.2.1]octane
10 mg
EPY0001166 Irbesartan 60 mg
EPY0001156 Irbesartan impurity A
1-(pentylamino)-N-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]cyclopentanecarboxamide
10 mg
EPI0375000 Isoconazole 200 mg
EPI0380000 Isoconazole nitrate 200 mg
EPI0400000 Isoemetine hydrobromide 25 mg
EPY0000858 Isoflurane 1.5 mL
EPY0000037 Isoflurane - Reference Spectrum unit
EPI0460000 Isoleucine 50 mg
EPI0465000 Isomalt 3000 mg
EPY0000070 Isomaltooligosaccharide 0.9 mg
EPI0500000 Isoniazid 100 mg
EPI0599990 Isoprenaline hydrochloride 50 mg
EPI0600000 Isoprenaline sulphate 500 mg
EPI0725000 Isopropyl hexadecanoate 100 mg
European Pharmacopoeia
252 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPI0750000 Isopropyl tetradecanoate 2 mL
EPI0775000 Isosorbide dinitrate 300 mg
EPI0775010 Isosorbide mononitrate 100 mg
EPI0775020 Isosorbide-2-nitrate 50 mg
EPI0800000 Isotretinoin 60 mg
EPI0900000 Isoxsuprine hydrochloride 50 mg
EPY0000366 Isradipine 125 mg
EPY0000367 Isradipine impurity D
methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethylpyridine-3,5-dicarboxylate
5 mg
EPI7000000 Itraconazole 150 mg
EPY0001100 Itraconazole for system suitability 15 mg
EPI8000010 Ivermectin 150 mg
EPY0000575 Ivy leaf standardised tincture 2 mL
EPY0000041 Josamycin 150 mg
EPY0000042 Josamycin propionate 150 mg
EPY0001315 Josamycin for peak identification 25 mg
EPK0100000 Kanamycin B sulphate 20 mg
EPK0200000 Kanamycin monosulphate 150 mg
EPY0000450 Ketamine hydrochloride Controlled Substance 10 mg
EPK0551000 Ketamine impurity A
1-[(2-chlorophenyl)(methylimino)methyl]cyclopentanol
50 mg
EPY0000246 Ketobemidone hydrochloride - Reference Spectrum unit
EPY0000244 Ketobemidone impurity B
1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidyl)ethanone
5 mg
EPY0000245 Ketobemidone impurity C
1-(4-(3-hydroxyphenyl)-4-piperidyl)propan-1-one
5 mg
EPK0600000 Ketoconazole 150 mg
EPK1000000 3-Ketofusidic acid 10 mg
EPK2000000 Ketoprofen 50 mg
EPK2000010 Ketoprofen impurity A
1-(3-benzoylphenyl)ethanone
10 mg
EPK2000015 Ketoprofen impurity C
3-[(1RS)-1-carboxyethyl]benzoic acid
5 mg
EPY0000486 Ketorolac trometamol 10 mg
EPY0000626 Ketorolac trometamol for peak identification 5 mg
EPY0000164 Ketotifen hydrogen fumarate - Reference Spectrum unit
EPY0000161 Ketotifen impurity G
4-(1-methylpiperidin-4-ylidene)-4H-benzo(4,5)cyclohepta(1,2-b)thiophen-9,10-dione
0.0225 mg
EPL0050000 Labetalol hydrochloride 80 mg
EPL0129000 Lactitol monohydrate 60 mg
EPY0000257 Lactobionic acid 100 mg
EPA1206000 Lactose (anhydrous) 100 mg
EPL0100000 Lactose 100 mg
EPL0130000 Lactulose 3000 mg
EPY0000188 Lactulose for system suitability 12 mg
EPY0000425 Lamivudine 150 mg
EPY0000518 Lamivudine for system suitability 1 10 mg
EPY0000426 Lamivudine for system suitability 2 10.3 mg
EPY0001030 Lamotrigine 10 mg
EPY0001031 Lamotrigine for peak identification 20 mg
EPY0001085 Lamotrigine for system suitability 10 mg
EPY0001032 Lamotrigine impurity E
2,3-dichlorobenzoic acid
10 mg
EPY0000773 Lansoprazole 60 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 253
Code Product Unit
EPY0000774 Lansoprazole for peak identification 1 mg
EPY0000654 Leflunomide 100 mg
EPY0000487 Leflunomide impurity A
4-(trifluoromethyl)aniline
25 mg
EPY0000674 Leflunomide for peak identification 1 mg
EPY0000685 Letrozole 70 mg
EPL0375000 Leucine 50 mg
EPL0376000 Leuprorelin 0.925 mg
EPL0376001 Leuprorelin - Reference Spectrum unit
EPY0000047 Levamisole for system suitability 60 mg
EPL0380000 Levamisole hydrochloride 50 mg
EPY0000048 Levamisole - Reference Spectrum unit
New EPY0001253 Levetiracetam 110 mg
EPY0001254 Levetiracetam impurity A (2RS)-2-(2-oxopyrrolidin-1-yl)butanoic acid 10 mg
EPY0001255 Levetiracetam impurity B (2Z)-2-(2-oxopyrrolidin-1-yl)but-2-enamide 10 mg
EPY0001256 Levetiracetam impurity C
pyridin-2-ol
10 mg
EPY0001257 Levetiracetam impurity D
(2R)-2-(2-oxopyrrolidin-1-yl)butanamide ((R)-etiracetam)
10 mg
EPL0390000 Levocabastine hydrochloride 125 mg
EPL0390008 Levocabastine impurity D
1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenylpiperidine-4-carboxylic acid
20 mg
EPL0399900 Levocarnitine 125 mg
EPL0399905 Levocarnitine impurity A
(E)-or(Z)-4-(trimethylammonio)but-2-enoate
50 mg
EPL0400000 Levodopa 100 mg
EPL0420000 Levodropropizine 60 mg
EPL0420002 Levodropropizine impurity A
(2R)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol(dextrodropropizine)
20 mg
EPY0001033 Levodropropizine impurity B
1-phenylpiperazine
50 mg
EPY0001048 Levodropropizine impurity C
2,3-epoxypropan-1-ol
300 mg
EPL0500000 Levomepromazine hydrochloride 100 mg
EPL0505000 Levomepromazine maleate 50 mg
EPL0551000 Levonorgestrel 30 mg
EPL0570000 Levothyroxine sodium 100 mg
EPL0595000 Lidocaine 50 mg
EPL0600000 Lidocaine hydrochloride 100 mg
EPL0650000 Lincomycin hydrochloride 250 mg
EPL0700000 Liothyronine sodium 50 mg
EPY0000860 Liothyronine for peak identification 0.0046 mg
EPY0001235 Lisinopril for system suitability 2 mg
EPL0702000 Lisinopril dihydrate 50 mg
EPL0702100 Lisinopril dihydrate for performance test 2x2 mg
EPY0001234 Lisinopril impurity F
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-cyclohexylpropyl]amino]hexanoyl]pyrrolidine-2-
carboxylic acid (cyclohexyl analogue)
0.01 mg
EPL0720000 Lithium clavulanate 125 mg
EPL0720800 Lithocholic acid 60 mg
EPY0000112 Lobeline hydrochloride 50 mg
EPL0745000 Lomustine 50 mg
EPL0750000 Loperamide hydrochloride 50 mg
EPY0000322 Loperamide hydrochloride for system suitability 15 mg
EPY0000341 Loperamide oxide monohydrate 20 mg
European Pharmacopoeia
254 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000688 Loratadine 60 mg
EPY0000603 Loratadine for system suitability 20 mg
EPY0000604 Loratadine impurity F
ethyl 4-[(11RS)-8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta
[1,2-b]pyridin-11-yl]piperidine-1-carboxylate
10 mg
EPY0000605 Loratadine impurity H
ethyl 4-oxopiperidine-1-carboxylate
50 mg
EPL0750500 Lorazepam Controlled Substance 100 mg
EPY0000576 Lorazepam for system suitability Controlled Substance 0.8 mg
EPY0000718 Lorazepam impurity D
(5RS)-7-chloro-5-(2-chlorophenyl)-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione
10 mg
EPY0001062 Losartan potassium 50 mg
EPY0001072 Losartan impurity D
2-butyl-4-chloro-1H-imidazole-5-carbaldehyde
6 mg
EPY0001076 Losartan for system suitability 0.0015 mg
EPL0790000 Lovastatin 40 mg
EPY0001136 Lovastatine for peak identification 20 mg
EPL0800000 Lynestrenol 50 mg
EPY0001034 Lynestrenol for peak identification 20 mg
EPY0000397 Lysine acetate 60 mg
EPL0900000 Lysine hydrochloride 50 mg
New EPY0001284 Lufenuron 140 mg
EPY0001261 Lufenuron for peak identification 0.4028 mg
EPY0001265 Lufenuron impurity G
2,5-dichloro-4-[[[(2,6-difluorophenyl)carbonyl]carbamoyl]amino]phenyl phenyl carbonate
15 mg
New EPY0001369 Macrogol 30 dipolyhydroxystearate 100 mg
EPY0000745 Macrogol 40 sorbitol heptaoleate 20 mg
EPY0001157 Macrogol polyvinyl alcohol grafted polymer 400 mg
EPM0088000 Magnesium aspartate dihydrate 60 mg
EPM0120000 Malathion 250 mg
EPM0120005 Malathion impurity A
diethyl(2RS)-2-[(methoxy)(methylsulfanyl)-S-phosphinothioyl]
butane dioate (isomalathion)
10 mg
EPM0120010 Malathion impurity B
diethyl(2RS)-2-(dimethoxy-S-phosphinothioyl)-butanedioate (maloxon)
10 mg
EPM0100000 Maleic acid 100 mg
EPY0000143 Malic acid - Reference Spectrum unit
EPM0160000 Maltitol 1200 mg
EPM0200000 Mannitol 1200 mg
EPM0206000 Maprotiline hydrochloride 100 mg
EPM0206040 Maprotiline impurity D
3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylprop-2-en-1-amine;
(dehydromaprotiline)
25 mg
EPY0000819 Marbofloxacin 10 mg
EPY0000820 Marbofloxacin for peak identification 20 mg
EPM0210000 Measles vaccine (live) BRP 5x80 mg
EPM0215000 Mebendazole 20 mg
EPY0000144 Mebendazole for system suitability 20 mg
EPY0000168 Mebendazole - Reference Spectrum unit
EPY0001086 Mebrofenin 120 mg
EPM0220000 Meclozine hydrochloride 150 mg
EPY0001310 Meclozine impurity B
4-chlorobenzhydrol
15 mg
EPY0001311 Meclozine impurity H
1-(4-chlorobenzhydryl)piperazine
15 mg
EPM0240000 Medronic acid 20 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 255
Code Product Unit
EPY0001107 Medronic acid impurity A Tris(1-methylethoxy)phosphane
60 l
EPY0001106 Medronic acid impurity B
Tetrakis(1-methylethyl)methhylenediphosphonate
40 l
EPM0250000 Medroxyprogesterone acetate 100 mg
EPM0250010 Medroxyprogesterone acetate for performance test 50 mg
EPY0000598 Medroxyprogesterone acetate for system suitability 10 mg
EPM0252600 Mefenamic acid 50 mg
EPY0001081 Mefenamic acid impurity A
2,3-dimethylaniline
100 mg
EPM0253000 Mefloquine hydrochloride 100 mg
EPM0260100 Megestrol acetate - Reference Spectrum unit
EPY0001209 Meglumine 10 mg
EPY0001080 Meloxicam 50 mg
EPY0001035 Meloxicam impurity A
ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide
5 mg
EPY0001036 Meloxicam impurity B
5-methylthiazol-2-amine
5 mg
EPY0001037 Meloxicam impurity C
N-[(2Z)-3,5-dimethylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2-
benzothiazine-3-carboxamide 1,1-dioxide
5 mg
EPY0001039 Meloxicam impurity D
N-[(2Z)-3-ethyl-5-methylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2-
benzothiazine-3-carboxamide 1,1-dioxide
5 mg
EPM0300000 Menadione 100 mg
EPM0350000 Menthol 150 mg
EPM0370000 Mepivacaine hydrochloride 100 mg
EPM0370020 Mepivacaine impurity B
(RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
60 mg
EPM0400000 Meprobamate Controlled Substance 100 mg
EPM0500000 Mepyramine maleate 1000 mg
EPY0000679 Mepyramine impurity A
N-(4-methoxybenzyl)pyridin-2-amine
10 mg
EPY0000680 Mepyramine impurity C
pyridin-2-amine
10 mg
New EPY0001252 Meropenem trihydrate 110 mg
EPY0000297 Mesalazine 125 mg
EPY0001040 Mesityl oxid 100 mg
EPY0000337 Mesna - Reference Spectrum unit
EPY0000316 Mesna impurity C
2-(acetylsulphanyl)ethanesulphonic acid
10 mg
EPY0000317 Mesna impurity D
2,2'-(disulphanediyl)bis(ethanesulphonic acid)
10 mg
EPY0000227 Meso-rich exametazime 0.5 mg
EPY0000097 Mesterolone 60 mg
EPY0000096 Mesterolone impurity A
17-hydroxy-1alpha-methylandrost-4-en-3-one
30 mg
EPM0600000 Mestranol 100 mg
EPY0000301 Metacresol - Reference Spectrum unit
EPM0600500 Metacycline hydrochloride 50 mg
EPM0600900 Metamizole sodium 100 mg
EPM0600905 Metamizole impurity A
4-formylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
15 mg
EPM0605000 Metformin hydrochloride 50 mg
EPY0000770 Methacrylic acid-ethylacrylate copolymer (1:1) type A 200 mg
EPY0000323 Methacrylic acid-ethyl acrylate copolymer (1:1) - type B 200 mg
European Pharmacopoeia
256 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPM0610000 Methacrylic acid-ethylacrylate copolymer (1:1) - Reference Spectrum unit
EPM0610030 Methacrylic acid-ethyl acrylate copolymer (1:1), dispersion 30% - Reference Spectrum unit
EPM0620000 Methacrylic acid-methylmethacrylate copolymer (1:1) - Reference Spectrum unit
EPM0630000 Methacrylic acid-methylmethacrylate copolymer (1:2) - Reference Spectrum unit
EPM0800000 Methadone hydrochloride - Reference Spectrum unit
EPY0000428 Methanol - Reference Spectrum unit
EPM0900000 Methaqualone - Reference Spectrum unit
EPY0000754 Methenamine 10 mg
EPM0950000 DL-Methionine 50 mg
EPM0960000 Methionine 50 mg
EPM1000000 Methotrexate 100 mg
EPY0000602 Methotrexate for peak identification 20 mg
EPY0000663 Methotrexate impurity C
(2S)-2-[[4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-
yl)methyl]methylamino]benzoyl]amino]pentanedioic acid
(N-methylfolic acid, methopteridine)
10 mg
EPM1000008 Methotrexate impurity D
4-[[(2-amino-4hydroxypteridin-6-yl)methyl]methyl-amino]benzoic acid
10 mg
EPY0000664 Methotrexate impurity E
4-[[(2,4-diaminopteridin-6-yl)methyl]methylamino]benzoic acid
(4-amino-N10-methylpteroic acid, APA)
10 mg
EPM1100000 3-Methoxymethyldopa 20 mg
EPM1300000 Methylatropine bromide 100 mg
EPM1400000 Methylatropine nitrate 100 mg
EPM1450000 Methylcarbidopa 1 mg
EPM1470000 Methyl 2-(4-chlorophenoxy)-2-methylpropionate 0.5 mL
EPM1500000 Methyldopa 50 mg
EPY0001083 Methyldopa for system suitability 0.024 mg
EPM1550000 Methylene chloride 2 mL
EPM1551000 2-(1-Methylethyl)pentanoic acid 25 mg
EPM1556000 Methyl 12-hydroxystearate 100 mg
EPY0000398 Methyl nicotinate 25 mg
EPY0000776 Methylergometrine maleate 10 mg
EPY0000777 Methylergometrine for system suitability 0.53 mg
EPM1625000 Methylnitrosoindoline 100 mg
EPM1650000 Methyl parahydroxybenzoate 150 mg
EPY0001017 Methylphenidate hydrochloride Controlled Substance 40 mg
EPY0000910 Methylphenidate impurity mixture 0.04 mg
EPM1700000 Methylphenobarbital Controlled Substance 500 mg
EPM1750000 Methylprednisolone 150 mg
EPM1755000 Methylprednisolone acetate 100 mg
EPM1755200 Methylprednisolone hydrogen succinate 125 mg
EPM1755220 Methylprednisolone hydrogen succinate for performance test 50 mg
EPY0000190 N-Methylpyrrolidone - Reference Spectrum unit
EPM1770180 Methyl ricinoleate 125 mg
EPY0000418 Methylrosanilinium chloride 40 mg
EPY0000407 Methylrosanilinium chloride for system suitability 10 mg
EPM1770200 Methyl stearate 100 mg
EPM1800000 Methyltestosterone 100 mg
EPY0000861 Methyltestosterone for system suitability 10 mg
EPM1800900 Methylthioninium chloride 50 mg
EPM1800902 Methylthioninium impurity A
3-(dimethylamino)-7-(methylamino)phenothiazin-5-ylium
20 mg
EPM1808000 Metixene hydrochloride 75 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 257
Code Product Unit
EPM1824990 Metoclopramide 100 mg
EPM1825000 Metoclopramide hydrochloride 50 mg
EPM1824995 Metoclopramide impurity A
4-(acetylamino)-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide
25 mg
EPM1825010 Metoclopramide impurity E
N,N-diethylethane-1,2-diamine
20 mg
EPY0000701 Metolazone 80 mg
EPY0000702 Metolazone for system suitability 10 mg
EPY0000171 Metoprolol succinate - Reference Spectrum unit
EPM1830000 Metoprolol tartrate 60 mg
EPY0000145 Metoprolol impurity A
(2RS)-1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
10 mg
EPM1845000 Metrifonate 100 mg
EPM1850000 Metronidazole 50 mg
EPM1851000 Metronidazole benzoate 50 mg
EPY0000069 Metronidazole benzoate - Reference Spectrum unit
EPY0000087 Metronidazole impurity A
2-methyl-4-nitroimidazole
10 mg
EPM1860000 Mexiletine hydrochloride 100 mg
EPY0000202 Mexiletine impurity C
1,1'-[(3,3',5,5'-tetramethylbiphenyl-4,4'-diyl)bisoxy]dipropan-2-amine
2 mg
EPY0000203 Mexiletine impurity D
(2RS)-2-(2,6-dimethylphenoxy)propan-1-amine
2 mg
EPM1875000 Mianserin hydrochloride 50 mg
EPY0001041 Mianserin impurity B
(14bRS)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]
pyrazino[1,2-a]azepine-8-sulfonic acid
10 mg
EPY0000862 Mianserin hydrochloride for system suitability 1.01 mg
EPM1880000 Miconazole 70 mg
EPM1900000 Miconazole nitrate 100 mg
EPM2200000 Midazolam Controlled Substance 50 mg
EPY0000562 Midazolam impurity C
acide 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo
[1,5-a][1,4]benzodiazepine-3-carboxylique
0.08 mg
EPY0000599 Midazolam for system suitability Controlled Substance 1 mg
EPY0000539 Milk thistle standardised dry extract 120 mg
EPM2280000 Minocycline hydrochloride 125 mg
EPM2300000 Minoxidil 50 mg
EPY0000705 Mirtazapine 10 mg
EPY0000721 Mirtazapine for system suitability 10 mg
EPY0000490 Misoprostol 30 mg
EPY0001162 Misoprostol for system suitability 5 mg
EPY0000378 Mitomycin 120 mg
EPM2305000 Mitoxantrone hydrochloride 60 mg
EPM2305005 Mitoxantrone impurity A
1-amino-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthracene-9,10-dione
5 mg
EPY0000635 Modafinil 110 mg
EPY0000636 Modafinil for system suitability 0.1 mg
EPY0000251 Molgramostim 0.3 mL
EPY0000821 Molsidomine 5 mg
EPY0000822 Molsidomine impurity B
N-Nitrosomorpholine
10 mg
EPY0000823 Molsidomine impurity D
morpholine-4-carbaldehyde
10 mg
EPM2900000 Mometasone furoate 100 mg
EPY0000028 Morantel hydrogen tartrate 50 mg
European Pharmacopoeia
258 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000451 Morphine hydrochloride Controlled Substance 25 mg
EPY0000452 Morphine sulphate Controlled Substance 40 mg
EPY0000830 Morphine for system suitability Controlled Substance 10 mg
EPY0000772 Moxidectin 70 mg
EPY0000747 Moxidectin for system suitability 10 mg
EPY0000703 Moxifloxacin hydrochloride 110 mg
EPY0000717 Moxifloxacin for peak identification 10 mg
EPY0000226 Moxonidine 50 mg
EPY0000222 Moxonidine impurity A
4,6-dichloro-N-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-amine
10 mg
EPM3600000 Mumps vaccine (live) BRP 5x33 mg
EPM3805000 Mupirocin - Reference Spectrum unit
EPM3805500 Mupirocin calcium - Reference Spectrum unit
EPM3806000 Mupirocin lithium 100 mg
EPY0000489 Mycophenolate mofetil 30 mg
EPY0000519 Mycophenolate mofetil for peak identification 10 mg
EPY0000692 Mycoplasma fermentans BRP 1 mL
EPY0000690 Mycoplasma hyorhinis BRP 1 mL
EPY0000691 Mycoplasma orale BRP 1 mL
EPY0000689 Mycoplasma synoviae BRP 1 mL
EPY0000485 Myo-inositol 1020 mg
EPN0020000 Nabumetone 60 mg
EPN0020020 Nabumetone impurity D
(E)-4-(6-methoxynaphthalen-2-yl)but-3-en-2-one
10 mg
EPN0020030 Nabumetone impurity F
6,6'-dimethoxy-2,2'-binaphthalenyl
10 mg
EPY0000146 Nadolol 100 mg
New EPY0001215 Nadolol impurity mixture 0.01 mg
EPN0025000 Nadroparin calcium 250 mg
EPY0000077 Naftidrofuryl - Reference Spectrum unit
EPY0000120 Naftidrofuryl impurity A
2-[(naphtalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoic acid
10 mg
EPY0000121 Naftidrofuryl impurity B
ethyl 2-[(naphtalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoate
25 mg
EPY0000331 Naftidrofuryl impurity F
2-[(diethylamino)ethyl 2-[(naphthalen-2-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoate
10 mg
EPN0050000 Nalidixic acid 100 mg
EPN0075000 Naloxone hydrochloride dihydrate 100 mg
EPY0000695 Naloxone for peak identification 10 mg
EPY0000400 Naltrexone hydrochloride 50 mg
EPY0000410 Naltrexone impurity C
N-(3-butenyl)-noroxymorphone
15 mg
EPY0000542 Nandrolone decanoate 5 mg
EPY0000547 Nandrolone decanoate for peak identification 10 mg
EPY0000548 Nandrolone decanoate for system suitability 10 mg
EPN0080000 Naphazoline hydrochloride 50 mg
EPN0100000 Naphazoline nitrate 10 mg
EPN0200000 Naphazoline impurity A
N-(2-aminoethyl)-2-(naphthalen-1-yl)acetamide (Naphthylacetylethylenediamine)
10 mg
EPN0250000 Naproxen 100 mg
EPY0000399 Naproxen (racemic) 10 mg
EPY0000631 Naproxen impurity L
1-(6-Methoxynaphthalen-2-yl)ethanone (Acetylnerolin)
10 mg
EPN0300000 Neamine 0.5 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 259
Code Product Unit
EPN0399000 Neohesperidin dihydrochalcone 125 mg
EPN0399004 Neohesperidin dihydrochalcone impurity B
7-[[2-O-(6-deoxy--L-mannopyranosyl)--D-glucopyranosyl]oxy]-5-hydroxy-2-
(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one (neodiosmin)
10 mg
EPN0400000 Neomycin sulphate 50 mg
EPN0401000 Neomycin sulphate for microbiological assay 25 mg
EPN0500000 Neostigmine bromide 50 mg
EPN0550000 Neostigmine metilsulfate 50 mg
EPN0559000 Netilmicin sulphate 2x25 mg
EPY0000520 Nevirapine (anhydrous) 30 mg
EPY0000521 Nevirapine for peak identification 0.058 mg
EPY0000388 Newcastle Disease Vaccine (inacativated) BRP 4 uc
EPY0000287 Nicergoline - Reference Spectrum unit
New EPY0001373 Nicergoline 50 mg
New EPY0001362 Nicergoline for peak identification 1 mg
EPY0001352 Nicergoline for system suitability 10 mg
EPY0000283 Nicergoline impurity A
[(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindol
[4,3-fg]quinolin-9-yl]methyl 5-chloropyridine-3-carboxylate
10 mg
New EPY0001356 Nicergoline imprity D
5-bromopyridine-3-carboxylic acid
20 mg
EPN0560000 Niclosamide (anhydrous) 50 mg
EPN0600000 Nicotinamide 50 mg
EPN0590000 Nicotine - Reference Spectrum unit
EPN0590200 Nicotine ditartrate 120 mg
EPY0001023 Nicotine for system suitability 1.25 mg
EPN0700000 Nicotinic acid 100 mg
EPY0001268 Nicotinic acid impurity mixture 0.12 mg
EPN0750000 Nifedipine 50 mg
EPN0750010 Nifedipine impurity A
Dimethyl 2,6-dimethyl-4-(2-nitrophenyl) pyridine-3,5-dicarboxylate
20 mg
EPN0750015 Nifedipine impurity B
Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl) pyridine-3,5-dicarboxylate
20 mg
EPY0000824 Niflumic acid 10 mg
EPY0000825 Niflumic acid impurity A
2-chloropyridine-3-carboxylic acid
10 mg
EPY0000826 Niflumic acid impurity B
2-hydroxy-N-(3-(trifluoromethyl)phenyl)pyridine-3-carboxamide
10 mg
EPY0000827 Niflumic acid impurity E
6-((3-(trifluoromethyl)phenyl)amino)pyridine-3-carboxylic acid
15 mg
EPY0000836 Nifuroxazide 10 mg
EPN0800000 Nikethamide 1 mL
EPY0000829 Nilutamide 110 mg
EPY0000894 Nilutamide impurity B
4-nitro-3-(trifluoromethyl)aniline
5 mg
EPN0845000 Nimesulide 100 mg
EPN0845008 Nimesulide impurity D
4-nitro-2-phenoxyaniline
0.004 mg
EPY0001237 Nimesulide for peak identification 10 mg
EPN0850000 Nimodipine 50 mg
EPN0850010 Nimodipine impurity A
2-methoxyethyl 1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl)
pyridine-3,5-dicarboxylate
1 mL
EPN0900000 Nitrazepam Controlled Substance 100 mg
EPN0900010 Nitrazepam impurity A
3-amino-6-nitro-4-phenylquinol-2-one
25 mg
European Pharmacopoeia
260 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPN0905000 Nitrendipine 60 mg
EPN0905005 Nitrendipine impurity A
ethyl methyl-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate;
(nitrophenylpyridine analogue)
30 mg
EPN0930000 Nitric oxide - Reference Spectrum unit
EPN0950000 Nitrofural 100 mg
New EPY0001377 Nitrofural for peak identification 0.11 mg
EPN1000000 Nitrosotriaminopyrimidine 50 mg
EPN1090000 Nizatidine 250 mg
EPN1090060 Nizatidine impurity F
(EZ)N
1
,N
1
-[thiazole-2,4-diylbis(methylenesulphanediylethylene)]
bis(N-methyl-2-nitroethene-1,1-diamine)
10 mg
EPN1080000 Nomegestrol acetate 100 mg
EPN1080005 Nomegestrol acetate impurity A
6-alpha-methyl-3,20-dioxo-19-norpregn-4-en-17-yl acetate
50 mg
New EPY0001314 1-nonadecanol 400 mg
EPY0000670 Nonivamide 10 mg
EPY0000755 Nonoxinol 9 10 mg
EPN1100000 Noradrenaline tartrate 200 mg
EPY0000681 Noradrenaline impurity D
4[(1R)-2-amino-1-methoxyethyl]benzene-1,2-diol
(Noradrenaline methyl ether)
15 mg
EPY0000682 Noradrenaline impurity E
2-chloro-1-(3,4-dihydroxyphenyl)ethanone
10 mg
EPY0000686 Noradrenaline impurity F
N-benzyl-1-phenylmethanamine
10 mg
EPN1130000 Norcyclobenzaprine 25 mg
EPN1140000 Nordazepam Controlled Substance
Dipotassium clorazepate impurity B
50 mg
EPN1200000 Norethisterone 100 mg
EPN1225000 Norethisterone acetate 100 mg
EPY0000522 Norethistherone for system suitability 10 mg
EPN1230000 Norfloxacin 50 mg
New EPY0001301 Norfloxacin for peak identification 10 mg
EPN1230010 Norfloxacin impurity A
7-chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
20 mg
EPY0001015 Norfloxacin for system suitability 8 mg
EPY0000724 Norgestimate 10 mg
EPY0000725 Norgestimate for system suitability 5 mg
EPN1250000 Norgestrel 30 mg
EPN1279000 Norpseudoephedrine hydrochloride Controlled Substance 50 mg
EPY0001296 Nortriptyline for system suitability 20 mg
EPN1280000 Nortriptyline hydrochloride 10 mg
EPN1300000 Noscapine 100 mg
EPN1400000 Nystatin 100 mg
EPO0100900 Octoxinol 10 300 mg
EPY0000368 Octyl gallate 30 mg
EPO0101000 Octyldodecanol 400 mg
EPO0120000 Ofloxacin 50 mg
EPO0120010 Ofloxacin impurity A
(RS)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido
[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (FPA)
20 mg
EPO0120050 Ofloxacin impurity E
(RS)-9-fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de]
[1,4]benzoxazine-6-carboxylic acid
20 mg
EPY0000805 Oleuropein 20 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 261
Code Product Unit
EPO0146000 Olsalazine sodium 60 mg
EPO0146010 Olsalazine sodium for performance test 60 mg
EPO0150000 Omeprazole 50 mg
EPY0001043 Omeprazole magnesium 10 mg
EPY0001042 Omeprazole for peak identification 10 mg
EPO0151000 Omeprazole impurity D
Omeprazole sulphone
5 mg
EPY0000218 Ondansetron hydrochloride dihydrate 200 mg
EPY0000197 Ondansetron for LC system suitability 10 mg
EPY0000196 Ondansetron for TLC system suitability 30 mg
New EPY0001345 Ondansetron impurity A
(3RS)-3-[(dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one
10 mg
EPY0000195 Ondansetron impurity D
9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one
10 mg
New EPY0001326 Ondansetron impurity E
Imidazole
10 mg
New EPY0001320 Ondansetron impurity F 10 mg
New EPY0001346 Ondansetron impurity G
(3RS)-3-[(1H-imidazol-1-yl)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one (C-
demethylondansetron)
10 mg
EPY0001125 Orbifloxacin 200 mg
EPY0001147 Orbifloxacin impurity mixture 0.0008 mg
EPO0180000 Orciprenaline sulphate 100 mg
EPY0000895 Orciprenaline for system suitability 5 mg
EPY0000101 Orphenadrine citrate 100 mg
EPY0000100 Orphenadrine hydrochloride 100 mg
EPY0001181 Orphenadrine for peak identification 0.42 mg
EPY0000102 Orphenadrine impurity E
(RS)-N,N-dimethyl-2-[(3-methylphenyl)phenylmethoxy]ethanamine
(meta-methylbenzyl isomer)
30 mg
New EPY0001337 Oseltamivir phosphate
impurity B free
300 mg
New EPY0001338 Oseltamivir impurity A
(3R,4R,5S)-5-acetamido-4-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid
10 mg
New EPY0001339 Oseltamivir impurity B
ethyl (1R,2R,3S,4R,5S)-4-acetamido-5-amino-2-azido-3-(1-
ethylpropoxy)cyclohexanecarboxylate
10 mg
New EPY0001340 Oseltamivir impurity C
(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid
10 mg
New EPY0001341 Oseltamivir impurity H
tributylphosphane oxide
30 mg
New EPY0001207 Osthole 20 mg
EPO0200000 Ouabain 150 mg
EPY0000638 Oxacillin sodium monohydrate 110 mg
EPY0000560 Oxacillin for peak identification 10 mg
EPY0000271 Oxaliplatin 250 mg
EPY0000272 Oxaliplatin impurity B
(SP-4-2)-diaqua[(1R,2R)-cyclohexane-1,2-diamine-kN,kN']platinum
(diaquodiaminocyclohexaneplatinum)
15 mg
EPY0000273 Oxaliplatin impurity C
(OC-6-33)-[(1R,2R)-cyclohexane-1,2-diamine-kN,kN'][ethanedioato(2-)-
kO,kO]dihydroxyplatinum
15 mg
EPY0000274 Oxaliplatin impurity D
(SP-4-2)-[(1S,2S)-cyclohexane-1,2-diamine-kN,kN'][ethanedioato(2-)-
kO,kO ]platinum (S,S-enantiomer of oxaliplatin)
10 mg
EPO0225000 Oxazepam Controlled Substance 50 mg
EPY0000543 Oxazepam for peak identification 0.008 mg
EPY0000350 Oxeladin hydrogen citrate 50 mg
European Pharmacopoeia
262 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000404 Oxeladin impurity C
2-(diethylamino)ethyl 2-ethyl-2-phenylbutanoate
10 mg
EPY0000390 Oxeladin impurity D
2-(2-diethylaminoethoxy)ethyl 2-phenyl-butyrate dihydrogen citrate
20 mg
EPO0225800 Oxfendazole for veterinary use 50 mg
EPY0000224 Oxfendazole impurity B
methyl[5-(phenylsulphonyl)-1H-benzimidazole-2-yl]carbamate
10 mg
EPY0000709 Oxitropium bromide 50 mg
EPY0000715
Oxitropium bromide impurity B
(1R,2R,4S,5S,7s)-7-[[(2S)-3-hydroxy-2-phenylpropanoyl)oxy]-9,9-dimethyl-3-oxa-9-
azoniatricyclo[3.3.1.0
2,4
]nonane (methylhyoscine)
15 mg
EPY0000713 Oxitropium bromide impurity D
(1R,2R,4S,5S,7s,9r)-9-ethyl-9-methyl-7-[(2-phenylprop-2-enoyl)oxy]-3-oxa-9-
azoniatricyclo[3.3.1.0
2,4
]nonane (apo-N-ethylhyoscine)
10 mg
EPO0240000 Oxolinic acid 50 mg
EPO0240005 Oxolinic acid impurity A
8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid
20 mg
EPO0240010 Oxolinic acid impurity B
ethyl 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxolo[4,5-g]quinoline-7-carboxylate
20 mg
EPO0250000 Oxprenolol hydrochloride 50 mg
EPO0260000 Oxibendazole 100 mg
EPO0270000 Oxybuprocaine hydrochloride 150 mg
EPO0288000 Oxybutynin hydrochloride 150 mg
EPO0288005 Oxybutynin impurity A
4-(diethylamino)but-2-ynyl(RS)-2-(cyclohex-3-enyl)-2-cyclohexyl-2-hydroxyacetate
10 mg
EPY0000492 Oxycodone hydrochloride Controlled Substance 100 mg
EPY0000453 Oxycodone impurity D
7,8-didehydro-4,5 alpha-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
(14-hydroxycodeinone)
50 mg
EPO0290000 Oxymetazoline hydrochloride 80 mg
EPY0001044 Oxymetazoline impurity A
N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]acetamide
10 mg
EPO0400000 Oxytetracycline 100 mg
EPO0500000 Oxytetracycline hydrochloride 20 mg
EPO0700000 Oxytocin 1 mg
EPO0770000 Oxytocin/Desmopressin validation mixture about 0.1 mg oxytocin + 0.1 mg desmopressin
per vial
0.2 mg
EPY0000698 Paclitaxel 40 mg
EPY0000699 Paclitaxel impurity C
N-debenzoyl-N-hexanoylpaclitaxel
5 mg
EPY0000700 Paclitaxel natural for peak identification 10 mg
EPY0000719 Paclitaxel semi-synthetic for peak identification 10 mg
EPY0000739 Paclitaxel semi-synthetic for system suitability 1 mg
EPP0090000 Palmitic acid 100 mg
EPY0000524 Pamidronate disodium pentahydrate 10 mg
EPP0100000 Pancrease powder (amylse and lipase) BRP 2000 mg
EPP0200000 Pancreas powder (protease) BRP 2000 mg
EPP0250000 Pancuronium bromide
Vecuronium impurity B
20 mg
EPY0000577 Pancuronium bromide for system suitability 20 mg
EPY0000835 Pantoprazole sodium sesquihydrate 20 mg
EPY0001001 Pantoprazole for system suitability 0.5055 mg
EPP0270000 Papaverine hydrochloride 25 mg
EPP0300000 Paracetamol 50 mg
EPY0000780 Paraffin (hard) 10 mg
EPY0000058 Paraffin (liquid) - Reference Spectrum unit
EPY0000913 Paraffin (White soft) 10 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 263
Code Product Unit
EPY0000912 Paraffin (Yellow soft) 10 mg
EPP0305000 Parnaparin sodium 250 mg
EPY0000578 Paroxetine hydrochloride (anhydrous) 100 mg
EPY0000281 Paroxetine hydrochloride hemihydrate 200 mg
EPY0000233 Paroxetine impurity A
(3S,4R)-3-[[1,3-benzodioxol-5-yloxy]methyl]-4-phenylpiperidine (desfluoroparoxetine)
15 mg
EPY0000579 Paroxetine hydrochloride (anhydrous) impurity C
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-1-benzyl-4-(4-fluorophenyl)piperidine
(N-benzylparoxetine)
10 mg
EPY0000256 Paroxetine impurity D
(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine ((+)-trans-
paroxetine)
5 mg
EPY0000580 Paroxetine impurity E
(3RS,4RS)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4fluorophenyl)piperidine (cis-paroxetine)
5 mg
EPY0000581 Paroxetine hydrochloride (anhydrous) impurity H
[(3S,4R)-1-benzyl-4-(4-fluorophenyl)piperidin-3-yl]methanol
10 mg
EPY0000630 Paroxetine for system suitability 5 mg
EPP0309000 Pefloxacin mesilate dihydrate 200 mg
EPP0309020 Pefloxacin impurity B
1-ethyl-6-chloro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(chlorinated homologue of pefloxacin)
10 mg
EPP0309030 Pefloxacin impurity C
1-ethyl-6-fluoro-5-(4-methylpiperazin-1yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(isopefloxacin)
0.01 mg
EPP0307000 Penbutolol sulphate 100 mg
EPP0307005 Penbutolol impurity A
(2S)-1-[2-(cyclopent-1-enyl)phenoxy]-3-[(1,1-dimethylethyl)amino]propan-2-ol
20 mg
EPP0310000 Penicillamine 100 mg
EPP0320000 Penicillamine disulphide
3,3-(disulphanediyl)bis[(2)-2-amino-3-methylbutanoic]acid
100 mg
EPP0400100 Pentaerythrityl tetranitrate diluted 600 mg
EPP0405000 Pentamidine diisetionate 30 mg
EPP0405500 Pentazocine - Reference Spectrum unit
EPP0405510 Pentazocine hydrochloride - Reference Spectrum unit
EPY0000417 Pentazocine lactate - Reference Spectrum unit
EPY0001051 Pentetate sodium calcium 100 mg
EPP0500000 Pentobarbital Controlled Substance 500 mg
EPP0510000 Pentoxifylline 100 mg
EPY0000076 Pentoxyverine hydrogen citrate - Reference Spectrum unit
EPY0000098 Pentoxyverine impurity A
1-phenylcyclopentanecarboxylic acid
10 mg
EPY0000099 Pentoxyverine impurity B
2-(diethylamino)ethyl-1-phenylcyclopentanecarboxylate (caramiphen)
10 mg
EPP0525000 Pepsin powder 2000 mg
EPY0000010 Pergolide mesilate 150 mg
EPY0000237 Perindopril impurity A
(2S,3aS,7aS)-octahydro-1Hindole-2-carboxylic acid
10 mg
EPY0000207 Perindopril for stereochemical purity 40 mg
EPY0000238 Perindopril tert-butylamine 40 mg
EPY0000771 Perindopril for peak identification 5 mg
EPP0550000 Perphenazine 100 mg
EPY0001045 Perphenazine for system suitability 5 mg
EPY0000021 Pertussis toxin BRP 2x0.05 mg
EPP0600000 Pethidine hydrochloride - Reference Spectrum unit
EPP0600002
Pethidine impurity A
1-methyl-4-phenylpiperidine (MPP)
20 mg
EPP0800000 Phenazone 20 mg
European Pharmacopoeia
264 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0001138 Phenazone impurity A
5-methyl-2-phenyl-2,4-dihydro-3-pyrazol-3-one
20 mg
EPP0850000 Pheniramine maleate 250 mg
EPP0900000 Phenobarbital Controlled Substance 200 mg
New EPY0001350 Phenobarbital impurity A
(5RS)-5-ethyl-2,6-diimino-5-phenyltetrahydropyrimidin-4(1H)-one
15 mg
New EPY0001351 Phenobarbital impurity B
(5RS)-5-ethyl-6-imino-5-phenyldihydropyrimidine-2,4(1H,3H)-dione
15 mg
EPP0950000 Phenoxyethanol 2 mL
EPP1000000 Phenoxymethylpenicillin 250 mg
EPP1100000 Phenoxymethylpenicillin potassium 250 mg
EPP1109000 Phentolamine mesilate - Reference Spectrum unit
EPY0001127 Phentolamine mesilate 10 mg
EPY0001251 Phentolamine mesilate for system suitability 10 mg
EPP1150000 Phenylalanine 60 mg
EPP1200000 Phenylbutazone 100 mg
EPY0000147 Phenylbutazone impurity B
(4-butyl-4-hydroxy-1,2-diphenyl-3,5)pyrazolidinedione
20 mg
EPP1240000 Phenylephrine 60 mg
EPP1250000 Phenylephrine hydrochloride 50 mg
EPY0000683 Phenylephrine hydrochloride for peak identification 2 mg
EPY0000229 Phenylmercuric acetate - Reference Spectrum unit
EPP1255100 Phenylmercuric borate - Reference Spectrum unit
EPP1260000 Phenylpropanolamine hydrochloride Drug Precursor 50 mg
EPP1290000 Phenytoin 100 mg
EPY0001167 Phenytoin for system suitability 20 mg
EPP1300000 Phenytoin sodium 250 mg
EPY0000493 Phloroglucinol (anhydrous) 210 mg
EPY0000761 Pholcodine Controlled Substance 10 mg
EPY0000798 Pholcodine for peak identification Controlled Substance 10 mg
EPY0000766
Phthalic acid
benzene-1,2-dicarboxylic acid
20 mg
EPP1500000 Phthalylsulfathiazole 100 mg
EPP1600000 Physostigmine salicylate 100 mg
EPP1605000 Physostigmine sulphate 100 mg
EPP1609000 Phytomenadione 150 mg
EPP1609010 trans-Epoxyphytomenadione 10 mg
EPY0001104 Picosulfate for system suitability 0.5 mg
EPP1645000 Picotamide monohydrate 125 mg
EPP1645005 Picotamide impurity A
4-methoxybenzene-1,3-dicarboxylic acid
25 mg
EPY0000124 Pidolate impurity B
(2S)-2-[[[(2S)-5-oxopyrrolidin-2-yl]carbonyl]amino]pentanedioic acid
60 mg
EPY0000123 Pidolic acid 125 mg
EPP1650000 Pilocarpine hydrochloride 50 mg
EPP1700000 Pilocarpine nitrate 50 mg
EPY0000106 Pilocarpine nitrate for system suitability 20 mg
EPY0000525 Pimobendan 10 mg
EPY0000401 Pimobendan for system suitability 0.1 mg
EPP1750000 Pimozide 150 mg
EPP1800000 Pindolol 100 mg
EPY0000061 Pipemidic acid trihydrate - Reference Spectrum unit
EPP1890000 Piperacillin 100 mg
EPP1900000 Piperazine adipate 250 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 265
Code Product Unit
EPP2000000 Piperazine citrate 250 mg
EPP2100000 Piperazine hydrate 250 mg
EPY0000288 Piracetam 120 mg
EPY0000038 Pirenzepine dihydrochloride monohydrate 250 mg
EPP2120000 Piretanide 100 mg
EPP2120002 Piretanide impurity A
4-phenoxy-3(1H-pyrrol-1-yl)-5-sulphamoylbenzoic acid
20 mg
EPP2130000 Piroxicam 100 mg
EPP2130100 Piroxicam for system suitability 10 mg
EPP2150000 Pivampicillin 50 mg
EPP2152000 Pivmecillinam hydrochloride 100 mg
EPP2152015 Pivmecillinam impurity C
methylene 2,2-dimethylpropanoate (2RS,4S)-2-[[[(hexahydo-1H-azepin-1-yl)
methylene]amino]methyl]-5,5-dimethylthiazolidin-4-carboxylate
10 mg
EPP2155001 Plastic additive 01
(2RS)-2-ethylhexyl)benzene-1,2-dicarboxylate
2 mL
EPP2155003 Plastic additive 03
N,N'-ethylenedialcanamide
100 mg
EPE0800000 Plastic additive 04
Epoxidised soya oil
500 mg
EPP2155005 Plastic additive 05
Epoxidised linseed oil
500 mg
EPP2155008 Plastic additive 08
Ethylene bis [3,3-bis[3-(1,1-dimethylethyl)-4-hydroxyphenyl]butanoate]
500 mg
EPP2155009 Plastic additive 09 pentaerythrityl tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate] 250 mg
EPP2155010 Plastic additive 10
4,4',4''-(2,4,6-trimethylbenzene-1,3,5-triyltrismethylene)-trio[2,6-bis(1,1-dimethylethyl)phenol]
250 mg
EPP2155011 Plastic additive 11
Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate
500 mg
EPP2155012 Plastic additive 12
Tris(2,4-di-1,1-dimethylethylphenyl)phosphite R
250 mg
EPP2155013 Plastic additive 13
1,3,5-tris(3,5-di-1,1-dimethylethyl-4-hydroxybenzyl)-1H,3H,5H-1,3,5-triazine-2,4,6-trione
250 mg
EPP2155014 Plastic additive 14
2,2'-Di(octadecycloxy)5,5'-spirobi(1,3,2,-dioxaphosphorinane) R
250 mg
EPP2155015 Plastic additive 15
Dioctadecyl disulphide
500 mg
EPP2155016 Plastic additive 16
Didodecyl 3,3'-thiodipropionate R
250 mg
EPP2155017 Plastic additive 17
Dioctadecyl 3,3'-thiodipropionate R
250 mg
EPP2155018 Plastic additive 18 100 mg
EPO0140000 Plastic additive 20
Oleamide R
100 mg
EPE1260000 Plastic additive 21
Erucamide R
100 mg
EPP2155022 Plastic additive 22
Copolymer of dimethyl butanedioate and 1-(2-hydroxyethyl)-2,2,6,6-tetramethylpiperidin-4-ol
Synonyms: copolymer of dimethyl succinate and (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-
yl)ethanol
100 mg
EPP2155023 Plastic additive 23
di(isooctyl)2,2'-[(dioctylstannylene)bis(thio)]diacetate containing about 27% of
(tri(isooctyl)2,2',2''-[monooctylstannylidyne)tris(thio)]triacetate
Tin-content of 15.4%
200 mg
EPP2160000 Poliomyelitis vaccine (inactivated) BRP 5x0.5 mL
EPP2161000 Poliomyelitis vaccine (oral) BRP 5x1 mL
EPP2163920 Poloxamer 124 30 mg
EPP2164009 Poloxamer 188 100 mg
EPP2164020 Poloxamer 237 100 mg
European Pharmacopoeia
266 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPP2164021 Poloxamer 338 100 mg
EPP2164030 Poloxamer 407 100 mg
EPP2170000 Polyacrylate - Reference Spectrum unit
EPP2400000 Polymyxin B sulphate 25 mg
EPY0000355 Polymyxin B sulphate for microbiological assay 25 mg
EPY0000289 Polysorbate 20 - Reference Spectrum unit
EPY0000290 Polysorbate 40 - Reference Spectrum unit
EPY0000291 Polysorbate 60 - Reference Spectrum unit
EPY0000007 Polysorbate 80 - Reference Spectrum unit
EPY0000792 Poly(vinyl acetate) dispersion 30% 1500 mg
EPP2600000 Poly(vinyl chloride) 100 mg
EPP2649610 Potassium clavulanate - Reference Spectrum unit
EPY0001168 Potassium clavulanate impurity G 5 mg
EPY0000315 Potassium hydrogen aspartate hemihydrate 50 mg
EPP2650000 Potassium sorbate 100 mg
New EPY0001275 Potassium sucrose octasulfate 100 mg
EPP2660000 Povidone 50 mg
EPY0000466 Povidone (iodinated) 10 mg
EPY0001266 Pramipexole dihydrochloride monohydrate 5 mg
EPY0001267 Pramipexole impurity D
(6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
5 mg
EPY0001187 Pramipexole for system suitability 15 mg
EPY0000215 Pravastatin sodium - Reference Spectrum unit
EPY0000223 Pravastatin impurity A
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8-[[(2S)-
2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(6'-epipravastatin)
0.1 mg
EPY0000204 Pravastatin 1,1,3,3-tetramethylbutylamine 30 mg
EPP2669000 Prazepam Controlled Substance 50 mg
EPP2670000 Praziquantel 150 mg
EPP2675000 Praziquantel impurity A
(11bRS)-2-benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
10 mg
EPP2680000 Prazosin hydrochloride 50 mg
EPP2698000 Prednicarbate 100 mg
EPP2698060 Prednicarbate impurity F
1,2-dihydroprednicarbate
10 mg
EPP2700000 Prednisolone 150 mg
New EPY0001355 Prednisolone for system suitability 10 mg
New EPY0001359 Prednisolone for peak identification 10 mg
EPP2800000 Prednisolone acetate 120 mg
EPY0000582 Prednisolone acetate for peak identification 10 mg
EPP2804000 Prednisolone hexanoate 10 mg
EPP2805000 Prednisolone pivalate 100 mg
EPP2810000 Prednisolone sodium phosphate 100 mg
EPP2900000 Prednisone 100 mg
EPP2920000 Pregnenolone isobutyrate 150 mg
EPY0000263 Prekallikrein activator in albumin BRP 3x1 mL
EPP2939000 Prilocaine 150 mg
EPP2939060 Prilocaine hydrochloride 100 mg
EPP2939025 Prilocaine impurity E
(RS)-N-(methylphenyl)-2-(propylamino)propanamide
25 mg
EPP2940000 Primaquine diphosphate 500 mg
EPP2950000 Primidone 150 mg
EPY0000369 Primidone for peak identification 5 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 267
Code Product Unit
EPP3000000 Probenecid 100 mg
EPP3050000 Procainamide hydrochloride 100 mg
EPP3090000 Procaine benzylpenicillin 250 mg
EPP3100000 Procaine hydrochloride 100 mg
EPP3200000 Prochlorperazine maleate 100 mg
EPP3300000 Progesterone 50 mg
EPY0000148 Progesterone impurity C
(20R)-20-hydroxypregn-4-en-3-one
10 mg
EPY0000179 Proguanil hydrochloride - Reference Spectrum unit
EPY0000181 Proguanil impurity C
1,5-bis(4-chlorophenyl)biguanide
10 mg
EPY0000182 Proguanil impurity D
1,5-bis(1-methylethyl)biguanide
10 mg
EPP3350000 Proline 60 mg
EPP3390000 Promazine hydrochloride 100 mg
EPP3400000 Promethazine hydrochloride 50 mg
EPY0000769 Promethazine impurity D
(2RS)-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine S-oxide
10 mg
EPY0000797 Promethazine for peak identification 10 mg
EPP3490000 Propacetamol hydrochloride - Reference Spectrum unit
EPY0000455 Propafenone hydrochloride 10 mg
EPY0000456 Propafenone impurity B
2E)-1-[2-[(2RS)-2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylprop-2-en-1-one
10 mg
EPY0000278 Propanol - Reference Spectrum unit
EPY0000016 Propofol 290 mg
EPY0000017 Propofol for peak identification 0.1 mL
EPY0000018 Propofol impurity J
2,6-bis (1-methylethyl)-1,4-benzoquinone
20 mg
EPP3500000 Propranolol hydrochloride 30 mg
EPP3600000 Propranolol hydrochloride for performance test 20 mg
EPY0000318 Propylene glycol dilaurate 100 mg
EPY0000319 Propylene glycol monolaurate 100 mg
EPP3640000 Propyl gallate 50 mg
EPP3650000 Propyl parahydroxybenzoate 100 mg
EPP3700000 Propylthiouracil 100 mg
EPP3750000 Propyphenazone 200 mg
EPP3760000 Protirelin 2x5.03 mg
EPP3760020 D-His Protirelin 0.1 mg
EPP3800000 Proxyphylline 100 mg
EPP3850000 Pseudoephedrine hydrochloride Drug Precursor 100 mg
EPY0000387 Pseudoisoeugenyl 2-methylbutyrate for peak identification 100 mg
EPP3900000 Purpureaglycoside A 25 mg
EPP4000000 Purpureaglycoside B 25 mg
EPY0000402 Pyrantel embonate 10 mg
EPY0000403 Pyrantel impurity A
1-methyl-2-[(Z)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine
20 mg
EPP4050000 Pyrazinamide 30 mg
EPP4099900 Pyridostigmine bromide 50 mg
EPP4099910 Pyridostigmine impurity A
pyridin-3-yl-dimethylcarbamate
20 mg
EPP4100000 Pyridoxine hydrochloride 100 mg
EPY0001226 Pyridoxine impurity A
6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
5 mg
EPP4200000 Pyrimethamine 250 mg
European Pharmacopoeia
268 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000659 Pyrrolidone 20 mg
EPY0001009 Quercetin dihydrate 20 mg
EPQ0100000 Quinidine sulphate 300 mg
EPQ0200000 Quinine sulphate 300 mg
EPR0100000 Rabies vaccine (inactivated) for veterinary use BRP 3x86 mg
EPY0000896 Racecadotril 110 mg
EPY0000897 Racecadotril impurity A
Ethanethioic acid
1 mL
EPY0000898 Racecadotril impurity G
benzyl[[(2RS)-2-benzyl-3-sulfanylpropanoyl]amino]acetate
10 mg
EPY0000902 Racecadotril for peak identification 5 mg
EPY0001134 Raloxifene hydrochloride 110 mg
EPY0001135 Raloxifene hydrochloride for peak identification 10 mg
EPR0145000 Ramipril 20 mg
EPR0145005 Ramipril impurity A
(2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(methoxycarbonyl)-3-phenylpropyl]amino]
propanoly]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(ramipril methylester)
10 mg
EPR0145010 Ramipril impurity B
(2S,3aS,6aS)-1-[(S)-2-[[(S)-1-[(methylethoxy)carbonyl]-3-phenylpropyl]
amino] propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(ramipril isopropyl ester)
10 mg
EPR0145015 Ramipril impurity C
(2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(ethoxycarbonyl)-3-cyclohexylpropyl]amino]
propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (hexahydroramipril)
10 mg
EPR0145020 Ramipril impurity D
ethyl(2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro
-1H-cyclopenta[e]pyrrolo[1,2a]pyrazin-2-yl]-4-phenylbutanoate
(ramipril diketopiperazine)
10 mg
EPR0150000 Ranitidine hydrochloride 100 mg
EPY0000416 Ranitidine impurity J
1,1'-N-[methylenebis(sulphanediylethylene)]bis
(N'-methyl-2-nitroethene-1,1-diamine)
0.00025 mg
EPY0000411 Ranitidine for system suitability 20 mg
EPY0000457 Repaglinide 20 mg
EPY0000458 Repaglinide for system suitability 6 mg
EPY0000459 Repaglinide impurity E
2-ethoxy-4-[2-[[(1R)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]
amino]-2-oxoethyl]benzoic acid
10 mg
EPR0200000 Reserpine 100 mg
EPR0250000 Residual solvents solution class I 1500 mg
EPY0000767 Resorcinol 20 mg
EPR0300000 Retinol acetate 1000 mg
EPR0290000 Retinol ester 100 mg
EPR0500500 Reviparin sodium 250 mg
EPY0000377 Ribavirin 2x100 mg
EPY0000353 Ribavirin for system suitability 1 mg
EPR0600000 Riboflavin (Vitamine B2) 100 mg
EPY0000757 Riboflavin for peak identification 0.1 mg
EPR0630000 Riboflavine sodium phosphate 250 mg
EPY0000662 Ribonucleic acid 100 mg
EPY0000149 Rifabutin 150 mg
EPY0000184 Rifabutin impurity A
1-(2-methylpropyl)piperidin-4-one
20 mg
EPR0700000 Rifampicin 500 mg
EPR0800000 Rifampicin quinone 100 mg
EPR0900000 Rifamycin B 50 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 269
Code Product Unit
EPR0950000 Rifamycin S 50 mg
EPR1000000 Rifamycin sodium 300mg
EPY0001074 Rifaximin 160 mg
EPY0001075 Rifaximin for system suitability 10 mg
EPY0000250 Rilmenidine dihydrogenophosphate - Reference Spectrum unit
EPY0000187 Rilmenidine for system suitability 30 mg
EPR1000600 Risperidone 50 mg
EPY0000370 Risperidone for system suitability 20 mg
New EPY0001276 Risperidone impurity K
3-[2-[4-(1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-
a]pyrimidin-4-one (desfluoro risperidone)
0.015 mg
EPR1300000 RK 13 cells
cell lines (kidney,rabbit) titration of live measles,
mumps and rubella vaccines
2x1 mL
EPY0000714 Ritonavir 80 mg
EPY0000706 Ritonavir for peak identification 10 mg
EPY0000594 Rocuronium bromide - Reference Spectrum unit
EPY0000527 Rocuronium for peak identification 10 mg
EPY0000742 Ropivacaine hydrochloride monohydrate 10 mg
EPY0000743 Ropivacaine impurity G
(+)-(2R)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide ((R)-ropivacaine)
5 mg
EPY0000786 Rosmarinic acid 40 mg
EPR1500000 Roxithromycin 125 mg
EPY0000220 Roxithromycin for system suitability 5 mg
EPR2000000 Rubella vaccine (live) BRP 5x18 mg
EPY0000494 Ruscogenins 10 mg
EPY0000105 Rutoside trihydrate 100 mg
EPS0040000 Saccharin 30 mg
EPS0050000 Saccharin Sodium 50 mg
EPS0100000 Salbutamol 50 mg
EPY0000030 Salbutamol impurity B
(1RS)-2-[(1,1-dimethylethyl)amino]-1-(4-hydroxyphenyl)ethanol
5 mg
EPY0000071 Salbutamol impurity D
5-[(1RS)-2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-
hydroxybenzaldehyde
5 mg
EPY0000031 Salbutamol impurity F
1,1'[oxybis[methylene(4-hydroxy-1,3-phenylene)]]bis
[2-[(1,1-dimethylethyl)amino]ethanol]
5 mg
EPY0000034 Salbutamol impurity G
2-[benzyl(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-hydroxymethyl)
phenyl]ethanone
5 mg
EPY0000032 Salbutamol impurity I
(1RS)-2-[(1,1-dimethylethyl)amino]-1-[3-(hydroxymethyl)-4-benzyloxyphenyl] ethanol
0.006 mg
EPY0001186 Salbutamol impurity J
2-[(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanone (salbutamone)
0.00045 mg
EPS0150000 Salbutamol sulphate 50 mg
EPY0001288 Salbutamol sulfate for system suitability 10 mg
EPY0000669 Salicin 50 mg
EPS0200000 Salicylic acid 100 mg
EPY0000405 Salicylic acid impurity B
4-hydroxyisophthalic acid
10 mg
EPY0000422 Salmeterol xinafoate 40 mg
EPY0000423 Salmeterol xinafoate for system suitability 25 mg
EPY0001052 Santonin 20 mg
EPY0001049 Saquinavir mesilate 70 mg
EPY0001056 Saquinavir for system suitability 0.3033 mg
European Pharmacopoeia
270 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000814 Selamectin 100 mg
EPY0000815 Selamectin for system suitability 5 mg
EPS0360000 Selegiline hydrochloride 50 mg
EPS0360090 (RS)-Selegiline hydrochloride 25 mg
EPS0400000 Senna extract 50 mg
EPS0450000 Serine 50 mg
EPS0460000 Sertaconazole nitrate 125 mg
EPY0000828 Sertraline hydrochloride 200 mg
EPY0000866 Sertraline for peak identification 2.8 mg
EPY0000867 Sertraline for system suitability 3.2 mg
EPY0001285 Sertraline impurity E 15 mg
EPY0000371 Sestamibi labelling kit 22 mg
EPY0001046 Sevoflurane 1 mL
EPS0500000 Silicone elastomer 2000 mg
EPS0600000 Silicone oil 1 mL
EPS0650000 Simvastatin 100 mg
EPY0001066 Simvastatin for peak identification 10 mg
EPS0660000 Sisomicin sulphate 50 mg
EPY0000014 Sodium alendronate 150 mg
EPS0695000 Sodium amidotrizoate 125 mg
EPY0000300 Sodium aminosalicylate dihydrate - Reference Spectrum unit
EPY0000039 Sodium ascorbate 50 mg
EPS0700000 Sodium calcium edetate 100 mg
EPS0710000 Sodium cetostearyl sulphate 100 mg
EPS0750000 Sodium cromoglicate 10 mg
New EPY0001300 Sodium cromoglicate for system suitability 20 mg
EPS0760000 Sodium cyclamate 100 mg
EPS0765000 Diclofenac sodium 100 mg
EPS0781000 Sodium hyaluronate - Reference Spectrum unit
EPS0780000 Sodium hyaluronate BRP 300 mg
EPY0000620 Sodium laurilsulfate 40 mg
EPY0000808 Sodium phenylbutyrate 5 mg
EPY0000809 Sodium phenylbutyrate impurity C
4-cyclohexylbutanoic acid
10 mg
EPS0785000 Sodium picosulphate 100 mg
EPY0000210 Sodium polystyrene sulphonate - Reference Spectrum unit
EPY0000268 Sodium propionate - Reference Spectrum unit
EPS0800000 Sodium salicylate 100 mg
EPS0808000 Sodium stearyl fumarate 50 mg
EPS0808060 Sodium stearyl maleate 10 mg
EPS0900000 Sodium taurocholate BRP 10000 mg
EPS0930000 Sodium valproate 150 mg
EPS0945000 Somatostatin 2.45 mg
EPS0947000 Somatropin 35 mg
EPY0000711 Somatropin/desamidosomatropin resolution mixture 33 mg
EPS0950000 Sorbic acid 10 mg
EPY0000385 1,4-Sorbitan 50 mg
EPS1000000 Sorbitol 1200 mg
EPY0000114 Sotalol hydrochloride 25 mg
EPY0000115 Sotalol impurity B
N-[4-[[(1-methylethyl)amino]acetyl]phenyl]methanesulphonamide
20 mg
EPY0001011 Spanish sage oil for peak identification 250 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 271
Code Product Unit
EPY0000597 Spectinomycin hydrochloride 100 mg
EPY0000549 Spectinomycin for system suitability 20 mg
EPY0000655 Spectinomycin sulphate tetrahydrate 10 mg
EPY0001126 Spike lavender oil 400 l
EPS1100000 Spiramycin 200 mg
EPY0000381 Spirapril hydrochloride monohydrate 60 mg
EPY0000332 Spirapril for system suitability 15 mg
EPS1200000 Spironolactone 100 mg
New EPY0001295 Spironolactone for system suitability 2.055 mg
EPY0000185 Squalane 0.25 mL
EPY0001050 St.John's wort standardised dry extract 500 mg
EPY0001091 Standardised artichoke leaf dry extract 60 mg
EPS1250000 Stanozolol 125 mg
EPS1250010 Stanozolol impurity A
(5,17)-17-hydroxy-17-methylandrostan-3-one
10 mg
EPS1300000 Starch BRP 50000 mg
EPY0000408 Stavudine 100 mg
EPY0000421 Stavudine for system suitability 10 mg
EPS1340000 Stearic acid
Plastic additive 19
100 mg
EPS1350000 Stearyl alcohol 250 mg
EPY0000868 Streptokinase for system suitability 30 l
EPS1400000 Streptomycin sulphate 100 mg
EPS1500000 Succinylsulfathiazole 100 mg
New EPY0001324 Sucralfate 10 mg
New EPY0001344 Sucralose 550 mg
New EPY0001342 Sucralose impurity B
1,6-dichloro-1,6-dideoxy--D-fructofuranosyl 6-chloro-6-deoxy--D-glucopyranoside (1,6,6-
trichloro-1,6,6-trideoxysucrose)
0.5 mg
EPS1600000 Sucrose 100 mg
EPS1608100 Sufentanil - Reference Spectrum unit
EPS1609000 Sufentanil citrate - Reference Spectrum unit
EPY0000529 Sulbactam sodium 10 mg
EPY0000528 Sulbactam 150 mg
EPY0000550 Sulbactam for peak identification 20 mg
EPS1700000 Sulfacetamide sodium 50 mg
EPS1800000 Sulfadiazine 100 mg
EPS1900000 Sulfadimidine 100 mg
EPS1950000 Sulfadoxine 50 mg
EPS1975000 Sulfafurazole 100 mg
EPS1975600 Sulfaguanidine 60 mg
EPS2000000 Sulfamerazine 100 mg
EPS2050000 Sulfamethizole 100 mg
EPS2100000 Sulfamethoxazole 50 mg
EPY0000412 Sulfamethoxazole impurity A
N-(4-(5-methyl)-isoxazol-3-ylsulphamoyl)phenylacetamide
5 mg
EPY0000413 Sulfamethoxazole impurity F
4-amino-N-(3-methylisoxazol-5-yl)benznesulphonamide
5 mg
EPS2150000 Sulfamethoxypyridazine 50 mg
EPS2151000 Sulfanilamide 100 mg
EPS2159100 Sulfapyridine 20 mg
EPS2155000 Sulfasalazine 2x250 mg
EPS2155010 Sulfasalazine derivative for resolution
2-hydroxy-5-[[4-[[(6-methylpyridin-2-yl)amino]-sulfonyl]phenyl]azo]benzoic acid
20 mg
European Pharmacopoeia
272 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPS2158000 Sulfathiazole 100 mg
EPS2159000 Sulfinpyrazone 30 mg
EPY0001238 Sulfinpyrazone for system suitability 0.5 mg
EPS2159010 Sulfinpyrazone impurity A
1,2-diphenyl-4-(2-phenylsulphonylethyl)pyrazolidine-3,5-dione
20 mg
EPS2159015 Sulfinpyrazone impurity B
1,2-diphenyl-4-(2-phenylthioethyl)pyrazolidine-3,5-dione
20 mg
EPS2160000 Sulfisomidine 50 mg
EPS2180000 Sulindac 50 mg
EPS2190000 Sulpiride 100 mg
EPS2191000 Sulpiride impurity A
[(2RS)-1-ethylpyrrolidin-2-yl]methanamine
20 mg
EPS2192000 Sulpiride impurity B
methyl 2-methoxy-5-sulphamoylbenzoate
20 mg
EPY0000530 Sultamicillin 10 mg
EPY0000531 Sultamicillin tosilate 200 mg
EPY0000532 Sultamicillin for peak identification 10 mg
EPY0000022 Sumatriptan succinate 50 mg
EPY0000026 Sumatriptan impurity mixture 3 mg
EPY0000027 Sumatriptan for system suitability 2 mg
EPS2200000 Suxamethonium chloride 1000 mg
EPS2400000 Suxibuzone 50 mg
EPS2400004 Suxibuzone impurity B
(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl ethyl butanedioate
10 mg
EPS2400006 Suxibuzone impurity C
4-butyl-4-(hydroxymethyl)-1,2-diphenyl-1,2-dihydro-4H-pyrazole-3,5-dione
10 mg
EPS5000001 Swine erysipelas bacteria, serotyp 1 (for vaccines-vet.use) BRP 1 mg
EPS5000002 Swine erysipelas bacteria, serotyp 2 (for vaccines-vet.use) BRP 1 mg
EPT0010000 Talampicillin hydrochloride 50 mg
EPT0014000 Tamoxifen citrate 80 mg
EPT0015000 Tamoxifen citrate for performance test 30 mg
EPY0000650 Tamsulosin hydrochloride 10 mg
EPY0000653 Tamsulosin racemate 10 mg
EPY0000651 Tamsulosin impurity D
2-methoxy-5[(2R)-2-[[2-(2-methyoxyphenoxy)ethyl]amino]propyl]benzenesulfonamide
10 mg
EPY0000652 Tamsulosin impurity H
(2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan-2-amine
10 mg
EPY0001102 Teicoplanin 52 mg
EPY0001047 Teicoplanin for identification 40 mg
EPY0000648 Telmisartan 30 mg
EPY0000649 Telmisartan for peak identification 10 mg
EPY0001003 Telmisartan for system suitability 0.26 mg
EPT0040000 Temazepam Controlled Substance 50 mg
EPY0000344 Temazepam impurity C
(3RS)-7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl acetate
Controlled Substance
5 mg
EPY0000345 Temazepam impurity D
(3RS)-7-chloro-3-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Controlled Substance
5 mg
EPY0000346 Temazepam impurity F
(5RS)-7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione
5 mg
EPY0000347 Temazepam impurity G
(5RS)-7-chloro-1,4-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione
5 mg
EPT0040800 Tenoxicam 100 mg
EPY0001114 Tenoxicam impurity mixture 0.0042 mg
EPY0000621 Terazosin hydrochloride dihydrate 40 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 273
Code Product Unit
EPY0000666 Terazosin for system suitability 0.5 mg
EPY0000622 Terazosin impurity A
2-chloro-6,7-dimethoxyquinazolin-4-amine
10 mg
EPY0000665 Terazosin impurity E
2,2`-(piperazine-1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine)
10 mg
EPY0000623
Terazosin impurity L
1-(furan-2-ylcarbonyl)piperazine
10 mg
EPY0000624 Terazosin impurity N
1-[[(2RS)-tetrahydrofuran-2-yl]carbonyl]piperazine
10 mg
EPY0000535 Terbinafine hydrochloride 10 mg
EPY0001143 Terbinafine for system suitability 10 mg
EPT0050000 Terbutaline sulphate 100 mg
EPT0050015 Terbutaline impurity C
1-(3,5-dihydroxyphenyl)-2-[(1,1- dimethylethyl)amino]-ethanone
15 mg
EPT0060000 Terconazole 250 mg
EPT0071000 Terfenadine 100 mg
EPT0080000 Terfenadine impurity A
1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl] butan-1-one
(ketone)
20 mg
EPT0100000 Testosterone 30 mg
EPT0200000 Testosterone acetate 10 mg
EPT0210000 Testosterone caproate 50 mg
EPT0240000 Testosterone decanoate 50 mg
EPY0000696 Testosterone decanoate for system suitability 0.4 mg
EPT0250000 Testosterone enantate 100 mg
New EPY0001312 Testosterone enantate for peak identification 10 mg
New EPY0001317 Testosterone enantate for system suitability 20 mg
New EPY0001313 Testosterone enantate impurity H
delta-5-testosterone-3,17-dienantate
10 mg
EPY0000342 Testosterone for impurity D identification 20 mg
EPY0000343 Testosterone for system suitability 20 mg
EPT0260000 Testosterone isocaproate 50 mg
EPY0000716 Testosterone isocaproate for system suitability 5 mg
EPT0300000 Testosterone propionate 50 mg
EPY0000170 Testosterone propionate - Reference Spectrum unit
EPT0400000 Tetanus vaccine (adsorbed) BRP 30 mg
EPY0001087 Tetra-O-acetyl-mannose triflate 60 mg
EPT0500000 Tetracaine hydrochloride 100 mg
EPY0001002 Tetracaine for system suitability 2 mg
EPT0550000 Tetracosactide 2x0.366mg
EPT0600000 Tetracycline hydrochloride 100 mg
EPY0001165 Tetrandrine 20 mg
EPY0000015 Tetrazepam - Reference Spectrum unit
EPY0000008 Tetrazepam impurity C
7-chloro-5-cyclohexyl-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
20 mg
EPY0000460 Tetryzoline hydrochloride 10 mg
EPY0000723 Thebaine Controlled Substance 10 mg
EPT0700000 Theobromine 100 mg
EPT0800000 Theophylline 100 mg
EPY0000294 Theophylline - Reference Spectrum unit
EPY0000336 Thiamazole 125 mg
EPY0000372 Thiamazol impurity A
2,2-dimethoxy-N-methylethanamine
15 mg
EPY0000373 Thiamazol impurity C
1-methyl-2-(methylsulphanyl)-1H-imidazole
20 mg
European Pharmacopoeia
274 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000467 Thiamine hydrochloride 10 mg
EPY0000059 Thiamine impurity E
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)
4-methyl-4-thiazolidine-2-thione
10 mg
EPY0000060 Thiamine nitrate - Reference Spectrum unit
EPT1100000 Thiamphenicol 125 mg
EPY0000546 Thioctic acid 110 mg
EPY0000592 Thioctic acid for system suitability 10 mg
EPY0000545 Thioctic acid containing impurity B 30 mg
EPY0000109 Thiomersal 30 mg
EPT1200000 Thiopental 500 mg
EPY0000704 Thioridazine 10 mg
EPT1300000 Thioridazine hydrochloride 100 mg
EPY0000541 Thioridazine for system suitability 0.21 mg
EPT1305100 Thioxanthene 20 mg
EPT1305000 Thioxanthone 10 mg
EPT1340000 Threonine 50 mg
EPT1350000 Thymol 50 mg
EPT1410000 Tiabendazole 50 mg
EPY0000414 Tiamulin for peak identification 10 mg
EPY0000333 Tiamulin hydrogen fumarate 500 mg
EPY0000379 Tiamulin - Reference Spectrum unit
EPY0000151 Tianeptine sodium - Reference Spectrum unit
EPY0000152 Tianeptine for system suitability 30 mg
EPY0000153 Tianeptine impurity A
ethyl 7-bromoheptanoate
20 mg
EPT1405000 Tiapride hydrochloride 60 mg
EPT1405050 Tiapride N-oxide 20 mg
EPT1410900 Tiaprofenic acid 50 mg
EPT1410910 Tiaprofenic acid impurity C
(2RS)-2-(5-benzoylthiophen-3-yl)propanoic acid
20 mg
EPY0000748 Tibolone - Reference Spectrum unit
EPY0000668 Tibolone for system suitability 10 mg
EPY0000465 Ticarcillin monosodium 250 mg
EPT1420010 Ticarcillin impurity A
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(thiophen-3-yl)acetyl]-amino]-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylic acid (decarboxyticarcillin)
50 mg
EPT1423000 Ticlopidine hydrochloride 50 mg
EPT1423025 Ticlopidine impurity F
6-(2-chlorobenzyl)4,5,6,7-tetrahydrothieno [3,2-c]pyridine
10 mg
EPY0000325 Tilidine hydrochloride hemihydrate - Reference Spectrum unit
EPY0001270 Timolol for system suitability 5.045 mg
EPT1450000 Timolol maleate 100 mg
EPY0000644 (R)-timolol 20 mg
EPT1470000 Tinidazole 100 mg
EPY0000899 Tinidazole impurity A
2-methyl-5-nitro-1H-imidazole
10 mg
EPT1471000 Tinidazole impurity B
1-(2-ethylsulphonylethyl)-2-methyl-4-nitroimidazole
20 mg
EPT1490000 Tinzaparin sodium 250 mg
EPY0000292 Tioconazole - Reference Spectrum unit
EPY0000282 Tioconazole for system suitability 50 mg
EPY0001188 Tiotropium bromide monohydrate 10 mg
EPY0001216 Tiotropium impurity F
dithiophen-2-ylmethanone
10 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 275
Code Product Unit
EPY0001179 Tiotropium impurity mixture 0.08 mg
EPY0001189 Tiotropium for system suitability 10 mg
EPT1500000 Tobramycin 51 mg
EPY0001210 Tobramycin for identification 250 mg
EPY0000383 All-rac-alpha-tocopherol for peak identification 15 mg
EPY0000384 All-rac-alpha-tocopheryl acetate for peak identification 15 mg
EPT1550000 alpha-Tocopherol 500 mg
EPT1600000 alpha-Tocopheryl acetate 500 mg
EPT1610000 RRR-alpha-Tocopheryl hydrogen succinate 125 mg
EPT1700000 Tolbutamide 100 mg
EPY0000154 Tolfenamic acid 100 mg
EPT1707000 Tolnaftate 60 mg
EPY0001123 Tolnaftate for system suitability 10 mg
EPY0000461 Torasemide anhydrous 10 mg
EPY0000462 Torasemide for system suitability 0.4 mg
New EPY0001366 Torasemide impurity E
ethyl[[4-[(3-methylphenyl)amino]pyridin-3-yl]sulfonyl]carbamate
0.0006 mg
EPY0000155 Tramadol hydrochloride 75 mg
EPY0000156 Tramadol impurity A
(1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol
15 mg
EPY0000157 Tramadol impurity E
(2RS)-2-[(dimethylamino)methyl]cyclohexanone
15 mg
EPY0000072 Tramazoline hydrochloride monohydrate 20 mg
EPY0000065 Tramazoline impurity A
N-(naphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine
10 mg
EPY0000066 Tramazoline impurity B
mixture of: 1-acetyl-2-[(5,6,7,8-tetrahydronaphthalen-1-yl)amino]-4,5-dihydro-1H-imidazole
and N-(4,5-dihydro-1H-imidazol-2-yl)-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
10 mg
EPY0000501 Trandolapril 10 mg
EPY0000495 Trandolapril impurity C
(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-3-cyclohexyl-1-
(ethoxycarbonyl)propyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid
(hexahydrotrandolapril)
10 mg
EPY0000496 Trandolapril impurity D
ethyl (2S)-2-[(3S,5aS,9aR,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl]-
4-phenylbutanoate (trandolapril diketopiperazine)
10 mg
EPT1810000 Tranexamic acid 50 mg
EPT1820000 Trapidil 50 mg
EPT1820002 Trapidil impurity A
5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
20 mg
EPT1820004 Trapidil impurity B
1,2,4-triazol-3-amine
20 mg
EPY0001172 Trehalose dihydrate 250 mg
EPT1850000 Tretinoin 50 mg
EPT1899000 3,4,6-Tri-O-acetyl-D-glucal - Reference Spectrum unit
EPG0400010 Triacetin - Reference Spectrum unit
EPT1899990 Triamcinolone 150 mg
EPT1900000 Triamcinolone acetonide 100 mg
EPT1950000 Triamcinolone hexacetonide 100 mg
EPY0000050 Triamcinolone impurity C
9-fluoro-11-16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione
10 mg
EPY0000837 Triamterene 10 mg
EPY0000870 Triamterene impurity B
2,7-diamino-6-phenylpteridin-4-ol
0.5 mg
EPT1975000 Triazolam Controlled Substance 10 mg
EPY0000165 Tribenoside 150 mg
European Pharmacopoeia
276 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPY0000166 Tribenoside impurity A
3,5,6-tri-O-benzyl-1,2-O-(1-methylethylidene)--D-glucofuranose
30 mg
EPY0001055 Tributyl acetylcitrate 1 mL
EPY0000279 Tri-n-butyl phosphate 300 L
EPY0000799 Tributyl acetylcitrate for peak identification 25 mg
EPT1977990 Tricaprin 150 mg
EPT1977995 Tricaproin 40 mg
EPT1978000 Tricaprylin 225 mg
EPY0000111 Trichloroacetic acid - Reference Spectrum unit
EPT1985000 Trichlorotrifluoroethane 2.5 mL
EPT1986000 Triethyl citrate - Reference Spectrum unit
EPT2000000 Trifluoperazine hydrochloride 100 mg
EPT2005000 Triflusal 50 mg
EPT2005010 Triflusal impurity B
2-hydroxy-4-(trifluoromethyl)benzoic acid
25 mg
EPY0000720 Triglycerol diisostearate 200 mg
EPY0000108 Trihexyphenidyl hydrochloride 100 mg
EPY0000068 Trihexyphenidyl impurity A
1-phenyl-3-(piperidin-1-yl)propan-1-one
20 mg
EPT2009000 Trilaurin 1250 mg
New EPY0001260 Trimebutine for system suitability 1.017 mg
New EPY0001319 Trimebutine maleate 10 mg
EPY0000092 Trimetazidine dihydrochloride - Reference Spectrum unit
EPY0000093 Trimetazidine for system suitability 50 mg
EPT2100000 Trimethadione 250 mg
EPT2200000 Trimethoprim 50 mg
EPY0000684 Trimethoprim for system suitability 0.00075 mg
EPT2200010 Trimethoprim impurity B
(2,4-diaminopyrimidin-5-yl)(3,4,5- trimethoxyphenyl)methanone
10 mg
EPT2450000 Trimethyltetradecylammonium bromide 200 mg
EPT2500000 Trimipramine maleate 100 mg
EPY0000759 Trimipramine for peak identification 0.51 mg
EPT2500100 Trimyristin 500 mg
EPT2501200 Tristearin 100 mg
EPT2545000 Trolamine 2250 mg
EPY0001184 Trolamine impurity A
Ethanolamine
250 mg
EPY0001183 Trolamine impurity B
Diethanolamine
1 mL
EPT2550000 Trometamol 100 mg
EPT2580000 Tropicamide 50 mg
EPY0001316 Tropicamide for peak identification 10 mg
EPY0001247 Tropicamide impurity C
(2RS)-3-hydroxy-2-phenylpropanoic acid (tropic acid)
10 mg
EPY0001248 Tropicamide impurity D
Phenylacetic acid Drug Precursor
10 mg
EPY0000616 Tropisetron hydrochloride 40 mg
EPY0000618 Tropisetron impurity B
1H-indole-3-carboxylic acid
10 mg
EPT2580300 Tropine 50 mg
EPY0000429 Trospium chloride 10 mg
EPY0000432 Trospium impurity A
Hydroxydiphenylacetic acid (benzilic acid)
20 mg
EPY0000431 Trospium impurity B
(1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl hydroxydiphenylacetate
15 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 277
Code Product Unit
EPY0000430 Trospium impurity C
(1R,3r,5S)-3-hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium]
5 mg
EPY0000497 Troxerutin 30 mg
EPT2600000 Trypsin BRP 100 mg
EPT2610000 Tryptophan 100 mg
EPT2800000 Tubocurarine chloride 100 mg
EPT2880000 Tylosin 150 mg
EPT2880100 Tylosin D 5 mg
EPY0000498 Tylosin phosphate for peak identification 10 mg
EPT2880200 Tylosin tartrate - Reference Spectrum unit
EPT2900000 Tyrosine 50 mg
EPT3000000 Tyrothricin 20 mg
EPU0020000 Ubidecarenone 50 mg
EPU0020001 Ubidecarenone for system suitability 1 mg
EPU0020008 Ubidecarenone impurity D
5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31,35-
nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]
benzene-1,4-dione
5 mg
EPU0100000 Uracil arabinoside 60 mg
EPU0600000 Urea 100 mg
EPU0800000 Ursodeoxycholic acid 100 mg
EPY0001163 Ursodeoxycholic acid for system suitability 1.26 mg
EPY0001225 Valaciclovir for system suitability 10 mg
EPY0000834 Valaciclovir hydrochloride (anhydrous) 100 mg
EPY0001096 Valaciclovir impurity D
2-[(2-amino-6-oxo-1,6dihydro-9H-purin-9-yl)methoxy]ethyl N-ethyl-L-valinate
10 mg
EPY0001097 Valaciclovir impurity E
2-[(2-amino-6-oxo-1,6dihydro-9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy)carbonyl]-L-valinate
10 mg
EPY0001098 Valaciclovir impurity F para-toluenesulfonate
2-hydroxyethyl L-valinate
12 mg
EPY0001099 Valaciclovir impurity G
N,N-dimethylpyridin-4-amine
10 mg
EPY0000583 Valerian standardised dry extract 400 mg
EPV0030000 Valine 50 mg
EPY0000584 Valnemulin hydrochloride 10 mg
EPY0000533 Valnemulin hydrogen tartrate 120 mg
EPY0000585 Valnemulin for peak identification 20 mg
EPY0000586 Valnemulin impurity E
(3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-
3a,9-propano-3aH-cyclopenta[8]annulen-8-yl 2-hydroxyacetate (pleuromulin)
10 mg
EPV0033000 Valproic acid 100 mg
EPY0001132 Valsartan 10 mg
EPY0001131 Valsartan for peak identification 10 mg
EPY0001145 Valsartan for system suitability 0.202 mg
EPV0045000 Vancomycin hydrochloride 100 mg
EPV0050000 Vanillin 100 mg
EPY0001198 Varicella vaccine (live) 420 mg
EPY0000561 Vecuronium bromide 10 mg
EPY0000625 Vecuronium for peak identification 10 mg
EPY0001093 Vedaprofen 5 mg
EPY0001118 Vedaprofen impurity mixture 0.006 mg
EPY0000587 Venlafaxine hydrochloride 50 mg
EPY0000588 Venlafaxine for system suitability 1 mg
EPV0100000 Verapamil hydrochloride 100 mg
European Pharmacopoeia
278 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
EPV0100018 Verapamil impurity I
(2RS)-2-(3,4-dimethoxyphenyl)-2-[2-[[2-(3,4)dimethoxyphenyl)-
ethyl](methyl)amino]ethyl]3-methylbutanenitrile
5 mg
EPV0100026 Verapamil impurity M
5,5'-[[2-(3,4)dimethoxyphenyl)ethyl]imino]bis[2-(3,4-dimethoxyphenyl)-
2-(1-methylethyl)pentanenitrile
10 mg
EPY0000661 Verbenalin 11 mg
EPV0180000 VERO cells 2x1 mL
EPV0200000 Viscosimeter calibration liquids 250 mL
EPV0300000 Vinblastine sulphate 5 mg
EPV0305000 Vinblastine sulphate - Reference Spectrum unit
EPV0400000 Vincristine sulphate 4.98 mg
EPV0405000 Vincristine sulphate - Reference Spectrum unit
EPV0500000 Vindesine sulphate 5.11 mg
EPV0500010 Vindesine sulphate - Reference Spectrum unit
EPY0000463 Vinorelbine tartrate 50 mg
EPY0000464 Vinorelbine impurity B
4-O-deacetylvinorelbine
7 mg
EPY0000589 Vinpocetine 10 mg
EPY0000590 Vinpocetine impurity A
(12RS,13aSR,13bSR)-13a-ethyl-12-hydroxy-2,3,5,6, 12,13,13a,13b-octahydro-1H-
indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (ethyl vincaminate)
10 mg
EPY0000591 Vinpocetine impurity B
(13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-
ij][1,5]naphthyridine-12-carboxylate (apovincamine)
10 mg
EPY0000790 Vinpocetine impurity C
ethyl(13aS,13bS)-13a-ethyl-9-methoxy-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-
de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (methoxyvinpocetine)
10 mg
EPY0000760 Vinpocetine impurity D
(12RS,13aRS,13bRS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-
de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine)
10 mg
EPY0000793 Vinyl acetate 200 mg
EPW0100000 Warfarin sodium 10 mg
EPY0000778 Warfarin sodium clathrate 10 mg
EPX0075000 Xylazine hydrochloride 125 mg
EPY0000158 Xylazine impurity C
2,6-dimethylphenyl isothiocyanate
50 mg
EPY0000159 Xylazine impurity E
N-(2,6-dimethylphenyl)-S-methyldithiourea
50 mg
EPY0001224 Xylazine impurity mixture 0.02 mg
EPX0080000 Xylitol 500 mg
EPX0100000 Xylometazoline Hydrochloride 100 mg
EPX0101000 Xylometazoline impurity A
N-(2-aminoethyl)-2-(4-1,1-dimethylethyl-2,6-dimethylphenyl)acetamide
10 mg
EPX0200000 Xylose 100 mg
EPY0000656 Yohimbine hydrochloride 20 mg
EPZ1900000 Zidovudine 60 mg
EPZ1902000 Zidovudine impurity A
1-[(2R,5S)-5-hydroxymethyl-2,5-dihydro-2-furyl]-5-methylpyrimidine-2,4(1H,3H)-dione
10 mg
EPZ1904000 Zidovudine impurity B
1-(3-chloro-2,3-dideoxy--D-ribofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
10 mg
EPZ2000000 Zinc acexamate 50 mg
EPZ2000010 Zinc acexamate impurity A
6-[[6-(acetylamino)hexanoyl]amino] hexanoic acid
50 mg
New EPY0001272 Ziprasidone for system suitability 1 10 mg
New EPY0001241 Ziprasidone for system suitability 2 0.465 mg
New EPY0001286 Ziprasidone hydrochloride monohydrate 100 mg
European Pharmacopoeia
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 279
Code Product Unit
EPZ2500000 Zolpidem tartrate Controlled Substance 200 mg
EPZ2500010 Zolpidem impurity A
N,N'-dimethyl-2-[7-methyl-2-(4-methylphenyl)imidazol
[1,2-a]pyridin-3-yl] acetamide
10 mg
EPZ3000000 Zopiclone Controlled Substance 60 mg
EPZ3001000 Zopiclone oxide 20 mg
EPY0000062 Zuclopenthixol decanoate - Reference Spectrum unit
EPY0000534 Zuclopenthixol for system suitability 0.1 mg
EPY0000083 Zuclopenthixol impurity B
2-chloro-9H-thioxanthen-9-one
10 mg
ATCC microbiology products
280 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
ATCC microbiology products
As a scientist you know the importance of using the best materials to support your quality control
programme. As Europes only officially authorized distributor of ATCC
) amp.
ATCC-7953 Geobacillus stearothermoplus (formerly Bacillus stearothermophilus) amp.
5.1.3. - Efficacy of antimicrobial preservation
ATCC-16404 Aspergillus niger amp.
ATCC-10231 Candida albicans amp.
ATCC-8739 Escherichia coli amp.
ATCC-9027 Pseudomonas aeruginosa amp.
ATCC-6538 Staphylococcus aureus subsp. aureus amp.
All care has been taken in compiling catalogue numbers, however users should consult the Pharmacopoeia
directly to confirm the testing requirements and recommended organisms before ordering or undertaking the
testing procedures as described in the Pharmacopoeia.
Certified Liquids for Viscosity Measurements in the European Pharmacopoeia
282 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Certified Liquids for Viscosity Measurements in the European
Pharmacopoeia
Newtonian liquids with a certified viscosity are supplied by Van Swinden Laboratorium BV and are
distributed by LGC Standards.
Liquids are available with kinematic viscosities up to 48000 mm
2
s
-1
and certified at temperatures between
15C and 140C.
Viscosities are certified in mm
2
s
-1
(kinematic viscosity, v) or in mPa
.
s (dynamic viscosity,)
1 mPa
.
s = 1 cps (centipoise) 1 mm
2.
s
-1
= 1 cst (centistoke)
Standard liquids are available from stock, in 250 ml packs and certified at 20C to following viscosities:
v = 0,6 ; 1,0 ; 2,2; 4,9 ; 1; 20 ; 31 ; 56 ; 67 ; 85 ; 100 ; 132 ; 167 ; 217 ; 262; 340 ; 423 ; 537 ; 644 ; 783 ;
1000 ; 1260 ; 1800 ; 3650 ; 5075 ; 10175 ; 18400 ; 46500
= 0,4 ; 1,0 ; 1,8; 4,0 ; 8,9 ; 17,0 ; 26,0 ; 48,0 ; 58,0 ; 74,0 ; 87,0 ; 116,0 ; 146,0 ; 191,0 ; 230,0 ; 300,0 ;
375,0 ; 474,0 ; 572,0 ; 700,0 ; 862,0 ; 1085 ; 1560 ; 3175 ; 4430 ; 8935 ; 16300 ; 41300
All viscosities are calibrated relative to the viscosity of pure water. Stated values are nominal values,
certified values will not deviate more than 10% from the nominal value.
The uncertainty of the certified viscosities is at least 0.3% at the lowest viscosity, increasing up to 0.5%
at 48000 mm
2.
s
-1
.
Shelf life
Standards up to 500 mPa
.
s are mineral oil based, and have a shelf life of 12 months from date of certification.
Above 500 mPa
.
s Polyisobutylene is used, these materials have a shorter shelf life, and should be ordered
as needed.
Liquids can be prepared and certified to any viscosity between 0.6 mm
2.
s
-1
and 80,000 mm
2.
s
-1
.
The price depends on the viscosity required, the degree of precision between nominal viscosity required and
certified viscosity achieved, and temperature of certification.
Additional charges are applied for extra certification temperatures and for certification of dynamic viscosity.
Please ask for a quotation.
Liquids supplied by customers may be certified for viscosity, charges vary: please ask for a quotation.
International Commission on Pharmaceutical Enzymes
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 283
International Commission on Pharmaceutical Enzymes
The Commission on Pharmaceutical Enzymes was formed in 1960, with a remit to establish quantitative
methods and an exact definition of enzyme activity for pharmacologically significant enzymes.
One consequence of the work of FIP Federation International Pharmaceutique has been the production
and certification of reference substances for both enzymes and substrates.
More recently the work of the Commission has been reflected in those monographs of the European
Pharmacopoeia which call for enzyme standards. The FIP products marked (EP) in this list are those which
are required in certain EP monographs.
Enzymes
Code Product Unit
FIP1 Fungal Amylase 2 g
FIP2(EP) Amylase (pancreatic) 2 g
FIP3 Fungal Protease 2 g
FIP4 Bromelain 250 mg
FIP5 Endocellulase 1 g
FIP6(EP) Chymotrypsin 100 mg
FIP7 Fungal Lipase 500 mg
FIP8(EP) Lipase (pancreatic) 2 g
FIP9 Lysozyme hydrochloride 250 mg
FIP10 Papain 2 g
FIP11(EP) Pepsin 2 g
FIP12(EP) Protease (pancreatic) 2 g
FIP13(EP) Trypsin 100 mg
FIP14(EP) Hyaluronidase 50 mg
Substrates
FIP15(EP) Enterokinase 500 mg
FIP16 Micrococcus Luteus sp. 1 g
FIP17 Starch (EP) 50 g
FIP18(EP) Casein 100 g
FIP19 Haemoglobin 10 g
FIP20 Hydroxyethylcellulose 100 g
FIP21 Sodium Taurocholate 10 g
FIP22(EP) Sodium hyaluronate 300 mg
European Pharmacopoeia Reagents
284 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
European Pharmacopoeia Reagents
Chapters 2 and 4 of the European Pharmacopoeia describe the preparation of several hundred reagents and
standards used for the testing of pharmaceutical raw materials.
LGC Standards offers a large number of these ready-to-use reagents and standard solutions within the
spectrum of this new catalogue.
The primary solutions for coloration are produced by LGC Standards, the other reagents are manufactured
by Reagecon. All are manufactured and tested in compliance with the prescriptions of EP. The products are
supplied with certificates of analysis. Lot numbers and expiry dates are stated on all product labels as well.
The reagents are always supplied as per the most recently issued EP supplement.
Reagents from other pharmacopoeias are also available on request. Please contact your local
LGC Standards office for further details.
Reagents as outlined in Chapter 2
Code Product Unit
REAEPPOSO1 Primary opalescence suspension 100 mL
Coloration: primary solutions
WESEPYS01 Coloration-primary solution yellow 100 mL
WESEPRS01 Coloration-primary solution red 100 mL
WESEPBS01 Coloration-primary solution blue 100 mL
Coloration: standard solutions
REAEP703 Standard solution B (brown) 125 mL
REAEP704 Standard solution BY (brownish yellow) 125 mL
REAEP706 Standard solution Y (yellow) 125 mL
REAEP705 Standard solution GY (greenish yellow) 125 mL
REAEP707 Standard solution R (red) 125 mL
REAHADM1 HCL dilution matrix (10 g/l HCl) 1 L
Reference buffer solutions - all @ 25C
REAEP168 ph Buffer solution 1.68 500 mL
REAEP401 ph Buffer solution 4.01 500 mL
REAEP687 ph Buffer solution 6.87 500 mL
REAEP741 ph Buffer solution 7.41 500 mL
REAEP918 ph Buffer solution 9.18 500 mL
Conductivity & resistivity solutions - @ 20C
REAEP1330 Conductivity standard
Electrolytic conductivity ............ 1330 S/cm at 20C
Resistivity .................................................. 752 cm
500 mL
REAEP133 Conductivity standard
Electrolytic conductivity .............. 133 S/cm at 20C
Resistivity ................................................ 7519 cm
500 mL
REAEP266 Conductivity standard
Electrolytic conductivity ............. 26.6 S/cm at 20C
Resistivity .............................................. 37594 cm
500 mL
Reagents as outlined in Chapter 4 (4.1.1) of Ph.Eur.
REA1000401 Acetic acid (30%) 1 L
REA1000402 Acetic acid, dilute (12%) 1 L
REA1000501 Acetic anhydride solution R1 1 L
REA1002501 Alcohol, aldehyde free 1 L
REA1004702 Ammonia, dilute R1 1 L
REA1004703 Ammonia, dilute R2 1 L
REA1005201 Ammonium carbonate solution 1 L
REA1007301 Anisaldehyde, solution 100 mL
REA1007302 Anisaldehyde, solution R1 100 mL
REA1009301 Barium chloride, solution R1 1 L
European Pharmacopoeia Reagents
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 285
Code Product Unit
REA1009401 Barium hydroxide, solution 1 L
REA1011601 Biuret reagent 1 L
REA1012601 Bromocresol green solution 100 mL
REA1012602 Bromocresol green-methyl red solution 100 mL
REA1012701 Bromocresol purple solution 100 mL
REA1012801 Bromophenol blue solution 100 mL
REA1012803 Bromophenol blue solution R2 100 mL
REA1012901 Bromothymol blue solution R1 100 mL
REA1015201 Calcium sulphate solution 1 L
REA1022901 Crystal violet solution 100 mL
REA1023100 Cupri-citric solution 1 L
REA1023300 Cupri-tartaric (Solution I 500 mL & Solution II 500 mL) 1 L
REA1031101 Dimidium bromide - sulphan blue mixed solution 1 L
REA1032101 Diphenylamine solution 1 L
REA1032102 Diphenylamine solution R1 1 L
REA1037702 Ferric ammonium sulphate solution R2 100 mL
REA1038100 Ferroin 100 mL
REA1039101 Formaldehyde solution 100 mL
REA1039401 Fuchsin solution, decolorised 100 mL
REA1039402 Fuchsin solution, decolorised R1 100 mL
REA1043101 Holmium perchlorate solution 1 L
REA1043501 Hydrochloric acid R1 1 L
REA1043503 Hydrochloric acid, dilute 1 L
REA1043504 Hydrochloric acid, dilute R1 1 L
REA1045901 Iodine bromide solution 1 L
REA1046300 Iodoplatinate reagent 200 mL
REA1048001 Lanthanum nitrate solution 1 L
REA1048101 Lead acetate cotton 10 g
REA1048102 Lead acetate paper Pack of 50
REA1052101 Mercuric bromide paper Pack of 50
REA1053601 Methoxyphenylacetic reagent 100 mL
REA1054801 Methyl orange mixed solution 100 mL
REA1054802 Methyl orange solution 100 mL
REA1055101 Methyl red mixed solution 100 mL
REA1055102 Methyl red solution 100 mL
REA1056700 Molybdovanadic reagent 100 mL
REA1056801 Mordant black 11 triturate 100 mL
REA1057601 Naphtobenzein solution 100 mL
REA1058303 Ninhydrin, solution 100 mL
REA1058304 Ninhydrin solution R1 100 mL
REA1058305 Ninhydrin solution R2 100 mL
REA1058402 Acide nitrique dilu 100 mL
REA1062901 Perchloric acid solution 100 mL
REA1063601 Phenol red solution 100 mL
REA1063603 Phenol red solution R2 500 mL
REA1063702 Phenolphthalein solution 100 mL
REA1063703 Phenolphthalein solution R1 100 mL
REA1065000 Phosphomolybdotungstic reagent 100 mL
REA1065200 Phosphomolybdotungstic solution 100 mL
REA1065801 Picric acid solution 100 mL
REA1065802 Picric acid solution R1 100 mL
REA1069101 Potassium chloride, 0.1 M 1 L
European Pharmacopoeia Reagents
286 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
REA1069201 Potassium chromate, solution 1 L
REA1069501 Potassium dichromate, solution 1 L
REA1069801 Potassium ferrocyanide, solution 100 mL
REA1070001 Potassium hydrogen phthalate, 0.2 M 1 L
REA1070302 Potassium hydroxide in alcohol (10% v/v) 1 L
REA1070303 Potassium hydroxide solution alcoholic 100 mL
REA1070501 Potassium iodide and starch solution 125 mL
REA1070502 Potassium iodide solution 1 L
REA1070600 Potassium iodobismuthate, solution 100 mL
REA1070602 Potassium iodobismuthate, solution R2 (short shelf life) 100 mL
REA1070902 Potassium permanganate, solution 1 L
REA1071301 Potassium pyroantimonate, solution 125 mL
REA1071600 Potassium tetraiodomercurate, solution alkaline (100 ml of both solutions) 200 mL
REA1075201 Ruthenium red solution 100 mL
REA1078301 Silver nitrate solution R1 1 L
REA1078302 Silver nitrate solution R2 1 L
REA1079301 Sodium carbonate solution
1 L
REA1081401 Sodium hydroxide solution 1 L
REA1081402 Sodium hydroxide solution dilute 1 L
REA1081404 Sodium hydroxide solution strong 1 L
REA10816005 Sodium hypochlorite solution strong 500 mL
REA1083901 Sodium sulfure solution 100 mL
REA1085103 Starch, solution 100 mL
REA1086804 Sulphuric acid, dilute 1 L
REA1089602 Thiocetamide solution 1 L
REA1090701 Thymolphthalein solution 100 mL
REA1094201 Tris(hydroymethyl) aminomethane solution 100 mL
REA1102301 Zinc acetate solution 1 L
REA1096601 Zinc chloride formic acid solution 1 L
REA1096602 Zinc chloride solution, iodinated 1 L
Standard solutions for limit tests as outlined in Chapter 4 (4.1.2) of Ph.Eur.
REA5000200 Aluminium standard solution (200 ppm Al) 100 mL
REA5000300C Ammonium standard solution (100 ppm NH4) 100 mL
REA5000500C Arsenic standard solution (10 ppm As) 100 mL
REA5000700C Cadmium standard solution (0.1% Cd) 100 mL
REA5000800C Calcium standard solution (400 ppm Ca) 100 mL
REA5000802C Calcium standard solution alcoholic (400 ppm Ca) 1 L
REA5000900C Chloride standard solution (8 ppm CI) 100 mL
REA5001000 Chromium standard solution (100 ppm Cr) 1 L
REA5001100 Copper standard solution (0.1% Cu) 100 mL
REA5001200C Ferrocyanide standard solution (100 ppm Fe) 100 mL
REA5001400C Fluoride standard solution (10 ppm F) 100 mL
REA5001600C Iron standard solution (20 ppm Fe) 100 mL
REA5001602C Iron standard solution (8 ppm Fe) 100 mL
REA5001701C Lead standard solution (100 ppm Pb) 100 mL
REA5001800C Lagnesium standard solution (100 ppm Mg) 100 mL
REA5002000C Nickel standard solution (10 ppm Ni) 100 mL
REA5002100C Nitrate standard solution (100 ppm NO3) 100 mL
REA5002200C Phosphate standard solution (5 ppm PO4) 100 mL
REA5002400C Potassium standard solution (100 ppm K) 100 mL
REA5002700C Sodium standard solution (200 ppm Na) 100 mL
European Pharmacopoeia Reagents
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 287
Code Product Unit
REA5002800C Sulphate standard solution (10 ppm SO4) 100 mL
REA5003100C Tin standard solution (5 ppm Sn) 1 L
REA5003401C Zinc standard solution (100 ppm Zn) 100 mL
Buffer solutions as outlined in Chapter 4 (4.1.3) of Ph.Eur.
REA4000100 Buffered acetone solution 1 L
REA4000600 Buffer solution pH 3.5 1 L
REA4001400 Acetate buffer solution pH 4.6 1 L
REA4004800 Phosphate buffer solution pH 7.4 1 L
REA4008300 Buffer (phosphate) solution pH 9.0 1 L
REA4007200 Ammonium chloride buffer solution pH 9.5 1 L
REA4007300 Ammonium chloride buffer solution pH 10.0 1 L
Volumetric solutions as outlined in Chapter 4 (4.2.2) of Ph.Eur.
REA3000100 0.1M Ammonium and cerium nitrate 1 L
REA3000200 0.01M Ammonium and cerium nitrate 1 L
REA3000300 0.1M Ammonium and cerium sulphate 1 L
REA3000500 0.1M Ammonium thiocyanate 1 L
REA3000600 0.1M Barium chloride 1 L
REA3000900 0.004M Benzethonium chloride 1 L
REA3001100 0.1M Cerium sulphate 1 L
REA3008700 1M Cupriethylenediamine hydroxide solution 1 L
REA3001300 0.1M Ferric ammonium sulphate 1 L
REA3001500 6M Hydrochloric acid 1 L
REA3001700 2M Hydrochloric acid 1 L
REA3001800 1M Hydrochloric acid 1 L
REA3002100 0.1M Hydrochloric acid 1 L
REA3008800 0.1M Hydrochloric acid, alcoholic 1 L
REA3002700 0.05M Iodine 1 L
REA3003100 0.1M Lead nitrate 1 L
REA3003300 0.1M Lithium methoxide 1 L
REA3003500 0.02M Mercuric nitrate 1 L
REA3003900 0.1M Perchloric acid 1 L
REA3004200 0.033M Potassium bromate 1 L
REA3002900 0.01M Iodine 1 L
REA3009100 11M Potassium hydroxide 1 L
REA3004800 0.1M Potassium hydroxide 1 L
REA3004900 0.5M Potassium hydroxide 1 L
REA3005000 0.5M Potassium hydroxide, alcoholic 1 L
REA3005100 0.1M Potassium hydroxide, alcoholic 1 L
REA3005300 0.02M Potassium permanganate 1 L
REA3005600 0.1M Silver nitrate 1 L
REA3009300 0.001M Sodium nitrate 1 L
REA3005800 0.1M Sodium arsenite 1 L
REA3005900 0.1M Sodium edetate 1 L
REA3006300 1M Sodium hydroxide 1 L
REA3006600 0.1M Sodium hydroxide 1 L
REA3007000 0.1M Sodium hydroxide, ethanolic 1 L
REA3007100 0.1M Sodium methoxide 1 L
REA3007200 0.1M Sodium nitrate 1 L
REA3007300 0.1M Sodium thiosulphate 1 L
REA3007800 0.5M Sulphuric acid 1 L
REA3008000 0.05M Sulphuric acid 1 L
European Pharmacopoeia Reagents
288 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
Code Product Unit
REA3008300 0.1M Tetrabutylammonium hydroxide 1 L
REA3008400 0.1M Tetrabutylammonium hydroxide in 2-propanol 1 L
REA3008600 0.1M Zinc sulphate 1 L
WHO International Standards for Antibiotics
Edition 2011/2012 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. 289
WHO International Standards for Antibiotics
In 2006, the EDQM has been designated a WHO Collaborative Centre for the International
Standards for Antibiotics (ISA).
These standards are essential in the standardisation and quality control of antibiotic material and
pharmaceutical products. They are supplied for assays described in the specifications for quality control
of antibiotic material. The EDQM is for example responsible for the establishment and storage of the
WHO ISA materials.
All biological preparations listed in this catalogue are supplied exclusively as WHO ISA materials for use as
primary standards in the establishment of National/Regional secondary working standards and for no other
purpose.
You can order the ISA materials directly with your supplies for other reference materials available from
LGC Standards. For further information please contact your local LGC Standards office.
Code Product Unit
EPISA_29078 Second International Standard for Amphotericin B 100 mg
EPISA_29384 Third International Standard for Nystatin 100 mg
EPISA_62_003 Bacitracin 100 mg
EPISA_62_008 Spiramycin 50 mg
EPISA_62_013 Dihydrostreptomycin 200 mg
EPISA_65_062 Colistin 75 mg
EPISA_66_231 Rifamycin SV 100 mg
EPISA_66_254 Colistin Methane Sulfonate 75 mg
EPISA_67_301 Polymoyxin B 75 mg
EPISA_68_041 Neomycin B 25 mg
EPISA_72_406 Neomycin 50 mg
EPISA_76_538 Erythromycin 75 mg
EPISA_76_539 Streptomycin 100 mg
EPISA_78_547 Bleomycin Complex A2/B2 7 mg
EPISA_80_543 Sisomicin 63 mg
EPISA_82_510 Tobramycin 11.2 mg
EPISA_83_521 Kanamycin 13 mg
EPISA_83_577 Netilmicin 7.5 mg
EPISA_90_704 Teicoplanin 54 mg
EPISA_92_670 Gentamicin 50 mg
EPISA_TYN Tylosin 40 mg
WHO International Standards for Antibiotics
290 Looking for impurity reference standards with CofAs? See our LGC impurity chapter from page 7 on. Edition 2011/2012
We constantly add new products to our range, so please
contact us to find out about our products and services and to
make sure you are automatically kept up to date by
subscribing to our free newsletter.
Please send an e-mail to pharma-news@lgcstandards.com
British
Pharmacopoeia
Pharmacope
Franaise
Pharmacopoeia
Helvetica
International
Pharmacopeia
Ultra-pure solvents from
LGC Standards
Ultra HPLC (UHPLC) requires solvents of superior
quality in order to achieve the optimum
performance of the instrument and columns.
UHPLC can provide very signifcant increases in
resolution, speed, and sensitivity, compared to
conventional HPLC. To ensure these benefts are
realised, and so gain the full benefts of invest-
ment in such sophisticated technology, solvents
of the highest purity are required.
The range of Optigrade
solvents combine:
The highest specifcation for UV
Low gradient shift
Minimal peak impurities
Lowest ionic background for MS detection
Our Optigrade
Food
ndustry
Environmental
Pharmaceutical
For further information or to place an order, please
contact your local office.
PoIydisperse standards
Monodisperse standards
Image anaIysis standards
Sieve caIibration standards
GeneraI purpose gIass
microspheres
GeneraI purpose basaIt
microspheres
www.|gcstandards.com
Standards
Excellence through measurement
FINE dividers x 12 v6_SS:Layout 1 08/08/2011 11:27 Page 1
Secondary Reference Standards traceable to USP, EP and BP
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 391
Secondary Reference Standards traceable to USP, EP and BP
Background
The concept of secondary standards derived by direct comparison with pharmacopoeial reference
standards is a proven one and recognised by all major regulation agencies and pharmacopoeias. Normally
such secondary standards are established by the laboratory that uses them afterwards. To source them
from a dedicated provider instead is a new concept and offers significant advantages.
Efficiency: You can focus your resources on value producing activities, rather than the routine.
Risk Mitigation: These standards are supplied by an independent 3rd party Reference Material Producer
working according to acknowledged ISO standards.
Economical savings: Attractively priced over pharmacopeial reference standards or in-house standards.
Generous Quantities: Product contains 2-20x the amount offered by the Pharmacopeias, allowing multiple
uses.
Certification
The Certificate of Analysis provided with the products in this catalogue section complies with the
requirements of ISO Guide 31 and is traceable to the available United States, European, and British
Pharmacopeial Reference Standard.
Furthermore, every current Secondary Reference Standard from this catalogue section is re-certified after
new pharmacopoeial lot or batch releases. Please contact your local LGC Standards office to obtain
updated certificates for the materials purchased via us.
About RTC
The certified reference materials displayed in this catalogue section are manufactured by RTC, the
Research Technology Corporation with headquarters in Laramie (WY) in the United States of America. We
are proud to offer them conveniently to you in mainland Europe.
RTC maintains the highest level of accreditation available in the industry like accreditation to ISO Guide 34
and ISO 17025.
Code Product Unit Price
RTC-PHR-1028 1,4-Benzoquinone 1 g AR
RTC-PHR-1072 2-Propanol 3x1.2 mL AR
RTC-PHR-1048 4-Hydroxybenzoic Acid 1 g AR
RTC-PHR-1005 Acetaminophen (Paracetamol) 1 g AR
RTC-PHR-1086 Acetanilide Melting Point Standard 1 g AR
RTC-PHR-1053 Albuterol Sulfate 1 g AR
RTC-PHR-1008 Ascorbic Acid 2 g BR
RTC-PHR-1003 Aspirin (Acetylsalicylic acid) 1 g AR
RTC-PHR-1073 Avobenzone 1 g AR
RTC-PHR-1088 Azithromycin 1 g BR
RTC-PHR-1050 Benzoic Acid 1 g AR
RTC-PHR-1019 Benzyl Alchohol 1 g AR
RTC-PHR-1022 Butylparaben (Butyl parahydroxybenzoate) 1 g AR
RTC-PHR-1009 Caffeine 1 g AR
RTC-PHR-1095 Caffeine Melting Point Standard 1 g AR
RTC-PHR-1067 Carbamazepine 1 g AR
RTC-PHR-1016 Chlorpheniramine Maleate 500 mg AR
RTC-PHR-1075 Cimetidine 1 g AR
RTC-PHR-1089 Cimetidine Hydrochloride 1 g AR
RTC-PHR-1044 Ciprofloxacin Hydrochloride 1g BR
RTC-PHR-1071 Citric Acid 1 g AR
RTC-PHR-1038 Clarithromycin 500 mg BR
RTC-PHR-1021 Clindamycin Phosphate 1 g BR
RTC-PHR-1058 Clotrimazole 1 g AR
Secondary Reference Standards traceable to USP, EP and BP
392 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Code Product Unit Price
RTC-PHR-1092 Cyclosporine 500 mg ER
RTC-PHR-1070 Dehydrated Alcohol 5x1.2 mL AR
RTC-PHR-1018 Dextromethorphan Hydrobromide 500 mg BR
RTC-PHR-1000 Dextrose (D-Glucose) 1 g AR
RTC-PHR-1045 Diethylene Glycol 1 g AR
RTC-PHR-1015 Diphenhydramine Hydrochloride 1 g AR
RTC-PHR-1090 Dopamine Hydrochloride 1 g AR
RTC-PHR-1068 Edetate Disodium 1 g AR
RTC-PHR-1039 Erythromycin 500 mg CR
RTC-PHR-1046 Ethylene Glycol 1 g AR
RTC-PHR-1011 Ethylparaben (Ethyl parahydroxybenzoate) 1 g AR
RTC-PHR-1055 Famotidine 1 g AR
RTC-PHR-1035 Folic Acid 1 g AR
RTC-PHR-1002 Fructose 1 g AR
RTC-PHR-1057 Furosemide 1 g BR
RTC-PHR-1049 Gabapentin 1 g CR
RTC-PHR-1020 Glycerin (Glycerol) 5 g AR
RTC-PHR-1027 Guaifenesin 1 g AR
RTC-PHR-1085 Homosalate 1 g AR
RTC-PHR-1032 Hydrochlorothiazide 1 g BR
RTC-PHR-1014 Hydrocortisone 500 mg BR
RTC-PHR-1004 Ibuprofen 1 g AR
RTC-PHR-1025 Lactose (anhydrous) 1 g AR
RTC-PHR-1024 Lactose monohydrate 1 g AR
RTC-PHR-1034 Lidocaine 1g AR
RTC-PHR-1007 Mannitol 1 g AR
RTC-PHR-1060 Mesalamine 1 g AR
RTC-PHR-1084 Metformin Hydrochloride 500 mg AR
RTC-PHR-1012 Methylparaben (Methyl parahydroxybenzoate) 1 g AR
RTC-PHR-1076 Metoprolol Tartrate 1 g AR
RTC-PHR-1052 Metronidazole 1 g AR
RTC-PHR-1040 Naproxen 500 mg CR
RTC-PHR-1033 Niacinamide (Nicotinamide) 1 g AR
RTC-PHR-1080 Octinoxate 1 g AR
RTC-PHR-1081 Octisalate 1 g AR
RTC-PHR-1083 Octocrylene 1 g AR
RTC-PHR-1059 Omeprazole 1 g BR
RTC-PHR-1074 Oxybenzone 1 g AR
RTC-PHR-1094 Phenacetin Melting Point Standard 1 g AR
RTC-PHR-1017 Phenylephrine Hydrochloride 500 mg AR
RTC-PHR-1078 Phytonadione 1 g AR
RTC-PHR-1043 Prednisolone 500 mg BR
RTC-PHR-1042 Prednisone 1 g BR
RTC-PHR-1051 Propylene Glycol 1.5 g AR
RTC-PHR-1010 Propylparaben (Propyl parahydroxybenzoate) 1 g AR
RTC-PHR-1036 Pyridoxine Hydrochloride 500 mg AR
RTC-PHR-1026 Ranitidine Hydrochloride 500 mg CR
RTC-PHR-1063 Residual Solvents Mixture - Class I 3x1.2 mL DR
Secondary Reference Standards traceable to USP, EP and BP
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 393
Code Product Unit Price
RTC-PHR-1064 Residual Solvents Mixture - Class IIA 3x1.2 mL DR
RTC-PHR-1065 Residual Solvents Mixture - Class IIB 3x1.2 mL DR
RTC-PHR-1066 Residual Solvents Mixture - Class IIC 3x1.2 mL DR
RTC-PHR-1054 Riboflavin 1 g AR
RTC-PHR-1013 Salicylic Acid 1 g AR
RTC-PHR-1006 Sorbitol 1 g AR
RTC-PHR-1001 Sucrose 1 g AR
RTC-PHR-1093 Sulfanilamide Melting Point Standard 1 g AR
RTC-PHR-1087 Sulfapyridine Melting Point Standard 1 g AR
RTC-PHR-1041 Tetracycline Hydrochloride 500 mg BR
RTC-PHR-1023 Theophylline 1 g AR
RTC-PHR-1037 Thiamine Hydrochloride 1 g CR
RTC-PHR-1056 Trimethoprim 1 g AR
RTC-PHR-1061 Valproic Acid 1 g AR
RTC-PHR-1091 Vanillin Melting Point Standard 1 g AR
RTC-PHR-1031 -Tocopherol 500 mg AR
RTC-PHR-1030 -Tocopheryl Acetate 500 mg AR
RTC-PHR-1029 -Tocopheryl Acid Succinate 500 mg AR
RTC-PHR-1096 L-Lysine Acetate 1 g AR
RTC-PHR-1097 L-Tyrosine 1 g AR
RTC-PHR-1098 N-Acetyl-L-Cysteine 1 g AR
RTC-PHR-1099 L-Isoleucine 1 g AR
RTC-PHR-1100 L-Phenylalanine 1 g AR
RTC-PHR-1105 L-Leucine 1 g AR
Secondary Reference Standards traceable to USP, EP and BP
394 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
We constantly add new products to our range, so please
contact us to find out about our products and services and to
make sure you are automatically kept up to date by
subscribing to our free newsletter.
Please send an e-mail to pharma-news@lgcstandards.com
Institute of Dyes and
Organic Products
Refractive index
CRMs
Reference materials for sports drugs
analysis from NMIA
National Measurement Institute of Australia (NMIA) produces some 200
state-of-the-art certifed reference materials for sports drugs applications.
Synthetic steroids and their metabolites
Endogenous steroids and their metabolites
Prohormones and their metabolites
Growth promotants and their metabolites
Various other substances of interest
NMIA has a third party accreditation as a
reference materials producer operating to
ISO Guide 34. Its reference materials are
supplied with a comprehensive analysis report
that includes:
Certifed property values with uncertainty statements
Homogeneity and stability studies on all materials
Traceability of assigned values to the international system of units
www.lgcstandards.com
Institute of Dyes and Organic Products
Edition 2011/2012 All your needs for pharmaceutical analysis email pharma@lgcstandards.com 397
Institute of Dyes and Organic Products
The use of colouring agents in pharmaceutical preparations and dose forms is widespread. In most
cases food colouring materials are used.
The following standards of dyes, used in the pharmaceutical and food industry, are listed with common
description, E code and colour index number (C.I.) for an easy assignment.
The IBPO is accredited by the Polish Centre for Testing and Certification according to the standard
PN-EN 45001 and ISO/IEC Guide 25:1990.
Each colour reference standard is supplied with a detailed certificate of analysis, which includes dye content
value determined by spectrophotometry and values of impurities.
Black
Code Product Unit
IBPO010 Brilliant Black PN (E 151) 1 g
Blue
IBPO015 Brilliant Blue FCF (E 133) 1 g
IBPO002 Indigotine (E 132) 1 g
IBPO012 Patent Blue V (E 131) 1 g
Brown
IBPO017 Brown HT(E 155) 1 g
Green
IBPO016 Brilliant Green BS (E 142) 1 g
Red
IBPO014 Allura Red AC (E 129) 1 g
IBPO005 Amaranth (E 123) 1 g
IBPO003 Azorubin (E 122) 1 g
IBPO011 Erythrosine (E 127) 1 g
IBPO004 Ponceau 4R (E 124) 1 g
IBPO013 Red 2 G (E 128) 1 g
Yellow
IBPO007 Quinoline Yellow (E 104) 1 g
IBPO009 Sunset Yellow FCF (E 110)
1 g
IBPO008 Tartrazine (E 102) 1 g
Refractive index CRMs
398 All your needs for pharmaceutical analysis email pharma@lgcstandards.com Edition 2011/2012
Refractive index CRMs
The revised EP general method 2.2.6 replaces CRS reference liquids with certified reference materials
available from suppliers of chemical reagents or materials certified for metrology.
11 liquid CRMs, certified by the Physical Chemistry Division of the Central Office of Measures (GUM),
Warsaw in Poland, cover the wide range of refractive index from 1,333 (water) to 1,657
(1-bromonaphthalene).
These CRMs are intended for calibration and checking refractive index scales of laboratory refractometers of
an uncertainty expected not less than 0,00005.
The n values we determined on a Pulfrich refractometer, previously calibrated with solid class 1 CRMs,
for which values were established using goniometric procedures.
All CRMs are supplied with a certificate. Certified values to 5 significant figures for the refractive index
at = 589.3 nm t = 20C and associated uncertainties are given.
Reference liquids are packed in glass ampoules or plastic drop-bottles.
Code Product Unit
PRG 7.21 Water
Refractive index ................................. 1.333 at 20 C
10 mL
PRG 7.1 2,2,4-Trimethylpentane
Refractive index ................................. 1.391 at 20 C
10 mL
PRG 7.11 Methylsilicone oil
Refractive index ................................. 1.405 at 20 C
10 mL
PRG 7.2 Methylcyclohexane
Refractive index ................................. 1.423 at 20 C
10 mL
PRG 7.12 Silicone oil DC 556
Refractive index ................................. 1.462 at 20 C
10 mL
PRG 7.20 Paraffin oil
Refractive index ................................. 1.475 at 20 C
10 mL
PRG 7.5 Toluene
Refractive index ................................. 1.496 at 20 C
10 mL
PRG 7.6 Chlorobenzene
Refractive index ................................. 1.524 at 20 C
10 mL
PRG 7.8 1-Bromonaphthalene
Refractive index ................................. 1.657 at 20 C
10 mL
PRG 7.9 1-Iodonaphthalene
Refractive index ................................. 1.702 at 20 C
10 mL
Publications
and
subscriptions
Microbiology catalogue including useful technical resource.
Available now from LGC Standards.
A comprehensive directory of ATCC
solvents form the heart of the LGC Standards solvent range. Each batch undergoes rigorous
testing in order to meet the demanding requirements of organic trace analysis every time.
Environmental analysts are now expected to detect trace levels of an increasingly wide range of organic
environmental contaminants including pesticides, PAHs, PCBs, PCDDs/PCDFs etc. with the highest possible
accuracy. Consequently even the lowest levels of impurity in the solvent can affect the precision of analytical
results. Picograde
solvents allows them to be used for residue analysis of trace quantities of organic contaminants
right down to ppb and ppt levels.
Optigrade
solvents
from LGC Standards has been designed to allow high resolution and sensitivity. Such Ultra HPLC solvents
combine the highest specification for: UV, low gradient shift, minimal peak impurities and lowest ionic
background for MS detection. All Ultra HPLC solvents are micro filtered at 0.1 m, have a residue following
evaporation of max 1 ppm and are packed under inert gas for improved shelf life. Also available are selected
buffers for mobile phase preparation and several blends of water and acetonitrile with formic acid, acetic acid
and trifluoroacetic acid are offered.
Introduction
406 Promochem
, Optigrade
, Cyclotainer
, Picograde
- U.S.SILICA COMPANY
Reagents / Sorbents
Edition 2011/2012 Promochem
CAS number 631-61-8
Assay (GC, on anhydrous basis) .............. 99 % min.
Water (KF) .............................................. 0.1 % max.
Filter test (1M in water) ........................... Passes test
pH (1M in water) ............................................. 6.0-7.5
Transmission
at 260 nm (1M in water) .................................... 96 %
at 280 nm (1M in water) .................................... 98 %
Chloride (Cl) ....................................... 0.0005% max.
Sulfate (SO
4) ........................................... 001% max.
Al ............................................................ 1 ppm max.
Ca .......................................................... 5 ppm max.
Fe ........................................................... 1 ppm max.
K ............................................................. 5 ppm max.
Mg .......................................................... 1 ppm max.
Na .......................................................... 5 ppm max.
100 g
SO-9679-B001 Formic acid UHPLC-MS Optigrade
UN 1779
CAS number 64-18-6
Assay (T, on anhydrous basis) ............................... 99 % min.
Water (KF) .............................................................. 1 % max.
Residue after evaporation .......................... 0.001 %w/w max.
Color (APHA) ............................................................ 10 max.
Gradient specification
HPLC gradient at 254 nm - H. Peak 0.005 AU max.
HPLC gradient at 254 nm - Drift 0.02 AU max.
Transmission
at 260 nm ............................................................... 15 % min.
at 270 nm ................................................................ 83% min.
at 280 nm ............................................................... 90 % min.
at 300 nm ................................................................ 97% min.
at 320 nm ................................................................ 98% min.
100 mL
SO-9668-B001 Trifluoroacetic acid UHPLC-MS Optigrade
UN 2699
CAS-Nr. 76-05-1
Assay (T) ................................................................... 99.95-100 %
Water (KF) ...................................................................... 0-0.02 %
Residue after evaporation ....................................... 0-0.001 %w/w
Color (APHA) ......................................................................... 0-10
Gradient specification
HPLC gradient 254 nm - H. Peak ............................... 0-0.002 AU
HPLC gradient at 254 nm - Drift.................................. 0-0.010 AU
Fluorescence at 254 nm (25%, as quinine) ...................... 0-1 ppb
Fluorescence at 365 nm (25%, as quinine) ...................... 0-1 ppb
Transmission
at 260 nm ....................................................................... 10-100 %
at 270 nm ....................................................................... 79-100 %
at 280 nm ....................................................................... 93-100 %
at 300 nm ...................................................................... 95-100 %
at 320 nm ....................................................................... 96-100 %
100 mL
High purity solvents and acids
Edition 2011/2012 Promochem
1 L
SO-2435-B025 Acetone HPLC Optigrade
2.5 L
SO-2435-B040 Acetone HPLC Optigrade
UN 1090
CAS-Nr. 67-64-1
C3H6O
Assay ...................................................... 99.5% min.
Water ....................................................... 0.5% max.
Non-volatile matter ............................. 0.0005% max.
Filtered through 0.2 m
1 L = 0.792 kg (at 20C)
Specification
Transmission
at 330 nm ................................................... 10% min.
at 340 nm ................................................... 79% min.
at 350 nm ................................................... 89% min.
at 370 nm ................................................... 98% min.
4 L
SO-1142-B010 Acetone Picograde
Gradient Grade 1 L
SO-9128-B025 Acetonitrile HPLC Optigrade
Gradient Grade
UN 1648
CAS-Nr. 75-05-8
C2H3N
Assay ..................................................... 99.8% min.
Water ..................................................... 0.02% max.
Non-volatile matter ............................. 0.0003% max.
Gradientspecification (210 nm) .......... 3.0 mAU max.
Fluorescence (as Quinine at 254 nm) ..... 1 ppb max.
Filtered through 0.2 m
1 L = 0.783 kg (at 20C)
Specification
Transmission
at 190 nm .................................................... 20% min
at 193 nm .................................................... 62% min
at 195 nm .................................................... 76% min
at 210 nm .................................................... 89% min
at 220 nm .................................................... 98% min
at 230 nm .................................................... 99% min
This solvent in glass bottles fulfills the specifications according to chapter 4 of the European Pharmacopoeia.
4 L
SO-9154-B010 Acetonitrile HPLC Optigrade
1 L
SO-2856-B025 Acetonitrile HPLC Optigrade
2.5 L
SO-2856-B040 Acetonitrile HPLC Optigrade
UN 1648
CAS-Nr. 75-05-8
C2H3N
Assay ...................................................... 99.8% min.
Water ..................................................... 0.02% max.
Non-volatile matter ............................. 0.0003% max.
Filtered through 0.2 m
1 L = 0.783 kg (at 20C)
Specification
Transmission
at 190 nm ................................................... 10% min.
at 200 nm ................................................... 79% min.
at 210 nm ................................................... 89% min.
at 220 nm ................................................... 95% min.
at 230 nm ................................................... 98% min.
at 235 nm ................................................... 99% min.
4 L
SO-9184-B010 Acetonitrile HPLC Optigrade
1 L
SO-9340-B025 Acetonitrile fr LC-MS Optigrade
UN 1648
CAS-Nr. 75-05-8
C2H3N
Assay ....................................................... 99.8% min
Water ..................................................... 0.02% max.
Non-volatile matter ............................. 0.0003% max.
Filtered through 0.2 m
1 L = 0.783 kg (at 20C)
Specification
Ca ........................................................0.1 ppm max.
K...........................................................0.1 ppm max.
Mg ........................................................0.1 ppm max.
Na ........................................................0.1 ppm max.
Transmission
at 195 nm .................................................. 78 % min.
at 200 nm .................................................. 95 % min.
at 220 nm .................................................. 98 % min.
at 240 nm .................................................. 99 % min.
2.5 L
SO-9640-B010 Acetonitrile UHPLC-MS Optigrade
1 L
SO-4680-B025 Acetonitrile 0.1 % formic acid UHPLC-MS Optigrade
UN 1648
CAS number 75-05-8
C2H3N
Assay ..................................................................... 0.095-0.105 %
Water (KF) ................................................................ 0.02 % max.
Purity of ACN (GC) .................................................. 99.97 % min.
Purity of formic acid .................................................... 99.0% min.
Gradient specification
HPLC gradient at 254 nm - H. Peak ...................... 0.002 AU max.
Fluorescence at 254 nm (as quinine) ....................... 0.5 ppb max.
Fluorescence at 365 nm (as quinine) ....................... 0.5 ppb max.
Transmission
at 210 nm ........................................................................ 5 % min.
at 230 nm ...................................................................... 15 % min.
at 254 nm ...................................................................... 90 % min.
Al ............................................................................... 30 ppb max.
Ca ............................................................................. 100 ppb min.
Fe ................................................................................ 50 ppb min.
K................................................................................ 100 ppb min.
Mg ............................................................................... 30 ppb min.
Na ............................................................................. 100 ppb min.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
High purity solvents and acids
412 Promochem
UN 1648
CAS number 75-05-8
C2H3N
Assay ..................................................................... 0.095-0.105 %
Purity of ACN (GC) ................................................... 99.97% min.
Purity of acetic acid (GC) ............................................ 99.9% min.
Gradient specification
HPLC gradient at 254 nm - H. Peak ..................... 0.002 AU max.
HPLC gradient at 254 nm - Drift............................ 0.010 AU max.
Fluorescence at 254 nm (as quinine) ........................0.5 ppb max.
Fluorescence at 365 nm (as quinine) ........................0.5 ppb max.
Transmission
at 210 nm ...................................................................... 20 % min.
at 230 nm ...................................................................... 50 % min.
at 254 nm ...................................................................... 98 % min.
Al ...............................................................................30 ppb max.
Ca ............................................................................100 ppb max.
Fe ...............................................................................50 ppb max.
K ...............................................................................100 ppb max.
Mg ..............................................................................30 ppb max.
Na ............................................................................100 ppb max.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
SO-4692-B025 Acetonitrile 0.1 % trifluoroacetic acid UHPLC-MS Optigrade
UN 1648
CAS number 75-05-8
C2H3N
Assay ..................................................................... 0.095-0.105 %
Water (KF) ................................................................ 0.02 % max.
Purity of ACN (GC) .................................................. 99.97 % min.
Purity of trifluoroacetic acid ...................................... 99.95 % min.
Gradient specification
HPLC gradient at 254 nm - H. Peak ................... 0.0002 AU max.
Fluorescence at 254 nm (as quinine) ........................0.5 ppb max.
Fluorescence at 365 nm (as quinine) ........................0.5 ppb max.
Transmission
at 210 nm ...................................................................... 20 % min.
at 230 nm ...................................................................... 50 % min.
at 254 nm ...................................................................... 90 % min.
Al ...............................................................................30 ppb max.
Ca ............................................................................100 ppb max.
Fe ...............................................................................50 ppb max.
K ...............................................................................100 ppb max.
Mg ..............................................................................30 ppb max.
Na ............................................................................100 ppb max.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
SO-9186-B025 Acetonitrile DNA. max. 0.001% water
UN 1648
CAS-Nr. 75-05-8
C2H3N
Assay ...................................................... 99.9% min.
Water by Karl Fischer titration.............. 0.001% max.
Non-volatile matter ............................. 0.0005% max.
1 L = 0.783 kg (at 20C)
2.5 L
SO-9180-B025 Acetonitrile DNA. max. 0.003% water
UN 1648
CAS-Nr. 75-05-8
C2H3N
Assay ...................................................... 99.9% min.
Water by Karl Fischer titration.............. 0.003% max.
Non-volatile matter ............................. 0.0005% max.
1 L = 0.783 kg (at 20C)
2.5 L
SO-1151-B010 Acetonitrile Picograde
1 L
SO-9052-B025 Cyclohexane HPLC Optigrade
UN 1145
CAS-Nr. 110-82-7
C6H12
Assay ...................................................... 99,5% min.
Water ..................................................... 0,02% max.
Non-volatile matter ............................. 0,0003% max.
Filtered through 0.2 m
1 L = 0,779 kg (at 20C)
Specification
Transmission
at 210 nm ................................................... 20% min.
at 220 nm ................................................... 48% min.
at 230 nm ................................................... 75% min.
at 245 nm ................................................... 94% min.
at 260 nm ................................................... 99% min.
2.5 L
SO-1179-B010 Cyclohexane Picograde
UN 1146
CAS-Nr. 287-92-3
C5H10
Assay ......................................................... 75% min.
Water ................................................... 0.005% max.
Non-volatile matter ............................. 0.0001% max.
Filtered through 0.2 m
1 L = 0.751 kg (at 20C)
Specification
Transmission
at 200 nm ................................................... 10% min.
at 215 nm ................................................... 50% min.
at 225 nm ................................................... 95% min.
at 300 nm ................................................... 99% min.
1 L
High purity solvents and acids
416 Promochem
(not stabilised) 1 L
SO-2854-B025 Diethyl ether HPLC Optigrade
(not stabilised)
UN 1155
CAS-Nr. 60-29-7
C4H10O
Assay ...................................................... 99.0% min.
Water ..................................................... 0.01% max.
Non-volatile matter ............................. 0.0005% max.
Peroxide ..................................................5 ppm max.
Filtered through 0.2 m
1 L = 0.713 kg (at 20C)
not stabilized
Specification
Transmission
at 215 nm ................................................... 10% min.
at 254 nm ................................................... 83% min.
at 280 nm ................................................... 95% min.
2.5 L
SO-1187-B010 Diethyl ether Picograde
2.5 L
SO-5407-B040 N,N-Dimethylacetamide HPLC Optigrade
CAS-Nr. 127-19-5
C4H9NO
Assay ...................................................... 99.0% min.
Water ..................................................... 0.03% max.
Non-volatile matter ............................. 0.0006% max.
Filtered through 0.2 m
1 L = 0.937 kg (at 20C)
Specification
Transmission
at 270 nm ................................................... 10% min.
at 280 nm ................................................... 50% min.
at 290 nm ................................................... 71% min.
at 310 nm ................................................... 89% min.
at 360 nm ................................................... 98% min.
4 L
SO-3240-B010 N,N-Dimethylacetamide Headspace Grade
CAS number 127-19-5
C4H9NO
Assay (GC, on anhydrous basis) ......... 99.99 % min.
Acidity (as acetic acid) .......................... 0.05 % max.
Water (KF) ............................................ 0.03 % max.
UV cutoff wavelength ............................. 190-268 nm
Transmission
at 268 nm .................................................. 10 % min.
at 275 nm .................................................. 55 % min.
at 300 nm .................................................. 85 % min.
at 350 nm .................................................. 98 % min.
at 400 nm .................................................. 99 % min.
Headspace test for O.V.I. ........................ passes test
1 L
High purity solvents and acids
Edition 2011/2012 Promochem
UN 2265
CAS-Nr. 68-12-2
C3H7NO
Assay ...................................................... 99.7% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0006% max.
Filtered through 0.2 m
1 L = 0.951 kg (at 20C)
Specification
Transmission
at 270 nm ................................................... 10% min.
at 275 nm ................................................... 50% min.
at 295 nm ................................................... 79% min.
at 310 nm ................................................... 89% min.
at 340 nm ................................................... 98% min.
2.5 L
SO-1189-B010 N,N-Dimethylformamide Picograde
1 L
SO-1189-B025 N,N-Dimethylformamide Picograde
UN 2265
CAS-Nr. 68-12-2
C3H7NO
Assay ...................................................... 99.0% min.
Water ....................................................... 0.2% max.
Non-volatile matter ............................... 0.001% max.
1 L = 0.951 kg (at 20C)
Specification
GC/ECD
In the GC-ECD chromatogram there are no interfering single signals in the retention time interval between
1,4-dichlorobenzene and decachlorobiphenyl, by a 500-fold concentration greater than that, given by 10 pg/mL
heptachlor-epoxide.
GC/FID
In the GC-FID chromatogram there are no interfering single signals in the retention time interval between n-octane
(C8) and n-tetracontane (C40), by a 500-fold concentration greater than that, given by 50 ng/mL n-undecane
(C11).
2.5 L
SO-3230-B010 N,N-Dimethylformamide Headspace Grade
UN 2265
CAS number 68-12-2
C3H7NO
Assay (GC, on anhydrous basis) ......... 99.99 % min.
Refractive index (20 C) ......................... 1.430-1.440
Water (KF) ............................................ 0.03 % max.
UV cutoff wavelength ............................. 190-268 nm
Transmission
at 270 nm .................................................. 30 % min.
at 275 nm .................................................. 60 % min.
at 300 nm .................................................. 90 % min.
at 320 nm .................................................. 97 % min.
Headspace test for O.V.I........................... passes test
1 L
1,3-Dimethyl-2-imidazolidinone (N,N'-Dimethylethyleneurea)
SO-3260-B005 1,3-Dimethyl-2-imidazolidinone (DMI) Headspace Grade
Assay (GC, on anhydrous basis) ........... 99.5 % min.
Refractive index (20 C) .......................... 1.470-1473
Water (KF) .............................................. 0.1 % max.
UV cutoff wavelength ............................. 190-270 nm
Transmission
at 275 nm .................................................. 40 % min.
at 300 nm .................................................. 85 % min.
at 325 nm .................................................. 95 % min.
at >350 nm ................................................ 98 % min.
Headspace test for O.V.I......................... passes test
500 mL
High purity solvents and acids
420 Promochem
(not stabilised) 1 L
SO-9002-B025 1,4-Dioxane HPLC Optigrade
(not stabilised)
UN 1165
CAS-Nr. 123-91-1
C4H8O2
Assay ...................................................... 99.5% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0002% max.
Filtered through 0.2 m
1 L = 1.034 kg (at 20C)
not stabilized
Specification
Transmission
at 225 nm ................................................... 31% min.
at 250 nm ................................................... 56% min.
at 270 nm ................................................... 79% min.
at 280 nm ................................................... 89% min.
at 295 nm ................................................... 98% min.
2.5 L
Ethanol
SO-9063-B010 Ethanol HPLC Optigrade
1 L
SO-9063-B025 Ethanol HPLC Optigrade
UN 1170
CAS-Nr. 64-17-5
C2H5OH
Assay ...................................................... 99.7% min.
Water ....................................................... 0.1% max.
Non-volatile matter ............................. 0.0004% max.
Filtered through 0.2 m
1 L = 0.789 kg (at 20C)
Specification
Transmission
at 210 nm ................................................... 20% min.
at 240 nm ................................................... 79% min.
at 260 nm ................................................... 98% min.
2.5 L
High purity solvents and acids
Edition 2011/2012 Promochem
UN 1171
CAS-Nr. 110-80-5
C4H10O2
Assay ...................................................... 99.5% min.
Water ..................................................... 0.08% max.
Non-volatile matter ............................. 0.0002% max.
Filtered through 0.2 m
1 L = 0.932 kg (at 20C)
Specification
Transmission
at 222 nm ................................................... 10% min.
at 225 nm ................................................... 18% min.
at 250 nm ................................................... 56% min.
at 300 nm ................................................... 98% min.
2.5 L
Ethyl acetate
SO-3442-B010 Ethyl acetate HPLC Optigrade
1 L
SO-3442-B025 Ethyl acetate HPLC Optigrade
2.5 L
SO-3442-B040 Ethyl acetate HPLC Optigrade
UN 1173
CAS-Nr. 141-78-6
CH3COOC2H5
Assay ...................................................... 99.5% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0005% max.
Filtered through 0.2 m
1 L = 0.897 kg (at 20C)
Specification
Transmission
at 225 nm ................................................... 10% min.
at 260 nm ................................................... 79% min.
at 280 nm ................................................... 89% min.
at 300 nm ................................................... 98% min.
4 L
SO-9345-B010 Ethyl acetate for LC-MS Optigrade
1 L
SO-9345-B025 Ethyl acetate for LC-MS Optigrade
UN 1173
CAS-Nr. 141-78-6
CH3COOC2H5
Assay ...................................................... 99,5% min.
Water ..................................................... 0,05% max.
Non-volatile matter ............................. 0,0005% max.
Filtered through 0.2 m
1 L = 0,897 kg (at 20C)
Specification
Ca ........................................................0,1 ppm max.
K...........................................................0,1 ppm max.
Mg ........................................................0,1 ppm max.
Na ........................................................0,1 ppm max.
Transmission
at 260 nm .................................................. 70 % min.
at 280 nm .................................................. 99 % min.
2.5 L
SO-1191-B010 Ethyl acetate Picograde
1 L
SO-5139-B025 n-Heptane HPLC Optigrade
2.5 L
SO-5139-B040 n-Heptane HPLC Optigrade
UN 1206
CAS-Nr. 142-82-5
C7H16
Assay ...................................................... 95.0% min.
Water ..................................................... 0.02% max.
Non-volatile matter ............................. 0.0003% max.
Filtered through 0.2 m
1 L = 0.685 kg (at 20C)
Specification
Transmission
at 197 nm ................................................... 10% min.
at 210 nm ................................................... 39% min.
at 225 nm ................................................... 79% min.
at 254 nm ................................................... 98% min.
4 L
SO-1210-B025 n-Heptane Picograde
1 L
SO-5167-B025 n-Hexane HPLC Optigrade
2.5 L
High purity solvents and acids
Edition 2011/2012 Promochem
UN 1208
CAS-Nr. 110-54-3
C6H14
Assay (of C6-isomers) ............................. 99.8% min.
Water ....................................................... 0.1% max.
Non-volatile matter ............................. 0.0003% max.
Filtered through 0.2 m
1 L = 0.659 kg (at 20C)
Specification
Transmission
at 195 nm ................................................... 10% min.
at 210 nm ................................................... 56% min.
at 220 nm ................................................... 79% min.
at 254 nm ................................................... 98% min.
at 280 nm ................................................... 99% min.
at 350 nm ................................................... 99% min.
4 L
SO-1244-B010 n-Hexane Picograde
UN 1208
CAS-Nr. 107-83-5
C6H14
Assay of C6-isomers ................................ 95.0% min.
Water ..................................................... 0.01% max.
Non-volatile matter ............................. 0.0002% max.
1 L = 0.653 kg (at 20C)
Specification
Transmission
at 195nm .................................................... 10% min.
at 210nm .................................................... 56% min.
at 217nm .................................................... 63% min.
at 220nm .................................................... 75% min.
at 245nm .................................................... 95% min.
2.5 L
SO-1251-B025 Iso-Hexane Picograde
Gradient Grade 1 L
SO-9260-B025 Methanol HPLC Optigrade
Gradient Grade
UN 1230
CAS-Nr. 67-56-1
CH3OH
Assay ...................................................... 99.9% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0003% max.
Gradientspecification (235 nm) ..........0.002 AU max.
Gradientspecification (254 nm) ..........0.001 AU max.
Fluorescence (as Quinine at 254 nm) ...... 1 ppb max.
Filtered through 0.2 m
1 L = 0.792 kg (at 20C)
Specification
Transmission
at 210 nm ................................................... 37% min.
at 220 nm ................................................... 56% min.
at 230 nm ................................................... 76% min.
at 235 nm ................................................... 83% min.
at 254 nm ................................................... 97% min.
at 280 nm ................................................... 99% min.
This solvent in glass bottles fulfills the specifications according to chapter 4 of the European Pharmacopoeia.
2.5 L
SO-3041-B010 Methanol HPLC Optigrade
1 L
SO-3041-B025 Methanol HPLC Optigrade
2.5 L
High purity solvents and acids
426 Promochem
UN 1230
CAS-Nr. 67-56-1
CH3OH
Assay ...................................................... 99.9% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0003% max.
Filtered through 0.2 m
1 L = 0.792 kg (at 20C)
Specification
Transmission
at 205 nm ................................................... 10% min.
at 220 nm ................................................... 56% min.
at 240 nm ................................................... 89% min.
at 254 nm ................................................... 96% min.
at 280 nm ................................................... 98% min.
at 350 nm ................................................... 99% min.
This solvent in glass bottles fulfills the specifications according to chapter 4 of the European Pharmacopoeia.
4 L
SO-9658-B010 Methanol UHPLC-MS Optigrade
1 L
SO-9658-B025 Methanol UHPLC-MS Optigrade
UN 1230
CAS number 67-56-1
CH3OH
Assay (GC, on anhydrous basis) ............................. 99.98 % min.
Water (KF) ................................................................. 0.03% max.
Residue after evaporation ............................... 0.0001 %w/w max.
Acidity (as acetic acid) ............................................ 0.002 % max.
Alkalinity (as ammonia) ......................................... 0.0001 % max.
Color (APHA) ......................................................................5 max.
Gradient specification
HPLC gradient at 220 nm - Drift.............................. 0.01 AU max.
HPLC gradient at 235 nm - Drift............................ 0.005 AU max.
HPLC gradient at 220 nm - H. Peak ..................... 0.004 AU max.
HPLC gradient at 235 nm - H. Peak ..................... 0.002 AU max.
Fluorescence at 254 nm (as quinine) ........................0.5 ppb max.
Fluorescence at 365 nm (as quinine) ........................0.3 ppb max.
1 L = 0.783 kg (at 20C)
Transmission
at 210 nm ...................................................................... 40 % min.
at 220 nm ...................................................................... 65 % min.
at 230 nm ...................................................................... 80 % min.
at 260 nm ...................................................................... 98 % min.
Al ................................................................................20 ppb max.
Ca ............................................................................100 ppb max.
Fe ...............................................................................20 ppb max.
K .................................................................................50 ppb max.
Mg ..............................................................................20 ppb max.
Na ............................................................................100 ppb max.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
SO-9356-B010 Methanol for LC-MS Optigrade
1 L
SO-9356-B025 Methanol for LC-MS Optigrade
UN 1230
CAS number 67-56-1
CH3OH
Assay ...................................................... 99.9% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0003% max.
Filtered through 0.2 m
1 L = 0.792 kg (at 20C)
Ca ....................................................... 0.1 ppm max.
K .......................................................... 0.1 ppm max.
Mg ....................................................... 0.1 ppm max.
Na ....................................................... 0.1 ppm max.
Transmission
at 210 nm .................................................. 40 % min.
at 220 nm .................................................. 60 % min.
at 235 nm .................................................. 80 % min.
at 260 nm .................................................. 98 % min.
2.5 L
SO-1263-B010 Methanol Picograde
UN 2398
CAS-Nr. 1634-04-4
C5H12O
Assay ...................................................... 99.7% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0006% max.
Filtered through 0.2 m
1 L = 0.742 kg (at 20C)
Specification
Transmission
at 225 nm ................................................... 32% min.
at 250 nm ................................................... 71% min.
at 300 nm ................................................... 89% min.
2.5 L
SO-1265-B010 Methyl-tert-butylether Picograde
1 L
SO-1265-B025 Methyl-tert-butylether Picograde
UN 2398
CAS-Nr. 1634-04-4
C5H12O
Assay ...................................................... 99.8% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0005% max.
1 L = 0.742 kg (at 20C)
Specification
GC/ECD
In the GC-ECD chromatogram there are no interfering single signals in the retention time interval between
1,4-dichlorobenzene and decachlorobiphenyl, by a 500-fold concentration greater than that, given by 10 pg/mL
heptachlor-epoxide.
GC/FID
In the GC-FID chromatogram there are no interfering single signals in the retention time interval between n-octane
(C8) and n-tetracontane (C40), by a 500-fold concentration greater than that, given by 50 ng/mL n-undecane
(C11).
2.5 L
High purity solvents and acids
428 Promochem
UN 1920
CAS-Nr. 111-84-2
C9H20
Assay ......................................................... 95% min.
Water ..................................................... 0.01% max.
Non-volatile matter ............................. 0.0003% max.
Filtered through 0.2 m
1 L = 0.719 kg (at 20C)
Specification
Transmission
at 200 nm ................................................... 10% min.
at 225 nm ................................................... 79% min.
at 250 nm ................................................... 89% min.
at 300 nm ................................................... 99% min.
1 L
SO-1271-B010 n-Nonane Picograde
UN 1265
CAS-Nr. 109-66-0
C5H12
Assay ...................................................... 95.0% min.
Water ..................................................... 0.01% max.
Non-volatile matter ............................... 0.001% max.
Filtered through 0.2 m
1 L = 0.626 kg (at 20C)
Specification
Transmission
at 200 nm ................................................... 10% min.
at 210 nm ................................................... 20% min.
at 215 nm ................................................... 50% min.
at 225 nm ................................................... 89% min.
at 240 nm ................................................... 98% min.
1 L
SO-1282-B010 n-Pentane Picograde
UN 1274
CAS-Nr. 71-23-8
CH3CH2CH2OH
Assay ...................................................... 99.8% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................... 0.001% max.
Filtered through 0.2 m
1 L = 0.804 kg (at 20C)
Specification
Transmission
at 225 nm ................................................... 31% min.
at 250 nm ................................................... 89% min.
at 270 nm ................................................... 98% min.
at 300 nm ................................................... 99% min.
2.5 L
Propan-2-ol
SO-3043-B010 Propan-2-ol HPLC Optigrade
1 L
SO-3043-B025 Propan-2-ol HPLC Optigrade
2.5 L
SO-3043-B040 Propan-2-ol HPLC Optigrade
UN 1219
CAS-Nr. 67-63-0
C3H8O
Assay ...................................................... 99.5% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0006% max.
Filtered through 0.2 m
1 L = 0.786 kg (at 20C)
Specification
Transmission
at 205 nm ................................................... 10% min.
at 220 nm ................................................... 50% min.
at 230 nm ................................................... 71% min.
at 254 nm ................................................... 95% min.
at 350 nm ................................................... 98% min.
4 L
SO-9352-B010 Propan-2-ol for LC-MS Optigrade
1 L
SO-9352-B025 Propan-2-ol for LC-MS Optigrade
UN 1219
CAS number 67-63-0
C3H8O
Assay ...................................................... 99.5% min.
Water ..................................................... 0.05% max.
Non-volatile matter ............................. 0.0006% max.
Filtered through 0.2 m
1 L = 0.786 kg (at 20C)
Ca ........................................................0.1 ppm max.
K...........................................................0.1 ppm max.
Mg ........................................................0.1 ppm max.
Na ........................................................0.1 ppm max.
Transmission
at 220 nm .................................................. 60 % min.
at 250 nm .................................................. 99 % min.
2.5 L
SO-1334-B010 Propan-2-ol Picograde
1 L
SO-2858-B025 Tetrahydrofuran HPLC Optigrade
2.5 L
High purity solvents and acids
Edition 2011/2012 Promochem
UN 2056
CAS-Nr. 109-99-9
C4H8O
Assay ...................................................... 99.8% min.
Water ..................................................... 0.03% max.
Non-volatile matter ............................. 0.0007% max.
Filtered through 0.2 m
1 L = 0.887 kg (at 20C)
not stabilized
Specification
Transmission
at 212 nm ................................................... 10% min.
at 225 nm ................................................... 31% min.
at 250 nm ................................................... 68% min.
at 300 nm ................................................... 98% min.
4 L
SO-9364-B010 Tetrahydrofuran for LC-MS Optigrade
1 L
SO-9364-B025 Tetrahydrofuran for LC-MS Optigrade
UN 2056
CAS number 109-99-9
C4H8O
Assay ...................................................... 99.8% min.
Water ..................................................... 0.03% max.
Non-volatile matter ............................. 0.0007% max.
Filtered through 0.2 m
1 L = 0.887 kg (at 20C)
not stabilised
Ca ........................................................0.1 ppm max.
K...........................................................0.1 ppm max.
Mg ........................................................0.1 ppm max.
Na ........................................................0.1 ppm max.
Transmission
at 250 nm .................................................. 80 % min.
at 290 nm .................................................. 99 % min.
2.5 L
Toluene
SO-4483-B010 Toluene HPLC Optigrade
1 L
SO-4483-B025 Toluene HPLC Optigrade
2.5 L
SO-4483-B040 Toluene HPLC Optigrade
UN 1294
CAS-Nr. 108-88-3
C7H8
Assay ...................................................... 99.7% min.
Water ..................................................... 0.03% max.
Non-volatile matter ............................. 0.0005% max.
Filtered through 0.2 m
1 L = 0.866 kg (at 20C)
Specification
Transmission
at 285 nm ................................................... 10% min.
at 288 nm ................................................... 39% min.
at 300 nm ................................................... 70% min.
at 335 nm ................................................... 95% min.
at 350 nm ................................................... 98% min.
4 L
SO-1350-B010 Toluene Picograde
(Isooctane) 1 L
SO-6043-B025 2,2,4-Trimethylpentane HPLC Optigrade
(Isooctane) 2.5 L
SO-6043-B040 2,2,4-Trimethylpentane HPLC Optigrade
(Isooctane)
UN 1262
CAS-Nr. 540-84-1
C8H18
Assay ...................................................... 99.5% min.
Water ..................................................... 0.02% max.
Non-volatile matter ............................. 0.0005% max.
Filtered through 0.2 m
1 L = 0.690 kg (at 20C)
Specification
Transmission
at 205 nm ................................................... 10% min.
at 220 nm ................................................... 63% min.
at 230 nm ................................................... 79% min.
at 254 nm ................................................... 98% min.
4 L
SO-1364-B010 2,2,4-Trimethylpentane (Isooctane) Picograde
2.5 L
SO-6795-B040 Water HPLC Optigrade
CAS-Nr. 7732-18-5
H2O
Specification
Fluorescence at 254 nm (as Quinine) ....................... 0.1 ppb max.
Fluorescence at 365 nm (as quinine) ....................... 0.1 ppb max.
Non-volatile matter .................................1 mg/L max.
Filtered through 0.2 m
pH ................................................................ 5,0 - 8,0
This solvent in glass bottles fulfills the specifications according to chapter 4 of the European Pharmacopoeia.
4 L
SO-9662-B010 Water UHPLC-MS Optigrade
1 L
SO-9662-B025 Water UHPLC-MS Optigrade
CAS number 7732-18-5
H2O
Residue after evaporation ............................... 0.0001 %w/w max.
Acidity (as Acetic acid) ............................................ 0.002 % max.
Alkalinity (as Ammonia) ...................................... 0.00005 % max.
Resistivity (at manuf.) ................................... 18.2 Mohm*cm min.
Gradient specification
HPLC gradient at 210 nm - H. Peak ...................... 0.002 AU max.
HPLC gradient at 254 nm - H. Peak .................... 0.0005 AU max.
Fluorescence at 254 nm (as quinine) ....................... 0.5 ppb max.
Fluorescence at 365 nm (as quinine) ....................... 0.5 ppb max.
TOC ........................................................................... 10 ppb max.
Filter test ..................................................................... Passes test
Ca ............................................................................ 0.1 ppm max.
K............................................................................... 0.1 ppm max.
Mg ............................................................................ 0.1 ppm max.
Na ........................................................................... 0.1 ppm max.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
SO-4661-B025 Water 0.1 % formic acid UHPLC-MS Optigrade
Assay ..................................................................... 0.095-0.105 %
Purity of formic acid (GC)........................................... 99.0 % min.
Gradient specification
HPLC gradient at 254 nm - H. Peak ...................... 0.002 AU max.
HPLC gradient at 254 nm - Drift ............................ 0.010 AU max.
Fluorescence at 254 nm (as quinine) ....................... 0.5 ppb max.
Fluorescence at 365 nm (as quinine) ...................... 0.5 ppb max.
Transmission
at 210 nm ........................................................................ 5 % min.
at 230 nm ....................................................................... 45% min.
at 254 nm ....................................................................... 99% min.
Al ............................................................................... 30 ppb max.
Ca ............................................................................ 100 ppb max.
Fe ............................................................................... 50 ppb max.
K............................................................................... 100 ppb max.
Mg .............................................................................. 30 ppb max.
Na ............................................................................ 100 ppb max.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
High purity solvents and acids
436 Promochem
Assay ..................................................................... 0.095-0.105 %
pH ...................................................................................... 3.2-3.4
Purity of acetic acid (GC) ........................................... 99.9 % min.
Gradient specification
HPLC gradient at 254 nm - H. Peak ..................... 0.002 AU max.
HPLC gradient at 254 nm - Drift............................ 0.010 AU max.
Fluorescence at 254 nm (as quinine) ........................0.5 ppb max.
Fluorescence at 365 nm (as quinine) ........................0.5 ppb max.
Transmission
at 210 nm ...................................................................... 20 % min.
at 230 nm ...................................................................... 75 % min.
at 254 nm ...................................................................... 99 % min.
Al ...............................................................................30 ppb max.
Ca ............................................................................100 ppb max.
Fe ...............................................................................50 ppb max.
K ...............................................................................100 ppb max.
Mg ..............................................................................30 ppb max.
Na ............................................................................100 ppb max.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
SO-4673-B025 Water 0.1 % trifluoroacetic acid UHPLC-MS Optigrade
Assay ..................................................................... 0.095-0.105 %
Purity of trifluoroacetic acid (GC) .............................. 99.95% min.
Gradient specification
HPLC gradient at 254 nm - H. Peak ..................... 0.002 AU max.
HPLC gradient at 254 nm - Drift............................ 0.010 AU max.
Fluorescence at 254 nm (as quinine) ....................... 0.5 ppb max.
Fluorescence at 365 nm (as quinine) ........................0.5 ppb max.
Transmission
at 210 nm ...................................................................... 25 % min.
at 230 nm ....................................................................... 85% min.
at 254 nm ....................................................................... 99% min.
Al ...............................................................................30 ppb max.
Ca ............................................................................100 ppb max.
Fe ...............................................................................50 ppb max.
K ...............................................................................100 ppb max.
Mg ..............................................................................30 ppb max.
Na ............................................................................100 ppb max.
Microfiltered through 0.1 m/bottled under inert gas
2.5 L
SO-9368-B010 Water for LC-MS Optigrade
1 L
SO-9368-B025 Water for LC-MS Optigrade
Specification
Fluorescence (as Quinine at 450 nm) . 1.10-7 g max.
Non-volatile matter ................................ 5 mg/L max.
Filtered through 0.2 m
pH ................................................................ 5,0 - 8,0
Ca ....................................................... 0.1 ppm max.
K .......................................................... 0.1 ppm max.
Mg ....................................................... 0.1 ppm max.
Na ....................................................... 0.1 ppm max.
Transmission
at 200 nm - 400 nm ................................... 99 % min.
2.5 L
Solvent mixtures
SO-9534-B040 Mixture Cyclohexane/Ethylacetate 1:1
Specification
GC/ECD
In the GC-ECD chromatogram there are no interfering single signals in the retention time interval between
1,4-dichlorobenzene and decachlorobiphenyl, by a 500-fold concentration greater than that, given by 10 pg/mL
heptachlor-epoxide.
GC/FID
In the GC-FID chromatogram there are no interfering single signals in the retention time interval between n-octane
(C8) and n-tetracontane (C40), by a 500-fold concentration greater than that, given by 50 ng/mL n-undecane
(C11).
4 L
Ordering Information
Edition 2011/2012 Promochem